Applied Epidemiology in Aboriginal and Torres Strait Islander Health by Arnold, Anna-Lena
i 
Applied Epidemiology in 
Aboriginal and Torres Strait Islander 
Health 
_____________________________________________________________________________ 
A thesis submitted for the degree of Master of Philosophy in Applied 
Epidemiology (MPhil Appl Epid) at the Australian National University 
Anna-Lena Arnold 
21 January 2016 
Evidence and Evaluation Section,  
Indigenous Health Division, Australian Government Department of Health 
Funded by:  
Australian Government Department of Health 
Field Supervisor: Rachel Meyer 
Academic Supervisors: Associate Professor Mahomed Patel and Dr Emily 
Fearnley 
ii 
Declaration of work 
This thesis is comprised of multiple discrete projects that were undertaken collaboratively 
with multiple stakeholders and the author acknowledges the contributions made by each 
of the stakeholders involved in the projects. Taken as a whole document, the author 
certifies that this thesis is an original work. None of the work has been previously 
submitted by me for the purpose of obtaining a degree or diploma in any university or 
other tertiary education institution. To the author’s best knowledge, this thesis does not 
contain material previously published by another person, except where a reference is 
made in the text. The author acknowledges that copyright of published works contained 
within this thesis resides with the copyright holders(s) of those works. 
Anna-Lena Arnold 
20/01/2016 
iii 
Acknowledgements 
During my MAE, I was very fortunate to have worked with many great inspiring people. In 
particular, I would like to express my gratitude to the people listed below. 
My academic and field supervisors, Associate Professor Mahomed Patel, Dr Emily Fearnley, 
Rachel Meyer, Hope Peisley and Dr Masha Somi – your continuous encouragement and guidance 
has not only enabled me to complete the MAE, but has enabled me to develop/shaped me as an 
epidemiologist. 
Associate Professor Martyn Kirk, for your understanding and encouragement, and for having the 
faith in me to put my name forward for pre-deployment training with the World Health 
Organization Regional Office for the Western Pacific (WHO WPRO). 
WHO WPRO, for giving me the opportunity to contribute to the response to the Ebola virus 
disease outbreak in Sierra Leone, and to my wonderful, inspiring Sierra Leonean colleagues “we 
are all in this together”. 
The lovely Evidence and Evaluation team, Hope Peisley, Rachel Meyer, Claudia Netterfield, Alice 
Church, Richard Percy, Aurysia Hii, Jessica Hanily, Samantha Siripol, Tamsin Porter, Jane Miller 
and Janet Bailey. Thank you for the laughter, friendship, for way too much Space cake, the games 
of Pandemic and for the greatest bat cave ever! 
The MAE2014 cohort, for being a brilliant bunch to share this ride with. I look forward to seeing 
and working with you all again in the great world of public health and epidemiology. I would also 
like to thank the MAE2013 cohort for your words of wisdom and also for your encouragement. 
To my ever supportive husband Timothy Smith, thank you for supporting me in the steps that I 
choose to take, for listening to my endless talking about my work and epidemiology, and for 
enjoying and embracing the ride with me. 
To the ‘the girls’, thank you for not only the support but for the fun and laughter that that keeps 
me sane. 
Finally, to my most wonderful family that I am blessed with, Lynn, Elaine, Jean, Maurice, Bronwyn, 
Rhona, Tom, Emily, Chris, Lisen, Steve, Kerchever, Jessica, Elliott, Alisa, Tyler, Caitlyn, Charlotte, 
Sophie and for now ‘Kerchina’, you guys are my rock. Without you, none of this would have been 
possible, and I cannot thank you all enough. 
iv 
Table of Contents 
Chapter 1 – Introduction 
Overview………………………………………………………………………………………………………………… 1-1 
Field placement – Evidence and Evaluation section, Indigenous Health Division……. 1-1 
Summary of core MAE activities……………………………………………………………………………… 1-1 
Chapter 2 – Primary Health Care Performance of a Primary Care Health Service in the 
Northern Territory using the Northern Territory Aboriginal Health Key Performance 
Indicators [closed chapter] 
Preface ............................................................................................................................. 2-1 
Abbreviations ................................................................................................................... 2-3 
Abstract ............................................................................................................................ 2-4 
Introduction ..................................................................................................................... 2-6 
Methods ........................................................................................................................... 2-9 
Results ................................................................................................................ …………2-11 
Discussion ...................................................................................................................... 2-26 
Conclusions .................................................................................................................... 2-35 
References ..................................................................................................................... 2-36 
Appendix 1: Map of primary health care services in the Northern Territory (NT) .... 2-39 
Appendix 2: Definitions of the Northern Territory Aboriginal Health Key Performance 
Indicators (NT AHKPI) variables .................................................................................... 2-40 
Chapter 3 - Evaluation of the Northern Territory Aboriginal Health Key Performance 
Indicators 
Table of Contents ............................................................................................................ 3-ii 
Preface ............................................................................................................................. 3-1 
Abbreviations ................................................................................................................... 3-3 
Abstract ............................................................................................................................ 3-4 
Background ...................................................................................................................... 3-8 
Methods ......................................................................................................................... 3-11 
Ethics .............................................................................................................................. 3-19 
Analysis .......................................................................................................................... 3-19 
Findings .......................................................................................................................... 3-19 
Discussion ....................................................................................................................3-124 
Conclusion ....................................................................................................................3-128 
v 
Recommendations ..........................................................................................................3-129 
Appendix 1: List of the Northern Territory Aboriginal Health Key Performance Indicators 
(NT AHKPIs) as at December 2015 .................................................................................3-130 
Appendix 2: Modified criteria to select indicators to monitor health care quality against 
which KPIs will be assessed from Health Care Quality Indicators Project - Conceptual 
Framework Paper, 2006 (11) .........................................................................................3-131 
Appendix 3: Participant information sheet as it appeared on SurveyMonkey, 2015..3-132 
Appendix 4: Participant consent form as it appeared on SurveyMonkey, 2015 .........3-133 
Appendix 5: Questionnaire for primary health care services as it appeared on 
SurveyMonkey, 2015 ..................................................................................................... 3-134 
Appendix 6: Questionnaire for higher level planners as it appeared on SurveyMonkey, 
2015 .................................................................................................................................3-136 
Appendix 7: Advertisement for evaluation of the NT AHKPIs as it appeared in the 
online Communicare newsletter ................................................................................... 3-139 
Appendix 8: Presentation I gave on the NT AHKPI evaluation at the CQI collaborative in 
Darwin, 10-11 November 2015......................................................................................3-140 
Appendix 9: Feedback from the pilot of the questionnaires ........................................3-143 
References ......................................................................................................................3-144 
Chapter 4 - Screening and managing anaemia in Aboriginal and Torres Strait Islander 
children aged 6 months to 3 years in the Northern Territory, 2008 -2013 
Preface ............................................................................................................................ 4-1 
Abbreviations .................................................................................................................. 4-3 
Abstract ........................................................................................................................... 4-4 
Introduction .................................................................................................................... 4-6 
Methods ........................................................................................................................ 4-11 
Results ........................................................................................................................... 4-14 
Discussion ...................................................................................................................... 4-19 
Conclusions ................................................................................................................... 4-26 
Recommendations ........................................................................................................ 4-27 
Appendix 1:  Human studies showing the health and behavioural impacts of anaemia and 
iron-deficiency anaemia by age and location (non-exhaustive list) ........................... 4-28 
Appendix 2: Primary health care services in the Northern Territory by patient information 
recall systems ................................................................................................................ 4-29 
Appendix 3: Variables sent from the Northern Territory Department of Health ..... 4-30 
References .................................................................................................................... 4-32 
vi 
Chapter 5.1 - An unusual cluster of cases of Ralstonia bacteraemia from 1 April to 26 June 
2014, in three states in Australia 
Preface ............................................................................................................................. 5.1-1 
Public health impact ........................................................................................................ 5.1-4 
Abbreviations ................................................................................................................... 5.1-5 
Abstract ............................................................................................................................ 5.1-6 
Introduction ................................................................................................................... 5.1-10 
Study objectives ............................................................................................................. 5.1-11 
Methods ......................................................................................................................... 5.1-11 
Results ............................................................................................................................ 5.1-14 
Conclusion ...................................................................................................................... 5.1-27 
Appendix 1: Safety advisory – potential bacterial contamination, Therapeutic Goods 
Administration, 2 May 2014 ......................................................................................... 5.1-30 
Appendix 2: Members of the Communicable Disease Network of Australia Working 
Group, 2014 ................................................................................................................... 5.1-32 
Appendix 3: Final Multi-jurisdictional outbreak investigation report to Communicable 
Disease Network of Australia, 26 May 2014 ................................................................ 5.1-33 
Appendix 4: ProMED alert – Ralstonia Pickettii, sepsis – Australia: contaminated 
propofol, alert 22 May 2014 ......................................................................................... 5.1-41 
Appendix 5: Focused literature review assessing the level of contamination that could 
be expected in the propofol solution at the time of administration if the propofol 
solution had been contaminated at the point of manufacture many weeks or months 
earlier ............................................................................................................................. 5.1-45 
Appendix 6: Line list of cases of Ralstonia bacteraemia ............................................. 5.1-57 
Appendix 7: Original Ralstonia case report form developed by Queensland Department 
of Health ........................................................................................................................ 5.1-59 
Appendix 8: Adapted Ralstonia case report form for multijurisdictional investigation into 
cases of Ralstonia bacteraemia 1 April to 26 June 2014 ............................................. 5.1-61 
Appendix 9: List of expert panel members who participated in the Delphi rounds .. 5.1-63 
Appendix 10: DiversiLab® results, including association with propofol ..................... 5.1-64 
Appendix 11: Frequency of Ralstonia isolated from blood cultures, number of requests 
for blood culture and number that were positive, 2009  - 2014 ................................ 5.1-65 
Appendix 12: Results of microbiological testing of propofol solution, flip-off caps and 
external surfaces of the rubber stoppers..................................................................... 5.1-66 
Appendix 13a: Simulated case-control study .............................................................. 5.1-75 
Appendix 13b: Simulated cohort study ........................................................................ 5.1-76 
vii 
Appendix 14: Assessing the standard of evidence based on the Bradford Hill framework
 ........................................................................................................................................ 5.1-77 
Appendix 15: Key points transcribed from each Panel Member’s response and 
facilitators’ conclusions on each question ................................................................... 5.1-80 
Appendix 16: List of the twelve questions and facilitators’ conclusions based on 
members responses in Round 2, members’ Round 3 comments on these conclusions 
and facilitators revised conclusions .............................................................................. 5.1-87 
Appendix 17a: Panel Members’ assessment of the plausibility of the six hypotheses in 
the various clinical settings ........................................................................................... 5.1-94 
Appendix 17b: Comments from Panel Members related to their responses in Table 1A.
 ........................................................................................................................................ 5.1-97 
Appendix 17c: Comments from Table 2A. .................................................................... 5.1-98 
References .................................................................................................................. 5.1-100 
Chapter 5.2 - The Ebola Virus Disease Outbreak in West Africa Experiences from the field 
in Sierra Leone, May - July 2015 
Preface ......................................................................................................................... 5.2-1 
Abbreviations ............................................................................................................... 5.2-8 
Abstract ........................................................................................................................ 5.2-9 
Background ................................................................................................................ 5.2-11 
Cluster X investigation in Port Loko district, Sierra Leone 2015 ............................. 5.2-18 
References ................................................................................................................. 5.2-27 
Appendix 1: Presentation to Indigenous Health Divisional Forum describing experiences 
from the field working as part of the response to the Ebola Virus Disease Outbreak in 
Sierra Leone, 28 October 2015 ................................................................................. 5.2-32 
viii 
Abstract 
My placement for the Master of Philosophy in Applied Epidemiology (MAE) degree was with 
the Evidence and Evaluation section, within the Indigenous Health Division, Australian 
Government Department of Health. In this thesis, I present projects undertaken which fulfil 
the requirements of the MAE program.  
Data analysis project: The Northern Territory Aboriginal Health Key Performance Indicators (NT 
AHKPIs) are a collection of key performance indicators that measure primary health care (PHC) 
performance. I conducted a study to explore how PHC service X was performing when 
compared with other PHC services in very remote areas and all NT PHC services, based on NT 
AHKPI performance. Analysis showed an overall improvement at PHC service X  from 2010 to 
2014, but similar to other PHC services located in very remote regions and to the NT overall, 
there remains an opportunity for improvement in the areas of antenatal care, child health 
outcomes, blood glucose levels for type 2 diabetics, blood pressure results and adult health 
checks. Please note - the NT AHKPIs are not currently in the public domain, this chapter is 
therefore a closed chapter, and is not presented in this thesis. 
Evaluation project: I evaluated the NT AHKPIs to assess the extent to which the NT AHKPIs are 
addressing their intended goals and to determine whether they were being used for 
other purposes; my approach to the evaluation was utilisation focused. Preliminary 
findings show that the KPIs are useful to inform service planning and continuous quality 
improvement, but there is room for improvement. Findings will be reported back to the 
NT AHKPI steering committee to inform ongoing strengthening of the NT AHKPI system. 
Epidemiological study: Anaemia in Aboriginal and Torres Strait Islander children in the NT is a 
public health problem. I undertook a study to describe the application of best 
practice guidelines for screening and management of children aged 6 months to 3 years with 
anaemia in the NT. Findings show that of 5,543 children, 63% were screened for 
anaemia. The prevalence of anaemia was 40% - a ‘severe’ public health problem as 
defined by the World Health Organisation (WHO). A very low proportion of anaemic 
children were recorded as treated according to best practice guidelines, however, our 
findings are subject to multiple potential biases and these findings need to be validated.
ix 
Outbreak investigation: I was a member of the Communicable Disease Network Australia team 
that investigated an unusual cluster of Ralstonia bacteraemia from 1 April to 26 June 2014 in 
three states in Australia. The objectives of this investigation were to assess the possibility of a 
causal association between the administration of propofol and Ralstonia bacteraemia, and to 
identify sources of the infections. The propofol solution passed all sterility and contamination 
tests, but 18% of the flip-off caps and external surfaces of the rubber stoppers were 
contaminated with a variety of bacterial species including R. mannitolylitica. These isolates 
were genetically indistinguishable from three out of eight isolates from patients with R. 
mannitolylitica bacteraemia. Findings from this study highlighted the need for proper aseptic 
techniques when administering intravenous injections. 
I spent ten weeks in Sierra Leone supporting the WHO’s response to the Ebola virus disease 
outbreak (EVD). I summarise my role and responsibilities in the outbreak, including a 
description of our investigation of a cluster of cases with EVD. 
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Chapter 1: Introduction and course requirements 
"Public health looks at illness and other risk factors in aggregate 
populations and comes up with wholesale solutions... Its philosophical base 
is social justice and its scientific base is epidemiology." - Bill Foege 
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Overview 
My field placement for the Master of Philosophy in Applied Epidemiology (MAE) 
commenced on 17 February 2014, in the Evidence and Evaluation Section, Systems 
Effectiveness Branch of the Indigenous Health Division (IHD) at the Australian 
Commonwealth Department of Health. My field supervisor was Rachel Meyer and my 
academic supervisors were Associate Professor Mahomed Patel and Dr Emily Fearnley. 
During this time I worked on three major projects and a range of other activities 
relevant to Aboriginal and Torres Strait Islander health and primary health care (PHC) in 
the Northern Territory (NT).  Investigating acute public health problems is not part of 
the work of the Evidence and Evaluation section, so in addition to the projects relevant 
to Aboriginal and Torres Strait Islander health, I also had the opportunity to work on 
three different outbreak investigations outside of the IHD. These projects included an 
investigation into an unusual cluster of Ralstonia bacteraemia in three states in 
Australia; assisting with a multijurisdictional outbreak investigation into cases of 
hepatitis A; and working with staff of the World Health Organization (WHO) in their 
response to the Ebola Virus Disease (EVD) outbreak in Sierra Leone in West Africa. 
This introductory chapter briefly describes my field placement, how my projects and 
activities meet the MAE course requirements and the impacts and potential impacts of 
these projects on public health. 
Field placement – Evidence and Evaluation section, Indigenous Health Division 
The Evidence and Evaluation section is responsible for the monitoring and evaluation of 
Indigenous Health programs managed or coordinated by the IHD. The aims of the 
section are to produce timely, accurate and meaningful information on program 
implementation, impacts and outcomes to inform policy and practice and improve the 
health outcomes of Aboriginal and Torres Strait Islanders. 
Summary of core MAE activities 
See also Table 1 on page 1-8. 
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Analysis of public health data [Closed chapter] 
The Northern Territory Aboriginal Health Key Performance Indicators (NT AHKPIs) are a 
set of indicators designed to measure performance of PHC services in the NT. I 
conducted a study to explore how one PHC service was performing when compared 
with performance of other PHC services in very remote areas and all NT PHC services, 
based on data from the NT AHKPIs [Chapter 2]. 
Public health impact 
This analysis was requested by the First Assistant Secretary of the IHD in response to 
the possibility of PHC service X being transitioned from a Northern Territory 
Department of Health (NT DoH) managed service to an Aboriginal Community 
Controlled Health Organisation (ACCHO). This analysis highlighted that similar to the NT 
overall and for all other services located in very remote regions of the NT, there remain 
opportunities for improvement. Identifying an area of need is the first step in being able 
to bring about actions. Our findings were reported back to the First Assistant Secretary, 
although PHC service X has not yet been transitioned from an NT DoH managed service 
to an ACCHO service. 
Evaluation of a health information system 
I evaluated the NT AHKPIs to assess whether the indicators were addressing their 
intended goals, whether they were being used for other purposes and how the system 
could be improved for greater usefulness. My approach to the evaluation was utilisation 
focused [Chapter 3]. 
Potential public health impact 
Consistent with the utilisation focused approach, a report on the findings and 
recommendations will be developed in collaboration with stakeholders to continue 
strengthening and developing the KPIs and the health outcomes of Aboriginal and 
Torres Strait Islanders. A summary of key findings will also be distributed to all who 
participated in the evaluation. 
Conduct and interpret an epidemiological study 
Anaemia in Aboriginal and Torres Strait Islander children in the NT is a severe public 
health problem. I undertook a study to assess the extent to which best practice 
guidelines recommended by the Central Australian Rural Practitioner’s Association 
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(CARPA) were being implemented for screening and management of children aged 6 
months to 3 years with anaemia in the NT [Chapter 4]. 
This study showed that the prevalence of anaemia among children aged 6 months to 3 
years attending NT DoH services between 2008 and 2013 is a ‘severe’ public health 
problem, as defined by WHO. It also provided evidence that a high proportion of 
anaemic children are not being treated according to the recommended CARPA 
guidelines. However, these latter findings need to be validated. 
Potential public health impact 
These findings will be disseminated to PHC clinic staff and presented at fora such as the 
annual CQI anaemia Collaboration, and the Annual Practical Paediatrics conference, to 
convince decision-makers and clinicians to change practise as a high priority. 
Field investigation of a public health problem (outbreak investigation) 
I participated in three field investigations of an acute public health problem. I was a 
member of the Communicable Disease Network Australia (CDNA) team that 
investigated an unusual cluster of Ralstonia bacteraemia from 1 April to 26 June 2014 in 
three states in Australia [Chapter 5.1]. 
This investigation highlighted the importance of strict aseptic techniques and the need 
for clearer instructions on the product information of medications, and ongoing 
continuing education for health professionals. This investigation also identified the need 
for guidelines on how to respond to multijurisdictional outbreaks of infectious diseases 
that are not notifiable in Australia. 
Based on our findings, The Therapeutic Goods Association (TGA) posted a reminder on 
their website  for all health professionals in Australia on the importance of using aseptic 
techniques when preparing and administering intravenous medications, with a 
particular focus on the need to swab the rubber stopper of any vial with a suitable 
disinfectant prior to drawing up sterile solutions. 
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Chapter 1 
I spent ten weeks in Sierra Leone participating in WHO’s response to the EVD outbreak. 
I led field investigations in three villages to identify contacts to place under quarantine, 
and supervised overall surveillance activities while responding to the needs of people 
under quarantine [Chapter 5.2]. 
No secondary transmission occurred in two of the three clusters or from the secret 
burial cluster that we investigated and advised on control measures. Although the 
international community was slow to respond to this outbreak in West Africa, the 
delayed multinational response efforts succeeded in controlling the outbreak. This 
response led to building up the skills for many of the local staff participating in the 
outbreak response and to rebuilding Sierra Leone’s health system. Sierra Leone 
currently (December 2015) remains EVD transmission free, but many organisations like 
WHO remain while the country maintains heightened surveillance and continues to 
strengthen surveillance systems, and to ensure the country is prepared to respond 
should EVD re-emerge.  In addition to this, WHO are now starting to focus on 
addressing other public health issues, such as the very high rates of maternal and child 
deaths. 
I shared my experience working in Sierra Leone with the IHD (my field placement) 
through a seminar presentation on EVD, how it is transmitted, a summary of the EVD 
outbreak in West Africa, my involvement in contributions to the response efforts, the 
challenges encountered by the local communities, health workers and multinational 
agencies, and particularly highlighting the importance of community engagement. It 
was discussed how we face similar challenges in Australia for remaining sensitive to 
cultural traditions, fear, misperceptions and lack of trust of Aboriginal and Torres Strait 
Islanders. Community engagement is integral to the success of any Aboriginal and 
Torres Strait Islander project or health program. 
I also assisted OzFoodNet with a multijurisdictional outbreak investigation into 19 cases 
of hepatitis A linked to the consumption of Brand A frozen mixed berries from China. I 
assisted with recruiting and interviewing controls for the case-control study [Chapter 
5.3 - Appendix]. 
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Critical review of scientific literature and write a scientific manuscript for a peer-reviewed 
journal 
As part of our investigation into the unusual cluster of cases of Ralstonia bacteraemia, I 
conducted a focused literature review to assess the level of contamination that could be 
expected in a vial of propofol solution at the time of administration if the propofol 
solution had been contaminated at the point of manufacture many weeks or months 
earlier. This review will also be submitted as a manuscript for a peer reviewed journal 
[Appendix 5, Chapter 5.1]. 
Report on a project to a non-scientific audience or in the form of a ministerial brief 
I contributed to the write up of multiple reports to the CDNA and Australian Health 
Principal Protection Committee reporting on the findings of the investigation into the 
cluster of cases Ralstonia bacteraemia. The final multi-jurisdictional report is shown in 
Appendix 3 of Chapter 5.1. 
I also provided input and/or contributed to the write up of the following ministerial 
briefs (these reports are not included in this bound volume): 
1. Minute to the Deputy Secretary on ‘Projects to address the high rates of
childhood anaemia in the Northern Territory as evident in the Northern Territory
Aboriginal Health Key Performance Indicators.’
2. ‘Information paper’ on the 2012-13 and 2013-14 Australian Institute of Health
and Welfare (AIHW) report on Hearing Health Outreach Services to Indigenous
children and young people in the NT.
3. I wrote a ‘Delegate Briefing Paper’ on a 2012-13 and 2013-14 AIHW report on
Hearing Health Outreach Services to Indigenous children and young people in
the NT.
4. Minute to the Minister on the Northern Territory Aboriginal Health Key
Performance Indicators.
5. Information brief: East Arnhem.
Conference and other presentations 
I presented a paper titled ‘Evaluation of the Northern Territory Aboriginal Health Key 
Performance Indicators’ to participants of the Continuous Quality Improvement (CQI) 
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Collaborative Workshop held in Darwin in the NT, 10 - 11 November 2015. My 
objectives were to inform them on the evaluation of the NT AHKPIs, its utilisation 
focused approach, and the preliminary findings; I also sought their suggestions for 
recruiting more responses related to the questionnaire I developed for the evaluation 
[Appendix 9, Chapter 4]. 
I presented my experiences from the field supporting WHO in their response to the EVD 
outbreak in Sierra Leone to the IHD on 28 October 2015 [Appendix 1, Chapter 5.2]. 
Prepare and conduct a teaching lesson for peers including a lesson from the field 
I participated in seven lessons from the field (I missed two while I was in Sierra Leone). 
One of these included one that I prepared for my peers on 24 February 2015. 
The objectives of my lesson from the field were to: 
1. explore reasons why a specific set of guidelines is needed to cover research in
Aboriginal and Torres Strait Islander people;
2. list and explain the six core values that underpin the guidelines for ethical
conduct in Aboriginal and Torres Strait Islander Health Research;
3. apply the six core values to one of your own MAE projects; and
4. discuss the implications of not considering these values in the design and
conduct of Aboriginal and Torres Strait Islander health research.
I contributed to and participated in a half-day teaching exercise conducted for first year 
MAE scholars in March 2015.  My MAE colleagues and I presented a lesson on ‘Bias in 
interpreting Aboriginal and Torres Strait Islander health data’. 
The objectives of our teaching session were to: 
1. describe and interpret a graph;
2. explain bias and the two major types of bias; and
3. identify biases in Aboriginal and Torres Strait Islander health data.
Records of these teaching activities are not shown in this bound volume. 
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Respond appropriately to public health enquiries 
I responded regularly to, and assisted with, analysing, interpreting and reporting on 
data, as well as contributing to ministerial briefs (listed above) under ‘Report on a 
project to a non-scientific audience or in the form of a ministerial brief’ section of this 
chapter. 
I contributed regularly to the International Communicable Disease Surveillance Report 
for CDNA on a roster with other MAEs at the Office of Health Protection at the 
Commonwealth Department of Health. 
Attend all residential teaching course blocks 
I attended all of the MAE four residential teaching course block sessions in 
February/March and August/September 2014, and February/March in 2015.
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Table 1: Chapters presented in this bound volume and how they meet the MAE course requirements 
MAE competencies Chapter 1  
Introduction 
Chapter 2 
Performance of 
a primary 
health care 
service in the 
NT (closed 
chapter) 
Chapter 3 
Evaluation of the 
NT Aboriginal 
Health Key 
Performance 
Indicators 
Chapter 4 
Screening and 
managing anaemia in 
Aboriginal and Torres 
Strait Islander 
children 
Chapter 5 
The unusual 
cluster of 
cases of 
Ralstonia 
bacteraemia 
Ebola virus 
disease outbreak 
in Sierra Leone  - 
experiences from 
the field 
Hepatitis 
A case 
control 
study 
Analysis of public health 
data 
✔ ✔ ✔ ✔ 
Evaluation of a health 
information system 
✔ 
Epidemiological study ✔ 
Acute field investigation ✔ ✔ ✔ 
Review of scientific 
literature 
✔ ✔ ✔ ✔ ✔ 
Late draft of scientific 
manuscript  
✔ 
Report for non-scientific 
audience 
Reports are 
listed in this 
chapter 
✔ 
Presentation at a 
national/local 
conference and other 
events
✔ ✔ 
Teaching and lesson 
from the field 
✔ 
Attend all course blocks ✔
CONFIDENTIAL   Chapter 2 [closed chapter] 
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Chapter 2 -  Primary Health Care Performance of a 
Primary Care Health Service in the Northern Territory 
using the Northern Territory Aboriginal Health Key 
Performance Indicators 
Closed chapter -  not presented in this thesis. 
“Primary health care is essential health care based on practical, 
scientifically sound and socially acceptable methods and technology made 
universally accessible to individuals and families in the community 
through their full participation and at a cost that the community and 
country can afford to maintain at every stage of their development in the 
spirit of self-reliance and self-determination.” (1) 
MAE course requirement: Data Analysis 
Chapter 3 
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Chapter 3 - Evaluation of the Northern Territory Aboriginal 
Health Key Performance Indicators 
MAE requirement: Evaluation of a Health Information System 
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Preface 
Investigatory role 
With much guidance from my supervisors, and in collaboration with the Northern 
Territory Aboriginal Health Key Performance Indicator (NT AHKPI) steering committee, I 
designed the methodology for the evaluation, completed the applications to ethics 
committees, and conducted the collection, analysis and interpretation of the data, writing 
the final report and reporting back to stakeholders and participants. 
Lessons learnt  
Although the benefit of conducting an utilisation-focused evaluation (UFE) is that it 
generates findings that are useful to stakeholders to inform decisions and improve 
performance, there are challenges to developing this approach. It requires a lot of time, 
flexibility, ongoing engagement and trust between the stakeholders and the evaluators. 
These challenges take time to overcome, an activity constrained by the short-time frame 
of the MAE program. It took us approximately nine months to get consensus from 
stakeholders on the study design, and a further seven months to obtain the required 
ethics and other approvals to start the evaluation. This left us with very little time to 
conduct the evaluation, interpret the results and develop the recommendations. These 
time constraints compromised our response rate and made it difficult to draw meaningful 
conclusions and recommendations for the stakeholders. 
 
Notwithstanding, the UFE approach was appropriate for this evaluation because its 
purpose was not to prove but to help improve the NT AHKPI system, and to empower the 
stakeholders to review the goals and modify the system for effectively achieving its goals 
(1). 
 
Even with more time, it still would have been challenging to improve on the response 
rate from staff of busy PHC services. Ideally, I would have visited a sample of PHC services 
to both optimise the response rate, and gain a better understanding of how the 
indicators are used and how the system could be improved.  
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Identifying and designing a method for evaluating a system for monitoring indicators 
where there was no pre-existing method (e.g. the CDC guidelines for evaluating a 
surveillance system) was challenging. It took time both to learn about the NT AHKPI 
system and to learn about other methods of evaluating this system. This project would 
not have been possible without the guidance I received from Mahomed Patel and the 
steering committee. 
Potential public health impact  
I shared initial findings with stakeholders and they requested that I continue to collect 
questionnaire data to collect stronger more meaningful evidence. This study is therefore 
still a work in progress.   
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Abstract 
Background 
The Northern Territory Aboriginal Health Key Performance Indicators (NT AHKPIs) are a 
collection of key performance indicators (KPIs) designed to measure performance of 
primary health care (PHC) services in the NT (2). There are currently 16 KPIs (two of which 
are sub component KPIs) that provide information on both process of care and health 
outcomes in the areas of maternal and child health and chronic disease services at the 
PHC level. The NT AHKPIs were introduced in 2009 and are currently collected from 84 
PHC services, including both Northern Territory (NT) Department of Health (DoH) services 
and Aboriginal Community Controlled Health Organisations (ACCHOS). The goals of the 
system are ‘To improve Primary Health Care (PHC) services for Aboriginal Australians in 
the NT by building capacity at the service level and the system level to collect, analyse and 
interpret data to: 
1. Inform understanding of trends in individual and population health outcomes; 
2. Identify factors influencing these trends; and 
3. Inform appropriate action, planning and policy development.' 
 
Although the KPIs have been used for planning of PHC services and CQI, the system has 
not been evaluated.  The objectives of this evaluation were to assess: 
1. whether the KPIs are addressing the intended goals of the monitoring system; 
2. whether the KPIs are being used for other purposes; and  
3. how the system could be improved for greater usefulness. 
 
Methods 
We chose two key approaches: 1) to evaluate each indicator and 2) assess the usefulness 
of the system as expressed by key stakeholders. I evaluated the individual KPIs using 
criteria recommended by the Organisation for Economic Co-operation and Development 
(OECD) for evaluating health indicators. I then developed two questionnaires to assess 
how the results were being used: one was targeted to users of the KPIs at the PHC level 
and the other, to higher level planners such as steering committee members, and staff at 
NT DoH and AMSANT.  
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Results 
KPIs assessed against the OECD criteria 
Importance and impact of what is being measured 
All the KPIs measure disease areas that affect Aboriginal and Torres Strait Islanders 
disproportionately when compared with non-Indigenous Australians. Policy makers and 
consumers were concerned of the disease condition related to all the KPIs.  
Can the health care system meaningfully address this disease area problem? 
 Yes - all disease areas are part of the core functions to be addressed by Aboriginal and 
Torres Strait Islander PHC services in the NT. Although they are influenced by a range of 
social and environmental health determinants, many of which go beyond the domain 
traditionally covered by PHC services.  
Scientific soundness 
Validity: are the data telling the truth? 
Systematic checks of the data are performed by the NT DoH to detect and remove errors. 
However, these checks do not identify all incorrect data entry errors or incomplete data. 
Double counting of clients is an issue for ACCHOs that use Communicare.  
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Most of the KPIs (13/16) have had changes to the definitions for either the numerator or 
denominator, but these changes have been well documented for trends to be interpreted 
meaningfully over time. Because zero reporting is not used, blank cells could imply either 
missing data or a zero. However, overall completeness of the data has improved 
substantially since the system was first implemented. 
Is there scientific evidence to support the measure? 
There is scientific evidence to support nine out of the 16 KPIs, although three of these are 
outcome indicators (KPIs 3, 5 and 6) and are therefore not good indicators of service 
performance. Seven out of 16 KPIs measure whether someone has been tested/screen 
for an abnormality but no data are recorded on the action and care provided following if 
an abnormality was detected. 
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Results from the questionnaires to PHC services on the usefulness of the indicators 
Of the questionnaires sent to 84 PHC services (52 NT DoH and 32 ACCHOs) only 13 
responded, covering 23 services. Sixty-two percent (8/13) of respondents use the 
indicators for service planning, CQI and feedback to communities. Fifteen percent (2/13) 
use them for service planning and CQI only, 15% (2/13) use them for service planning 
only, and one uses them for CQI and feedback to communities. Overall, most respondents 
(69%) found the indicators to be ‘very useful’ for service planning, and CQI, and half of the 
respondents found them ‘very useful’ for feedback to communities. Ninety-two percent 
(12/13) reported the indicators to be valuable. Participants explore variations in the 
indicators by speaking with other staff and with the community, and cross referencing 
with other reports.  
Results from questionnaires to higher level planners 
We received eight questionnaires from higher level planners. Eighty-five percent (11/13) 
use the reports for CQI and supporting services in their planning and 18% (2/11) can’t 
access the reports. Overall, most respondents (71%) found the indicators to be ‘very 
useful’ for planning, and CQI (80%), but less than half found them ‘very useful’ for policy 
development. The higher level planners use other reports and datasets to explore 
variations in trends of the indicators. Thirty-eight percent (3/8) thought that there are 
changes that could be made to the governance of the NT AHKPIs that would support 
continuous improvement of the system and 68% (5/8). Suggested improvements 
included: promoting the reports and making them more widely available; improving the 
comparability between data from PCIS and Communicare; and giving Communicare the 
ability to collect data across multiple clinics for one client. 
 
For both staff at the PHC level and higher level planners, data on trends were the most 
useful aspects of the Community Health Centre (CHC) and the Health Service Delivery 
Area (HSDA) reports. Overall weaknesses of the reports were that they contain too much 
data while lacking context, and they aren’t sent frequently enough. 
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Conclusion 
Findings from the questionnaires revealed that the KPIs are considered a very valuable 
tool being used to inform planning of PHC services, but information on whether the 
action and planning is ‘appropriate’ is not collected. The results of KPIs cannot address 
objectives 1 and 2 (‘inform understanding of trends in individual and population health 
outcomes’ and ‘identify factors influencing these trends’) because data aren’t collected on 
the social and environmental determinants related to the health conditions and events 
being measured.  
The response rate for our study was very small and therefore unlikely to be 
representative of the study population of health staff related to the PHC services. This 
limits us from being able to draw meaningful or generalizable conclusions or 
recommendations until in-depth interviews and focus group discussions can be 
conducted with all relevant staff. We need more robust evidence to assess whether the 
indicators are addressing their intended goals effectively, and how the system could be 
improved for greater usefulness.  
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Background 
In 1999 the Northern Territory Aboriginal Health Forum (NT AHF) identified the need to 
identify and monitor a common set of indicators on process of clinical care and health 
outcomes referred to as the ‘key performance indicators’ (KPIs). The KPIs were designed 
to inform planning of primary health care (PHC) services in the Northern Territory (NT) 
(2). The set of KPIs were focused on specific outcomes related to the management of 
chronic disease, antenatal care, and infant, child and adult health.  
 
An extensive amount of work went into the design and development of the indicators. 
Pam Gollow (project manager on the development of the NT AHKPIs) detailed this 
process in the document titled ‘The development of a performance reporting system for 
Indigenous primary health care’ (3). The document included literature reviews of 
indicator sets used for performance measurement in the health sector and multiple 
workshops to brainstorm ideas, to establish an agreed understanding of the purpose of a 
performance reporting system, to develop a framework to guide its development and to 
establish criteria for selecting the indicators that were listed as:  
 
1. ‘Is the measure useful from the service provision point of view? 
2. Is the measure useful from the funding point of view? 
3. How frequently should the measure be reported? 
4. Is data available / are there any quality issues?’ 
 
Workshop participants (Listed in Table 1) used these criteria to include or exclude 
indicators. By the end of this process, of the eligible 44 KPIs, 12 were accepted for 
inclusion. Since then a further three KPIs (KPIs numbers 13 - 15) were accepted for use in 
2013 based on suggestions from the clinical reference group (CRG) (Appendix 1). A list of 
the organisations and individuals involved in the development of the NT AHKPIs is shown 
in Table 1 and the development process is shown in Figure 1. 
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Table 1: Organisations and individuals involved with the development of the KPIs 
Project team 
Project advisor: Professor Tony Barnes 
Cooperative Research Centre (CRC) Program leader: Dr Ross Bailie 
Project Manager (part-time): Pam Gollow 
Project Officer (casual): Dr George Latham 
Steering Committee 
The Primary Health Care Steering Committee included representatives from three 
partners  of the Aboriginal Health Forum (AHF):  
-NT Department of Health  
-The Commonwealth Department of Health 
-Aboriginal Medical Services Alliance of the Northern Territory (AMSANT) 
Northern Territory Aboriginal Health Forum (NTAHF) 
-Aboriginal Medical Services Alliance Northern Territory (AMSANT) 
-Northern Territory Department of Health 
-Commonwealth Department of Health 
 
 
Figure 1: Flowchart of workshop and consultation process (3) 
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The NT AHKPIs are a collection of indicators that measure the performance of PHC 
services (4). There are currently 16 KPIs (two of which are sub component KPIs) to 
monitor both process of care and health outcomes in the areas of chronic disease, 
antenatal care, and infant, child and adult health at the primary health care (PHC) level 
(Appendix 1). The NT AHKPIs were introduced in 2009 and are currently collected from 84 
primary health care services, including both Northern Territory (NT) Department of 
Health (DoH) services (52 services) and Aboriginal Community Controlled Health 
Organisations (ACCHOS) (32 services).  The system’s goals are stated as: 
 
‘To improve Primary Health Care (PHC) services for Aboriginal Australians in the NT by 
building capacity at the service level and the system level to collect, analyse and interpret 
data to: 
1. Inform understanding of trends in individual and population health outcomes; 
2. Identify factors influencing these trends; and 
3. Inform appropriate action, planning and policy development’ (5). 
Continuous Quality Improvement and the NT AHKPIs 
A major use of the NT AHKPIs has been for continuous quality improvement (CQI) of PHC 
services as well as for clinical data audits. CQI is defined as ‘the use of good quality data 
about systems, processes and outcomes to assist health care teams to develop and 
implement plans for improving the quality of care provided to patients and to 
communities, and to do this in a cyclical and ongoing approach’ (6). It is the ongoing 
collection, use and analysis of data on organisational system performance, to facilitate 
continuous improvement of primary health care delivery (7, 8).  
Data and reporting of the indicators 
The NT AHKPI consists of clinical data already being collected as part of the normal 
functioning of the PHC services. The necessary data that make up the 16 KPIs are 
forwarded from electronic record systems at each of the PHC services and sent to a 
central data repository at the NT DoH corporate data warehouse, on six a monthly basis 
for a 12-month reporting period. In the NT there are two electronic patient information 
systems that are used: Communicare and Primary Care Information System (PCIS). Within 
both of these systems there is an inbuilt mechanism for reporting of NT AHKPI data. At 
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the NT DoH corporate warehouse, the data are checked. The data are then sent back to 
the PHC services in the form of a report to give services the opportunity to review the 
data and provide any contextual or interpretive information. 
 
Three different reports summarise the NT AHKPIs for use by service providers and higher 
level planners, but are not for public distribution.  
 
1. Community Health Centre (CHC) report – summarises the KPIs for each of the PHC 
services for the last reporting period and for all reporting periods. It provides a 
comparison to the NT average. This report is distributed to PHC services at 6 
monthly intervals.  
2. HSDA report – summarises the KPIs for each of the health service delivery areas 
for the last reporting period and for all reporting periods. It provides a comparison 
to the NT average. This report is distributed to the NT AHF at 6 monthly intervals.   
3. De-identified HSDA report – same as the above but de-identified (2).  
The objectives of this evaluation  
Although the KPIs have been used for planning of PHC and CQI at the service level since 
the introduction of the system in 2009, the system has not been evaluated. The 
objectives of this evaluation were to assess: 
1. whether the KPIs are addressing the intended goals of the monitoring system; 
2. whether the KPIs are being used for other purposes; and  
3. how the system could be improved for greater usefulness. 
 
Methods 
My approach to this evaluation was utilisation-focused where the primary purpose was to 
generate information meaningful for the stakeholders to continue strengthening and 
developing the KPIs aimed at strengthening PHC services and health outcomes among 
Aboriginal and Torres Strait Islanders.  
Utilisation-focused evaluation 
Because the overall aim of the evaluation was to help assess and to strengthen this 
system, we opted for an utilisation focused approach which ‘begins with the premise that 
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evaluations should be judged by their utility and actual use’ (9). This approach was 
developed by Michael Patton and is based on the principle that an evaluation should be 
planned and designed in a way that generates findings that are useful to stakeholders of 
the project to inform decisions and improve performance. One of the essential elements 
of a utilisation-focused evaluation (UFE) is that users of the system are engaged from the 
beginning and throughout every phase of the evaluation; with formulating key questions, 
the design and data collection tools, analysis, interpretation, recommendations are all 
done in collaboration with people who use the system and have the ability to implement 
the changes recommended by the evaluation.  
 
To address the objectives of the evaluation, we chose two key approaches: 1) to evaluate 
each indicator and 2) assess the usefulness of the system as expressed by key 
stakeholders drawing on surveys of all people who use the indicators at the PHC level and 
of higher level planners, and a review of documents. These documents include: a review 
of literature and a review of the ‘Definitions’ manuals (10) for the indicators and the ‘Data 
Receiving Protocol’ which outlines the processes and rules for extraction of the data (5). 
Specific evaluation questions and methods for data collection are outlined in Table 2.
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Table 2: Evaluation questions and methods used to assess the extent to which the system is meeting its stated objectives 
NT AHKPI 
objective 
Evaluation question Suggested method to answer 
questions 
Data sources People to interview 
1.To inform 
understanding 
of trends in 
individual and 
population 
health 
outcomes 
 
Are the KPIs important 
and scientifically 
sound? 
 
Assess the appropriateness of 
the KPIs using internationally 
recognised criteria for 
evaluating indicators posed by 
Organisation for Economic Co-
operation and Development 
(11)  
The KPIs N/A 
Do the analyses and 
interpretation of the 
data describe and 
explain trends in 
individual and 
population outcomes? 
Review NT AHKPI community 
and health service area reports 
 
Community health centre report 
Regional health centre report available 
on the NT AHKPI website 
(http://www.nt.gov.au/health/ahkpi/) 
N/A 
Is this information 
disseminated in an 
appropriate and timely 
manner to the 
intended users 
responsible for taking 
action? 
 
Confirm with the steering 
committee who the 
information was intended to 
reach, and how the recipients 
were expected to use and act 
on the information 
Questionnaire to members of steering 
committee and CQI facilitators  
 
-Ask all steering committee members if 
they would like to participate either via 
email  
-CQI coordinators and facilitators 
(Contact PHC CEO to request 
permission to obtain contact details for 
the CQI coordinators) 
Interview health staff from 
PHC services across NT  
 
Send questionnaire electronically to all 
84 services  
Send questionnaire electronically to 
CQI facilitators  
All 84 services 
CQI coordinators and facilitators 
(Contact PHC CEO to request 
permission to contact & obtain contact 
details for CQI coordinator) 
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NT AHKPI 
objective 
Evaluation question Suggested method to answer 
questions 
Data sources People to interview 
Interview steering committee, 
AMSANT staff, NT DoH and 
Commonwealth Department 
of Health staff  
-Send questionnaire to members of 
steering committee and AMSANT.  
-Physically give questionnaire to 
Commonwealth DoH  
 
 
-Ask steering committee members who 
would like to take part in the 
evaluation 
-Contact Liz Moore (member of 
AMSANT) and ask for her advice on the 
best way to approach members of 
AMSANT 
-Questionnaire to Commonwealth 
Department of health staff 
-Review NT AHKPI documents 
and interview NTG data 
managers about data flow and 
feedback loops 
-Ask NTG data managers (Liana Riley 
and Daniel Atkins) directly 
-Liana Riley and Daniel Atkins 
2.To identify 
factors 
influencing 
these trends 
How do you explore 
variations you see in 
your NT AHKPIs over 
time? (e.g. explore 
other data sources 
such as work force data 
or speak to the 
community or staff) 
-Interview health staff from 
PHC  
-Interview steering committee, 
clinical reference group, 
AMSANT staff, NT DoH and 
Commonwealth Department 
of Health  
-Send questionnaire electronically to 
all 84 services  
-Send questionnaire to members of 
steering committee and AMSANT  
-Physically give questionnaire to 
Commonwealth DoH  
-All 84 services 
-Ask steering committee members who 
would like to take part in the 
evaluation 
-Contact Liz Moore (member of 
AMSANT) and ask for her advice on the 
best way to approach members of 
AMSANT 
-Questionnaire to identified 
Commonwealth Department of health 
staff 
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NT AHKPI 
objective 
Evaluation question Suggested method to answer 
questions 
Data sources People to interview 
Were the factors 
described in the NT 
AHKPI system 
documents and 
community and health 
service area reports? 
Review NT AHKPI documents 
and community health centre 
and health service delivery 
area reports 
-NTAHKPI documents listed at: 
http://www.nt.gov.au/health/ahkpi/ 
-Community health centre report 
-Regional health centre repor 
N/A 
3.To inform 
appropriate 
action, 
planning and 
policy 
development 
 
Once you have 
explored variations in 
your NT AHKPIs, how 
do you act on the 
findings to a) improve 
service performance b) 
to make future plans? 
 
-Interview health staff from 
PHC services across NT 
-Interview CQI facilitators and 
2 coordinators 
-Interview steering committee, 
clinical reference group, 
AMSANT staff, NT DoH and 
Commonwealth Department 
of Health to ask what these 
factors are and how they are 
collected 
 
 
-Send a questionnaire electronically to 
all services  
-Send questionnaire electronically to 
CQI facilitators  
-All 84 services 
-Contact PHC CEO and request 
permission to contact and obtain 
contact details for the CQI coordinator 
-Ask steering committee members who 
would like to take part in the 
evaluation 
-Contact Liz Moore (member of 
AMSANT) and ask for her advice on the 
best way to approach members of 
AMSANT 
-Give questionnaire to identified Give 
to identified Commonwealth 
Department of health staff 
 
Is there evidence that 
the NT AHKPIs have 
been used at the 
service for service 
planning, CQI and 
community feedback? 
 
Survey/interview CQI 
facilitators and 2 coordinators, 
steering committee, AMSs, 
AMSANT staff, NT DoH and 
Commonwealth Department 
of Health  
 
-Send questionnaire electronically to 
all services  
-Send questionnaire electronically to 
CQI facilitators  
-Send questionnaire to members of 
steering committee and AMSANT.  
-Physically give questionnaire to 
-All 84 services  
-Contact PHC CEO and request 
permission to contact and obtain 
contact details for the CQI coordinator 
-Contact Liz Moore (member of 
AMSANT) and ask for her advice on the 
best way to approach members of 
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NT AHKPI 
objective 
Evaluation question Suggested method to answer 
questions 
Data sources People to interview 
 
 
 
 
 
Case studies e.g. NT & 
Commonwealth Department 
of Health along with other 
stakeholders noticed that the 
anaemia KPI was high and 
remaining high. This prompted 
action from a variety of 
different groups to try to 
understand why this was 
happening and what can be 
done to try to fix this problem 
Commonwealth DoH  AMSANT 
-Ask steering committee members who 
would like to take part in the 
evaluation 
-Give questionnaire to identified 
Commonwealth Department of health 
staff 
Is there evidence that 
the NT AHKPIs have 
been used at a planning 
and policy? 
 
Survey/interview steering 
committee, AMSANT staff, NT 
DoH and Commonwealth 
Department of Health about 
how programs have 
responded.  
 
-Send questionnaire to members of 
steering committee, AMSANT, CRG, NT 
DoH  
-Physically give questionnaire to 
Commonwealth DoH  
-Contact Liz Moore (member of 
AMSANT) and ask for her advice on the 
best way to approach members of 
AMSANT 
-Ask steering committee members who 
would like to take part in the 
evaluation 
-Give questionnaire to identified 
Commonwealth Department of health 
staff 
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NT AHKPI 
objective 
Evaluation question Suggested method to answer 
questions 
Data sources People to interview 
What are the processes 
to transform 
information from the 
system into action, 
planning and policy 
development?  
 
 
Survey/interview steering 
committee, AMSANT staff, NT 
DoH and Commonwealth 
Department of Health 
 
-Send questionnaire to members of 
steering committee, AMSANT, NT DoH  
-Physically give questionnaire to 
Commonwealth DoH  
-Ask steering committee members who 
would like to take part in the 
evaluation 
-Contact Liz Moore to ask for her 
advice on the best way to approach 
members of AMSANT 
-Give to identified Commonwealth 
Department of health staff 
 What are the 
governance 
arrangements for the 
NT AHKPI system?  
 
 
-Could any changes to 
the governance 
arrangements support 
continuous 
improvement? 
Review NT AHKPI documents 
available on NTG website 
(http://www.nt.gov.au/health/
ahkpi/) for information on 
governance 
 
-Survey/interview steering 
committee, AMSANT staff NT 
DoH and Commonwealth 
Department  
 
-Review NT AHKPI documents available 
on NTG website 
(http://www.nt.gov.au/health/ahkpi/) 
-Send questionnaire to members of 
steering committee, AMSANT, NT DoH, 
CQI facilitators  
-Physically give questionnaire to 
Commonwealth DoH  
-Contact PHC CEO and request 
permission to contact and obtain 
contact details for the CQI coordinator 
-Contact Liz Moore to ask for her 
advice on the best way to approach 
members of AMSANT 
-Ask steering committee members who 
would like to take part in the 
evaluation 
-Give to identified Commonwealth 
Department of health staff 
To explore 
how else, the 
NT AHKPIs are 
used 
How do you or your 
service use the NT 
AHKPIs 
What value do you see 
to the NT AHKPIs? 
Interview health staff from 
PHC services across NT 
 
Send questionnaire electronically to all 
84 services  
 
All 84 services  
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Assessing the NT AHKPIs using criteria of the Organisation for Economic Co-operation and 
Development for evaluating KPIs 
I evaluated the individual KPIs using criteria recommended by the Organisation for 
Economic Co-operation and Development (OECD) for evaluating KPIs (Appendix 2). I 
modified the criteria by excluding the one criteria of ‘feasibility of obtaining 
internationally comparable data’ as it was not relevant for our evaluation.  
Questionnaires 
I developed two questionnaires in close collaboration with members of the steering 
committee and with staff in the Indigenous Health Division at the Australian 
Commonwealth Department of Health. One targeted to users of the KPIs at the PHC 
level and the other targeted to higher level planners such as steering committee 
members, and staff at NT DoH and AMSANT. I conducted the surveys using 
SurveyMonkey, a free online tool for creating online surveys (12). 
 
I first piloted the questionnaires for PHC planners with staff of one PHC service in the 
NT, to staff at NT DoH and AMSANT as well as to the higher level planners of NT DoH 
and AMSANT. 
 
After revising the questionnaires, I sent the survey-link to the Chief executive officer 
(CEO) of AMSANT for distribution to all CEOs of ACCHOs (n=32) and to a general 
manager at NT DoH for distribution to all CEOs of NT DoH services (n=52). The 
questionnaires and information provided to participants in survey monkey are shown in 
Appendices 3 to 6. 
 
To optimise participation rates, we tried to reach and inform more people about the 
evaluation through the Communicare newsletter (Appendix 7), and I presented the 
evaluation at the ‘CQI Collaborative Workshop’ in Darwin in the NT from 10 and 11 of 
November 2015 (Appendix 8). 
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Ethics 
I obtained ethics approvals from the following ethics committees and organisations: 
1. The Human Research Ethics Committee of the Northern Territory Department of 
Health and Menzies School of Health Research - HREC-2015-2357 
2. The Central Australian Human Research Ethics Committee -  HREC-15-300  
3. The Australian National University Human Research Ethics Committee - 
2015/324  
4. AMSANT 
5. NT DoH 
6. NT AHKPI steering committee 
 
I started the ethics approval process in March 2015 and received my final approval to 
proceed with the evaluation in September 2015. 
Analysis 
I provided descriptive summaries for the assessment of the KPIs using the OECD criteria, 
and descriptive summaries for the responses to both of the questionnaires.  
Findings 
Summary of assessment of the NT AHKPIs using the Organisation for Economic Co-
operation and Development criteria for evaluating KPIs  
 
In this section I describe the findings based on the OECD assessments of the individual 
indicators.  This is then followed by the individual assessments for each of the KPIs. 
Importance of what is being measured 
What is the impact on health and on health expenditure? 
With the exception of KPI 1 (which does not measure any specific disease outcomes), 
the other KPIs measure outcomes that have a negative impact on the health of 
Aboriginal and Torres Strait Islanders. For all disease areas measured, there is a gap 
between the actual and potential levels of achievable health. Moreover, all the disease 
areas measured, affect Aboriginal and Torres Strait Islanders disproportionately when 
compared with non-Indigenous Australians. 
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Are policy makers and consumers concerned about the disease? 
Policy makers and consumers were concerned of the disease condition related to all the 
KPIs. All disease areas (with the exception of KPI 1) are discussed in the Aboriginal and 
Torres Strait Islander Health Performance Framework1 (13).  
Can the health care system meaningfully address this disease area problem? 
All disease areas are part of the core functions to be addressed by Aboriginal Primary 
Health care services in the NT. Although each of these disease areas has their own 
unique challenges to delivery, they are also influenced by a range of social and 
environmental health determinants, many of which go beyond the domain traditionally 
covered by PHC services. While, the PHC system can contribute to addressing these 
disease areas, the environmental and social determinants of health must be addressed 
to improve health outcomes.  
Scientific soundness 
Validity: are the data telling the truth? 
Does the information collected measure what it is supposed to measure? (I.e. has the 
indicator been tested and validated to measure what it is intended to measure?) 
 
Each of the KPIs has its unique limitations (outlined in the next section of this chapter), 
but general limitations that apply to all the KPIs are as follows: 
1. Residents seeking treatment outside of the local PHC service will not be included 
in these KPIs for that service. 
2. The data reflect only what has been documented in the electronic patient 
record. The KPIs rely on correct information being entered into the electronic 
database and being correctly extracted by the NT DoH warehouse. If a client is 
not entered into the system, they will not be captured in the KPIs. If a health 
worker enters incorrect results into the system, this will bias assessment of 
indicators. 
                                                 
1 The Aboriginal and Torres Strait Islander Health Performance Framework was developed to support a 
coordinated approach to address the complex factors that contribute to the poor health outcomes of 
Aboriginal and Torres Strait Islander Australians. The report is considered the evidence base for Aboriginal 
and Torres Strait Islander health policy. http://www.health.gov.au/indigenous-hpf 
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3. If there are uncertainties on the total number of residents in the community 
(the denominator population), results of KPIs based on estimates of proportions 
will be biased.  
Do the results fall within a plausible range? 
For KPI 7 - one service reported numerators of resident clients on a chronic disease 
management plan that exceeded the denominator population yielding proportions for 
that service of 108% in 2010 and 128% in 2011. All other calculated proportions for the 
remaining KPIs and PHC services were within plausible ranges (0% and 100%). 
Is there reasonable assurance that the data recording (into electronic medical record) 
and subsequent collection (of aggregate data using appropriate software) methods 
being used do not produce consistently over-counting or under-counting? 
Systematic checks of the data are performed once the data reach the NT DoH 
warehouse. If the data do not meet the rules [outlined in the Data Receiving Protocol 
(DRP)] (5), the submission of the data fails and a violation report is sent to the AHKPI 
team who then contacts the PHC service to investigate the problem. Once the data are 
submitted (and meets the DRP rules) an initial report is generated, spot checked for 
errors and compared to previous reports at the NT DoH warehouse. If errors are 
detected, the PHC service is requested to resubmit data and reports are re-generated 
and checked again. Acceptable reports are sent out to the PHC services once more to 
comment on data quality; if the services detect errors at this point, the services are 
encouraged to contact the AHKPI team to arrange for re-submission of the data. These 
system checks do not identify incomplete data or all data entry errors as described in 
the previous section. 
 
These system checks also do not assess the variability of different testing devices (such 
as the HemoCue that measures levels of haemoglobin to screen for anaemia) used in 
different PHC services and whether these testing devices have been standardised 
regularly and/or stored appropriately.  
 
Double counting of clients is also an issue for ACCHOs that use the Communicare 
patient information system but not for NT DoH PHC patients because their electronic 
information systems are linked. Someone who has attended a NT DoH service may also 
Chapter 3 
 
3-22 
 
be counted in an ACCHO service, and there may also be double counting of clients 
between ACCHOs.  
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the data collection methods for measuring, calculating or recording this KPI 
changed over time? 
Yes, all KPIs have had some changes since the system was implemented. KPIs 3, 4.2 and 
13 have had minor changes that are unlikely to affect comparisons over time.  
 
The other KPIs (1, 2, 5 - 12, 14) have had major changes to either of the definitions of 
the numerator and/or denominator and therefore direct comparisons between years 
should be made with caution. 
How complete are the data? 
Overall, the completeness of the data has improved since the system was first 
implemented.  In 2010, all KPIs had at least one PHC service (range 1 to 4 PHC services) 
that didn’t report any data (numerator and denominator) data. In 2011, 11/12 KPIs had 
at least one PHC service that did not report any data (range 1 to 5 PHC services). In 
2012, all services reported on all of the KPIs. In 2013, at least one PHC service did not 
report any data for 3 out of the 15 KPIs, and in 2014 at least one PHC service (range 1 to 
8 PHC services) did not report on 4 out of the 16 KPIs (Table 3). 
 
The KPIs for all reporting years had at least one numerator cell that was left blank 
(details shown under the individual KPI assessments). One KPI had up to 78 blank 
numerator cells (KPI 11). Because zero reporting is not used in the NT AHKPI reporting 
system, blank cells could imply either missing data or a zero.  
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Table 3: The number of PHC services that did not report data (numerator and 
denominator data) by KPI and reporting year 
KPI 2010 2011 2012 2013 2014 
1 2 1 0 0 0 
2 4 3 0 2 2 
3 4 2 0 2 2 
4.1 3 2 0 0 0 
4.2 N/A N/A N/A 2 3 
5 2 5 0 0 0 
6 2 5 0 0 0 
7 1 1 0 0 0 
8.1 2 1 0 0 0 
8.2 N/A N/A N/A 0 0 
9 2 1 0 0 0 
10 1 1 0 0 0 
11 1 1 0 0 0 
12 1 0 0 0 0 
13 N/A N/A N/A N/A 0 
14 N/A N/A N/A 13 8 
*N/A means data were not collected for these KPIs during that reporting year 
 
Are the data collection and analysis methods documented in writing and being used to 
ensure the same procedures are followed each time? 
Yes, all the data collection and analysis methods are documented for all KPIs in 
‘Northern Territory Aboriginal Health Key Performance Indicators System: Data 
Receiving Protocol, October 2013, Version 2.05’ (5). 
Is there scientific evidence available to support the measure? 
The following KPIs have been recommended by EURO-PERISTAT and/or WHO, or are 
internationally recognised, or there is evidence to support the measure: 
1. KPI 2 - timing of first antenatal visit; 
2. KPI 3 - proportion of low birth weight infants; 
3. KPI 4.1 and 4.2 – proportion of children fully immunised and who are immunised 
on time; 
4. KPI 5 - proportion of children < 5 years who are underweight;  
5. KPI 6 - proportion of children who are anaemic; and 
6. KPI 7 - proportion of clients with type 2 diabetes and/or coronary heart disease 
and who have a chronic disease management plan 
7. KPI 12 – proportion of women who have had at least one Pap smear test. 
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8. KPI 14 - proportion of clients with ARF /RHD who are prescribed to be requiring 
2-4 weekly BPG penicillin prophylaxis and have received injections 
 
Although there is scientific evidence to support these, KPIs 3, 5, and 6 are highly 
influenced by a range of socioeconomic and environmental factors that are beyond the 
domain of PHC services and therefore are not good indicators of service performance.  
 
The following KPIs measure only whether someone has been tested / screened for an 
abnormality, but no data are recorded on the action and quality of care provided 
following if an abnormality was detected.  
1. KPI 8.1 – proportion of clients who have had an HbA1c test; 
2. KPI 8.2 – proportion of clients whose HbA1c levels are within certain levels 
3. KPI 9 – proportion of diabetic patients with albuminuria who are on ACE/and or 
ARB; 
4. KPIs 10 and 11 – proportion of clients who had a full adult check; 
5. KPI 12 – proportion of women who had at least one pap smear test; and 
6. KPI 13 – proportion of clients who have type 2 diabetes and have good blood 
pressure control. 
 
KPI 1 monitors only the workload for a PHC service and can be used for planning and 
resource allocation. It does not measure the content or quality of the services provided. 
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Individual KPI assessments 
KPI 1 - ‘Number of episodes of health care and client contacts’ (10) 
Rationale 
‘Measures the uptake of the service as well as equity in access to health services between health 
centres within a Health Service Delivery Area’ (10). 
 
Definition 
1. ‘Episode: An ‘episode of care’ is contact between an individual client and a service by 
one or more staff to provide health care. For example, an episode of care that is 
provided for a client’s sickness, injury, counselling, health education, screening, or other 
health related issues. An episode of care begins when a client visits a health service to 
receive health care. A client may be seen by an Aboriginal Health Worker, and/or a 
Nurse and/or a GP during an episode of care. This represents one episode of care. If this 
client comes back another day, this is a second episode care. In NT AHKPI, an episode of 
health care includes: 
a. episodes of health care delivered over the phone 
b. episodes of residential care 
 
2. Client contact: The numbers of health professionals who have contact with a client 
during an episode of health care. For example, if a client saw three different health 
professionals, Aboriginal Health Worker, and a Nurse and a GP in an episode of care, 
this would equal three client contacts. Telephone consultation: are clinical consultations 
that are to do with client clinical advice and result in a dated entry being made in the 
client health record’ (10). 
 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
This indicator provides information only on volume of care 
provided by the PHC service.  
 
In 2011-2012, the second largest component of health 
spending in Australia was for PHC services - $50.6 billion or 
36.1% of total health expenditure (14). 
 
Are policy makers and 
consumers concerned about 
the disease? 
Not applicable because this indicator does not measure any 
specific diseases. 
Can the health care system 
meaningfully address this 
disease area problem? 
Not applicable because this indicator does not measure any 
specific diseases. 
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Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been 
tested and validated to 
measure what it is intended 
to measure?) 
Yes, this indicator measures what it is supposed to measure 
- how many client contacts and episodes of care have 
occurred within the reporting period.  
 
Do the results fall within a 
plausible range? 
Using 2010 to 2014 NT AHKPI data, the range reported from 
PHC services for: 
 episodes of care: 314 to 892,202 
 clients contacts:  367 to 112,033 
Is there reasonable 
assurance that the data 
recording (into electronic 
medical record) and 
subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all episodes of 
care and client 
contacts captured 
by the PHC 
service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation.  
 
This KPI won’t identify residents who 
seek care outside of the PHC service.  
 
If there are uncertainties surrounding 
the total number of residents in the 
community, the coverage rates will 
also be uncertain. This may be an issue 
in areas where there are transient 
groups.  
These limitations apply to all of the 
KPIs. 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. If the data do not 
meet the rules [outlined in the Data 
Receiving Protocol (DRP)] (5), the 
submission of the data fails and a 
violation report is sent to the AHKPI 
team who then contacts the PHC 
service to investigate the problem. 
Once the data are submitted (and 
meets the DRP rules) an initial report is 
generated, spot checked for errors and 
compared to previous reports at the 
NT DoH warehouse. If errors are picked 
up, the community health centre is 
requested to resubmit data and 
reports are re-generated and checked 
again. 
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When the reports are acceptable, they 
are sent out to the community health 
services once more to comment on 
data quality, if the communities pick 
up errors at this point here the 
communities are encouraged to 
contact the AHKPI team to arrange for 
re-submission of the data and the data 
would go through the same checking 
process again. 
 
These system checks will not identify 
incomplete data (e.g. a resident who 
attends the service to be tested, 
screened and/or treated but who is not 
recorded into the system by the 
healthcare worker.  
 
These system checks also won’t 
identify all incorrect data entries. They 
may pick up on obvious errors where 
the numerators and/or denominators 
fall outside of plausible ranges but they 
will not pick up on all errors.  
These systematic checks and 
limitations apply to all of the KPIs. 
Although not applicable to this KPI, 
these system checks will not assess the 
variability of different testing devices 
used in different PHC services and 
whether these testing devices have 
been standardised regularly and/or 
stored appropriately. This limitation 
only applies to KPIs that require testing 
devices such as the HemoCue for the 
KPI 6 (proportion of children tested for 
anaemia and who are anaemic). 
Were both 
numerators and 
denominators 
correct?   
From 2009 to 2013, this indicator 
refers only to numerator data without 
any reference to denominators.   
It is not possible to determine whether 
the number of episodes of care, or 
client contacts are correct without 
cross referencing with other datasets. 
This limitation applies to all of the KPIs. 
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Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the data 
collection 
methods for 
measuring, 
calculating or 
recording this KPI 
changed over 
time? 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change: Added age groupings 
disaggregation. 
Calculation -Level/unit of counting 
From: (Undefined) 
To: The number of episodes for health 
care clients who were aged 
a) 0-4 years 
b) 5-14 years 
c) 15-24 years 
d) 25-44 years 
e) 45-64 years 
f) 65 years and over 
Change: Specified period to include 
calendar year 
Calculation - Specified period 
From: Financial year 
To: Financial year or Calendar year.’ 
2013 March 2.0.2 No changes made. 
2013 Sept 2.0.3 ‘Change: Add population denominator to 
allow for calculation of ratio of episodes of 
health care to population  
Description: inclusion of a population 
denominator  
From: Numerator  
1. The number of episodes of health care 
during reporting period.  
2. The number of client contacts during 
reporting period.  
Denominator  
Not applicable.  
To: Numerator  
1. The number of episodes of health care 
during reporting period.  
2. The ratio of episodes of health care to 
population during reporting period.  
3. The number of client contacts during 
reporting period.  
Denominator  
1. The population count as at the end of the 
reporting period.  
From: Level/unit of counting  
1. Episode of care and population will be 
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disaggregated by:  
a. sex  
b. age group  
c. Indigenous status  
d. residential status  
e. locality  
2. Client’s ages are calculated according to 
the date of the episode of care.  
3. Client’s residential statuses are 
determined according to the date of the 
episode of care.  
Counting rules—inclusions, exclusions  
a. Include episodes of care and client 
contact for both community residents and 
visitors and out-of-hours service contacts.  
b. Excludes group contacts e.g. antenatal 
classes, men’s groups etc. To:  
To: Level/unit of counting  
1. Episode of care will be disaggregated by:  
a. sex  
b. age group  
c. Indigenous status  
d. residential status  
e. locality  
2. Client’s ages are calculated according to 
the date of the episode of care.  
3. Population ages are calculated according 
to the end of the reporting period.  
4. Client’s residential statuses are 
determined according to the date of the 
episode of care.  
Counting rules—inclusions, exclusions  
a. Include episodes of care and client 
contact for both community residents and 
visitors and out-of-hours service contacts.  
b. Include live population count as at the 
end of the reporting period.  
Excludes group contacts e.g. antenatal 
classes, men’s groups etc.’ 
2014 April 2.0.4 ‘Change: Add population denominator to 
allow for calculation of ratio of episodes of 
health care to population 
Description: Denominator segment to allow 
for health care provided ratio. 
From: Numerator 
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a. The number of episodes of health care 
during reporting period. 
b. The number of client contacts during 
reporting period. 
To: The calculation includes episodes of 
health care provided ratio: 
Episodes of health care provided ratio: 
Number of episodes of health care provided 
to residents / Total resident population. 
Numerator 
a. The number of episodes of health care 
during reporting period. 
b. The number of client contacts during 
reporting period. 
Denominator 
a. The resident population count as at the 
end of the reporting period. 
Level/unit of counting 
1. Episode of care and population will be 
disaggregated by: 
a. sex 
b. age group 
c. Indigenous status 
d. residential status 
e. locality 
2. Client’s ages are calculated according to 
the date of the episode of care. 
3. Population ages are calculated according 
to the end of the reporting period. 
4. Client’s residential statuses are 
determined according to the date of the 
episode of care.' 
 
2014 Oct 2.0.7 No changes made. 
 
How complete are 
the data? 
 
Calendar 
Year 
Missing data 
2010 -2 PHC services missing all data fields 
2011 -1 PHC service missing all data fields 
2012 -No missing data 
2013 -No missing data 
2014 -No missing data 
 
Are the data 
collection and 
analysis methods 
documented in 
Yes, all data collection methods and analysis methods are 
documented for all of the KPIs in ‘Northern Territory Aboriginal Health 
Key Performance Indicators System: Data Receiving Protocol, October 
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writing and being 
used to ensure the 
same procedures 
are followed each 
time? 
2013, Version 2.05’ available at: http://www.nt.gov.au/health/ahkpi/ 
(2).  
Is there scientific 
evidence available 
to support the 
measure? 
This indicator monitors workload for a PHC service and can be used 
for PHC service planning and resource allocation. It does not measure 
the content or quality of the services provided. 
 
 
 
KPI 2 - ‘Timing of first antenatal visit for regular clients delivering Indigenous babies’ 
 
Rationale 
‘The aim of the antenatal care is to maximise the health outcomes of the mother and the baby. It 
aims to identify and manage risk factors or complications early, and to monitor progress with 
information and support during pregnancy’ (10). 
 
Definition 
‘The number and proportion of regular clients who are residents, who gave birth to Indigenous 
babies during reporting period and who attended first antenatal visit (at any health service 
locality) before 13 weeks’ gestation, disaggregated by age group, Indigenous status and locality. 
And the number and proportion of regular clients who are residents, who gave birth to 
Indigenous babies during reporting period and who attended first antenatal visit (at any health 
service locality) after 13 weeks (including 13 week) and before 20 weeks’ gestation, 
disaggregated by age group, Indigenous status and locality.  
 
Indigenous baby: 
Indigenous baby is a baby with at least one parent who identifies as Indigenous (born to mothers 
who are either Indigenous or non-Indigenous) 
 
First antenatal visit: 
The guidelines of a ‘first antenatal visit’ are below: 
1. Blood Pressure test 
2. Order mid-stream urine for microscopy, culture and sensitivities. 
3. Order blood group and antibody test.’ 
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Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
There is an association between inadequate and late access to 
antenatal care services and increased risk of poor pregnancy 
outcomes such as stillbirths, perinatal deaths, foetal growth 
retardation, low birth weight and pre-term births (15).  
 
Between 30% and 50% of maternal deaths occur as a result of 
inadequate care during pregnancy (16). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes. Antenatal care is an indicator in the National 
Indigenous Reform Agreement (17), with improved access 
to antenatal care being a focus of the agreement. 
(18). 
 
Australian Governments are investing in a range of 
initiatives to improve access to antenatal care and 
preventive health practices (13). 
Can the health care system 
meaningfully address this 
disease area problem? 
Yes. Antenatal care is one of the core functions of 
Aboriginal Comprehensive Primary Health Care (3). 
Although there are challenges to delivery, the provision of 
physically accessible and culturally appropriate services, and 
the availability of transport influence whether pregnant 
women accesses antenatal care. Educational, socio-
economic and financial issues also influence attendance (19, 
20).  An audit of antenatal services in Western Australia 
reported that 75% of services did not provide culturally 
appropriate models of care (21).  
 
This is an indicator of access to antenatal care which is 
influenced by not only the physical presence of PHC services 
but also the social conditions of the mother (22). 
 
 
Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
This is an indicator that has been recommended and 
validated by EURO-PERISTAT through a standardised list of 
perinatal indicators developed by an expert panel (23). The 
goal of this panel is to develop valid and reliable indicators 
that can be used to monitor and evaluate perinatal health in 
the European Union (24). 
 
This indicator measures access to care but it does not 
provide any information on the content or quality of the 
antenatal care services. 
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Standard uncertainties around the KPI being able to 
measure/detect the disease condition are detailed under 
KPI 1. 
Do the results fall within a 
plausible range? 
Yes. Using 2010 to 2014 NT AHKPI data the observed ranges 
were: 
 Antenatal visit < 13 weeks = 1% to 98% 
 Antenatal visit ≥ 13 weeks < 20 weeks = 1% to 86% 
 Antenatal visit ≥ 20 weeks = 1% to 93% 
 Not recorded = 1% to 44% 
 Did not visit = 1% to 35% 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all pregnant 
mothers in the 
community 
captured at the 
PHC service? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
 
Were both 
numerators and 
denominators 
correct?   
Yes - all numerators and denominators 
fell into plausible ranges: 
Year Do numerators add up to 
denominator? 
2010 Yes 
2011 Yes 
2012 Yes 
2013 Yes 
2014 Yes 
Numerator:  
‘The number of resident women aged: 
a. less than 20 
b. 20-34 years 
c. 35 years and over 
and who attended first antenatal visit: 
a. before 13 weeks’ gestation 
b. at 13 weeks or after, but before 20 
weeks 
c. at or after 20 weeks of pregnancy 
d. did not attend an antenatal visit 
e. not recorded whether attended an 
antenatal visit 
and who are: 
a. Indigenous 
b. non-Indigenous 
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and who gave birth to Indigenous 
babies during the reporting period.’ 
 
Denominator: 
‘The number of resident women aged: 
a. less than 20 
b. 20-34 years 
c. 35 years and over 
and who gave birth to an Indigenous 
baby during the reporting period.’ 
 
 
It is not mentioned what happens if a 
woman has an abortion or 
miscarriages. 
 
 
 
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the 
data 
collection 
methods for 
measuring, 
calculating or 
recording 
this KPI 
changed over 
time? 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 Specified to have had first antenatal care at 
any health service locality  
2013 March 2.0.2 Updated definition of a ‘first antenatal visit’ 
from: 
- The definition of a ‘first antenatal visit’ is the 
clinical assessment according to the ‘Women’s 
Business Manual’ 
to: 
- the date all three of the following tests are 
conducted:  
 
1. Blood Pressure Test 
2. Mid-stream urine for microscopy, culture 
and sensitives 
3. Order blood group and antibody test 
2013 Sept 2.0.3 Updated definition of a ‘first antenatal visit’ 
from:  
- the date all three of the follow tests are 
conducted: 
1. Blood pressure test 
2. Mid-stream urine microscopy, culture and 
sensitivities 
3. Order blood group and antibody test 
to: 
-the guidelines of a ‘first antenatal visit’ 
below: 
1. Blood Pressure Test 
Chapter 3 
 
3-35 
 
2. Order mid-stream urine for microscopy, 
culture and sensitives,  
3. Order blood group and antibody test  
2014 April 2.0.4 No changes made  
2014 Oct 2.0.7 No changes made 
 
How 
complete are 
the data? 
Year Missing data 
2010 -4 PHC services missing all data fields 
-No missing data for remaining PHC services 
-Zero reporting not used for numerator data -  unclear 
whether blank cells were omissions or intended to be a zero 
2011 -3 PHC services missing all data fields 
-No missing data for remaining PHC services 
-Zero reporting not used for numerator data -  unclear 
whether blank cells were omissions or intended to be a zero 
2012 -0 PHC services missing all data fields 
-Zero reporting not used for numerator data -  unclear 
whether blank cells were omissions or intended to be a zero 
2013 -2 PHC services missing all data fields 
-No missing data for remaining PHC services 
-Zero reporting not used for numerator data -  unclear 
whether blank cells were omissions or intended to be a zero 
2014 -2 PHC services missing all data fields 
-No missing data for remaining PHC services 
-Zero reporting not used for numerator data -  unclear 
whether blank cells were omissions or intended to be a zero 
 
Are the data 
collection 
and analysis 
methods 
documented 
in writing and 
being used to 
ensure the 
same 
procedures 
are followed 
each time? 
Yes. See details under KPI 1. 
Is there 
scientific 
evidence 
available to 
support the 
measure? 
This indicator is among those recommended by EURO-PERISTAT (25). 
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KPI 3 - ‘Number and proportion of low, normal and high birth weight Indigenous babies’ 
Rationale 
‘The birth weight of an infant is a principle determinant of their chances of survival and good 
health. Low birth weight is a risk factor for neurological and physical anomalies, the risk of 
adverse outcomes increasing with decreasing birth weight. Low birth weight may be an indicator 
of inadequate foetal growth, resulting from pre-term birth or foetal growth restriction or both. 
Low birth weight is one of the major determinants of perinatal mortality. Infants weighing less 
than 2,500 grams are almost 40 times more likely to die within the first 28 days than of infants 
of normal birth weight.’  
The Northern Territory has the highest incidence of low birth weight in Australia. Mothers less 
than 20 years old had the highest occurrence and the incidence of low birth weight babies 
amongst Indigenous mothers, almost twice the rate of non-Indigenous mothers’ (10). 
 
Definition 
‘The number and proportion of low, normal and high birth weight Indigenous babies who were 
live born during the reporting period and who were born to resident mothers, which are 
disaggregated by birth weight group, mother’s Indigenous status, mother’s age group and 
mother’s locality. 
 
Indigenous baby 
Indigenous baby is a baby with at least one parent who identifies as Indigenous (born to mothers 
who are both Indigenous or non-Indigenous) 
 
Birth weight 
Birth weight is the first weight of the baby obtained after birth (National Health Data 
Dictionary). 
Low, normal and high birth weights are less than 2,500 grams (World Health Organisation), 
between 2500 to 4499 grams, and 4500 grams and over respectively’ (10). 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
Low birth weight increases an infant’s risk of: 
1.  dying during the first year of life 
2. neurological and physical disabilities 
3. developing a wide range of illnesses childhood and 
adulthood such as type 2 diabetes, high blood pressure and 
mortality from cardiovascular and renal diseases in    
adulthood and pulmonary causes in childhood (26, 27).  
Low birth weight in babies is twice as common among babies 
born to Aboriginal and Torres Strait Islander mothers compared 
to those with non-Indigenous mothers (13% compared to 6%)  
(13). 
The mean birth weight of newborn infants in a certain area is 
indicative of the quality of maternal and child health care 
services and the degree of socioeconomic development of that 
particular area  (28). 
 
Are policy makers and 
consumers concerned about 
the disease? 
Yes - Australian governments have invested in a range of 
initiatives aimed at improving child health. In October 2008, 
COAG agreed to the National Partnership Agreement on 
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Indigenous Early Childhood Development with joint funding 
$564 million over six years. This includes: 
1. Support for 85 New Directions: Mothers and Babies 
Services which provide ATSI families with access to antenatal 
care; practical advice and assistance with parenting, and health 
checks for children. 
2. Health for Life programme which aims is to improve 
access to antenatal, postnatal and child health care. This 
program aims to improve pregnancy, birth and child health 
outcomes (including birth weight) (13). 
Can the health care system 
meaningfully address this 
disease area problem? 
Yes, with targeted programmes: 
1. Analysis of the perinatal dataset show that an increase in 
antenatal visits is associated with a decreased likelihood of 
low birth weight. 
2. Research also shows that appropriate antenatal care and 
a health environment for the mother can improve the 
chances that a baby will have a healthy weight 
3. Improvements in health services such as antenatal and 
acute care for pregnant women are important to reduce the 
occurrence of pre-term delivery and to improve foetal 
growth during pregnancy. 
4. Data from the Healthy for Life Program show that there 
has been a decline in the proportion of low birth weight 
Indigenous babies in the program and an increase in the 
number and proportion of Indigenous women who made an 
antenatal visit before 13 weeks of pregnancy. 
 
Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
The low birth weight rate is the most commonly used indicator 
to make comparisons across populations. However, this KPI has 
the following limitations: 
1. Most infants in the NT are weighed at the hospital – 
information could be missing on the discharge 
summary or not all of the information could be getting 
transcribed from the discharge summary from the 
hospital to the PHC database. 
2. the <2500g definition does not include small for 
gestational age and severely small for gestational age 
newborns, whose birth weight is between the 10th 
percentile and the 2500g threshold 
3. ‘2500g cut-off selects a very complex group of: a) Term 
small for gestational age and severely small for 
gestational age newborns (more than 2 or even 3 SD of 
Chapter 3 
 
3-38 
 
the standard); b) Preterm small for gestational age and 
severely small for gestational age newborns; c) Preterm 
newborns that are appropriately grown for gestational 
age (AGA) with a lower perinatal risk, i.e. ‘late preterm’, 
and d) even a small group of Term AGA newborns. 
These four phenotypes have very different morbidity 
and mortality rates and long-term outcomes, requiring 
different preventive and therapeutic interventions. The 
relative contribution of each phenotype to the total 
incidence of low birth weight also varies according to 
the population, just as the contribution of multiple 
pregnancies (close to 15% of all low birth weight) varies 
according to these phenotypes’ (29). 
Do the results fall within a 
plausible range? 
Using 2010 to 2014 NT AHKPI data the range reported from 
PHC services for: 
 Low birth weight babies = 0% to 100% 
 Normal birth weight babies = 0% to 100% 
 High birth = 0% to 100% 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all Aboriginal 
and Torres Strait 
Islander babies in 
the community 
captured at the PHC 
service database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
 
Were both 
numerators and 
denominators 
correct?   
Yes - all numerators and denominators 
fell into plausible ranges: 
 
Year Do numerators add up to 
denominator? 
2010 Yes 
2011 Yes 
2012 Yes 
2013 Yes 
2014 Yes 
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Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the data 
collection methods 
for measuring, 
calculating or 
recording this KPI 
changed over time? 
 
Definition version Changes made as written in the NT 
AHKPI Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change: Specified period to include 
calendar year 
Calculation - Specified period 
From: 
Financial year 
To: 
Financial year or Calendar year.’ 
2013 March 2.0.2 No changes made 
2013 Sept 2.0.3 No changes made 
2014 April 2.0.4 No changes made 
2014 Oct 2.0.7 No changes made 
 
How complete are 
the data? 
 
Calendar 
Year 
Missing data 
Low birth 
weight 
Normal birth 
weight 
High birth weight 
2010 -4 PHC services 
missing all data 
fields 
-blank 
numerator cells 
for 29 services  
-No missing 
data for 
remaining PHC 
services 
-4 PHC services 
missing all data 
fields 
- blank 
numerator cells 
for 2 services 
-No missing data 
for remaining 
PHC services 
-4 PHC services 
missing all data 
fields 
- blank numerator 
cells for 71 
services 
-No missing data 
for remaining PHC 
services 
2011 -2 PHC services 
missing all data 
fields 
- blank 
numerator cells 
for 35 services  
-No missing 
data for 
remaining PHC 
services 
-2 PHC services 
missing all data 
fields 
- blank 
numerator cells 
for 2 services 
-No missing data 
for remaining 
PHC services 
 
 
-2 PHC services 
missing all data 
fields 
- blank numerator 
cells for 67 
services 
-No missing data 
for remaining PHC 
services 
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2012 -0 PHC services 
missing all data 
fields 
-blank 
numerator cells 
for 41 services  
-No missing 
data for 
remaining PHC 
services 
-0 PHC services 
missing all data 
fields 
-blank 
numerator cells 
for 0 services  
-No missing data 
for remaining 
PHC services 
 
 
-0 PHC services 
missing all data 
fields 
-blank numerator 
cells for 73 
services 
-No missing data 
for remaining PHC 
services 
  
 
2013 -2 PHC services 
missing all data 
fields 
-blank 
numerator cells 
for 35 services  
-No missing 
data for 
remaining PHC 
services 
-2 PHC services 
missing all data 
fields 
-blank 
numerator cells 
for 1 services  
-No missing data 
for remaining 
PHC services 
-No missing data 
for remaining 
PHC services 
-2 PHC services 
missing all data 
fields 
-blank numerator 
cells for 71 
services 
-No missing data 
for remaining PHC 
services 
-No missing data 
for remaining PHC 
services 
2014 -1 PHC service 
missing all data 
fields 
-blank 
numerator cells 
for 40 services 
-No missing 
data for 
remaining PHC 
services 
-1 PHC service 
missing all data 
fields 
-blank 
numerator cells 
for 1 service 
-No missing data 
for remaining 
PHC services 
 
 
-1 PHC service 
missing all data 
fields 
-blank numerator 
cells for 72 
services 
-No missing data 
for remaining PHC 
services 
 
 
 
 
Are the data 
collection and 
analysis methods 
documented in 
writing and being 
used to ensure the 
same procedures 
are followed each 
time? 
Yes. See details under KPI 1. 
Is there scientific 
evidence available 
to support the 
measure? 
Low birth weight is used as an indicator of child health internationally 
(30, 31). 
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KPI 4.1 - ‘Number and proportion of Indigenous children fully immunised at 1, 2 and 6 
years of age’ 
Rationale 
‘Immunisation is a highly cost effective intervention in reducing morbidity and mortality rates in 
vaccine preventable diseases. Health system effectiveness in providing vaccination services can 
be measured by vaccination coverage at key milestones (12 and 24 months of age)’ (32). 
Definition ‘Proportion of resident Indigenous children who are: 
1. 6 months to less than 1 year 
2. year to less than 2 years 
3. 2 years to less than 6 years. 
and who have received all age appropriate immunisations as per the NT immunisation schedule’ 
(10). 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
Since the introduction of childhood vaccinations, deaths 
from vaccine-preventable diseases in Australia have fallen 
by 99%. It is estimated that vaccinations have saved 
approximately 
78,000 lives (33) and have reduced the disparities in 
diseases between Indigenous and non-Indigenous 
populations (34). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes. There are a range of Government funded immunisation 
programs: 
- the National Immunisation Program (provides free 
childhood vaccines to eligible Australians);  
- the National Human Papillomavirus (HPV) 
vaccination program. 
The Australian Government has provided facilitation 
incentive payments to state and territory government 
through the National Partnership Agreement on Essential 
Vaccines (NPEV) since 2009 (13). 
Can the health care system 
meaningfully address this 
disease area problem? 
Yes, immunisations are one of the core functions of 
Aboriginal Comprehensive Primary Health Care (3). The level 
of immunisation coverage is reflective of the strength and 
effectiveness of primary health care (13). 
Vaccination coverage is generally high for Aboriginal and 
Torres Strait Islander children. In December 2013, the 
national vaccination coverage for Aboriginal and Torres 
Strait Islander children aged 1 year was 86%, 91.4% for 
children aged 2 years, and 92.8% for children aged 5 years, 
with the highest coverage rates reported in the NT  (13). 
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Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Standard uncertainties around the KPI being able to 
measure/detect the disease condition are detailed under 
KPI 1. 
Do the results fall within a 
plausible range? 
Using 2010 to 2014 NT AHKPI data the observed ranges 
were: 
 6 months to < 1 year = 0% - 100% 
 1 year to ≤ 2 years = 0% - 100% 
 2 years to < 6 years = 0% - 100% 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all children 
within the 
specified age 
groups in the 
community 
captured by the 
PHC service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
Were both 
numerators and 
denominators 
correct?   
Yes - all numerators and denominators 
fell into plausible ranges: 
Year Do numerators add up to 
denominator? 
2010 Yes 
2011 Yes 
2012 Yes 
2013 Yes 
2014 Yes 
 
Numerator:  
‘1. The number of resident children 
aged 6 months to less than 1 year. 
2. The number of resident children 
aged 1 year to less than 2 years. 
3. The number of resident children 
aged 2 years to less than 6 years and 
who have received all age appropriate 
immunisations as per the NT 
immunisation schedule as at the end of 
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the reporting period.’ 
 
Denominator: 
‘1. The number of resident children 
aged 6 months to less than 1 year. 
The number of resident children aged 1 
year to < 2 years. 
The number of resident children aged 2 
years to < 6 years as at the end of the 
reporting period.’ 
 
 
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the 
data 
collection 
methods for 
measuring, 
calculating 
or recording 
this KPI 
changed 
over time? 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change: specified period to include calendar 
year 
Calculation – Specified period 
From: Financial year 
To: Financial year or Calendar year.’ 
2013 March 2.0.2 No changes made 
2013 Sept 2.0.3 ‘Change: Update definition 
Description: Updated definition of fully 
immunised 
From: Proportion of resident Indigenous 
children who are: 
1. 6 months to less than 1 year 
2. 1 year to less than 2 years 
3. 2 years to less than 6 years 
and who are fully immunised according to the 
National Reporting Standard. 
 To: Proportion of resident Indigenous children 
who are: 
1. 6 months to less than 1 year 
2. 1 year to less than 2 years 
3. 2 years to less than 6 years 
and who have received all age appropriate 
immunisations as per the NT immunisation 
schedule.’ 
2014 April 2.0.4 ‘Change: Re-number KPI 
Description: Renumber KPI 1.4 to 1.4.1 
From: AHKPI 1.4 Fully immunised children 
To: AHKPI 1.4.1 Fully immunised Children.’ 
2014 Oct 2.0.7 No changes made 
 
 
 
 
How 
complete 
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are the 
data? 
Year Missing data 
2010 - 3 PHC services missing all data fields 
- Zero reporting not used so can’t be certain if there are 
missing data for 5 PHC services that have blank cells for 
- No missing data for remaining PHC services 
2011 - 2 PHC services missing all data fields 
- Zero reporting not used so can’t be certain if there are 
missing data for 9 PHC services that have blank cells for 
-No missing data for remaining PHC services 
2012 - Zero reporting not used so can’t be certain if there are 
missing data fields for 10 PHC services that have blank cells 
for 
- No missing data for remaining PHC services 
2013 - Zero reporting not used so can’t be certain if there are 
missing data fields for 10 PHC services that have blank cells 
for 
- No missing data for remaining PHC services 
2014 - Zero reporting not used so can’t be certain if there are 
missing data fields for 6 PHC services that have blank cells for 
- No missing data for remaining PHC services 
 
Are the data 
collection 
and analysis 
methods 
documented 
in writing 
and being 
used to 
ensure the 
same 
procedures 
are followed 
each time? 
Yes. See details under KPI 1. 
Is there 
scientific 
evidence 
available to 
support the 
measure? 
It is an indicator used by the Australian Government to measure 
performance against the National Health Performance Framework (NHPF). 
There is a slight difference between the indicators however, with regard to 
the last age group category – the NT AHKPI reports for children aged 2 to < 6 
years, whereas the NHPF indicator reports for children aged < 5 years (35).  
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KPI 4.2 - ‘Number and proportion of children who have received immunisations on time’ 
Rationale: ‘This indicator will assess immunisation timeliness in children less than twelve months 
using a more stringent definition of fully immunised than the existing NTAHF immunisation 
indicator. This indicator will thus provide additional information which will assist with improving 
immunisation timeliness in younger children who are at high risk of adverse outcomes from 
vaccine preventable diseases’ (10). 
Definition:  ‘Proportion of children between one and 12 months who have received all age 
appropriate immunisations on time’ (10). 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
Delayed immunisations increase the risk for vaccine 
preventable diseases. Delayed immunisations and illness 
from vaccine-preventable disease is a significant problem 
for Aboriginal and Torres Strait Islander peoples (36-38). It’s 
a particular problem for infants in the first year of their life, 
putting them at risk of serious infections such as those 
caused by Haemophilus influenza and Streptococcus 
pneumoniae (39). The proportion of long delays among a 
cohort of Aboriginal and Torres Strait Islander children born 
in 2001 was 3 to 5 times higher in comparison to non-
Indigenous children born during the same period across 
Australia (36). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes. The Australian Government funds the National 
Immunisation Program which provides free childhood 
vaccinations. In addition to the vaccines provided as part of 
the standard vaccine schedule, the pneumococcal vaccine 
and the Hepatitis A vaccine are also provided free to 
Indigenous children living in high risk areas (40).   
Can the health care system 
meaningfully address this 
disease area problem? 
Little is known regarding the reasons for longer delays in 
Aboriginal and Torres Strait islander immunisations for 
children (39). However, factors causing delays in other 
populations include: socioeconomic disadvantage (41-43), 
coming from a large family, being a teenage or single 
parent, maternal smoking (44), poor understanding of the 
immunisation schedule (45), and the timeliness of the 
vaccine being outweighed by other more serious illnesses 
occurring in the child or in the family at the same time (46). 
The barriers specific to Aboriginal and Torres Strait Islander 
peoples will need to be explored if they are to be addressed 
successfully. However, timeliness can be improved by 
providing parents with reminders and offering opportunistic 
vaccinations when children attend health centres for any 
reason. 
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Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Standard uncertainties around numerator and denominator 
(people being seen outside of PHU, or not being entered 
into the system, or being incorrectly entered) are detailed 
under KPI 1. 
Do the results fall within a 
plausible range? 
Using 2013 to 2014 NT AHKPI data the range reported for 
the proportion of children who received immunisations on 
time from PHC services were: 
 0% to 100% 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all children 1 
to 12 months of 
age in the 
community 
captured by the 
PHC service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
carried out once the data reach the NT 
DoH warehouse. Please see detail of 
this and it limitations under KPI 1. 
Were both 
numerators and 
denominators 
correct?   
Yes - all numerators and denominators 
fell into plausible ranges: 
Year Do numerators add up to 
denominator? 
2010 N/A 
2011 N/A 
2012 N/A 
2013 Yes 
2014 Yes 
Numerator: 
‘The number of resident children who 
are 1 month to less than 12 months of 
age and who have received all age 
appropriate immunisations on the NT 
Immunisation Schedule according to 
the counting rules set out below.’ 
Denominator:  
‘The number of resident children who 
are 1 month to less than or equal to 12 
months of age.’ 
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Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the data collection 
methods for measuring, 
calculating or recording 
this KPI changed over 
time? 
 
Definition version Changes made as written in the NT 
AHKPI Definitions Manual Year Month Version 
2010 Oct 1.3.3 N/A 
2013 March 2.0.2 N/A 
2013 Sept 2.0.3 ‘Change: New indicator 
Description: additional KPI indicator 
added to KPI reporting.’ 
 
2014 April 2.0.4 No changes made. 
2014 Oct 2.0.7 ‘Change: Re-number KPI 
Description: Renumber KPI 1.13 to 
1.4.2 
From: AHKPI 1.13 Timeliness of 
Immunisations 
To: AHKPI 1.4.2 Timelines of 
Immunisations.’ 
 
How complete are the 
data? 
 
Calendar 
Year 
Missing data 
2010 N/A 
2011 N/A 
2012 N/A 
2013 - 2 PHC services missing all data fields 
- 3 empty numerator cells: unclear whether these 
were omissions or intended to be zeros 
- Zero reporting not used. We therefore cannot 
interpret the significance of these missing vales 
- No missing data for remaining PHC services 
2014 - 3 PHC services missing all data fields 
- 3 empty numerator cells: unclear whether these 
were omissions or intended to be zeros 
- Zero reporting not used. We therefore cannot 
interpret the significance of these missing vales 
- No missing data for remaining PHC services 
 
Are the data collection 
and analysis methods 
documented in writing 
and being used to 
ensure the same 
procedures are 
followed each time? 
Yes. See details under KPI 1. 
Is there scientific 
evidence available to 
support the measure? 
Immunisation is one of the most successful and cost-effective public 
health interventions (47). Reducing the number of delayed 
immunisations will reduce the risk for vaccine preventable diseases 
(36-38). 
 
 
Chapter 3 
 
3-48 
 
KPI 5 - ‘Number and proportion of children less than 5 years of age who are 
underweight’ 
 
Rationale 
‘Weight for age is a sensitive measure of growth in children. The calculation does not require 
height so coverage is generally better than weight for height’ (10). 
 
Definition 
‘The number and proportion of children less than 5 years of age who are residents and who are 
less than -2 standard deviations away from the mean weight for age’ (10). 
 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
This is an important indicator for monitoring the nutritional 
status of children. There is an increased risk of illness and 
mortality for children who are underweight (48). It is 
estimated that 45% of all deaths among children under five 
years of age is caused by malnutrition (49).  
 
Are policy makers and 
consumers concerned about 
the disease? 
Yes. In 1998 The Northern Territory (NT) Department of 
Health implemented a program called the Growth 
Assessment and Action (GAA) program (50) (now known as 
‘The Healthy Kids under 5 Program’) which aims to monitor, 
promote, and improve growth of children aged zero to five 
years in remote communities of the NT (51). 
 
Can the health care system 
meaningfully address this 
disease area problem? 
Yes. ‘The Healthy Kids Under 5 Program’ program is one of 
the core functions of Aboriginal Comprehensive Primary 
Health Care in the NT (3).  One of the key elements of this 
program is child health checks which allows for prevention, 
early detection, intervention and treatment (51). 
 
Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Limitations to this indicator include: 
 
Low weight for age can be reflective of either wasting (low 
weight for height) or stunting or both. Therefore, this 
indicator may be difficult to interpret. The United Nations 
state that the indicators: underweight, stunting, and 
wasting, should be analysed and presented together since 
they measure and reflect different features of child 
malnutrition (52), but this indicator only collects 
information on the proportion of children who are 
underweight. 
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Changes in a child’s body measurements can have multiple 
causes such as insufficient nutrient intake, stress, disease, 
infection, and genetic background and therefore 
interpretation and plans for how to meaningfully address 
any problems detected could be difficult (48). 
 
Other standard uncertainties around the KPI being able to 
measure/detect the disease condition are detailed under 
KPI 1. 
Do the results fall within a 
plausible range? 
Using 2010 to 2014 NT AHKPI data, the range reported from 
health centres for: 
 the proportion of children weighed were 31% to 
100%; and 
 the proportion of children underweight were 0% to 
100%. 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all children < 5 
years in the 
community 
captured by the 
PHC service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
 
Were both 
numerators and 
denominators 
correct?   
It is difficult to know if the numerators 
and the denominators were correct 
without cross referencing with other 
datasets but all numerators and 
denominators were within plausible 
ranges and no numerator exceeded the 
denominator.  
This assumes however that the scales 
used to measure the weight are tested 
and standardised regularly. 
 
 
The calculation includes underweight 
and coverage ratio: 
a. Underweight ratio: Number 
underweight/Number measured 
b. Coverage ratio: Number 
measured/Total population 
Numerator:  
a. The number of resident children 
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who are less than 5 years of 
age at the date for weight 
measurement and who are 
more than -2 standard 
deviations away from the mean 
weigh for age during the 
reporting period 
b. The number of resident children 
less than 5 years of age at the 
date for weight measurement 
and who were measured for 
weight at least once during the 
reporting period.’ 
 
Denominator: 
c. The number of resident children 
who were less than five years of 
age at the beginning of the 
reporting period or were born 
during the reporting period and 
who were measured for weight 
at least once during the 
reporting period 
d. The number of resident children 
are less than 5 years of age at 
the beginning of the reporting 
period or were born during the 
reporting period.’ 
 
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the data 
collection 
methods for 
measuring, 
calculating or 
recording this KPI 
changed over 
time? 
 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change from CDC 2000 to WHO 2006 
reference base definition. Definition of Z 
scores  
from: 
Standard deviations (Z scores) are derived 
from methodologies defined by the USA 
National Centre for Health Statistics 
http://www.cdc.gov/nchs/nhanes.htm 
to: Standard deviations (Z scores) are 
derived from methodologies defined by 
the World Health Organisation Child 
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growth Standards 
2006.(http://www.who.int/childgrowth/sta
ndards/en/).’ 
2013 March 2.0.2 Removed all references to GAA data 
collection. ‘Data can also be sourced 
from the GAA Survey (Growth Assessment 
and Action) for most remote 
communities. Currently there are Annual 
GAA surveys in April. Data is collected at 
remote clinics and loaded into the DoH 
data warehouse. Calculations are applied 
to the raw data to produce statistical 
reports that are distributed to 
participating communities. Data 
validation is done for each survey round 
and data ‘out of range’ (< ‐3 or >3) are 
verified with the remote clinic before 
publication of the annual survey results. 
Data are from remote communities only. 
Not all communities participate in the 
survey at any given survey round and 
there have been approximately 80 
communities who have ever participated. 
Approximately 60‐65 communities 
participate in any survey round. Each 
clinic would need to provide population 
breakdown by age 
group/gender/Indigenous status and their 
data from GAA report.’ 
2013 Sept 2.0.3 No changes made. 
2014 April 2.0.4 No changes made. 
2014 Oct 2.0.7 No changes made. 
 
 
How complete are 
the data? 
 
Year Missing data 
2010 - 2 PHC services missing all data fields 
- 7 empty numerator cells: unclear whether this was an 
omission or intended to be a zero for the number of 
children underweight 
- No missing data for remaining PHC services 
2011 - 5 PHC services missing all data fields 
- 6 empty numerator cells: unclear whether this was an 
omission or intended to be a zero for the number of 
children underweight  
- No missing data for remaining PHC services 
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2012 - 0 PHC services missing all data fields 
- 22 empty numerator cells: unclear whether this was an 
omission or intended to be a zero for the number of 
children underweight 
- No missing data for remaining PHC services 
2013 - 0 PHC services missing all data fields 
- 30 empty numerator cells where zeros should be for the 
number of children underweight: unclear whether this 
was an omission or intended to be a zero for the number 
of children underweight  
- No missing data for remaining PHC services 
2014 - 0 PHC services missing all data fields 
- 30 empty numerator cells: unclear whether this was an 
omission or intended to be a zero for the number of 
children underweight  
- No missing data for remaining PHC services 
 
 
Are the data 
collection and 
analysis methods 
documented in 
writing and being 
used to ensure the 
same procedures 
are followed each 
time? 
Yes. See details under KPI 1. 
Is there scientific 
evidence available 
to support the 
measure? 
Child growth is internationally recognized as an important indicator of 
nutritional status and health in populations (48). 
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KPI 6 - ‘Number and proportion of children between 6 months and 5 years of age who 
are anaemic’ 
Rationale 
‘Haemoglobin levels are an indicator of the oxygen carrying capacity of the blood and are one 
indicator of nutritional status. Haemoglobin can be measured easily in the primary health care 
setting and results can be obtained instantly using a haemoglobinometer’ (10). 
 
Definition 
‘The number and proportion of children who are residents, who are: 
a. ≥  6 months and < 12 months of age and whose haemoglobin level is less than 105 g/L, 
or 
b. ≥ 12 months and < 5 years of age and whose haemoglobin level is less than 110 g/L 
(53)‘ (10). 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
Anaemia has adverse effects on many areas of child health 
including cognitive, behavioural and physical development, as 
well as immune function (54-56). Children with iron deficiency 
anaemia (IDA) in infancy are more likely to fail to complete 
secondary school, be single, and have negative emotions (57). If 
anaemia or IDA is left untreated, developmental delays can 
persist into adulthood impacting work and economic 
productivity (58). The World Health Organisation (WHO) 
considers anaemia as a public health problem when the 
prevalence of anaemia is > 5% (55). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes. In 1998 The Northern Territory (NT) Department of 
Health implemented a program called the Growth 
Assessment and Action (GAA) program (50) (now known as 
‘The Healthy Kids under 5 Program’) which aims to monitor, 
promote, and improve growth of children aged zero to five 
years in remote communities of the NT (51) and childhood 
anaemia is monitored as part of this program. 
Can the health care system 
meaningfully address this 
disease area problem? 
Yes. ‘The Healthy Kids Under 5 Program’ program is one of 
the core functions of Aboriginal Comprehensive Primary 
Health Care in the NT (3).  One of the key elements of this 
program is child health checks which allows for prevention, 
early detection, intervention and treatment (51). Depending 
on the Haemoglobin (Hb) levels of the child, anaemia in the 
NT is treated with iron, albendazole (if they live in the Top 
End of the NT). If a child’s Hb is < 90g/L folate is given and a 
full blood test is requested. The Central Australian Rural 
Practitioners Association manual recommends that all 
anaemic children (regardless of Hb levels) should be 
followed up (53). 
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Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Limitations with this indicator include: 
 
Anaemia has many potential causes (59, 60). This indicator 
does not provide information on what the causes of 
anaemia may be. For example measuring levels of Hb does 
not indicate iron deficiency anaemia; this is measured using 
serum ferritin which requires a full blood examination (53). 
 
Currently the HemoCue haemoglobinometer is used in the 
NT to screen for anaemia (61). It’s reported to have good 
sensitivity (85%) and specificity (94%) in detecting anaemia 
(62, 63). The sensitivity is reported to reach 100% in 
controlled laboratory conditions (64). However, the 
reproducibility, accuracy and precision of the HemoCue 
results are highly dependent on the conditions under which 
the test has been conducted, whether venous or capillary 
blood has been collected and whether the HemoCue 
products have been stored in appropriate storage 
conditions, particularly in humid climates (65, 66). 
 
Children tested for anaemia outside of the local PHC will not 
be captured as part of this KPI. 
 
This KPI relies on the correct information being entered into 
the electronic database. If a child is tested but is not 
entered into the system, they will not be captured as part of 
this KPI. If a child is tested, and the Hb results are entered 
incorrectly into the system this will not reflect the truth. 
 
If there are uncertainties surrounding the total number of 
resident children between 6 months and 5 years residing in 
the community, it can make it difficult to estimate the 
accurate coverage of children tested for anaemia. This may 
be an issue for areas where there are transient groups. 
Do the results fall within a 
plausible range? 
Using 2010 to 2014 NT AHKPI data, the range reported from 
health centres for: 
 the proportion of children tested were 10% to 100%; 
and 
 the proportion of children anaemic were 0% to 72%. 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
Are all children 
aged between 6 
month and < 5 
years in the 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
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aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
community 
captured by the 
PHC service’s 
database? 
Was the 
calculation 
performed 
correctly? 
The calculation includes anaemic ratio 
and coverage ratio: 
1. Anaemic Ratio: Number 
Anaemic/Number Measured 
2. Coverage Ratio: Number 
Measured/Total Population 
 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
 
Were both 
numerators and 
denominators 
correct?   
It is difficult to know if the numerators 
and the denominators were correct 
without cross referencing with other 
datasets but all numerators and 
denominators were within plausible 
ranges and no numerator exceeded the 
denominator. 
 
Numerator:  
‘1. The number of resident children, 
who are: 
a. ≥ 6 months and < 12 months of age 
at the date for anaemia measurement 
and whose Hb level is < 105 g/L during 
the reporting period. 
or 
b. > 12 months and < 5 years of age at 
the date for anaemia measurement 
and whose Hb level is < 110 g/L during 
the reporting period. 
 
2. The number of children who are 
residents and who are ≥ 6 months and 
< 5 years of age and who have been 
measured for anaemia during the 
reporting period. 
 
*Child’s ages are calculated according 
to the date for anaemia measurement.’ 
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Denominator: 
‘1. The number of resident children who 
are ≥ 6 months and < 5 years of age at 
the beginning of the reporting period 
or were born during the first six months 
of the reporting period and who have 
been measured for anaemia during the 
reporting period. 
 
2. The number of resident children who 
are ≥ 6 months and < 5 years of age at 
the beginning of the reporting period 
or were born during the first six months 
of the reporting period. 
 
*Child’s ages are calculated to the end 
of reporting period to include those 
who are less than six years of age. (E.g. 
includes all children who were < 5 years 
of age at the beginning of the reporting 
period or were born during the first 6 
months of the reporting period.’ 
 
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the 
data 
collection 
methods for 
measuring, 
calculating or 
recording this 
KPI changed 
over time? 
 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change: Align anaemia cut off to revised 
CARPA definition. 
 
Definition 
From: The number and proportion of children 
who are residents, who are ≥ 6 months and < 
5 years of age and whose haemoglobin level 
is < 110 g/L (WHO definition). 
 
To: The number and proportion of children 
who are residents, who are: 
a.  ≥ 6 months and < 12 months of age 
and whose haemoglobin level is less 
than 105 g/L 
or 
b. ≥ 12 months and < 5 years of age and 
whose haemoglobin level is less than 
110 g/L (53) 
 
Calculation – Numerator 
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From: 
‘1. The number of children who are residents, 
who are ≥ 6 months and < 5 years of age and 
whose haemoglobin level is <  110 g/L (WHO 
definition (60)) during the reporting period. 
2. The number of children who are residents, 
who are ≥ 6 months and < 5 years of age and 
who have been measured for anaemia during 
the reporting period. 
 
To: 
1. The number of children who are residents, 
who are: 
a. ≥ 6 months and < 12 months of age and 
whose haemoglobin level is less than 105 g/L 
 or  
b. ≥ 12 months and < 5 years of age and 
whose haemoglobin level is less than 110 g/L 
during the reporting period. 
2. The number of children who are residents, 
who are : 
a. ≥6 months and < 5 years of age and who 
have been measured for anaemia during the 
reporting period. 
 
Calculation - Denominator 
From: 
1. The number of children who are residents, 
who are ≥ 6 months and < 5 years of age and 
who have been measured for anaemia during 
the reporting period. 
2. The number of children who are residents, 
who are ≥ 6 months and < 5 years of age 
during the reporting period. 
To: 
1. The number of children who are residents, 
who are: 
a. ≥ 6 months and < 5 years of age 
and who have been measured for anaemia 
during the reporting period 
2. The number of children who are residents, 
who are:  
a. ≥6 months and < 5 years of age during the 
reporting period. 
 
Sound methodology 
From: Methodology is based on WHO 
definitions 
To: Methodology is based on CARPA 
definitions 
Change: Specified period to include calendar 
year 
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Calculation - Specified period 
From: Financial year 
To: Financial year or Calendar year.’ 
2013 March 2.0.2 ‘Change: Data Quality and Availability. 
Description: Removed all references to GAA 
data collection. 
Data are provided to most remote 
communities from the GAA Survey (Growth 
Assessment and 
Action). Currently there are Annual GAA 
surveys in April. Data are collected at remote 
clinics and loaded into the DoH data 
warehouse. Calculations are applied to the 
raw data to produce statistical reports that 
are distributed to participating communities. 
Data validation is done for each surveyaround 
and data ‘out of range’ (< ‐3 or >3) are 
verified with the remote clinic before 
publication of the annual survey results. Data 
is from remote communities only. Not all 
communities participate in the survey at any 
given survey round and there have been 
approximately 80 communities who have ever 
participated. Approximately 60‐65 
communities participate in any survey round.’ 
2013 Sept 2.0.3 No changes made. 
2014 April 2.0.4 No changes made. 
2014 Oct 2.0.7 ‘Change: Update to include disaggregation by 
age group 
Description: To give further breakdown of 
anaemia by age groups, 6-12months, 12-24 
month and 24-60 months.  
From:  
Level/unit of counting: 
Disaggregated by: 
a. locality 
b. Indigenous status 
To:  
Level/unit of counting: 
Disaggregated by: 
a. locality 
b. Indigenous status 
c. Age groups.’ 
 
How 
complete are 
the data? 
 
Year Missing data 
2010 - 2 PHC services missing all data fields 
- 1 empty numerator cell: unclear whether this was an 
omission or intended to be a zero for the number of children 
tested for anaemia (Zero reporting had been used for this 
KPI) 
- No missing data for remaining PHC services 
2011 - 5 PHC services missing all data fields 
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- No missing data for remaining PHC services 
2012 - 0 PHC services missing all data fields 
- 2 empty numerator cells: unclear whether this was an 
omission or intended to be a zero for the number of children 
tested for anaemia (Zero reporting had been used for this 
KPI) 
- No missing data for remaining PHC services 
2013 - 0 PHC services missing all data fields 
- 7 empty numerator cells: unclear whether this was an 
omission or intended to be a zero for the number of children 
tested for anaemia (Zero reporting had been used for this 
KPI) 
- No missing data for remaining PHC services 
2014 - 0 PHC services missing all data fields 
- 3 empty numerator cells: unclear whether this was an 
omission or intended to be a zero for the number of children 
tested for anaemia (Zero reporting had been used for this 
KPI) 
- No missing data for remaining PHC services 
 
Are the data 
collection 
and analysis 
methods 
documented 
in writing and 
being used to 
ensure the 
same 
procedures 
are followed 
each time? 
Yes. See details under KPI 1. 
Is there 
scientific 
evidence 
available to 
support the 
measure? 
Measuring an individual’s Hb (the iron-carrying component of red blood 
cells) is the most convenient and common way of detecting anaemia (63, 
64) and is recommended by the WHO (60).  
 
The Hb cut off for children aged ≥ 6 and < 12 months differs from the WHO 
definition. The authors of CARPA argue that reference values for normal Hb 
levels for children in this age group are not well established and are 
extrapolated from an older population (67). As a result they have decided 
to use a lower the cut off to < 105 g/L for this age group based on two 
studies (68, 69) to reduce the number of iron injections and their potential 
side effects to this cohort of children who may not need it (67). 
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KPI 7 - ‘Number and proportion of resident clients aged 15 years and over with Type II 
Diabetes and/or Coronary Heart Disease who have a chronic disease management plan’ 
 
Rationale 
 ‘Preventable chronic diseases are responsible for a significant burden of disease for Aboriginal 
people and if poorly controlled increase hospitalisations, complications and the cost of 
healthcare. Care plans are the foundation for providing appropriate long-term care and an 
increase in the proportion will demonstrate improved health service delivery’ (10). 
 
Definition 
‘The number and proportion of resident Indigenous clients, who are 15 years old and over, who 
have been diagnosed with Type II diabetes and/or Coronary Heart disease and who have a valid 
Chronic Disease  
Management Plan at the end of reporting period. 
 
Coronary Heart Disease (also referred to as Ischemic Heart Disease): 
Based on NPCC Guidelines Coronary Heart Disease includes: 
1. Myocardial infarction 
2. Angina  
3. Unstable angina pectoris 
4. Revascularisation as evidenced by angioplasty with or without a stent 
5. Coronary artery bypass surgery 
 
CHD’s primary feature is insufficient blood supply to the heart itself. The two major clinical forms 
are heart attack (the insufficient blood supply is sudden and extreme) and angina. 
 
Type II diabetes: 
Type II diabetes includes the common major form of diabetes, which results from defect(s) in 
insulin secretion, almost always with a major contribution from insulin resistance. Type II 
diabetes does not include: Type I diabetes, Gestational diabetes mellitus, Secondary diabetes, 
impaired fasting glycaemia or impaired glucose tolerance. 
 
Chronic Disease Management Plan: 
Chronic Disease Management Plans for the purpose of this indicator are defined as: 
1. MBS item 721 - General Practitioner Management Plan (GPMP), (Medicare Benefit 
       Schedule) (Item 721 and 723) (Medicare Australia 2007) or 
2. Alternative Chronic Disease Management Plan in the form of General Practitioner (or 
equivalent) Management Plan that cannot be claimed that includes the following items 
in clinical guidelines and protocols for developing an alternative GPMP. 
 
The following mandatory items are included in the alternative General Practitioner 
Management Plan: 
a) Assessing the patient to identify and/or confirm the entire patients health care needs, 
problems and relevant conditions 
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b) Agreeing management goals with the patient for the changes to be achieved by the 
treatment and services identified in the plan 
c) Identifying any actions to be taken by the patient 
d) Identifying treatment and services that the patient is likely to need and making 
arrangements for provision of these services and ongoing management 
e) Documenting the patient’s needs, goals, patient actions, treatment/services and a 
review date i.e. completing the GPMP document or  
3. MBS Item 723 - Chronic Disease Management Plan Team Care Arrangements (TCA), 
f) (Medicare Benefit Schedule) (Item 721 and 723) (Medicare Australia 2007) or 
4. Alternative Chronic Disease Management Plan in the form of TCA’s that includes the following 
items in clinical guidelines and protocols for developing an alternative TCA. 
 
The following mandatory items are included in the alternative Team Care Arrangement: 
a) Discussing with the patient which treatment/service providers should be asked to  
b) Gaining the patient’s agreement to share relevant information about their medical 
history, diagnoses, GPMP etc. (with or without restrictions) with the proposed providers; 
c) Contacting the proposed providers and obtaining their agreement to participate, 
realising that they may wish to see the patient before they provide input but that they 
may decide to proceed after considering relevant documentation, including any current 
GPMP; 
d) Collaborating with the participating providers to discuss potential treatment/services 
they will provide to achieve management goals for the patient; 
e) Documenting the goals, the collaborating providers, the treatment/services they have 
agreed to provide, any actions to be taken by the patient and a review date i.e. 
completing the TCA document; and 
f) Providing the relevant parts of the TCA to the collaborating providers and to any other 
persons who, under the TCA, will give the patient the treatment/services mentioned in 
the TCA.’ 
 
Numerator(s): 
‘Chronic Disease Management Plan (MBS Item 721 – General Practitioner Management Plan - 2 
year reporting period) 
The number of resident clients who are aged 15 years and over and who have been diagnosed 
with: 
a. Type II diabetes 
b. Coronary heart disease 
c. Type II diabetes & coronary heart disease, and who have a current MBS item 721 Chronic 
Disease Management Plan that was initiated within the previous 2 reporting periods. A current 
MBS item 721 Chronic Disease Management Plan is valid for two years. Therefore, all clients 
with a current and valid MBS item 721 Chronic Disease Management Plan at the end of the 
reporting period should be included in the count for this numerator, not just those who received 
a MBS item 721 Chronic Disease Management Plan within the reporting period. 
 
Chronic Disease Management Plan (MBS Item 721 – General Practitioner Management Plan - 1 
year reporting period) 
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The number of resident clients who are aged 15 years and over and who have been diagnosed 
with: 
a. Type II diabetes 
b. Coronary heart disease 
c. Type II diabetes & coronary heart disease, and who have a current MBS item 721 Chronic 
Disease Management Plan that was initiated within the previous reporting period. 
 
Alternative Chronic Disease Management plan (Alternative General Practitioner Management 
Plan – 2 year reporting period) 
The number of resident clients who are aged 15 years and over and who have been diagnosed 
with: 
a. Type II diabetes 
b. Coronary heart disease 
c. Type II diabetes & coronary heart disease, and who have an alternative Chronic Disease 
Management Plan in the form of a General Practitioner Management Plan that was initiated 
within the previous 2 reporting periods. A current alternative Chronic Disease Management Plan 
is valid for two years. Therefore, all clients with a current/valid management plan at the end of 
the reporting period should be included in the count, not just those who received a management 
plan within the reporting period. 
 
Chronic Disease Management Plan (MBS Item 723 - Team Care Arrangements – 2 year reporting 
period) 
The number of resident clients who are 15 years of age and over and who have been diagnosed 
with: 
a. Type II diabetes 
b. Coronary Heart Disease 
c. Type II diabetes & coronary heart disease and who have a current MBS item 723 Chronic 
Disease Management Plan Team Care Arrangement that was initiated within the previous 2 
reporting periods. A current MBS item 723 Team Care Arrangement is valid for two years. 
Therefore, all clients with a current/valid Team Care Arrangement at the end of the reporting 
period should be included in the count, not just those who received a Team Care Arrangement 
plan within the reporting period. 
 
 
Chronic Disease Management Plan (MBS Item 723 - Team Care Arrangements – 1 year reporting 
period) 
The number of resident clients who are 15 years of age and over and who have been diagnosed 
with: 
a. Type II diabetes 
b. Coronary Heart Disease 
c. Type II diabetes & coronary heart disease, and who have a current MBS item 723 Chronic 
Disease Management Plan Team Care Arrangement that was initiated within the previous 
reporting period. 
 
Alternative Chronic Disease Management Plan (Alternative Team Care Arrangements – 2 year 
reporting period) 
Chapter 3 
 
3-63 
 
The number of resident clients who are aged 15 years and over and who have been diagnosed 
with: 
a. Type II diabetes 
b. Coronary heart disease 
c. Type II diabetes & coronary heart disease, and who have an alternative Chronic Disease 
Management Plan Team Care Arrangement in the form of a General Practitioner Management 
Plan, Team Care Arrangement that was initiated within the previous 2 reporting periods. A 
current alternative Team Care Arrangement is valid for two years. Therefore, all clients with a 
current/valid Team Care Arrangement at the end of the reporting period should be included in 
the count, not just those who received a Team Care Arrangement plan within the reporting 
period. 
 
Alternative Chronic Disease Management Plan (Alternative Team Care Arrangements – 1 year 
reporting period) 
The number of resident clients who are aged 15 years and over and who have been diagnosed 
with: 
a. Type II diabetes 
b. Coronary heart disease 
c. Type II diabetes & coronary heart disease, and who have an alternative Chronic Disease 
Management Plan Team Care Arrangement in the form of a General Practitioner Management 
Plan, Team Care Arrangement that was initiated within the previous reporting period. 
 
Alternative Chronic Disease Management plan (Alternative General Practitioner Management 
Plan – 1 year period) 
The number of resident clients who are aged 15 years and over and who have been diagnosed 
with: 
a. Type II diabetes 
b. Coronary heart disease 
c. Type II diabetes & coronary heart disease, and who have an alternative Chronic Disease 
Management Plan in the form of a General Practitioner Management Plan that was initiated 
within the previous reporting period. 
 
Denominator (for MBS Item 721, 723 and Alternative GPMP & TCA Care Plans) 
The number of resident clients who are aged 15 years and over and who have been diagnosed 
with: 
a. Type II diabetes 
b. Coronary heart disease. 
c. Type II diabetes & coronary heart disease’ (10). 
 
 
 
 
 
 
 
 
Chapter 3 
 
3-64 
 
 
 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
Chronic disease is estimated to contribute to 70% of the health 
gap between Aboriginal and Torres Strait Islanders and non-
Indigenous Australians (70). 
 
Cardiovascular disease (CVD) was the leading cause of death for 
Indigenous Australians in 2008-2012. It accounts for 25% of 
deaths in Indigenous Australian and for 24% of the gap in death 
rates between Indigenous and non-Indigenous Australians (71). 
The age adjusted rate for CVD is nearly twice as high in 
Indigenous Australians compared to non-Indigenous 
Australians (71). Indigenous people are more likely to die from 
CVD when they are young or in their middle age compared to 
non-Indigenous Australians (72). 
 
Type 2 diabetes was the second leading specific cause of 
death for Indigenous Australians, accounting for 8% of 
deaths (71). In 2012-2013, the age adjusted rate for 
developing type 2 diabetes in Indigenous Australians was 
three times higher in Indigenous Australians compared to 
non-Indigenous Australians and onset of disease occurs at a 
younger age (13). 
Around 45% of Indigenous Australians aged ≥ 15 years who 
reported having diabetes also reported having a circulatory 
disease (73). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes, diabetes and CVD are in the ‘2014 Aboriginal and 
Torres Strait Islander Health Performance Framework’  (13). 
There are a range of Government initiatives for both 
diseases such as: 
1. The Diabetes Care Project pilot - tests new models 
of healthcare arrangements for people with Type 1 
and 2 diabetes. 
2. The Indigenous Australians Health programme - 
provides diabetes prevention and management 
through comprehensive primary health care 
(diabetes and CVD). 
3. The national recommendations for the better 
cardiac care for Aboriginal and Torres Strait Islander 
people. 
4. The Australian Government-funded essential service 
standards (ESSENCE) project - identifies areas of 
care that needed to reduce the disparity in access 
and outcomes for circulatory disease. 
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Lighthouse project – aims to change the acute care sector 
to improve care and outcomes for Indigenous Australians 
with CVD (13). 
Can the health care system 
meaningfully address this 
disease area problem? 
Culturally appropriate, family centred approaches, 
engagement with communities and working collaboratively 
across the continuum of care and prevention are needed for 
primary health care to be successful in addressing these 
disease areas (74).  
Other strategies to address the challenges in this disease 
area included: good disease management guidelines, 
support to address local factors, appropriate staffing and 
training polices, defined roles for practitioners and 
education and health promotion in the community with 
strong community engagement (75). 
 
Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Limitations with this indicator include:  
This indicator measures how many resident clients (who 
need it) have a chronic disease management plan. It does 
not measure what the total care is or whether the quality of 
the care provided is appropriate and effective for individual 
needs. 
MBS (Medicare Benefit Schedule) items are not claimed by 
all organisations because the service may not be eligible to 
claim, there may not be a general practitioner present to 
make the claim, or services may not be completing the 
reporting in a way that meets the requirements for MBS 
billing (AIHW). 
Other standard uncertainties around the KPI being able to 
measure/detect the disease condition are detailed under 
KPI 1. 
Do the results fall within a 
plausible range? 
Using 2010 to 2014 NT AHKPI data, the range reported from 
health centres for: 
 Chronic disease management plan = 0% to 128% 
(108% for one PHC in 2010 and 128% for one PHC in 
2011) 
 Alternative team arrangement plan = 0% to 99% 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
Are resident 
clients’ ≥ 15 years 
with Type II 
Diabetes and/or 
Coronary Heart 
Disease in the 
community 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
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produce consistently over-
counting or under-counting? 
captured by the 
PHC service’s 
database? 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
Were both 
numerators and 
denominators 
correct?   
No, for one service the numerators 
exceeded the denominators giving a 
total proportion of resident clients on 
a chronic disease management plan for 
one service being 108% in 2010 and 
128% in 2011. 
For the remaining years and services, 
yes - all numerators and denominators 
fell into plausible ranges: 
Year Do numerators add up to 
denominator? 
2010 No 
2011 No 
2012 Yes 
2013 Yes 
2014 Yes 
 
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the data 
collection methods 
for measuring, 
calculating or 
recording this KPI 
changed over 
time? 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change: Specified period to include calendar 
year 
Calculation - Specified period 
From: Financial year 
To: Financial year or Calendar year 
Change: Data sourcing to exclude paper 
based systems sources. 
Data quality and availability 
From: The data collection method will 
depend on a clinic’s information system. If a 
clinic has an electronic information system 
e.g. Communicare, Ferret, PCIS or Interim 
Data Collection Tool, the data required to 
calculate this performance indicator will be 
extracted directly from their database. For 
those systems that cannot disaggregate 
data, aggregated data is acceptable for a 
short period. 
To: The data collection method will depend 
on a clinic’s information system e.g. 
Communicare, Ferret, or 
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PCIS, the data required to calculate this 
performance indicator will be extracted 
directly from their database.’ 
2013 March 2.0.2 ‘Change: Calculation 
Description: Consolidated denominator 
definition for MBS item 721, 723 & 
Alternative. 
From denominator:  
Denominator for MBS Item 721 and 
Alternative 
The number of Indigenous adults who are: 
1. Male 
2. Female 
Who were aged: 
a) 15‐24 years 
b) 25‐44 years 
c) 45‐64 years 
d) 65 years and over 
Who are regular clients of the service that 
have been diagnosed with: 
1. Type II Diabetes 
2. Coronary Heart Disease 
Denominator for MBS Item 723 and 
Alternative 
The number of Indigenous adults who are: 
1. Male 
2. Female 
Who were aged : 
a) 15‐24 years 
b) 25‐44 years 
c) 45‐64 years 
d) 65 years and over 
Who are regular clients of the service that 
have been diagnosed with: 
1. Type II Diabetes 
2. Coronary Heart Disease 
To:  Denominator for MBS Item 721, 723 and 
Alternative GPMP and TCA Care Plans 
The number of Indigenous adults who are: 
1. Male 
2. Female 
and who were aged : 
a. 15‐24 years 
b. 25‐44 years 
c. 45‐64 years 
d. 65 years and over 
and who are regular clients of the service 
that have been diagnosed with: 
i) Type II Diabetes 
ii) Coronary Heart Disease 
Change: Counting rules 
Description: Update the counting rules to 
reflect a distinct count of clients for the 
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reporting period. 
From:  
To: If there is more than one 721 in the 
reporting period, only count the latest one. 
Similarly, count only one 723 in the reporting 
period. 
Change: Specified period 
Description: adding an additional time period 
to the KPI 
From: Financial year or Calendar year. 
To:  
1. Collect data every financial year or 
calendar year for the previous year 
2. Collect data every financial year or 
calendar year for the previous 2 years.’ 
2013 Sept 2.0.3 No change. 
2014 April 2.0.4 No change. 
2014 Oct 2.0.7 No change. 
 
How complete are 
the data? 
 
Year Missing data 
2010 - 1 PHC service missing all data fields (including numerator 
and denominator) 
- Zero reporting not used. We therefore cannot interpret the 
significance of a missing value for all 84 services 
2011  - 1 PHC service missing all data fields (including numerator 
and denominator) 
- Zero reporting not used. We therefore cannot interpret the 
significance of a missing value for all 84 services 
2012 - 0 PHC services missing all data fields 
- Zero reporting not used. We therefore cannot interpret the 
significance of a missing value for all 84 services 
2013 - 0 PHC service missing all data fields 
- Zero reporting not used. We therefore cannot interpret the 
significance of a missing value for all 84 services 
2014 - 0 PHC service missing all data fields 
- Zero reporting not used. We therefore cannot interpret the 
significance of a missing value for all 84 services 
 
 
Are the data 
collection and 
analysis methods 
documented in 
writing and being 
used to ensure the 
same procedures 
are followed each 
time? 
Yes. See details under KPI 1. 
Is there scientific 
evidence available 
to support the 
measure? 
Treatment and management of chronic disease requires long-term planned 
chronic disease programs (76). Organised management of chronic diseases 
at the primary health care level can delay progression of disease and lead 
to improved health outcomes (77-81). 
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KPI 8.1 - ‘Number and proportion of resident clients aged 15 years and over with Type II 
Diabetes who have had an HbA1c measurement result recorded’ 
Rationale:  
‘Glycosylated haemoglobin (HbA1c) is an index of average blood glucose level for the previous 2 
to 3 months and is used to monitor blood sugar control in diabetic people. It is a marker of the 
increased risk of developing atherosclerosis, myocardial infarction, strokes, cataracts and loss of 
the elasticity of arteries, joints and lungs. 
The US Diabetes Control and Complications Trial and the UK Prospective Diabetes Study have 
established that the risk of diabetic complications is strongly associated with previous 
hyperglycaemia and that any reduction in HbA1c is likely to reduce the risk of complications.’ 
 
Definition:  
‘The number and proportion of regular clients who are residents, who are 15 years old and over, 
who have been diagnosed with Type II diabetes and who have had an HbA1c measurement 
result recorded within the previous 6 months AND regular clients who are residents, who are 15 
years old and over, who have been diagnosed with Type II diabetes and who have had an HbA1c 
measurement result recorded within the previous 12 months, which are disaggregated by 
gender by age group by locality’ (10). 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
Type 2 diabetes was the second leading specific cause of 
death for Indigenous Australians, accounting for 8% of 
deaths (71). The age adjusted prevalence for type 2 
diabetes in Indigenous Australians was three times higher 
Indigenous Australians in 2012-2013 compared to non-
Indigenous Australians and starts at a younger age (13). 
 
Poorly-controlled blood glucose in diabetics increases the 
risk of overall mortality (82) and diabetic complications such 
as gangrene that requires amputation (83), end stage 
kidney disease (84), and eye disease, particularly diabetic 
retinopathy (85). Indigenous Australians with type 2 
diabetes have a ten-fold greater risk of kidney failure due to 
diabetes compared to non-Indigenous Australians (86). Early 
identification of poorly controlled blood sugar with the high 
HbA1c levels allows for improved treatment to delay or 
prevent complications. 
Are policy makers and 
consumers concerned about 
the disease? 
Yes diabetes is in the ‘2014 Aboriginal and Torres Strait 
Islander Health Performance Framework’ (13). 
The Australian Government has funded the following 
initiatives: 
1. The Diabetes Care Project pilot that tests new 
models of healthcare arrangements for people with 
type 1 and type 2 diabetes. 
2. The Indigenous Australians Health programme -
provides diabetes prevention and management 
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through comprehensive primary health care 
General practitioner health assessments for Indigenous 
Australians under the Medical Benefits Scheme. These 
health assessments include follow-on care and incentive 
payments for improved management, and cheaper 
medicines through the Pharmaceutical Benefits Scheme 
(13). 
Can the health care system 
meaningfully address this 
disease area problem? 
Yes, but a multidisciplinary (including social and/or mental 
health professionals), culturally appropriate approach (13) 
with targeted education of patients are key to successful 
programs (87). 
 
Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Limitations with this indicator include:  
Even though HbA1c is the gold standard indicator for 
glycaemic control, there are a range of other conditions 
which can affect the normal life cycle of erythrocytes and 
therefore the HbA1c results. For example, in individuals with 
haemolytic anaemia, the average life of an erythrocyte is 
abnormally shorter; this results in a lower HbA1c levels, 
regardless of glycaemia. Conversely, in individuals with 
aplastic anaemia, the age of the erythrocytes are older, 
resulting in higher HbA1c levels regardless of glycaemia 
(88). There are a range of other conditions such as genetic 
conditions, vitamin B deficiencies, use of certain 
medications and alcoholism which can also affect the HbA1c 
levels independent of glycaemia (89). 
 
It is not known whether different point of care devices are 
used to test for HbA1c levels at different PHC services 
throughout the NT, which would results in variations in 
sensitivity and specificity of the results across the NT. 
Different storage conditions, would also have an effect on 
the sensitivity and/or specificity of the testing device.  
Other standard uncertainties around the KPI being able to 
measure/detect the disease condition are detailed under 
KPI 1. 
Do the results fall within a 
plausible range? 
Using 2010 to 2014 NT AHKPI data the range reported from 
PHC services were: 
 6% to 100% 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
Are type 2 
diabetics in the 
community 
captured by the 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
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aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
PHC service’s 
database? 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
Specific to this KPI, these systems do 
not assess the possible variation 
between different HbA1c devices used 
through the NT or whether these 
devices are tested and standardised 
regularly. 
Were both 
numerators and 
denominators 
correct?   
Numerator:  
‘The number of resident clients who are 
aged 15 years and over who have been 
diagnosed with type II diabetes, and 
who have had one or more HbA1c tests 
(If a client has more than one HbA1c 
test during reporting period, counts the 
last one only).’ 
Denominator:  
‘The number of resident clients who are 
aged 15 years and over and who have 
been diagnosed with type II diabetes.’ 
Year Do numerators add up to 
denominator? 
2010 Yes 
2011 Yes 
2012 Yes 
2013 Yes 
2014 Yes 
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Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the 
data 
collection 
methods for 
measuring, 
calculating or 
recording this 
KPI changed 
over time? 
 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change: Data sourcing to exclude paper 
based systems sources. 
Data quality and availability 
From: 
The data collection method will depend on a 
clinic’s information system. If a clinic has an 
electronic information system e.g. 
Communicare, Ferret, Interim Data Collection 
Tool or PCIS, the data required to calculate 
this performance indicator will be extracted 
directly from their database. If a clinic’s 
records are paper-based, the data will be 
input manually via the web-based data input 
system. 
To: 
The data collection method will depend on a 
clinic’s information system e.g. Communicare, 
Ferret, Interim Data Collection Tool or PCIS, 
the data required to calculate this 
performance indicator will be extracted 
directly from their database.’ 
2013 March 2.0.2 No changes made. 
2013 Sept 2.0.3 ‘Change: Update definition 
Description: Updated definition to refine 
reporting period 
From: The number and proportion of resident 
Aboriginal clients who, have type II diabetes 
and whose HbA1c measurement result, 
recorded within either the previous 6 months 
or 12 months was within certain levels. 
To: The number and proportion of resident 
Aboriginal clients who, have type II diabetes 
and whose HbA1c measurement result, 
recorded within the previous 12 months was 
within certain levels.’ 
2014 April 2.0.4 ‘Change: Re-number KPI 
Description: Renumber KPI 1.8 to 1.8.1 
From: AHKPI 1.8 HbA1c Tests 
To: AHKPI 1.8.1 HbA1c Tests.’ 
2014 Oct 2.0.7 ‘Change: Update to reflect two reporting 
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periods, 6 month and 12 month. 
Description: Addition of a 12-month reporting 
period to the KPI to allow data comparison 
between KPI 1.8.1 and KPI 1.8.2. 
From: Indicator: 8.1 Number and proportion 
of resident clients aged 15 years and over 
with Type II Diabetes who have had an HbA1c 
test in the last 6 months 
To: Indicator: 8.1 Number and proportion of 
resident clients aged 15 years and over with 
Type II Diabetes who have had an HbA1c 
measurement result recorded 
From: Definition: The number and proportion 
of Indigenous and non-Indigenous clients who 
are residents, who are 15 years old and over, 
who have been diagnosed with Type II 
diabetes and who have had an HbA1c test 
during reporting period, which are 
disaggregated by gender by age group by 
locality. 
To: Definition: The number and proportion of 
regular clients who are residents, who are 15 
years old and over, who have been diagnosed 
with Type II diabetes and who have had an 
HbA1c measurement result recorded within 
the previous 6 months AND regular clients 
who are residents, who are 15 years old and 
over, who have been diagnosed with Type II 
diabetes and who have had an HbA1c 
measurement result recorded within the 
previous 12 months, which are disaggregated 
by gender by age group by locality. 
From: Numerator: The number of resident 
clients who are aged 15 years and over who 
have been diagnosed with type II diabetes, 
and who have had one or more HbA1c tests 
during the last six months of the reporting 
period. 
To: Numerator: The number of resident clients 
who are aged 15 years and over who have 
been diagnosed with type II diabetes, and 
who have had one or more HbA1c tests 
From: Level/unit of counting: 
From: Client’s ages are calculated according 
to the end of reporting period. 
Client’s residential statuses are determined 
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according to the end of reporting period. 
To: Level/unit of counting: 
Client’s ages are calculated according to the 
end of reporting period. 
Client’s residential statuses are determined 
according to the end of reporting period. 
Calculated separately for 6 months and 12 
months. 
From: Counting rules: 
Include: Type II diabetes only.’ 
 
 
How 
complete are 
the data? 
 
Year Missing data 
2010 - 2 PHC services missing all data fields 
- No missing data for remaining PHC services 
2011 - 1 PHC services missing all data fields 
- No missing data for remaining PHC services 
2012 - 0 PHC services missing all data fields 
- No missing data for remaining PHC services 
2013 - 0 PHC services missing all data fields 
- No missing data for remaining PHC services 
2014 - 0 PHC services missing all data fields 
- No missing data for remaining PHC services 
 
 
Are the data 
collection 
and analysis 
methods 
documented 
in writing and 
being used to 
ensure the 
same 
procedures 
are followed 
each time? 
Yes. See details under KPI 1. 
Is there 
scientific 
evidence 
available to 
support the 
measure? 
HbA1c is internationally accepted as the gold standard index of glycaemic 
control, endorsed by the WHO (89) and is the best risk marker for diabetic 
microvascular complications (88). 
 
This indicator however only assesses whether a test was taken, it does not 
collect any information on what action was taken if a high HbA1c result was 
observed. 
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KPI 8.2 - ‘The number and proportion of Aboriginal clients with type II diabetes and 
whose HbA1c measurements are within certain levels’ 
 
Rationale 
‘Glycosylated haemoglobin is an index of average blood glucose level for the previous 2-3 
months and is used to monitor blood sugar control in people with diabetes. The level of control is 
a marker for increased risk of developing complications including vision loss, neuropathy, and 
renal disease and to a lesser extent, cardiovascular complications. The UKPDS study 
demonstrated significant reductions in microvascular complications with intensive control of 
diabetes. More recently the ADVANCE study demonstrated a significant reduction in both renal 
disease and cardiovascular disease in patients with improved blood pressure and diabetes 
control’ (10). 
 
Definition 
‘The number and proportion of resident Aboriginal clients who have type II diabetes and whose 
HbA1c measurement result recorded within the previous 12 months was within certain levels’ 
(10). 
 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
Type 2 diabetes was the second leading specific cause of 
death for Indigenous Australians; accounting for 8% of all 
deaths in adults (71).  
 
Eleven percent of Aboriginal and Torres Strait Islander 
people had diabetes. The age adjusted prevalence for 
diabetes (type 1 and 2) in Aboriginal and Torres Strait 
Islander Australians was three times higher Indigenous 
Australians in 2012-2013 compared to non-Indigenous 
Australians and starts at a younger age (rate ratio of 3.3) 
(90). 
 
Poorly-controlled blood glucose in diabetics increases the 
risk of overall mortality (82) and diabetic complications such 
as gangrene that requires amputation (83), end stage 
kidney disease (84), and eye disease, particularly diabetic 
retinopathy (85). Indigenous Australians with type 2 
diabetes have a ten-fold greater risk of kidney failure due to 
diabetes compared to non-Indigenous Australians (86). Early 
identification of poorly controlled blood sugar with the high 
HbA1c levels allows for improved treatment to delay or 
prevent complications. 
Are policy makers and 
consumers concerned about 
the disease? 
Yes, diabetes is in the ‘2014 Aboriginal and Torres Strait 
Islander Health Performance Framework’ (13). The 
Australian Government funds the following initiatives: 
1. The Diabetes Care Project pilot that tests new models of 
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healthcare arrangements for people with Type 1 and type 2 
diabetes. 
2. The Indigenous Australians Health programme - provides 
diabetes prevention and management through 
comprehensive primary health care (diabetes and CVD) (13). 
3. General practitioner health assessments for Indigenous 
Australians under the Medical Benefits Scheme. These health 
assessments include follow-on care and incentive payments for 
improved management, and cheaper medicines through the 
Pharmaceutical Benefits Scheme (13). 
Can the health care system 
meaningfully address this 
disease area problem? 
Yes, diabetes is in the ‘2014 Aboriginal and Torres Strait 
Islander Health Performance Framework’ (13). 
The Australian Government has funded the following 
initiatives: 
1. The Diabetes Care Project pilot that tests new models of 
healthcare arrangements for people with type 1 and type 2 
diabetes. 
2. The Indigenous Australians Health programme -provides 
diabetes prevention and management through 
comprehensive primary health care 
3. General practitioner health assessments for Indigenous 
Australians under the Medical Benefits Scheme. These 
health assessments include follow-on care and incentive 
payments for improved management, as well as cheaper 
medicines through the Pharmaceutical Benefits Scheme 
(13). 
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Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
This KPI measures whether the HbA1c levels are within the 
normal range or whether they are elevated to reflect poor 
control of blood glucose level. The KPI does not provide any 
information on what action was taken to improve HbA1c 
levels if elevated. Further limitations for using HbA1c as an 
indicator for glycaemic control are detailed under KPI 8.1  
(Number and proportion of resident clients aged ≥ 15years 
and over with type 2 diabetes who have had an HbA1c 
measurement result recorded). 
Other standard uncertainties around the KPI being able to 
measure/detect the disease condition are detailed under 
KPI 1. 
Do the results fall within a 
plausible range? 
Using 2013 to 2014 NT AHKPI data the range reported from 
PHC services for HbA1c test results were: 
 ≤ 7% = 12% to 77% 
 >7% ≤ 8% = 0% to 38% 
 > 8% < 10% = 0% to 47% 
 ≥ 10% = 3% to 59% 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all Aboriginal 
and Torres Strait 
Islander residents 
with type 2 
diabetes in the 
community 
captured by the 
PHC service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
Were both 
numerators and 
denominators 
correct?   
Numerator:  
‘The number of resident Aboriginal 
clients who have been diagnosed with 
type II diabetes who have had one or 
more HbA1c tests during the reporting 
period with the most recent test being: 
1.  less than or equal to 7% OR 
less than or equal to 53 
mmol/mol; 
2.  greater than 7% but less than 
or equal to 8% OR greater than 
53 mmol/mol but less than or 
equal to 64 mmol/mol; 
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3.  greater than 8% but less than 
10% OR greater than 64 
mmol/mol but less than 86 
mmol/mol; 
4. greater than or equal to 10% 
OR greater than or equal to 86 
mmol/mol 
If a client has more than one HbA1c 
during reporting period count the last 
one only.” 
Denominator:  
‘The number of resident Aboriginal 
clients who have been diagnosed with 
type II diabetes and who have had one 
or more HbA1c tests during the 
reporting period’ (10). 
Year Do numerators add up to 
denominator? 
2010 N/A 
2011 N/A 
2012 N/A 
2013 Yes 
2014 Yes 
 
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the data 
collection methods 
for measuring, 
calculating or 
recording this KPI 
changed over time? 
Definition version Changes made as written in the NT 
AHKPI Definitions Manual Year Month Version 
2010 Oct 1.3.3 N/A 
2013 March 2.0.2 ‘Change: New indicator 
Description: additional KPI indicator 
added to KPI reporting (Please see 
AHKPI1.14 for full details)’ 
*(this KPI was KPI 14 when first added 
to the system) 
2013 Sept 2.0.3 ‘Change: Update definition 
Description: Updated definition to refine 
reporting period 
From: The number and proportion of 
resident Aboriginal clients who, have 
type II diabetes and whose HbA1c 
measurement result, recorded within 
either the previous 6 months or 12 
months was within certain levels. 
To: The number and proportion of 
resident Aboriginal clients who, have 
type II diabetes and whose HbA1c 
measurement result, recorded within 
the previous 12 months was within 
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certain levels.’ 
2014 April 2.0.4 ‘Change: Re-number KPI 
Description: Renumber KPI 1.14 to 1.8.2 
From: AHKPI 1.13 HbA1c Measurements 
To: AHKPI 1.8.2 HbA1c Measurements.’ 
2014 Oct 2.0.7 ‘Change: Update to clarify counting 
rules. 
Description: KPI to only have inclusion 
rules rather than both inclusion and 
exclusion rules. 
From: Counting rules: 
Include: Type II diabetes only 
Exclude: 
1. Type 1 diabetes, 
2. gestational diabetes mellitus, 
3. previous gestational diabetes 
mellitus 
4. impaired fasting glucose 
To: Counting rules: 
Include: Type II diabetes only.’ 
 
How complete are 
the data? 
Calendar 
Year 
Missing data 
2010 N/A 
2011 N/A 
2012 N/A 
2013 -0 PHC services missing all data fields 
-3 empty numerator cells: unclear whether these 
were omissions or intended to be zeros 
-No missing data for remaining PHC services 
2014 -0 PHC services missing all data fields 
-3 empty numerator cells: unclear whether these 
were omissions or intended to be zeros 
-No missing data for remaining PHC services 
 
Are the data 
collection and 
analysis methods 
documented? 
Yes. See details under KPI 1. 
Is there scientific 
evidence available to 
support the 
measure? 
HbA1c is internationally accepted as the gold standard index of 
glycaemic control, endorsed by the World Health Organization (89) 
and is the best risk marker for diabetic microvascular complications 
(88). Studies have shown reductions in diabetic complications in 
type 2 diabetic patients with controlled blood glucose levels (91-93). 
However, to control blood glucose, actions such as improving diet, 
taking appropriate medications, and lifestyle changes are required 
(94). This indicator does not measure what action, if any, was taken 
by the general practitioner or the patient to control blood glucose 
levels and therefore to reduce subsequent complications of 
diabetes. 
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KPI 9 - ‘Number and proportion of diabetic patients with albuminuria who are on ACE 
inhibitor and/or ARB’ (10) 
Rationale 
 ‘Renal disease is a major complication of diabetes. It is first diagnosed by the detection of 
protein in the urine (albuminuria). Control of high blood pressure is important in slowing the 
progression of renal disease. Use of Angiotension Converting Enzyme inhibitor and/or 
Angiotension Receptor Blocker have been demonstrated to significantly improve BP control and 
renal deterioration’ (10). 
Definition  
 ‘The number and proportion of Indigenous and non-Indigenous clients who are residents, who 
are 15 years old and over, who have been diagnosed with Type II diabetes with albuminuria 
(urine ACR >3.4) who are on an ACE (Angiotension Converting Enzyme) inhibitor and/or ARB 
(Angiotension Receptor Blocker) during reporting period. ACE inhibitor drugs include: Ramipril, 
Perindopril. ARB drugs include: Ibersartan, Candisartan’ (10). 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
In 2012–13, 18% of Aboriginal and Torres Strait Islander 
people aged ≥ 18 years had indicators of chronic kidney 
disease, were as likely as non-Indigenous Australians to 
have indicators of chronic kidney disease (rate ratio of 2.1) 
(95) and signs of kidney disease appear more frequently at 
an earlier age for Aboriginal and Torres Strait Islanders 
compared to non-Indigenous Australians (13). 
 
 
During 2008-12, 2.5% of deaths among Aboriginal and 
Torres Strait Islanders were due to kidney disease (13), and 
death due to kidney disease is 2.6 times the rate for non-
Indigenous Australians, after adjusting for age differences 
between the two populations (13). 
 
In 2011-2013, care involving dialysis was the leading cause 
of hospitalisation (45%) for Aboriginal and Torres Strait 
Islander Australians, 10 times the rate for non-Indigenous 
Australians (13). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes - diabetes is in the ‘2014 Aboriginal and Torres Strait 
Islander Health Performance Framework’ (13).  
The Australian Government funds a range of initiatives, 
some of which include the following:  
1. The Diabetes Care Project pilot that- tests new models of 
healthcare arrangements for people with Type 1 and type 2 
diabetes. 
2. The Indigenous Australians Health programme - provides 
diabetes prevention and management through 
comprehensive primary health care. 
 3. The ‘essential service standards’ (ESSENCE) project 
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identifies areas of care that are needed to reduce disparity 
in accesses and outcomes for Aboriginal and Torres Strait 
Islanders with high blood pressure. 
3. General practitioner health assessments for Indigenous 
Australians under the Medical Benefits Scheme. These 
health assessments include measurement of blood pressure 
and incentive payments for improved management, as well 
as cheaper medicines through the Pharmaceutical Benefits 
Scheme (13). 
Can the health care system 
meaningfully address this 
disease area problem? 
Yes - early identification of signs of kidney disease 
complications in people with diabetes is one of the core 
functions of Aboriginal Comprehensive Primary Health Care 
 
However, the causes of kidney disease in Aboriginal and 
Torres Strait Australians are multifactorial including both 
environmental and metabolic risk factors such as diabetes 
(96). Culturally appropriate, family centred approaches, 
engagement with communities and working collaboratively 
across the continuum of care and prevention are needed for 
primary health care to be successful in addressing these 
disease areas (74). Factors such as having a community 
based model, patient education, and education and 
empowerment of local health workers, have been 
associated  with better control of hypertension and prevention 
of the associated complications (97). 
 
 
 
Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
The number of people with albuminuria is being detected 
through this KPI however, whether they are being 
appropriately and effectively treated to control blood 
pressure or delay progression of kidney disease is not 
known. 
 
This indicator does not assess the content or quality of care 
that was provided if the clinician found that ARB or ACE 
wasn’t successfully controlling blood pressure and renal 
disease. 
 
It is also uncertain how albuminuria is measured i.e. is it 
measured using a point of care device or is a specimen sent 
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to the laboratory for testing? We can therefore not draw 
any conclusions about the sensitivity and specificity of the 
test used to inform this KPI. 
 
Other standard uncertainties around the KPI being able to 
measure/detect the disease condition are detailed under 
KPI 1. 
Do the results fall within a 
plausible range? 
Using 2014 NT AHKPI data, the range of resident clients with 
type 2 diabetes and albuminuria who are on the following 
treatments: 
 ACE inhibitor: 0% to 100%*  
 ARB: B 0% to 100%* 
 Both ACE and ARB 0% to 100%* 
*Reflecting the proportion of people with albuminuria who 
are being treated 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all Aboriginal 
and Torres Strait 
Islander clients 
with type 2 
diabetes and 
albuminuria in the 
community 
captured by the 
PHC service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
 
Were both 
numerators and 
denominators 
correct?   
Yes, but there are limitations. Standard 
uncertainties around numerator and 
denominator (people being seen 
outside of the PHC service, or not 
being entered into the system or being 
incorrectly entered) are detailed under 
KPI 1. 
 
Numerator 
‘1. The number of resident clients who 
are 15 years of age and over, and who 
have been diagnosed with type II 
diabetes with albuminuria and who are 
on an ACE inhibitor during the 
reporting period. 
2. The number of resident clients who 
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are 15 years old and over and who 
have been diagnosed with type II 
diabetes with albuminuria and who are 
on an ARB during the reporting period. 
3. The number of resident clients who 
are 15 years of age and over and who 
have been diagnosed with type II 
diabetes with albuminuria and who are 
on both ACE inhibitor and ARB during 
the reporting period.’ 
 
Denominator: ‘The number of resident 
clients who are 15 years of age and 
over and who have been diagnosed 
with type II diabetes with albuminuria.’ 
 
Year Do numerators add up to 
denominator? 
2010 Yes 
2011 Yes 
2012 Yes 
2013 Yes 
2014 Yes 
 
 
 
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the data collection 
methods for measuring, 
calculating or recording 
this KPI changed over 
time? 
Definition version Changes made as written in the 
NT AHKPI Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change: Correct ACR cut off 
Counting rules—inclusions, 
exclusions: 
From: Include type II diabetic 
patients with ACR > 3.5 
To: Include type II diabetic 
patients with ACR > 3.4 
 
Change: Specified period to 
include calendar year 
Calculation - Specified period 
From: Financial year 
To: Financial year or Calendar 
year 
 
Chapter 3 
 
3-84 
 
Change: Data sourcing to exclude 
paper based systems and 
pathology labs and pharmacies 
sources. 
 
Data quality and availability 
From: The data collection method 
will depend on a clinic’s 
information system. If a clinic has 
an electronic information system 
e.g. Communicare, Ferret, or 
PCIS, the data required to 
calculate this performance 
indicator will be extracted 
directly from their database. If a 
clinic’s records are paperbased, 
the data will be input manually 
via the web-based data input 
system. 
The numerator required to 
calculate this indicator can also 
be sourced by combining data 
from pathology labs and 
pharmacies using the client’s 
HRN number. Pathology labs can 
provide the HRN number of 
patients whose ACE test result is 
greater than 3.4 (i.e. patients 
with albuminuria) and 
pharmacies can provide the 
names of patients who are on an 
ACE inhibitor or ARB. 
To: The data collection method 
will depend on a clinic’s 
information system e.g. 
Communicare, Ferret, or PCIS, the 
data required to calculate this 
performance indicator will be 
extracted directly from their 
database.’ 
 
2013 March 2.0.2 No changes. 
2013 Sept 2.0.3 No changes. 
2014 April 2.0.4 No changes. 
2014 Oct 2.0.7 No changes. 
 
How complete are the  
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data? Calendar 
Year 
Missing data 
2010 -2 PHC services missing all data fields 
-Numerator data missing for1 services for ACE, 10 
services for ARB and 19 services for ACE and ARB 
-No data missing for the remaining PHC services 
2011 -1 PHC service missing all data fields 
-Numerator data missing for 1 PHC service for ACE, 
19 services for ARB, 29 for ACE and ARB. Unclear 
whether these were omissions or intended to be 
zeros 
-No data missing for remaining PHC services 
2012 -Numerator data missing for 6 PHC services for ARB 
and 14 services for ACE and ARB. Unclear whether 
these were omissions or intended to be zeros 
-No data missing for remaining PHC services 
2013 -Numerator data missing for 1 PHC service for ACE, 
4 services for ARB, 24 for ACE and ARB. Unclear 
whether these were omissions or intended to be 
zeros 
-No data missing for remaining PHC services 
2014 -Numerator data missing for 6 PHC services for ARB 
and 38 services for ACE and ARB. Unclear whether 
these were omissions or intended to be zeros 
-No data missing for remaining PHC services 
 
 
Are the data collection 
and analysis methods 
documented in writing 
and being used to ensure 
the same procedures are 
followed each time? 
Yes. See details under KPI 1. 
Is there scientific 
evidence available to 
support the measure? 
Good control of blood pressure in people with type 2 diabetes 
reduces the progression of both microvascular and macro vascular 
complications, including renal disease (98). ARB or ACE improves 
blood pressure control and renal deterioration in type 2 diabetics. 
However, this indicator does not assess whether the ARB or ACE 
have successfully controlled the blood pressure and renal 
deterioration in the resident clients. Although data on blood 
pressure control amongst type 2 diabetics is collected for KPI 13. 
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KPI 10 - ‘Number and proportion of Indigenous resident clients aged 15 to 54 years who 
have had full adult health check’  (10)  
Rationale: ‘The evidence for screening well people for asymptomatic disease is well established 
for a specified number of conditions. Screening detects the disease at an earlier stage, and this 
allows good clinical management with the aim of reducing and preventing complications. Adult 
health checks indicate quality of primary health care services, with a focus on health promotion 
and prevention. It is also a major strategy to identify and treat sexually transmitted infections, 
which are mainly asymptomatic’ (10). 
 
Definition:  ‘The number resident clients who are 15 years to and less than 55 years of age and 
who have a current complete: 
1. MBS item 715 Indigenous adult health check, or  
2. Alternative Indigenous adult health check similar to MBS item 715. 
 
The following mandatory items are included in the alternative Adult Health Checks for those 
aged 15–54 years: 
 
Taking the patient’s medical history 
1. Medical history, current health problems and health risk factors 
2. Relevant family medical history 
3. Medication usage–including OTC and medication from other doctors 
4. Immunisation status (refer to the appropriate current age and sex immunisation schedule) 
5. Sexual and reproductive health 
6. Physical activity, nutrition and alcohol, tobacco or other substance use 
7. Hearing loss 
8. Mood (depression and self-harm risk) 
9. Family relationships, social circumstances, and whether the patient is a carer or cared for by 
another person 
 
Examining the patient 
1. Measurement of the patient’s blood pressure, pulse rate and rhythm 
2. Measurement of height and weight to calculate BMI, and if indicated, measurement of waist 
circumference for central obesity 
3. Oral examination (gums and dentition) 
4. Ear and hearing examination (otoscopy and if indicated, a whisper test) 
5. Urinalysis (dipstick) for proteinuria 
 
Undertaking or arranging any required investigation 
Arrange or undertake any investigations as clinically indicated and consider the need for the 
following tests, in particular, in accordance with national or regional guidelines: 
1. Fasting blood sugar and lipids 
2. Pap smear 
3. STI testing 
4. Mammography 
Assessing the patient using the information gained in the health check 
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Overall assessment of the patient including the patient’s level of cardiovascular risk based on 
consideration of evidence from patient history, examination results and results of any 
investigations 
Initiating intervention activities as required 
1. Risk factors assessment and discussion with patient or patient’s parent or carer
2. Provision of preventative advise and intervention where required
3. Interventions may include:
4. Initiation of treatment, referral and/or immunisation
5. Education, advice and /or assistance in relation to smoking, nutrition, alcohol/other substance
use, physical activity (SNAP), reproductive health issues e.g. pre-pregnancy education/
counselling safer sex and/or social and family issues
6. Other interventions as considered necessary.’
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
These health checks cover a number of chronic, 
communicable and sexually transmissible infections (STIs). 
Chronic diseases such as cardiovascular disease, diabetes, 
kidney and circulatory diseases and STIs  can have serious 
long term consequences, disproportionately affect 
Aboriginal and Torres Strait Islander peoples (13, 35) and 
represent a substantial and increasing portion of health 
care expenditure (99 , 100, 101). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes – these general practitioner health assessments for 
Indigenous Australians under the Medical Benefits Scheme 
are funded by the Australian Government. These 
assessments include incentive payments for improved 
management, as well as cheaper medicines through the 
Pharmaceutical Benefits Scheme (102). 
Can the health care system 
meaningfully address this 
disease area problem? 
This is a screening test, so it depends on whether the 
disease detected can be treated but yes – full adult health 
checks are one of the core functions of Aboriginal and 
Torres Strait Islander Primary Health care. 
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Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Standard uncertainties around the KPI able to 
measure/detect the disease condition are detailed under 
KPI 1. 
Do the results fall within a 
plausible range? 
Using 2010 to 2014 NT AHKPI data the range reported for 
the proportion of Aboriginal and Torres Strait Islander 
resident clients aged 15 to 55 years who had a full adult 
health check from PHC services were: 
 Full adult health check: 0% to 92% 
 Similar alternative adult health check: 0% to 67% 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all Aboriginal 
and Torres Strait 
Islander resident 
clients aged 15 to 
54 years in the 
community 
captured by the 
PHC service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
 
Were both 
numerators and 
denominators 
correct?   
 Yes. 
Year Do numerators add up to 
denominator? 
2010 Yes 
2011 Yes 
2012 Yes 
2013 Yes 
2014 Yes 
 
Numerator:  
‘MBS Item 715 Indigenous Adult Health 
Check 
The number of resident Indigenous 
clients who are aged 15 years to less 
than 55 years of age and who have a 
current and complete MBS Item 715 
Indigenous adult health check at the 
end of the current reporting period. 
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Alternative Indigenous Adult Health 
Check 
The number of resident Indigenous 
clients who are aged 15 years to less 
than 55 years of age and who have a 
current and complete Alternative 
Indigenous Health Check at the end of 
the current reporting period.’ 
Denominator:  
‘Number of resident Indigenous clients 
who are aged 15 years to less than 55 
years of age as at the end of the 
reporting period.’ 
 
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the 
data 
collection 
methods for 
measuring, 
calculating or 
recording this 
KPI changed 
over time? 
 
 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change: Collapsing of Medicare Item No 
710 into 715. 
 
Definition 
From: …who have a current complete MBS 
item 710 Indigenous adult health or 
alternative Indigenous adult health check 
similar to MBS item 710 during reporting 
period. 
To:…who have a current complete: 
a. MBS item 715 Indigenous adult health 
or 
b. alternative Indigenous adult health 
check similar to MBS item 715. 
 
The following mandatory items are 
included in the alternative Adult Health 
Checks for those aged 15–54 
years: 
 
[Inserted 24 Alternative Care Plan 
‘mandatory items’ from the ‘SCARF 
Technical specifications for 
Essential Indicators Version 4.0 July 2010’]. 
 
Calculation Numerator 
From:…who have a current and complete 
MBS Item 710 adult health check at the 
end of the current 
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reporting period and were aged: 
a. 15-24 years (Item 710) 
b. 25-44 years (Item 710) 
c. 45-54 years (Item 710) 
 
To:…who have a current and complete 
MBS Item 715 adult health check at the 
end of the current 
reporting period and were aged: 
d. 15-24 years (Item 715) 
e. 25-44 years (Item 715) 
f. 45-54 years (Item 715) 
 
Change: Specified period to include 
calendar year 
Calculation - Specified period 
 
From: Financial year 
 
To: Financial year or Calendar year 
 
Change: Data sourcing to exclude paper 
based systems sources. 
Data quality and availability 
 
From: The data collection method will 
depend on a clinic’s information system. If 
a clinic has an electronic information 
system e.g. Communicare, Ferret, or PCIS, 
the data required to calculate this 
performance indicator will be extracted 
directly from their database. If a clinic’s 
records are paper based, the data will be 
input manually via the web-based data 
input system. 
 
To: The data collection method will depend 
on a clinic’s information system e.g. 
Communicare, Ferret, or 
PCIS, the data required to calculate this 
performance indicator will be extracted 
directly from their database. 
 
Change: Statement of alignment to 
Healthy For Life. 
 
Sound methodology 
Added  
Definition is aligned to the ‘SCARF 
Technical specifications for Essential 
Indicators Version 4.0 July 
2010’ that is being developed as a national 
standard.’ 
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2013 March 2.0.2 ‘Change: Counting Rules 
 
Description: Update the counting rules to 
correctly reflect current CARPA 
recommendations. 
 
To: CARPA recommends all adults over 15 
years have a health check every 2 years. 
Therefore, all adults who have had a 
health check in the 2 years prior to the end 
of the reporting period should be included 
in the count, not just those who received a 
health check within the reporting period. 
Each client to be counted once only. 
Population is as at ‘end of reporting 
period.’ 
 
Change: Specified period 
Description: Added an additional time 
period to the KPI 
From: Financial year or Calendar year. 
To: Two-year period commencing on either 
1st July or 1st January.’ 
2013 Sept 2.0.3 No changes made. 
2014 April 2.0.4 No changes made. 
2014 Oct 2.0.7 No changes made. 
 
How 
complete are 
the data? 
 
Calendar 
Year 
Missing data 
Full adult health check 
Missing data 
Alternative similar health check 
2010 -1 PHC service missing all 
data fields 
-4 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
zeros 
 
-1 PHC service missing all data 
fields 
-65 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
zeros 
-1 PHC service used zero 
reporting 
2011 -1 PHC service missing all 
data fields 
-4 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
zeros 
-Zero reporting not used. 
We therefore cannot 
interpret the significance of 
a missing value for these 
services 
-1 PHC service missing all data 
fields 
-58 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
zeros 
-Zero reporting not used. We 
therefore cannot interpret the 
significance of a missing value 
for these services 
 
2012 -0 PHC services missing all 
data fields 
-2 empty numerator cells: 
unclear whether these were 
-0 PHC services missing all data 
fields 
-56 empty numerator cells: 
unclear whether these were 
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omissions or intended to be 
zeros 
-Zero reporting not used. 
We therefore cannot 
interpret the significance of 
a missing value for these 
services 
omissions or intended to be 
zeros 
-Zero reporting not used. We 
therefore cannot interpret the 
significance of a missing value 
for these services 
 
2013 -No missing data  -54 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
zeros 
-Zero reporting not used. We 
therefore cannot interpret the 
significance of a missing value 
for these services 
2014 -No missing data -2 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
zeros 
-Zero reporting not used. We 
therefore cannot interpret the 
significance of a missing value 
for these services 
 
 
Are the data 
collection 
and analysis 
methods 
documented 
in writing and 
being used to 
ensure the 
same 
procedures 
are followed 
each time? 
Yes. See details under KPI 1. 
Is there 
scientific 
evidence 
available to 
support the 
measure? 
Health checks allow for early detection and early treatment of disease, they 
improve the frequency of preventive care and support for patient 
behaviour change (103), however, this KPI only measures whether a health 
check was conducted, it does not assess what action was taken after or the 
impact on health outcomes. 
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KPI 11 - ‘Number and proportion of Indigenous resident clients aged 55 years and over 
who have had full adult health check’ 
Rationale: ‘The evidence for screening people for asymptomatic disease is well established for a 
specified number of conditions. Screening detects the disease at an earlier stage, and this allows 
good clinical management with the aim of reducing and preventing complications’ (10). 
 
Definition:   
‘The number of resident clients who are 55 years old and over and who have a current complete:  
 
MBS item 715 Indigenous adult health or Alternative Indigenous adult health check similar to 
MBS item 715. 
 
The following mandatory items are included in the alternative Adult Health Checks for those 
aged 55 years and over: 
 
Taking the patient’s medical history 
1. Medical history, current health problems and health risk factors 
2. Relevant family medical history 
 
Examining the patient 
Medical 
1. Medication review 
2. Measurement of the patient’s blood pressure, pulse rate and rhythm 
3. Continence 
4. Immunisation status (refer to the appropriate current age and sex immunisation schedule) 
5. Measurement of height and weight to calculate BMI, and if indicated, measurement of waist 
circumference for central obesity 
6. Urinalysis (dipstick) for proteinuria 
7. Trichiasis check where indicated 
8. Skin examination 
9. Reproductive and sexual health examination 
10. Physical function 
11. Activities of daily life 
12. Falls in the last 3 months 
13. Psychological function 
14. Cognition 
15. Mood 
Social function 
16. Availability and adequacy of paid and unpaid help when needed or wanted 
17. Caring for another person 
18. Consultation with the patients carer (where applicable).’ 
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Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
These health checks cover a number of chronic, 
communicable and sexually transmissible infections (STIs). 
Chronic diseases such as cardiovascular disease, diabetes, 
kidney and circulatory diseases and STIs  can have serious 
long term consequences, disproportionately affect 
Aboriginal and Torres Strait Islander peoples (13, 35) and 
represent a substantial and increasing proportion of health 
care expenditure (99 , 100, 101). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes – these general practitioner health assessments for 
Indigenous Australians under the Medical Benefits Scheme 
are funded by the Australian Government. These 
assessments include incentive payments for improved 
management, as well as cheaper medicines through the 
Pharmaceutical Benefits Scheme (102). 
Can the health care system 
meaningfully address this 
disease area problem? 
This is a screening test, so it depends on whether the 
disease detected can be treated but yes – full adult health 
checks are one of the core functions of Aboriginal and 
Torres Strait Islander Primary Health care.  
 
Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Standard uncertainties around the KPI able to 
measure/detect the disease condition are detailed under 
KPI 1. 
 
 
Do the results fall within a 
plausible range? 
Using 2010 to 2014 NT AHKPI data the range reported for 
the proportion of Aboriginal and Torres Strait Islander 
resident clients aged ≥ 55 years who had a full adult health 
check from PHC services were: 
 
 Full adult health check: 0% to 100% 
 Similar alternative adult health check: 0% to 83% 
 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all Aboriginal 
and Torres Strait 
Islander resident 
clients aged 15 to 
54 years in the 
community 
captured by the 
PHC service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
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Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
 
Were both 
numerators and 
denominators 
correct?   
Yes - all numerators and denominators 
fell into plausible ranges: 
Year Do numerators add up to 
denominator? 
2010 Yes 
2011 Yes 
2012 Yes 
2013 Yes 
2014 Yes 
Numerator:  
‘MBS Item 715 Indigenous Adult Health 
Check (55+) 
The number of resident Indigenous 
clients who are aged 55 years and over 
and who have a current and complete 
MBS Item 715 adult health check as at 
the end of the reporting period 
Alternative Indigenous Adult Health 
Check (55+) 
The number of resident Indigenous 
clients who are aged 55 years and over 
and who have a current and complete 
Alternative Indigenous Health Check as 
at the end of the reporting period.” 
Denominator:  
‘Number of resident Indigenous clients 
who are aged 55 years and over as at 
the end of the reporting period.’ 
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Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the 
data 
collection 
methods for 
measuring, 
calculating or 
recording this 
KPI changed 
over time? 
 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change: Collapsing of Medicare Item No 
704/706 into 715 and further alignment to 
Healthy For Life definitions for alternative 
care plans. 
 
Definition 
From:…who have a current complete MBS 
item 704 or 706 Indigenous adult health or 
alternative 
Indigenous adult health check similar to 
MBS item 704 or 706 during reporting 
period. 
 
To:…who have a current complete: 
a. MBS item 715 Indigenous adult health 
or 
b. alternative Indigenous adult health 
check similar to MBS item 715 during 
reporting period. 
 
The following mandatory items are 
included in the alternative Adult Health 
Checks those aged 55 years and 
over: [Inserted 18 Alternative Care Plan 
‘mandatory items’ from the ‘SCARF 
Technical specifications for 
Essential Indicators Version 4.0 July 2010’]. 
 
Calculation Numerator 
From:…who have a current and complete 
MBS Item 704 or 706 adult health check at 
the end of the 
current reporting period and were aged: 
a. 55-64 years (Item 704) 
b. 65 years and above (Item 704) 
c. 55-64 years (item 706) 
d. 65 years and above (Item 706) 
To: …who have a current and complete 
MBS Item 715 adult health check at the 
end of the current 
reporting period and were aged: 
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a. 55-64 years (Item 715) 
b. 65 years and above (Item 715) 
 
Counting rules—inclusions, exclusions: 
From: Adult health checks must include the 
criteria of the MBS items 710, 704 or 706 
(as appropriate). 
 
The health check must be complete to be 
included in the data collection process 
(initiation is not sufficient). 
Adult health checks (item 710) are valid for 
two years, therefore all adults with a 
current/valid health check at the end of 
the reporting period should be included in 
the data collection process, not just those 
adults who received a health check during 
the reporting period. 
 
Adult health checks (item 704 and 706) are 
valid for one year, therefore all adults with 
a current/valid health check at the end of 
the reporting period should equate to all 
adults who received a health check in the 
reporting period. 
 
To: Adult health checks must include the 
criteria of the MBS item 715. 
 
The health check must be complete to be 
included in the data collection process 
(initiation is not sufficient). 
 
Adult health checks (item 715) are valid for 
one year, therefore all adults with a 
current/valid health check at the end of 
the reporting period should be included in 
the data collection process, not just those 
adults who received a health check during 
the reporting period. 
 
Change: Specified period to include 
calendar year 
Calculation - Specified period 
From: Financial year 
To: Financial year or Calendar year 
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Change: Data sourcing to exclude paper 
based systems and Medicare Australia 
sources. 
 
Data quality and availability 
 
From: The data collection method will 
depend on a clinic’s information system. If 
a clinic has an electronic information 
system e.g. Communicare, Ferret, or PCIS, 
the data required to calculate this 
performance indicator will be extracted 
directly from their database. If a clinic’s 
records are paperbased, the data will be 
input manually via the web-based data 
input system. The numerator data required 
to calculate this indicator can also be 
obtained from Medicare Australia by 
requesting a report on the number of 704 
and 706 item claims by provider location. 
 
To: The data collection method will depend 
on a clinic’s information system. If a clinic 
has an electronic information system e.g. 
Communicare, Ferret, or PCIS, the data 
required to calculate this performance 
indicator will be extracted directly from 
their database. 
 
Change: Statement of alignment to Healthy 
For Life. 
Sound methodology 
Added: 
Definition is aligned to the ‘SCARF 
Technical specifications for Essential 
Indicators Version 4.0 July 
2010’ that is being developed as a national 
standard.’ 
2013 March 2.0.2 ‘Change: Definition 
Description: Minor edit to correct 
sentence. 
 
From: The following mandatory items are 
included in the alternative Adult Health 
Checks those aged 55 years and over: 
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To: The following mandatory items are 
included in the alternative Adult Health 
Checks for those 
aged 55 years and over: 
 
Change: Counting Rules 
Description: Add definition to counting 
rules to correctly reflect the data 
requirements for this KPI 
 
To: CARPA recommends all adults over 15 
years have a health check every 2 years. 
Therefore, all adults who have had a 
health check in the 2 years prior to the end 
of the reporting period should be included 
in the count, not just those who received a 
health check within the reporting period. 
Each client to be counted once only. 
Population is as at ‘end of reporting 
period.’ 
 
Change: Specified period 
Description: Added an additional time 
period to the KPI 
From: Financial year or Calendar year. 
To: Two year period commencing on either 
1st July or 1st January.’ 
2013 Sept 2.0.3 No changes made. 
2014 April 2.0.4 No changes made. 
2014 Oct 2.0.7 No changes made. 
 
 
How 
complete are 
the data? 
 
Calendar 
Year 
Missing data 
Full adult health check 
Missing data 
Alternative similar health check 
2010 -1 PHC service missing all 
data fields 
-21 empty numerator 
cells: unclear whether 
these were omissions or 
intended to be zeros 
-1 PHC service missing all data 
fields 
-78 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
zeros 
2011 -1 PHC service missing all 
data fields 
-14 empty numerator 
cells: unclear whether 
these were omissions or 
-1 PHC service missing all data 
fields 
-78 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
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intended to be zeros zeros 
2012 -8 empty numerator cells: 
unclear whether these 
were omissions or 
intended to be zeros 
-82 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
zeros 
2013 -4 empty numerator cells: 
unclear whether these 
were omissions or 
intended to be zeros 
-67 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
zeros 
2014 -1 empty numerator cell: 
unclear whether these 
were omissions or 
intended to be zeros 
-16 empty numerator cells: 
unclear whether these were 
omissions or intended to be 
zeros 
 
 
Are the data 
collection 
and analysis 
methods 
documented 
in writing and 
being used to 
ensure the 
same 
procedures 
are followed 
each time? 
Yes. See details under KPI 1. 
Is there 
scientific 
evidence 
available to 
support the 
measure? 
Health checks allow for early detection and early treatment of disease, they 
improve the frequency of preventive care and support for patient 
behaviour change (103), however, this KPI only measures whether a health 
check was conducted, it does not assess what action was taken after or the 
impact on health outcomes. 
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KPI 12 - ‘Number and proportion of resident women who have had at least one Pap test 
during reporting period’ 
Rationale ‘Increasing participation in cervical screening is important to reduce the number of 
women who present with cervical cancer and ultimately die from the disease. A range of 
strategies actively targets women in the 20-69 years inclusive age group. It is recommended that 
women in the target age group, who have ever been sexually active, have a pap smear every two 
years.’ 
Definition ’The number and proportion of women aged 20-69 years inclusive who are residents 
and who have had at least one pap smear test during the specified reporting period’ (10). 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
Between 2012 and 2013, the incidence of cervical cancer in 
Indigenous women was more than twice that of non-
Indigenous women and the age-adjusted mortality rate was 
4 times the non-Indigenous rate (104). Indigenous women 
are reported to have poorer outcomes (105). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes, in early 1991, The Australian Government implemented 
The National Cervical Screening Program. This program 
encourages women aged 20-69 years to have two yearly 
Papanicolaou (Pap) smear tests to screen for cervical 
abnormalities. It also provides training for Pap smear testing 
and runs quality assurance programs for diagnostic 
laboratories. The aim of this program is to diagnose and 
treat cervical abnormalities early with the aim of reducing 
the incidence of cervical cancer and mortality from cervical 
cancer (106). 
Can the health care system 
meaningfully address this 
disease area problem? 
Yes, screening services are available and part of the core 
functions of primary health care in the NT.  
Since the introduction of The National Cervical Screening 
Program, it is estimated that 70% of squamous cell carcinomas 
of the cervix have been prevented by early diagnosis and 
management of cervical abnormalities (107-109). However, 
there is evidence that there is under screening amongst 
Indigenous women (104). A range of barriers to cervical 
screening for Indigenous women have been identified which 
include: a lack of culturally appropriate services, linguistic 
barriers, fear and misunderstanding of the procedure and of 
cervical cancer itself, feelings of shame and embarrassment, 
fear about lack of confidentiality of results and geographical 
(physical accessibility) barriers (110-112). Community 
participation in planning and delivery, having an Indigenous 
health worker who focuses on public health education and 
promotion, and having a female GP, increase the uptake of 
cervical screening (111). Using approaches such as these will be 
needed to address the aforementioned barriers to ensure the 
health care system can meaningfully address this disease area.  
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Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Limitations with this indicator include:  
The Pap test is used as a screening tool as part of The National 
Cervical Screening Program. While this is a useful indicator, 
it is not diagnostic of cervical cancer; it just identifies those 
who may have abnormalities in the cells of the cervix, 
particularly pre-cancerous lesions. If abnormal cells are 
found, further testing is required to confirm a diagnosis 
(104). Furthermore, Pap smear tests collect a sample of cells 
from the surface of the cervix at a certain point in time. This 
sample is then examined in a laboratory. There are high quality 
standards in place as part of the National Cervical Screening 
Program to monitor the quality of laboratories in Australia that 
report on cervical cytology results (106). However, this testing 
system does not accurately detect all abnormalities that may be 
present in the cervix. The specificity of the test to detect 
precancerous abnormalities ranges from 62% to 98% and the 
sensitivity of a single Pap smear test ranges from 40% to 86% 
(113). The strength and accuracy of this indicator relies on 
repeated screening visits at regular intervals to allow for 
detection of precancerous abnormalities during the 
precancerous stage (113). 
 
There are some cervical cancers (e.g. small and large cell 
neuroendocrine cancers of the cervix) that do not have a 
precancerous stage, and therefore won’t be detected by 
cervical screening (114).  
 
This KPI only assesses who has been screened for cervical 
abnormalities – it does not assess what happened once an 
abnormality is detected. 
 
Other standard uncertainties around the KPI being able to 
measure/detect the disease condition are detailed under 
KPI 1. 
Do the results fall within a 
plausible range? 
Using 2010 to 2014 NT AHKPI data the range reported from 
PHC services were: 
 0% to 97% 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
Are all women 
aged 20-69 years 
in the community 
captured by the 
PHC service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
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methods being used do not 
produce consistently over-
counting or under-counting? 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
 Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
Were both 
numerators and 
denominators 
correct?   
Yes - all numerators and denominators 
fell into plausible ranges: 
Year Do numerators add up to 
denominator? 
2010 Yes 
2011 Yes 
2012 Yes 
2013 Yes 
2014 Yes 
Numerator: 
‘1. The number of resident women 
aged 20-69 years inclusive and who 
have had at least one pap smear test 
during the previous 2 reporting periods. 
2. The number of resident women aged
20-69 years inclusive and who have had
at least one pap smear test during the
previous 3 reporting periods.
3. The number of resident women aged
20-69 years inclusive and who have had
at least one pap smear test during the
previous 5 reporting periods.’
Denominator:  
‘The number of resident women aged 
20-69 years of age.’
Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the 
data 
collection 
methods for 
measuring, 
calculating or 
recording this 
KPI changed 
over time? 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 ‘Change: Specified age group 
Rationale 
From: …women in the 18-70 years age group. 
To: …women in the 20-69 years inclusive age 
group. 
Definition 
From:…women in the 18-70 years age group. 
To:…women in the 20-69 years inclusive age 
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group. 
 
Calculation – Numerator 
From: The number of women aged 18-70 years 
who are residents and who have had at least 
one PAP smear test during reporting period. 
To: The number of women aged 20-69 years 
inclusive who are residents and who have had 
at least one 
pap smear test during reporting period and 
were aged: 
a. 20-34 years 
b. 35-49 years 
c. 50-69 years 
 
Calculation – Denominator 
From: The number of women aged 18-70 years 
who are residents at the end of reporting 
period 
 
To: The number of women aged 20-69 years 
inclusive who are residents at the end of 
reporting period 
and were aged: 
a. 20-34 years 
b. 35-49 years 
c. 50-69 years 
 
Change: Specified period to include calendar 
year 
Calculation - Specified period 
From: Collect data every financial year for the 
previous 2 financial years 
To: Collect data every financial year or 
calendar year for the previous 2 financial or 
calendar years 
Change: Data sourcing to exclude paper based 
systems and pathology lab sources. 
Data quality and availability 
From: The data collection method will depend 
on a clinic’s information system. If a clinic has 
an electronic information system e.g. 
Communicare, Ferret, or PCIS, the data 
required to calculate this performance 
indicator will be extracted directly from their 
database. If a clinic’s records are paper based, 
the data will be input manually via the web-
based data input system. 
The numerator data required to calculate this 
indicator can also be sourced from pathology 
labs e.g. Western Diagnostic Pathology, who 
can provide the number of PAP smear tests 
done by them by provider number in the 
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reporting period. 
 
To: The data collection method will depend on 
a clinic’s information system e.g. 
Communicare, Ferret, or PCIS, the data 
required to calculate this performance 
indicator will be extracted directly from their 
database’ (10). 
 
2013 March 2.0.2 ‘Change: Counting Rules 
From: ‐ 
To: Each client to be counted only once… 
 
Change: Specified period 
 
Description: adding an additional time period 
to the KPI 
From: Collect data every financial year or 
calendar year for the previous 2 financial or 
calendar years. 
To:  
1. Collect data every financial year or 
calendar year for the previous 2 
financial or calendar years. 
 
2. Collect data every financial year or 
calendar year for the previous 3 
financial or calendar years. 
 
3. Collect data every financial year or 
calendar year for the previous 5 
financial or calendar years.’ 
 
 
2013 Sept 2.0.3 No changes made. 
 
2014 April 2.0.4 No changes made. 
 
2014 Oct 2.0.7 No changes made. 
 
 
 
How 
complete are 
the data? 
 
Year Missing data 
2010 - 1 PHC services missing all data fields 
- 1 empty numerator cell: unclear whether this was an 
omission or intended to be a zero 
- No missing data for remaining PHC services 
2011 - 1 empty numerator cell: unclear whether this was an 
omission or intended to be a zero 
-No missing data for remaining PHC services 
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2012 -No missing data for PHC services 
2013 -No missing data for PHC services 
2014 -No missing data for PHC services 
 
 
Are the data 
collection 
and analysis 
methods 
documented 
in writing and 
being used to 
ensure the 
same 
procedures 
are followed 
each time? 
Yes. See details in KPI 1. 
Is there 
scientific 
evidence 
available to 
support the 
measure? 
Cervical cancer has a precancerous stage that can last for many years before 
the disease becomes invasive. This provides an opportunity for detection and 
treatment (115). Studies show that regular screening for cervical cancer for 
women aged 20-69 (and subsequent management of abnormalities) 
reduces risk of mortality from cervical cancer (104, 116-118).  
 
This KPI only assesses how many women have been screened, it does not 
provide any information on what happened once and abnormality was 
found and on the quality of case that was given. 
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KPI 13 - ‘Number and proportion of Indigenous clients who have diabetes type 2 and 
who have good BP control within 12 month period’ 
Rationale  
‘Good control of BP in people with diabetes reduces the incidence of cardiovascular disease and 
delays the progression of renal disease’ (10). 
 
Definition:   
‘Number and proportion of Aboriginal clients aged 15 and over who have type 2 diabetes and 
who have good BP control’ (10). 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
In 2011-2012, type 2 diabetes was the second leading 
specific cause of death for Aboriginal and Torres Strait 
Islander Australians, accounting for 8% of all adult deaths 
(71).  
 
In 2012–13, 20% of Aboriginal and Torres Strait islander 
people aged ≥ 18 years had high blood pressure (140/90 
mm/Hg). Aboriginal and Torres Strait Islander people aged  
≥ 18 years were more likely than non-Indigenous people to 
have high blood pressure (rate ratio of 1.2) (119). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes - diabetes is in the ‘2014 Aboriginal and Torres Strait 
Islander Health Performance Framework’ (13).  
 
The Australian Government funds a range of initiatives, 
some of which include the following:  
1. The Diabetes Care Project pilot that- tests new models of 
healthcare arrangements for people with Type 1 and type 2 
diabetes. 
2. The Indigenous Australians Health programme - provides 
diabetes prevention and management through 
comprehensive primary health care. 
 3. The ‘essential service standards’ (ESSENCE) project 
identifies areas of care that are needed to reduce disparity 
in accesses and outcomes for Aboriginal and Torres Strait 
Islanders with high blood pressure. 
3. General practitioner health assessments for Indigenous 
Australians under the Medical Benefits Scheme. These 
health assessments include measurement of blood pressure 
and incentive payments for improved management, as well 
as cheaper medicines through the Pharmaceutical Benefits 
Scheme (13). 
Can the health care system 
meaningfully address this 
disease area problem? 
Yes – measurement and effective management of blood 
pressure is one of the core functions of Aboriginal 
Comprehensive Primary Health Care.  
 
Chapter 3 
 
3-108 
 
High blood pressure is associated with a range of life style 
factors and socioeconomic determinants (120, 121), some 
of which go beyond the control of the health care system.  
 
Factors such as having a community based model, patient 
education, and education and empowerment of local health 
workers, have been associated  with better control of 
hypertension and prevention of the associated complications 
(97). 
 
 
 
Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Standard uncertainties around the KPI being able to 
measure/detect the disease condition are detailed under 
KPI 1. 
 An accurate diagnosis of high blood pressure can be 
affected by the general practitioner taking the test 
and reading the results, the instrument used and on 
the patient (122, 123).  
 This indicator does not provide any information on 
what proportion of patients had their blood 
pressure under control within the last 12 months. 
Do the results fall within a 
plausible range? 
Using 2014 NT AHKPI data the range reported from PHC 
services for: 
 The proportion of type 2 diabetic clients with a 
blood pressure reading ≤ 130/180 = 24% to 80%  
 The proportion of clients with type 2 diabetes who 
had a blood pressure test = 29% to 100%  
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all Aboriginal 
and Torres Strait 
Islander clients 
aged ≥ 15 years 
who have type 2 
diabetes in the 
community 
captured by the 
PHC service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
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Were both 
numerators and 
denominators 
correct?   
Yes - all numerators and denominators 
fell into plausible ranges: 
Year Do numerators add up to 
denominator? 
2010 N/A 
2011 N/A 
2012 N/A 
2013 N/A 
2014 Yes 
 
Numerator: 
‘a. The number of resident clients who 
are indigenous, have Type II diabetes 
and whose blood pressure 
measurement result, recorded within 
the previous 6 months, was less than or 
equal to 130/80 mmHg. 
b. The number of resident clients who 
are indigenous, have Type II diabetes 
and who have had a blood pressure 
measurement result, recorded within 
the previous 6 months.’ 
 
Denominator: 
‘a. The number of resident clients who 
are indigenous, have Type II diabetes 
and who have had a blood pressure 
measurement result, recorded within 
the previous 6 months. 
b. The number of resident clients, who 
are indigenous, have Type II diabetes.’ 
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Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the 
data 
collection 
methods for 
measuring, 
calculating or 
recording this 
KPI changed 
over time? 
 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 N/A 
 
2013 March 2.0.2 N/A 
2013 Sept 2.0.3 N/A 
 
2014 April 2.0.4 Change: New indicator 
Description: additional KPI added to KPI 
reporting. 
 
2014 Oct 2.0.7 No changes made. 
 
How 
complete are 
the data? 
 
Calendar 
Year 
Missing data 
2010 N/A 
2011 N/A 
2012 N/A 
2013 N/A 
2014 -No missing numerator or denominator data for any of the 
PHC services 
 
Are the data 
collection 
and analysis 
methods 
documented 
in writing and 
being used to 
ensure the 
same 
procedures 
are followed 
each time? 
Yes. See details under KPI 1. 
Is there 
scientific 
evidence 
available to 
support the 
measure? 
Good control of blood pressure in people with type 2 diabetes reduces the 
progression of microvascular and macro vascular complications (98). However, 
as with the control of blood glucose levels, controlling blood pressure requires 
action such as life style changes and or taking appropriate medications (94). 
This indicator does not measure what action, if any, was taken by the general 
practitioner or the patient to control blood pressure levels and therefore to 
reduce subsequent complications of diabetes. 
 
Chapter 3 
 
3-111 
 
KPI 14 - ‘Number and proportion of Indigenous ARF / RHD clients who are prescribed to 
be requiring 2-4 weekly BPG Penicillin Prophylaxis and have received injections over a 12 
month period’ 
Rationale ‘4 weekly BPG Penicillin secondary prophylaxis is currently the most cost effective 
intervention in preventing a recurrence of Acute Rheumatic Fever (ARF) and hence the 
deterioration of the heart valves (mitral and aortic) and subsequently the development of 
Rheumatic Heart Disease (RHD)’ (10). 
 
Definition ‘The proportion of Indigenous patients with a diagnosis of ARF or RHD who are 
prescribed as requiring 4 weekly BPG penicillin injections over a 12 month period and receive 
injections (adherence)’ (10). 
Importance of what is being measured 
What is the impact on health 
and on health expenditure? 
The prevalence of ARF and RHD in Aboriginal and Torres 
Strait Islander Australians living in the NT was 20.3 per 
1,000, 4.5 per 1,000 in northern and central regions of 
Queensland (QLD), and 3.3 per 1,000 in Western Australia 
(WA) (13). These prevalence rates are amongst the highest 
in the world (124-127).  
 
Aboriginal and Torres Strait Islanders have a seven-fold 
greater risk of being hospitalised from Acute Rheumatic 
Fever (ARF) and Rheumatic Heart Disease (RHD) (128), and 
nearly 20 fold greater risk to die from these diseases 
compared to non-Indigenous Australians (129). 
Are policy makers and 
consumers concerned about 
the disease? 
Yes, there are range of Government funded initiatives 
implemented aimed at reducing the prevalence and impact 
of ARF/RHD: 
1. The Better Cardiac Care for Aboriginal and Torres 
Strait Islander People initiative aimed at 
strengthening the diagnosis, notification and follow 
up of RHD, 
2. The Essential Service Standards for Equitable 
National Cardiovascular Care (ESSENCE) for 
Aboriginal and Torres Strait Islander People project. 
This project identifies areas of care that are needed 
to reduce the disparity in access and outcomes for 
circulatory diseases including cardiovascular 
conditions associated with RHD. This program is also 
developing and piloting a primary health 
cardiovascular care resource kit. 
3. RHD registers and control programmes in NT, WA, 
QLD and SA to improve case detection, diagnosis 
and access to antibiotic injections (secondary 
prophylaxis) 
4. The National Coordination Unity that develops 
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national education, training and self-management 
resource and is developing a performance 
monitoring system, to improve collection of data 
and reporting on incidence and prevalence of ARF 
and RHD (13). 
Can the health care system 
meaningfully address this 
disease area problem? 
Register based control programmes that include improved 
patient care, patient education and regular delivery of 
secondary prophylaxis have been shown to be effective in 
controlling this disease (127), and there has been some 
success with current control programs in place in the NT, 
SA, QLD and in New South Wales (130). However, 
interventions that also address the socioeconomic 
determinants (overcrowded housing, poor nutrition, poor 
hygiene and sanitation, and poor access to appropriate 
healthcare services (131)) that underpin this disease are key 
to the successful prevention and management of these 
diseases (127).  ARF has been successfully controlled in 
many developed communities and countries around the 
world through addressing these socioeconomic factors 
(131). 
 
Scientific soundness 
Validity: are the data telling the truth? 
Does the information 
collected measure what it is 
supposed to measure? (I.e. 
has the indicator been tested 
and validated to measure 
what it is intended to 
measure?) 
Standard uncertainties around the KPI being able to 
measure/detect the disease condition are detailed under 
KPI 1. 
Do the results fall within a 
plausible range? 
Using 2013 to 2014 NT AHKPI data the range of resident 
clients prescribed to be requiring prophylaxis and who have 
received injections over a 12-month period from PHC 
services was: 
 0% to 100% 
Is there reasonable assurance 
that the data recording (into 
electronic medical record) 
and subsequent collection (of 
aggregate data using 
appropriate software) 
methods being used do not 
produce consistently over-
counting or under-counting? 
Are all clients who 
are prescribed to be 
requiring 2-4 
weekly BPG 
Penicillin 
Prophylaxis in the 
community 
captured by the 
PHC service’s 
database? 
This criterion requires comparison with 
other datasets which is not possible as 
part of this evaluation. 
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Were the data 
correctly extracted 
by the NT DoH 
warehouse? 
 Systematic checks of the data are 
performed once the data reach the NT 
DoH warehouse. Please see detail of this 
and it limitations in KPI 1. 
Were both 
numerators and 
denominators 
correct?   
Yes - all numerators and denominators 
fell into plausible ranges. 
 
Year Do numerators add up to 
denominator? 
2010 N/A 
2011 N/A 
2012 N/A 
2013 Yes 
2014 Yes 
 
The numerator is categorised into 3 
groups:  
The number of resident Indigenous 
clients who have been diagnosed with 
ARF/RHD who are prescribed to be 
requiring 2-4 weekly BPG Penicillin 
Prophylaxis and: 
 
a. have received 80% of their injections 
due at the end of the reporting period. 
 
b. have received equal to or greater 
than 50% to less than 80% of their 
injections due at the end of the 
reporting period. 
 
c. have received less than 50% of their 
injections due at the end of the 
reporting period.  
 
Denominator:  
‘The number of resident Indigenous 
clients who have been diagnosed with 
ARF/RHD and who are prescribed to be 
requiring 2-4 weekly BPG Penicillin 
Prophylaxis during the reporting 
period.’ 
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Reliability: does the measure provide stable results across various populations and 
circumstances? 
Have the 
data 
collection 
methods for 
measuring, 
calculating or 
recording this 
KPI changed 
over time? 
 
Definition version Changes made as written in the NT AHKPI 
Definitions Manual Year Month Version 
2010 Oct 1.3.3 N/A 
2013 March 2.0.2 ‘Change: New indicator 
Description: additional KPI indicator added to 
KPI reporting.’ 
2013 Sept 2.0.3 No changes made. 
2014 April 2.0.4 No changes made. 
2014 Oct 2.0.7 ‘Change: numerator  
From: The number of resident Indigenous 
clients who have been diagnosed with 
ARF/RHD who are prescribed to be requiring 
2-4 weekly BPG Penicillin Prophylaxis and have 
received 80% of their injections due at the end 
of the reporting period.’ 
To: ‘a. The number of resident Indigenous 
clients who have been diagnosed with 
ARF/RHD who are prescribed to be requiring 
2-4 weekly BPG Penicillin Prophylaxis and have 
received 80% of their injections due at the end 
of the reporting period. 
b. The number of resident Indigenous clients 
who have been diagnosed with ARF/RHD who 
are prescribed to be requiring 2-4 weekly BPG 
Penicillin Prophylaxis and have received equal 
to or greater than 50% to less than 80% of 
their injections due at the end of the reporting 
period. 
c. The number of resident Indigenous clients 
who have been diagnosed with ARF/RHD who 
are prescribed to be requiring 2-4 weekly BPG 
Penicillin Prophylaxis and have received less 
than 50% of their injections due at the end of 
the reporting period.’ 
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How 
complete are 
the data? 
 
Calendar 
Year 
Missing data 
2010 N/A 
2011 N/A 
2012 N/A 
2013 - 13 PHC services missing all data fields 
- 23 empty numerator cells: unclear whether these were 
omissions or intended to be zeros 
- Zero reporting not used. We therefore cannot interpret the 
significance of these missing vales 
- No missing data for remaining PHC services 
2014 - 8 PHC services missing all data fields 
- 16 empty numerator cells: unclear whether these were 
omissions or intended to be zeros 
- Zero reporting not used. We therefore cannot interpret the 
significance of these missing vales 
- No missing data for remaining PHC services 
 
 
Are the data 
collection 
and analysis 
methods 
documented 
in writing and 
being used to 
ensure the 
same 
procedures 
are followed 
each time? 
Yes. See details under KPI 1. 
Is there 
scientific 
evidence 
available to 
support the 
measure? 
Reducing the prevalence and impact of RHD requires early diagnosis of ARF 
and effective delivery of secondary prophylaxis (132). Secondary 
prophylaxis is a cost-effective way of controlling RHD at the population 
level (133); however adherence to regular prophylaxis regimens is critical 
for this to be effective. 
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Pilot-testing the survey questionnaires 
We received feedback (shown in Appendix 9) from six individuals from staff at one PHC 
service in NT, and from staff at NT DoH and AMSANT, but no feedback for the survey to 
the higher level planners in time for incorporating their suggestions. Overall, feedback 
was it was a good, well designed survey that was not ‘too onerous’. Suggestions for 
improving the questionnaire included allowing more space for comments and having 
more questions with tick box responses to reduce the time for completing the 
questionnaire. However, we did not adopt the latter suggestion because we preferred 
to receive open-ended responses. 
Results from the questionnaire to primary health care staff 
Of the questionnaires sent to 84 PHC (52 NT DoH and 32 ACCHOs) we received only 13 
responses, covering 23 services, from the following individuals (Table 4).  
 
Table 4: Job roles and affiliations of respondents to questionnaire to PHC staff 
Job Number of respondents Number of PHC services 
covered 
CQI facilitator 2 7 
District manager 
2 One unspecified and the 
other covers Top End 
Central district 
Assistant manager of a 
PHC outreach team 
1 1 (did not state service) 
Primary health care 
manager 
5 5 
Data Integrity/Medicare 
Claims Coordinator 
1 8 
Information and reporting 
coordinator 
1 1 
Clinic coordinator 1 1 
Total 13 23 
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In the following section, I first state the question as posed in the questionnaire and 
follow this with my assessment of the responses. 
How do you or your service use the NT AHKPIs? 
All respondents use the indicators for planning their primary health care services.  
Do you use the NT AHKPIs for service planning, CQI, Feedback to communities, other 
(please specify)? 
Sixty-two percent (8/13) of respondents use the indicators for service planning, CQI and 
feedback to communities. One of these respondents added: ‘I also use it to promote 
efficient service and innovative programs within the communities’. Fifteen percent 
(2/13) use them for service planning and CQI only, 15% (2/13) use them for service 
planning only, and one uses them for CQI and feedback to communities.  
How useful were the NT AHKPIs in assisting with service planning, CQI, Feedback to 
communities, and other (please specify)? 
Overall, most respondents (69%) found the indicators to be ‘very useful’ for service 
planning, and CQI, and half of the respondents found them ‘very useful’ for feedback to 
communities (Table 5). The two respondents who selected the other option found them 
‘very useful’ for ‘Staff motivation. Realigning resources across a district’ and for 
‘Feedback to Managers on progress and work completed’. 
 
Table 5: Participant responses to question 6: ‘How useful were the NT AHKPIs in 
assisting with service planning, CQI, feedback to communities and other’ 
  
Service planning 
n (%) 
CQI 
n (%) 
Feedback to communities 
n (%) 
Other 
n (%) 
Very useful 9 (69) 9 (69) 6 (50) 3 (100) 
Somewhat useful 4 (31) 4 (31) 3 (25) 
 Not very useful 
  
1 (8.3) 
 Not useful at all 
  
2 (16) 
 Total responses 13 13 12 3 
 
What value do you see to the NT AHKPIs? 
All except one respondent reported the indicators to be valuable; this person lived in a 
community where only 30% of the population are Aboriginal and/or Torres Strait 
Islander.  
Chapter 3 
 
3-118 
 
How do you explore variations you see in the NT AHKPIs over time (e.g. explore other 
data sources such as work force data or speak to the community or staff)? 
Sixty-two per cent (8/13) of respondents answered this question, and overall they 
explore variations by speaking with their staff and with the community, and cross 
referencing with other reports such as the ‘Traffic Light Report’, and audits of PCIS.  
NT AHKPI reports 
Which NT AHKPI reports do you use? (Please tick one or all options that apply) 
Forty-six percent (6/13) of services use both the Community Health Centre (CHC) 
reports and the Health Service Delivery Area (HSDA) reports, 38% (5/13) use only the 
CHC report and 8% (1/13) use only the HSDA Report. One service did not respond to 
this question.  
 
What do you find most useful in each of the report(s) that you use?  
Seventy-eight percent (10/13) of respondents identified the most useful aspects of the 
CHC report and 69% (9/13) of the HSDA report. Data on trends over time were the most 
useful aspects of both reports. Additionally, for the HSDA report 23% (3/13) found the 
comparisons to the region and other services to be most useful.  
What are the weaknesses of each of the report(s) that you use?   
Fifty-three percent (7/13) of respondent identified weaknesses of the CHC report and 
39% (5/13) of the HSDA report. Weakness of these reports include: aggregated and 
retrospective data, lack of context and missing data (‘does not cover 5-15-year-old 
school age children’ and ‘Some KPIs rely on a claiming GP’). One answer was difficult to 
interpret ‘confusion about STI data collection’. 
How could the report(s) that you use be improved to make it more useful for: service 
planning, CQI, Other? 
Eighty five per cent (11/13) of respondents answered this question for the CHC report, 
and 23% (3/13) for the HSDA report. Suggested improvements are shown in Table 6.   
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Table 6: Participant responses to question ‘How could the report(s) that you use be 
improved to make it more useful for: service planning, CQI, other’ 
Community Health Centre Report Health Service Delivery Report 
‘More KPIs. More frequent reports e.g. quarterly’ ‘More KPIs’ 
‘Improve accuracy. Add context. Condense. Summarize 
key findings and issues with a sort of executive report’ 
‘We break down some of the KPIs 
to be more meaningful’ 
‘We pretty much make the most of it as is’ ‘Have it broken into the month‘s 
that the activities occurred and 
we could then pinpoint the times 
when work decreases or occurs’ 
‘Have it broken into the months that the activities 
occurred and we could then pinpoint the times when work 
decreases or occurs’ 
 
‘Monthly’  
‘Looking at adult immunisations including Hep B and 
fluvax’ 
 
‘Removed all of the blurb (add as an appendix) to shorten 
length of reports’ 
 
‘Perhaps community feedback data could be more 
appropriate’ 
 
‘Better training for people using the KPIs to improve data 
entry. Currently there is minimal training. There is good 
PCIS support but I think there are a lot of data entry errors 
and I don't think everyone is included in the system. For 
example with childhood anaemia, people can fail to 
include them into the system’ 
 
‘I would like to see as much emphasis on the non-clinical 
KPIs, especially workforce-related KPIs but presently they 
seem more of an 'optional extra'.  They don't pick up 
population program work at all, especially lifestyle 
matters like smoking, obesity and AOD, which is a pity’ 
 
‘Have it broken into the months that the activities 
occurred and we could then pinpoint the times when work 
decreases or occurs’ 
 
‘Report can be very time consuming in its layout. Most 
clinicians only want trend reports and graphs’ 
‘Report can be very time 
consuming in its layout. Most 
clinicians only want trend reports 
and graphs’ 
‘If more frequent reports, there would be an opportunity 
to flag areas on the decline or receive reassurance that 
the team is on the "right pathway" to improving 
outcomes’ 
‘If more frequent reports, there 
would be an opportunity to flag 
areas on the decline or receive 
reassurance that the team is on 
the "right pathway" to improving 
outcomes’ 
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Results from the questionnaire to higher level planners 
We received eight completed questionnaires from higher level planners. Their jobs and 
affiliations are listed in Table 7. 
 
Table 7: Job roles and affiliations of respondents to questionnaire to higher level 
planners 
Job role of respondent Organisation 
Associate Program Leader Health 
Promotion 
NT DoH 
CQI Facilitator Did not state 
Associate Program Leader Child Youth 
Health Strategy Unit 
NT DoH 
CQI Program Coordinator AMSANT and steering committee 
General Manager PHC services NT DoH and steering committee 
General practitioner Congress Regional Health Services and 
steering committee 
CQI Coordinator Central Australian Aboriginal Congress 
Communicare support AMSANT and steering committee 
 
 
In the following section, I first state the question as posed in the questionnaire and 
follow this with my assessment of the responses. 
 
How do you use the NT AHKPIs? 
All respondents answered this question. Eighty-five percent (11/13) use the reports for 
CQI and supporting services in their planning and 18% (2/11) can’t access the reports.  
Do you use the NT AHKPIs for planning, policy development, CQI, Other (please specify)? 
Sixty-three percent (5/8) of higher level planners use the indicators for planning, policy 
development, and CQI. One added under the ‘other’ option ‘Epidemiology - e.g. 
diabetes prevalence’. Thirteen percent (1/8) use them for planning and CQI. Twenty-five 
percent (2/8) selected the ‘other’ option and added:  
- ‘If I did get these reports, I would use them for planning and policy development’  
- ‘Not directly, only for support - in all of the above [planning, policy development, 
CQI]’.  
Overall, most respondents (71%) found the indicators to be ‘very useful’ for planning, 
and CQI (80%), but less than half found them ‘very useful’ for policy development (Table 
8). One participant selected other and added ‘Unable to access data other than through 
other's presentations’. 
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Table 8: Responses from higher level planners to question 5 ‘How useful were the NT 
AHKPIs in assisting with planning, policy development, CQI, and other’ 
  
Planning 
n (%) 
Policy development 
% (n) 
CQI 
% (n) 
Other 
%(n) 
Very useful 5 (71) 3 (43) 4 (80) 
 Somewhat useful 2 (29) 4 (57) 1 (20) 
 Not very useful 
    Not useful at all 
    Total responses 7 7 5 
  
NT AHKPI reports and data 
Fifty percent (4/8) of higher level planners use both data and the reports, 25% (2/8) use 
only the reports, and 25% (2/8) selected the ‘other’ option and added: 
-  ‘I would like to if had easy access’ 
- ‘The reports are not distributed widely to our strategy unit area but would be 
valuable.  They should be made more widely available’ 
 
Thirty-eight percent (3/8) of respondents use all three reports (CHC, HSDA and the de-
identified HSDA reports). One uses the de-identified HSDA and CHC reports. Twenty-five 
percent (2/8) use only the de-identified HSDA report. One uses the CHC report and 
added: ‘Run reports from Communicare in between reporting periods to monitor 
progress’. 
Why do you choose this report? (Please answer for each that apply to you) 
Overall, the reports identify needs and show trends over time, however the HSDA 
report and the de-identified HSDA report provide comparisons with other regions. 
What do you find most useful about each of the report(s) that you use? 
Overall, respondents found the data on trends over time were the most useful aspects 
of all of the reports. Additionally, the CHC report ‘allows understanding and promotion 
at local level’, is ‘useful data format, relevant to service delivery’ and ‘well laid out and 
easy to read’, and additionally for the HSDA and de-identified HSDA reports, they 
provide a ‘NT wide picture’. 
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‘What are the weaknesses of each of the report(s) that you use?’ 
Half of the respondents provided information on what they identified as weaknesses of 
the NT AHKPI reports.  
Weakness of the CHC report include: they lack context, small numbers, too much data 
and the data are ‘questionable’ with an ‘unclear population base’. 
 
Weaknesses of the HSDA report include that they lack context, the calendar and 
financial year data are combined, and the data are aggregated and the weakness of the 
de-identified HSDA reports is that there is not enough detail. 
How could the report(s) that you use be improved to make it more useful for Planning, 
Policy, CQI, other? 
Overall, suggested improvements included identifying services, combining financial and 
calendar year exploring ways to eliminate patients being counted more than once and 
to have the data and reports more widely available.  
How do you think the NT AHKPIs are being used at the service level? 
All respondents answered this question. Overall, the KPIs are used for CQI, to measure 
performance for feedback to communities and to boards.  
What factors do you think are promoting their use at the service level? 
All respondents answered this question. Factors that were identified as promoting their 
use at the service level included: realising the value of the indicators, a need for 
reporting, CQI strategy and familiarity and usefulness of the data.  
What factors do you think are hindering their use at the service level? 
Seventy-five percent (6/8) of participants responded to this question. Overall, the 
factors identified as hindering use of the KPIs at the service level included: high staff 
turnover and lack of confidence in the quality of the data.  
How do you explore variations you see in the NT AHKPIs over time (e.g. explore other 
data sources such as work force data or speak to the community or staff)? 
Seventy-five percent (6/8) of respondents answered this question. Overall, higher level 
planners use other reports and datasets to try ‘to get a more complete picture’ as well 
as speaking to other health service staff or staff at AMSANT.  
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Once you have explored variations in the NT AHKPIs, how do you act on the findings to 
improve service performance and to make plans for the future? 
Seventy-five percent (6/8) provided an answer to this question. Overall, to improve 
service planning, actions that are taken include: creating a ‘plan-do-study-act’ (PDSA) 
plan, talk to staff, train and mentor staff, health promotion activities and ‘a whole range 
of CQI activities’.   
Are there any changes that could be made to the governance of the NT AHKPIs that 
would support continuous improvement of the system? 
Thirty-eight percent (3/8) responded ‘yes’ and 68% (5/8) responded ‘don’t’ know’. 
Overall, suggested changes included:  
1. promoting the reports and making them more widely available; 
2. improving the comparability between data from PCIS and Communicare; and  
3. giving Communicare the ability to collect data across multiple clinics for one 
client. 
Any other comments or suggestions you may have are welcome. 
One person added ‘These reports are kept closely by some areas and are not shared.  
They would be valuable to inform planning and policy development, and program 
management that I know of - but I am sure would have other applications if we had 
access to the information.  These reports need to be shared more widely’. 
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Discussion  
To address the objectives of the evaluation, we chose two key approaches: 1) to 
evaluate each indicator and 2) assess the usefulness of the system as expressed by key 
stakeholders drawing on surveys of all people who use the indicators at the PHC level 
and of higher level planners. I will discuss the findings from these two approaches 
separately. 
Indicators evaluated against OECD criteria 
Importance of the KPIs and can the health care system meaningfully address the disease 
area 
With the exception of KPI 1, the KPIs assess important disease areas that policy makers 
are concerned about, and that are part of the core functions of PHC for Aboriginal and 
Torres Strait Islanders in the NT. Although each of the disease areas has their own 
unique challenges to delivery, they are also influenced by a range of social and 
environmental health determinants, many of which go beyond the domain traditionally 
covered by PHC services. Culturally appropriate, family centred approaches, 
engagement with communities and working collaboratively across the continuum of 
care (74), support to address local factors and good disease guidelines are needed for 
primary health care to be successful in addressing all of these disease areas (75). 
Scientific soundness of the KPIs 
Overall, the quality of the data that inform the KPIs is good and has improved 
substantially since the system was first introduced. NT DoH conducts systematic checks 
to validate the data before distributing the summary reports to services and higher level 
planners. However, these checks do not identify incomplete or incorrect data entries. 
 
No information is collected on the variability of diagnostic testing devices used to 
inform some of the KPIs (e.g. Hemocue to screen for anaemia by testing Hb levels). It 
could be worth considering collecting this information so that comparability of the 
testing device that inform some of the KPIs across services could be assessed. 
 
Changes have been made to either the numerator and/or denominators definitions for 
13/16 KPIs since the system was first introduced which affects the reliability of these 
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KPIs over time. However, these changes have been fully documented and are available 
on the NT AHKPI website to enable meaningful interpretation of the trends. 
 
It is not possible to assess completeness of the data because zero reporting is not used 
and the significance of blank numerator cells remains unknown. However, the 
proportion of services reporting no data (no numerator and denominator data) has 
improved substantially since the system was first introduced. 
 
The value of nine of the 16 indicators is supported by good scientific evidence to 
support 9/16 KPIs, however, of these, 3 KPIs (low birth weight babies, underweight 
children and anaemic children) are outcome indicators that are highly influenced by a 
range of environmental and socioeconomic factors and can therefore not be used as a 
valid reflection of the performance of a PHC service.  
 
Seven of the 16 KPIs measure the proportion of resident clients who have been 
screened/tested for an abnormality; they capture provision of services but not the 
remedial action taken once a problem was identified. Collecting information on how 
these abnormal findings are managed is the first step to understanding whether action 
is ‘appropriate’. 
How the indicators are meeting their intended goals 
‘Inform understanding of trends in individual and population health outcomes’ 
The KPIs describe trends and this is cited as being one of the most important aspects of 
the NT AHKPI reports, however they do not inform understanding of trends. This 
requires data to be collected on the social and environmental determinants related to 
health conditions being measured. Participants make up for this by exploring variations 
in trend data through speaking with their staff and with the community, and cross 
referencing with other reports.  
‘Identify factors influencing these trends’ 
The same applies to this objective. The indicators do not meet this objective because 
they do not provide any contextual information, or provide any information on the 
social and environmental determinants of health associated with the measured disease 
areas. As stated by one of the respondents ‘They provided limited information on a 
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small range of indicators. To really understand what is happening from a CQI perspective 
you usually have to get further data to really explore the situation. However, that is the 
nature of indicators - I don’t think it would be good to too many KPIs or too complex 
data reports’. To identify factors influencing these trends, respondents explore other 
sources of information such as exploring other datasets, and speaking to staff and the 
community. This has also been reported by a previous evaluation which found that the 
indicators are not generally used for CQI on their own (134). 
‘Inform appropriate action, planning and policy development’ 
The results show that the indicators are used to inform action, and planning and to a 
lesser degree policy development. All services reported using the KPIs for either service 
planning and CQI. All higher level planners (who have access to the KPIs) use the KPIs to 
support services in their planning and CQI. These findings are consistent with a previous 
study that evaluated the CQI Quality Improvement Investment Strategy (134). 
 
Whether the action is ‘appropriate’ cannot be determined through this evaluation or 
through the indicators because no information is collected on how problems are 
addressed once they are identified. For example, with regard to KPI 6 (proportion of 
children tested for anaemia and who are anaemic), information should also be collected 
on whether anaemic children were treated and how they were treated. The OECD state 
that providing screening tests is a ‘process measure of quality’ that has construct validity 
when the screening test is linked to earlier detection of disease and a better prognosis 
(11). The following KPIs (2, 3, 5, 6, 8.1, 8.2, 9, 10, 11, 12, and 13) do allow for earlier 
detection of disease, however, the action taken by the individual and the health worker 
is what will make a difference to the prognosis, and make a difference to the health 
status of that individual and the community. 
Are the NT AHKPIs being used for other purposes 
A major use of the indicators has been for CQI of PHC services (134). This has been 
previously reported but is not stated in the system’s original goals. In addition to this, 
they are also used to motivate staff. 
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How can the reports and processes be improved? 
Overall, condensing the reports whilst providing them on a more frequent basis and 
disaggregating the results so they can be used more ‘operationally’ are suggestions for 
how the reports can be improved. These suggestions reflect the busy environment in 
PHC. The NT AHKPI data appear to be a valuable, useful source of information for 
people at the PHC level, however as stated by one respondent, there is ‘too much data’. 
Providing an executive summary at the beginning of each of the reports, reducing the 
overall content of each of the reports, while providing them more frequently may 
further improve the system. 
Limitations  
This evaluation is subject to multiple biases and I have categorised these in terms of 
selection and measurement biases. 
Measurement bias 
- The major source of measurement bias for this study is my interpretation of the 
open-ended responses from the participants. Interpreting answers is subjective 
and my interpretation may have introduced my own ideas about the indicators.  
- Even though we piloted the questionnaire, they were not validated. The way we 
worded the questions may have also introduced bias into the study.  
The effect of these biases is uncertain.  
 
Selection bias 
- Our very small response rate means our findings are not generalizable to the 
source population. 
- By conducting the survey online, we may have excluded services located in 
remote areas where internet access can be limited. Although I did try to 
counteract this by taking hard copies of the questionnaires with me to CQI 
Collaborative Workshop, and by giving participants the option to complete the 
questionnaire with me over the telephone. 
- By sending the questionnaires to services via the CEOs of the services, the 
questionnaires may not have reached all staff. In the original study proposal, we 
had included visiting a sample of services which would have reduced this 
selection bias but due to time constraints this could not be done.  
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Conclusion 
Findings from the questionnaires revealed that the KPIs are considered a very valuable 
tool being used to inform planning of PHC services, but information on whether the 
action and planning is ‘appropriate’ is not collected. The results of KPIs cannot address 
objectives 1 and 2 (‘inform understanding of trends in individual and population health 
outcomes’ and ‘identify factors influencing these trends’) because data aren’t collected 
on the social and environmental determinants related to the health conditions and 
events being measured.  
The response rate for our study was very small and therefore unlikely to be 
representative of the study population of health staff related to the PHC services. This 
limits us from being able to draw meaningful or generalizable conclusions or 
recommendations until in-depth interviews and focus group discussions can be 
conducted with all relevant staff. We need more robust evidence to assess whether the 
indicators are addressing their intended goals effectively, and how the system could be 
improved for greater usefulness.  
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Recommendations  
* I have shared initial findings with stakeholders and they requested that I continue to 
collect questionnaire data to collect stronger more meaningful evidence. This study is 
therefore still a work in progress and recommendations are still to be developed with the 
stakeholders in line with UFE guidance. 
 
Recommendations based on assessment using OECD criteria 
1. Introduce KPIs that assess the quality of treatments and services to determine if 
action is ‘appropriate’. 
 
2. Use zero reporting so that there is a clearer understanding of what is a missing 
value and what is a zero. 
 
3. Consider removing or modifying objectives 1 ‘inform understanding of trends in 
individual and population health outcomes’ and 2 ‘Identify factors influencing 
these trends’ from the overarching goals of the NT AHKPI system. These 
objectives go beyond what KPIs are able to do. 
 
Recommendation based questionnaires 
4. Continue collecting questionnaires to collect stronger, more meaningful 
evidence that can help to further strengthen the system. 
 
5. Conduct focus groups with higher level planners to understand how the KPIs are 
used for the development of policy and how they might be improved to make 
them more useful. 
 
6. Condense the reports, provide an executive summary at the beginning of the 
reports and provide them more frequently. 
 
7. Consider making the reports more widely available to all NT DoH and AMSANT 
staff. 
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Appendix 1: List of the Northern Territory Aboriginal Health Key Performance Indicators 
(NT AHKPIs) as at December 2015 
 
1. Number of episodes of health care and client contacts*. 
2. Timing of first antenatal visit for regular clients delivering Indigenous babies. 
3. Number and proportion of low, normal and high birth weight Indigenous babies. 
4.1. Number and proportion of Indigenous children fully immunised at 1, 2 and 6 years 
of age. 
4.2. Proportion of children who have received immunisations on time. 
5. Number and proportion of children less than 5 years of age who are underweight. 
6. Number and proportion of children between 6 months and 5 years of age who are 
anaemic. 
7. Number and proportion of clients aged 15 years and over with type 2 diabetes and/or 
coronary heart disease who have a chronic disease management plan. 
8.1. Number and proportion of resident clients aged 15 years and over with type 2 
diabetes who have had a glycosylated haemoglobin (HbA1c) test in the last 6 months. 
8.2. The number and proportion of Indigenous clients with type 2 diabetes and whose 
HbA1c measurements are within certain levels. 
9. Number and proportion of diabetic patients with albuminuria who are on Angiotensin 
Converting Enzyme Inhibitor (ACE) inhibitor and/or Angiotensin Receptor Blocker (ARB). 
10. Number and proportion of Indigenous clients aged 15 to 55 years who have had a 
full adult health check. 
11. Number and proportion of Indigenous clients aged 55 years and over who have had 
a full adult health check in the past 12 months. 
12. Number and proportion of women who had had at least one Papanicolaou (PAP) 
smear test during reporting period. 
13. Number and proportion of Indigenous clients who have type 2 diabetes and who 
have good blood pressure (BP) control within a 6 month period. 
14. Number and proportion of Indigenous Acute Rheumatic fever (ARF)/ Rheumatic 
Heart Disease (RHD) patients who are prescribed to be requiring 2-4 weekly Benzathine 
Penicillin G (BPG) penicillin prophylaxis and have received 80% of their injections over a 
12 month period. 
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Appendix 2: Modified criteria to select indicators to monitor health care quality against 
which KPIs will be assessed from Health Care Quality Indicators Project - Conceptual 
Framework Paper, 2006 (11)(11) 
* Feasibility of obtaining internationally comparable data criterion has been removed
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Appendix 3: Participant information sheet as it appeared on SurveyMonkey, 2015 
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Appendix 4: Participant consent form as it appeared on SurveyMonkey, 2015 
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Appendix 5: Questionnaire for primary health care services as it appeared on 
SurveyMonkey, 2015 
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Appendix 6: Questionnaire for higher level planners as it appeared on SurveyMonkey, 
2015 
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Appendix 7: Advertisement for evaluation of the NT AHKPIs as it appeared in the online 
Communicare newsletter 
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Appendix 8: Presentation I gave on the NT AHKPI evaluation at the CQI collaborative in 
Darwin, 10-11 November 2015 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
3-141 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
3-142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
3-143 
 
Appendix 9: Feedback from the pilot of the questionnaires 
 
A clinic coordinator: ‘I think survey was good asking how useful the NTKPI were and what we 
used them for also the weakness and how they could improve them’. 
  
Data Integrity/Medicare Claims Coordinator: ‘I have completed the survey today and find no 
problems with the questions etc’. 
  
Director of Director of Medical Services, Primary Health Care: ‘I have looked at the version for 
Primary Health Care services. Overall, I think it is a nicely designed survey. There is some useful 
information at the beginning, and the survey content and length are fine. Some of the 
questions ask for comments (e.g., questions 8, 9, 11, 15, 16, 17, 18). It would be a good idea 
to allow multi-line edit boxes for these questions. There doesn't seem to be a limit to the 
number of characters when you type into the boxes provided. However, it is difficult to keep 
track of your answer, as less than 60 characters are visible at a time’. 
  
Another comment: ‘The dedicated CQI/kpi enthusiasts will be more than happy to write in 
boxes. The less enamored would probably prefer boxes just to tick’. 
  
District Manager: ‘Not too onerous, no, but I'm with X in terms of the tick-a-box format being 
more attractive to someone with multiple tasks and responsibilities on their mind’. 
  
General Manager: ‘It doesn't look too onerous, but having said that how many staff are likely 
to complete it????’. 
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Chapter 4 - Screening and managing anaemia in Aboriginal 
and Torres Strait Islander children aged 6 months to 3 years 
in the Northern Territory, 2008 -2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
‘Three areas are critical foundations for healthy child development: stable, 
responsive, and nurturing caregiving with opportunities to learn; safe, 
supportive, physical environments; and appropriate nutrition.’ Margaret 
Chan, Director-General, World Health Organization (1) 
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Preface 
Investigatory role 
As lead investigator for this project I designed the study, prepared the applications to 
ethics committees, requested and analysed the data, interpreted and compiled the 
findings, and reported the results to stakeholders. 
 
Lessons learnt 
I learnt that it can take a long time to access de-identified electronic medical record data. 
We first requested the data in February of 2015 and received the final dataset in mid-
November 2015. The application process was lengthy, complex, and at times confusing, 
but I received great support from NT DoH through the application process for which I am 
thankful. 
 
I learnt that data collected for administrative purposes rather than research can be 
limited in terms of completeness, validity and usefulness, but they can still provide a rich 
source of information to inform health programs and policy meaningfully.  
 
Through this project I also learnt how to manage, structure and merge large datasets with 
multiple observations per record in Stata. 
 
Potential public health impact 
This study provides evidence that the prevalence of anaemia among children aged 6 
months to 3 years attending NT DoH services between 2008 and 2013 is a ‘severe’ 
public health problem, as defined by WHO, and that there is a need to improve the 
screening and management of anaemia in children, while providing culturally 
appropriate nutritional education and access to healthy food. 
These findings will be disseminated to primary health care clinic staff and presented 
at other fora such as the annual Continuous Quality Improvement (CQI) anaemia 
Collaboration, and the Annual Practical Paediatrics conference, to convince decision-
makers and clinicians to change practise as a high priority. 
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Abstract 
Introduction 
Anaemia remains a persistent health challenge for Aboriginal and Torres Strait Islander 
children in the Northern Territory (NT). The latest data from the 2014 NT Aboriginal 
Health Key Performance Indicators (NT AHKPIs) revealed that 22% of Aboriginal and 
Torres Strait Islander children aged 6 months to 5 years tested for anaemia, were anaemic 
(unpublished NT AHKPI data, 2015) with little change over the last five annual reporting 
periods, ranging between 22% and 28%. According to the categories defined by the World 
Health Organization (WHO), this is a public health problem that must be addressed 
effectively. Reports of Continuous Quality Improvement (CQI) Program of the ‘Audit and 
Best Practice for Chronic Disease’ (ABCD) National Partnership indicate that best practice 
guidelines for the management of anaemia are poorly implemented in NT primary health 
care (PHC) services. We aimed to assess how well the guidelines recommended by the 
Central Australian Rural Practitioners Association (CARPA) for the management of 
anaemia among children aged 6 months to 3 years attending NT Department of Health 
(DOH) were being implemented by PHC services. 
 
Methods 
NT DoH extracted and de-identified medical electronic record data for Aboriginal and 
Torres Strait Islander children aged 6 months to 3 years attending NT DoH services 
between 2008 and 2013. Data were forwarded to me in five separate Excel spreadsheets 
within the same Excel file. I imported the data into Stata, cleaned and reshaped the data 
and merged the files as a one-to-one merge matching on the ‘Child Person ID’ and ‘Result 
Date’ variables. I produced frequency tables to show the demographic profile of the 
cohort, and the number and proportion of children who were anaemic. I cross tabulated 
categorised Hb levels based on the guidelines recommended by CARPA with the 
Accessibility/Remoteness Index of Australia (ARIA), age group and treatment. I used the 
Pearson’s chi-squared test to determine statistically significant differences between 
binary and categorical variables. Results were considered significant if P-values were < 
0.05. 
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Results 
Sixty-three percent (3,475/5,543) of children were screened for anaemia at least once 
during the study period. The median age when Hb was first tested was 12 months (range 
6 to 37 months). At the time of first screening, 40% (1,394/3,475) of children were 
anaemic. Seven percent (256/3,475) had an Hb < 90 g/L and 2.5% (87/3,475) had an Hb 
< 80g/L. The prevalence was highest in children aged 6 -11 months, and decreased with 
increasing age. The prevalence of anaemia was highest in ‘very remote’ areas and 
decreased with decreasing remoteness. Twenty-one percent (290/1,394) of anaemic 
children had records of treatment with albendazole and the median duration of 
treatment was for 3 days (range 0 to 8 days). Less than 1% (13/1,394) of anaemic children 
were recorded to have been treated with iron. Only 23% (325/1,394) of anaemic children 
were followed up at or within 4 weeks of diagnosis.  
 
Conclusion 
The prevalence of anaemia among children aged 6 months to 3 years attending NT DoH 
services between 2008 and 2013 is a ‘severe’ public health problem, as defined by WHO. 
The prevalence was highest amongst children aged 6-11 months as may have been 
expected, and in ‘very remote’ areas, suggesting inadequate access to, and intake of, iron 
rich foods required to support rapid growth during this stage of life.  
Although, based on the data collected, a very low proportion of anaemic children were 
recorded as treated according to best practice guidelines, our findings are subject to 
multiple potential biases described under the  ‘limitations’ section. 
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Introduction 
Background 
What is anaemia? 
Anaemia is a condition in which the number of red blood cells and/or haemoglobin (Hb) 
concentration is inadequate to meet the physiological needs of the body (2). These needs 
vary by age, gender, residential elevation above sea level, smoking behaviour, and 
pregnancy status (3).  
The major cause of anaemia worldwide is iron deficiency anaemia (IDA), (4, 5) and other 
causes include:  
1. nutritional deficiencies such as folate, vitamin A, and vitamin B12 deficiencies 
(leading to impaired red blood cell production) (3); 
2. acute and chronic inflammation e.g. infections of childhood, end-stage renal 
disease and cancer (leading to red blood cell destruction and/or impaired red 
blood cell production/impedes release of stored iron) (3); 
3. parasitic infections (leading to blood loss and/or impaired red blood cell 
production) (3);  
4. inherited or acquired blood disorders (leading to impaired red blood cell 
production and/or excessive red blood cell destruction) (3); 
5. blood loss from trauma/injury (6). 
Types and causes of anaemia in the Northern Territory  
Peer-reviewed publications reporting the types of anaemia among children in the NT are 
limited and obsolete with the last publication in 1994 (7-9). Results from these studies 
are consistent with global trends where IDA was the major cause of anaemia (7-10) (Table 
1). In the NT,  IDA in children has been attributed to one or more of the following causes: 
maternal anaemia before and during pregnancy, late introduction and insufficient intake 
of iron-rich solids in breastfed children, low birth weight, recurrent infections and 
intestinal worms (11).  
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Table 1: Peer-reviewed publications on causes of anaemia in Aboriginal and Torres Strait 
Islander children in the NT (7-9) 
Author 
(publication) 
Year Location Study 
population 
Cause of Anaemia 
Crotty (7)   1958 Katherine n=28 
aged 7 months-
6 years 
Iron and protein deficiency 
Watson (8) 1986 Yirrkala, East 
Arnhem land 
n=47 
aged ≥ 5 years 
 74% of cases caused by 
iron deficiency -attributed 
partly (no proportion 
given) to hookworm 
infestation and the 
remainder caused by 
nutritional deficiencies 
 11% caused by folate 
deficiency 
 4% iron and folate 
deficiency 
 11% unknown 
Walker (9)  1994  NT-based 
hospital study  
25% of children 
admitted to 
hospital 
(number not 
stated) 
Iron deficiency 
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Prevalence of Anaemia in the Northern Territory  
Anaemia remains a persistent health concern for Aboriginal and Torres Strait Islander 
children in the NT. The latest data available from the NT Aboriginal Health Key 
Performance Indicators (AHKPIs1) in 2014 revealed that 22% of Aboriginal and Torres 
Strait Islander children aged 6 months to 5 years tested for anaemia were anaemic 
(unpublished 2015 NT AHKPI data), with little change over the last five annual reporting 
periods, ranging from 22% to 28% (Figure 1).     
 
 
Figure 1: The proportion of Aboriginal and Torres Strait Islander children aged 6 months 
- 5 years tested and recorded as anaemic in the NT from 2010 - 2014 (unpublished 2015 
NT AHKPI data) 
 
The Healthy Under Five Kids (HU5K2) study reported that 30% (491/1629) of Aboriginal 
and Torres Strait Islander children aged 0-3 years attending NT Department of Health 
(DOH) Primary Health Care (PHC) services in 2012 were anaemic (12). The World Health 
Organization (WHO) defines a prevalence of anaemia ≥ 40.0% as a ‘severe public health 
problem’, a prevalence of 20.0-39.9% as a ‘moderate public health problem’, a prevalence 
                                                 
1 The NT AHKPI data are collected from all 84 primary health care services [both Northern Territory 
Government and Aboriginal Community Controlled Health Organisations (ACCHOs)] across the NT 
2 The HU5K program is a schedule of visits at key age milestones for children aged 0-5 years. This involves 
routine collection of measurements of weight; height/length and haemoglobin. The program is designed 
to provide a consistent platform of care, support and information for parents, to address key determinants 
of child health. The overall aim of the program is to improve the growth and nutritional status of children 
in the NT. 
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of 5.0-19.9% as a ‘mild public health problem’ and a prevalence of  ≤ 4.9% as ‘normal’ 
(13). Based on these criteria, the prevalence of anaemia in children aged 0-3 years in the 
NT is a ‘moderate’ public health problem that must be addressed. 
Evidence of the impact of anaemia on cognitive and other developmental pathways  
Anaemia or IDA have adverse effects on many aspects of child health including cognitive, 
behavioural and physical development, as well as immune function (13-15). Most studies 
investigating the health impacts of anaemia have focused on IDA. There is a large body 
of research that shows anaemia and IDA have adverse effects on many areas of child 
health including: cognitive, physical and social development, the immune system, and on 
homeostatic responses (Appendix 1). Animal studies have also shown that other adverse 
effects such as increased heavy-metal absorption (16), or impaired thyroid function (17) 
can also occur as a result of iron deficiency. The bulk of these studies have focused 
specifically on exploring the impact of anaemia and IDA on cognitive development and as 
a result there is strong evidence that anaemia and IDA are associated with poorer 
cognitive development in infants, preschool and school-aged children (18, 19). If anaemia 
or IDA is left untreated, developmental delays can persist into adulthood to impact on 
work and economic productivity (20).  But whether IDA is the only cause of cognitive 
impairment remains unclear. Owing to the large number of socioeconomic and 
environmental disadvantages (poverty, low birth weight, malnutrition poor education 
among mothers, lack of stimulation at home) that are often associated with anaemia and 
can themselves affect children’s development, a causal link between anaemia and these 
adverse health outcomes is yet to be fully established because of the difficulty to be able 
to control for all of these factors in study designs (18, 21). 
Some animal studies have provided a number of possible mechanisms through which iron 
deficiency can affect the developing brain (22-25), such as through hypo-myelination 
(reduced amount of myelin in spinal cord, brain, or peripheral nerves) or delayed neuro-
maturation (26), but overall, the exact biological mechanisms behind the relationship 
between anaemia and IDA and cognitive development remain relatively unclear.  
Lozoff (1998) states that when trying to determine the cause of anaemia and IDA, a 
conceptual model of contributing factors must include environmental as well as biological 
determinants as these mechanisms are not mutually exclusive (27, 28). 
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Management of anaemia in the Northern Territory 
In the NT, low birth weight (<2,500g) and pre-term babies are first screened for anaemia 
at one month of age (11). For children with a birth weight of > 2500g who are not 
premature, screening commences at six months of age and continues every six months 
to five years of age (11). For children who are anaemic but who have a Hb of ≥ 90g/L, 
treatment with iron and albendazole (where hookworm is common - in the Top End of 
NT, north of Ti Tree (11)) is recommended with follow up at 4 weeks. For children with 
Hb < 90 g/L, treatment with iron, folic acid and albendazole are recommended, as well as 
a full blood examination, medical review and follow-up (Table 2).  
 
Table 2: Management of anaemia recommended in Central Australian Rural 
Practitioners Association (CARPA) Standard Treatment Manual (11)  
Result What it means What to do 
Low for age but Hb 
level 90g/L or 
more 
‘Likely to be iron deficient’ -Give iron orally or by injection 
-Where hookworm infestation is 
common – give albendazole for 3 
days 
-Follow-up  
-If Hb < 100 g/L – medical review 
Hb < 90g/L at any 
age 
“May be other cause of 
anaemia” (other than 
IDA) 
-If Hb < 80g/L – medical consult 
straight away 
-Treat as above AND give folic acid 
-Full blood examination 
-Medical review  
-Follow up 
‘Encourage healthy eating and diet high in iron for strong blood’ 
 
CQI reports of the ABCD National Partnership indicate that best practice guidelines for 
management of anaemia are poorly implemented (29, 30).  These reports incorporate 
data from NT, Queensland (QLD), South Australia (SA), Western Australia (WA), and New 
South Wales (NSW) for children aged < 6 years.  
Aims 
The aim of this study was to assess how well the best-practice guidelines recommended 
by CARPA for screening and management of anaemic Aboriginal and Torres Strait Islander 
children aged 6 months to 3 years the NT were being implemented. 
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Methods 
Study population 
Our study population was Aboriginal and Torres Strait Islander children aged 6 months to 
3 years attending at least one of the 52 NT DoH PHC services that have electronic records 
recorded in Primary Care Information System (PCIS). This age group was chosen because 
the prevalence of anaemia is usually highest in this age group (12, 31-34) and decreases 
with increasing in age (35).  
 
We had originally intended to include infants aged < 6 months in this analysis. However, 
Hb is not tested routinely in this age group except for children with a birth weight < 2,500g 
as they are ‘likely to become iron deficient’ (11) in their first 6 months. CARPA 
recommends a medical review for this age group as well as giving iron from one to six 
months of age (11). At the time of data extraction, NT DoH advised that data for 
gestational weight in PCIS were of ‘very poor quality’ and recommended we request data 
from the Perinatal National Minimal Dataset and link them with the PCIS data from NT 
DoH. This process required amendments to our original ethics applications and we 
received this advice too late to re-apply for ethics approval. Infants aged < 6 months were 
therefore excluded from this analysis.  
 
Only data from health services managed by NT DoH were included in this analysis because 
they use the same PCIS and we required approval from only five general manager 
executives for 52 NT DoH services. ACCHOs use a different patient information system 
(Communicare). Furthermore, to extract data from the 32 ACCHOs, we required 
approvals from each of the 32 individual services. Owing to time constraints, we decided 
to focus our study only on NT DoH services.  
 
The years 2008 and 2013 were selected because most PHC services only started using 
the PCIS in 2008. A map showing the distribution of PCIS PHC services is shown in 
Appendix 2.   
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Data sources 
Primary Care Information System medical electronic data 
NT DoH extracted and de-identified medical electronic record data from 2008 to 2013 
from the PCIS for 52 PHC NT DoH services across the NT and forwarded them to me via 
email in a password protected Excel Spreadsheet. Demographic details and results of Hb, 
full blood examination (FBE), weight, height/length and treatment details were sent in 
five separate Excel spreadsheets within the same Excel file. The variables from NT DoH 
and the variables used in this analysis are shown in Appendix 3.  
 
I imported the Excel spreadsheets into Stata and saved the files as separate Stata data 
files. I cleaned and checked the data for errors and duplicates using descriptive analyses 
to summarise the data using ‘Codebook’ ‘Summarize’ ‘Describe’ ‘Duplicates Report’ and 
‘Duplicates List’. I checked outliers and erroneous data with supervisors in the NT (who 
are familiar with the datasets) for a decision to be made on whether these data should 
be included or excluded.  I dropped duplicates. I reshaped the data from long to wide 
format so that the data could be merged. I merged Hb test results for the cohort’s first 
screening visit to the demographic data as a one-to-one merge, matching on the ‘Child 
Person ID’ variable. I calculated the age of the children by subtracting the PCIS birth date 
from the first Hb visit date.  I created categorised Hb levels based on the CARPA 
Guidelines (Table 3). To determine how many anaemic children received treatment, I 
merged the treatment data (variables are listed below) with the Hb test results and 
demographic data using a one-to-one merge matching on ‘Child Person ID’ and ‘Result 
Date’(after renaming ‘Dose start date’ to ‘Result date’ so that the variables could be 
merged) (Figure 2).  The ‘Dose duration’ variable had 39% (2,916/7,564) missing data, so 
I created a new variable for dose duration by subtracting ‘Dose End Date’ from ‘Dose Start 
Date’.  CARPA defines areas north of Ti Tree in the NT as locations were hookworm is 
common (11). Services north of Ti Tree were coded accordingly to identify the proportion 
of children receiving albendazole in these areas. 
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Figure 2: The datasets consisting of de-identified electronic medical record data sent by 
NT DoH that were merged using a one-to-one merge for the analysis. Variables that were 
matched on are highlighted by the red boxes 
 
Table 3: Diagnosis of anaemia by age groups using the Central Australian Rural 
Practitioners Association Guidelines 
Age group Anaemia if haemoglobin (g/L) is less 
than 
6-11 months 105 
1 – 4 years 110  
5 -7 years 115 
8 – 11 years 119 
12 – 15 years  (male) 125 
12 – 15 years (female) 118 
* The age group relevant to this study is highlighted by the red box 
 
The Accessibility/Remoteness Index of Australia  
I used The Accessibility/Remoteness Index of Australia (ARIA) based on the road distance 
from a point or place to the nearest service centre (36) (Table 4). I categorised PHC 
services accordingly. 
 
Table 4: Accessibility/Remoteness Index of Australia (ARIA) categories 
ARIA category Definition 
Highly accessible ‘Relatively unrestricted accessibility to a wide range of 
goods and services and opportunities for social 
interaction’ 
Accessible ‘Some restrictions to accessibility of some goods, service 
and opportunities for social interaction’ 
Moderately accessible ‘Significantly restricted accessibility of goods, services 
and opportunities for social interaction’ 
Remote ‘Very restricted accessibility of goods, services and 
opportunities for social interaction’ 
Very remote ‘Very little accessibility of goods, services and 
opportunities for social interaction’ 
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Statistical analyses  
I produced frequency tables to show the demographic profile of the cohort and the 
number and proportion of anaemic children. I cross tabulated categorised Hb levels 
based on the CARPA guidelines with ARIA, age group and different types of documented 
treatment types. I used the Pearson’s chi-squared test to determine statistically 
significant differences between binary and categorical variables. Results were considered 
significant if P-values were < 0.05. 
Ethics 
I obtained ethics approvals from: 
1.  The Human Research Ethics Committee of the Northern Territory Department of 
Health and Menzies School of Health Research (HREC-2015-2340) 
2. The Central Australian Human Research Ethics Committee (HREC-15-291) 
3. The Australian National University Human Research Ethics Committee (2015/313) 
4. NT DoH 
Results 
Electronic medical record data were available for 5,543 children aged 6 months to 3 
years. Of these, 98.7% (n=5,469) were Aboriginal, 1% (n=59) were Aboriginal and Torres 
Strait Islander and 0.3% (n=15) were Torres Strait Islanders. 
 
Of 52 services, three were ‘moderately accessible’, eight were ‘remote’ and 41 were ‘very 
remote’. Twenty-four services were located north of Ti Tree. 
Screening for anaemia 
Sixty-three percent (3,475/5,543) of children were screened for anaemia at least once. 
The median age when Hb was first tested was 12 months (range 6 to 37 months).   
Prevalence of anaemia  
At the time of first screening, 40% (1,394/3,475) of children were anaemic. The 
prevalence was highest in children aged 6 -11 months, and decreased with increasing age 
(Table 5). 
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Table 5: Prevalence of anaemia among Aboriginal and Torres Strait Islander children aged 
6 months to 3 years attending NT DoH services at first screening, by age groups, 2008-
2013 
Age groups No. tested and % 
with anaemia1 
 
No. tested and % 
with Hb < 90 g/L   
No. tested and % with 
Hb < 80 g/L  
 
6-11 months 734 (53%)  178 (70%)  63 (72%)  
12-23 months  462 (33%) 68 (27%) 19 (22%) 
24 -37 months 198 (14%) 10 (3.9%) 5 (5.7%) 
Total 1394  256  87 
1 Anaemia defined as haemoglobin <105 g/L in children aged 6 months to 12 months and 
haemoglobin <110 g/L in children aged 12 months - <5 years  
 
The prevalence of anaemia was highest in ‘very remote’ areas and decreased with 
decreasing remoteness (Table 6). The numbers were too small to draw any meaningful 
conclusions for moderate and severe anaemia (Tables 7 and 8). 
 
Table 6: Prevalence of anaemia among Aboriginal and Torres Strait Islander children aged 
6 months to 3 years attending NT DoH services at first screening, by 
Accessibility/Remoteness Index of Australia (ARIA), 2008-2013 
ARIA Anaemic Total 
Yes 
n (%) 
No 
n (%) 
Moderately accessible 34 (25%) 100 (75%) 134 
Remote 145 (30%) 334 (70%) 479 
Very Remote 1,215 (42%) 1,647 (58%) 2,862 
Total 1,394 2,081 3,475 
χ2 (2) = 38, P = <0.01 
 
Table 7: Prevalence of ‘moderate’ anaemia among Aboriginal and Torres Strait Islander 
children aged 6 months to 3 years attending NT DoH services at first screening, by 
Accessibility/Remoteness Index of Australia (ARIA), 2008-2013 
ARIA Anaemic < 90 g/L at any age Total 
Yes 
n (%) 
No 
n (%) 
Moderately accessible          7 (5.2%) 127 (95%) 134 
Remote 19 (4.0%) 460 (96%) 479 
Very Remote 230 (8.0%) 2,632 (92%) 2,862 
Total 256 3,219 3,475 
χ2 (2) = 11, P = 0.004 
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Table 8: Prevalence of ‘severe’ anaemia among Aboriginal and Torres Strait Islander 
children aged 6 months to 3 years attending NT DoH services at first screening, by 
Accessibility/Remoteness Index of Australia (ARIA), 2008-2013 
ARIA Anaemic < 80 g/L at any age Total 
Yes 
n (%) 
No 
n (%) 
Moderately accessible 2 (1.5%) 132 (98.5%) 134 
Remote 5 (1.0%) 474 (99%) 479 
Very Remote 80 (2.8%) 2,782 (97%) 2,862 
Total 87 3,388 3,475 
χ2 (2) = 5.7, P = 0.057 
 
Management compared with the Central Australian Rural Practitioners Association 
guidelines  
 
Anaemic children with Hb ≥ 90g/L should be treated with iron and albendazole (where 
hookworm is common) and have a follow-up Hb test 4 weeks later. Duration of treatment 
with albendazole should be for 3 days (11). Duration of treatment with iron depends on 
the weight of the child (not assessed in this analysis). For anaemic children with Hb < 90 
g/L, treatment with iron, folic acid and albendazole are recommended, as well as a full 
blood examination, medical review and follow up (11) (Table 9).  
 
Less than 1% (13/1,394) of anaemic children were recorded to have been treated with 
iron (Table 9). Only 20% (290/1,394) of anaemic children had a record of treatment with 
albendazole and the median duration of treatment was 3 days (range 0 to 8 days) (Table 
9). But only 12% (163/1,394) were recorded to have had albendazole for 3 days (Table 
10). Of the children living in areas where hookworm is ‘common’ 28% (233/824) were 
treated with albendazole. Of those who had a follow up visit and Hb test at or within 4 
weeks, all (n=325) were still anaemic. 
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Table 9: Proportion of Aboriginal and Torres Strait Islander anaemic children aged 6 
months to 3 years attending NT DoH services treated according to Central Australian 
Rural Practitioners Association (CARPA) Guidelines, 2008-2013 
Haemoglobin 
(Hb) result 
Central Australian 
Rural Practitioners 
Association (CARPA) 
Guidelines 
Documented 
treatment 
n (%) 
Treatment 
not 
documented 
n (%) 
Total 
Low for age 
but Hb level  
≥ 90 g/L 
Give iron medicine 
oral or intramuscular 
injection 
13 (0.93%) 1,381 (99%) 1,394 
Where hookworm is 
common – give 
albendazole for 3 
days 
3 days 163 (12%) 1,104 (79%) 1,394 
Total 290 (21%) 
Follow-up at 4 weeks 325 (23%) 1,069 (77%) 1,394 
If Hb < 100g/L – 
medical review 
Data not available to assess this 
Hb < 90 g/L 
at any age 
If Hb < 80g/L – 
medical consult 
straight away 
Data not available to assess this 
Give iron medicine 
oral or intramuscular 
injection 
3 (1.2%) 253 (98.8) 256 
Where hookworm is 
common – give 
albendazole for 3 
days 
   3 days       9(3.5%) 186 (73%) 256 
Total 70 (27%) 
Give folic acid 29 (11%) 227 (89%) 256 
Full blood 
examination 
Dates of full blood examination result do not 
match haemoglobin test result dates so one-
to-one merge was not possible as part of this 
analysis 
Medical review Data not available to assess this 
Follow-up at 4 weeks 89 (35%) 167 (65%) 256 
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 Table 10: Duration of albendazole treatment for anaemic children, 2008-2013 
Duration of albendazole treatment 
(days) 
No. (%) of children treated 
0 89 (32%) 
1 1 (0.36%) 
2  20 (7%) 
3 163 (58%) 
4 1 (0.36%) 
6 3 (1.07%) 
7 1 (0.36%) 
8 3 (1.07%) 
Total 281 
*Data on ‘DoseEndDate’ missing for nine children so dose duration could not be
calculated
Management of children with haemoglobin < 90 g/L 
Overall, 1% (3/256) were treated with iron and only 27% (70/256) were treated with 
albendazole. The median duration of treatment with albendazole was 2 days (range 0 to 
8 days) (Table 9). Of the children living in areas where hookworm is ‘common’ 36% 
(52/146) were treated with albendazole. Ninety-two percent (236/256) had a follow-up 
visit, however only 35% (89/256) were seen within or at 4 weeks (Table 9). Of those who 
had a follow-up visit and Hb test within or at 4 weeks, 61% (54/89) still had Hb < 90g/L. 
Management of children with haemoglobin < 80 g/L 
For children with Hb < 80 g/L, 93% (81/87) had a follow up visit, however only 40% (35/87) 
were followed up within or at 4 weeks of being diagnosed with anaemia, and of these 
27% (22/81) were still anaemic at the time of their second visit.  
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Discussion 
The early identification and management of anaemia are essential to prevent the long 
term consequences of anaemia particularly during early years of development. This study 
provides further evidence of the high prevalence of anaemia among Aboriginal and 
Torres Strait Islander children in the NT, and some evidence that a high proportion of 
these anaemic children are not being managed according to CARPA Guidelines, however 
these findings need to be validated. 
The prevalence of anaemia 
The prevalence of anaemia is very high among Aboriginal and Torres Strait Islander 
children aged 6 months to 3 years attending NT DoH services. Although the prevalence 
(40%) was slightly lower than the estimated global average (47%) (37), it is a ‘severe’ 
public health problem as defined by WHO (38).  
 
It is not possible to compare our findings with other studies in the NT because of 
differences in age group, physical location of the study participants, and due to the 
temporal differences in data collection. However, our findings are consistent with a study 
conducted in six remote communities (four in the NT, one in QLD and one in the East 
Kimberley region in WA) conducted between 2010 and 2012. In that study 44% (n=73) of 
children aged 0-24 months, and 56% (n=91) aged between 6 and 9 months, were anaemic 
(39). In another study conducted on a smaller cohort (n=398) of Aboriginal infants aged 
6 months to 12 months living in northern NT, 68% (n=398) were anaemic (40).   
 
The prevalence of anaemia in our study is higher than that reported in the NT AHKPI data 
(range 22% -28% between 2010 and 2014). While the latter include children aged 6 
months to 5 years attending both NT governed DoH services and ACCHOs, our results 
refer only to children aged 6 months to 3 years attending NT DoH services. 
 
The prevalence of anaemia in our study is higher than the prevalence reported by the 
HU5K program in 2012 when 37% of children aged <12 months, 28% of children aged 1 
to < 3 years, and 16% of children aged 3 to < 5 years were anaemic. It is possible this 
difference in prevalence could be related to a different study period and the fact that 
HU5K also draws on data from non-government organisations who agreed to be part of 
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that program (details for these organisations are not given in the relevant published 
reports (12).  
 
Consistent with previous findings (12, 32-34), the prevalence of anaemia was highest 
amongst children aged 6 to 11 months and decreased with increasing age. The 6 - 24 
month age group represents the peak prevalence of iron deficiency in children (31) when 
there is a higher need for iron due to rapid growth (10, 33, 34, 41).  By 6 months, neonatal 
iron stores start to deplete and complementary iron rich foods (among other nutrients) 
are needed for rapid growth (42, 43). Major causes of IDA in this age group are the 
delayed introduction of solid iron rich foods and exclusive consumption of low-iron milks 
such as cow, goat’s or soy milk (44). The prevalence decreases with decreasing rate of 
growth over time and lowered iron requirements. These findings highlight the 
importance of access to education, good nutrition and effective clinical screening and 
management. A study of one remote community in the NT showed that parental 
knowledge of anaemia and the importance of good nutrition was good but this 
knowledge was not put into practice by parents. Reasons for this must be explored among 
all communities in the NT. It is critical not only to treat children in this age group 
effectively for anaemia but also to close the gap in the health inequalities  between 
Aboriginal and Torres Strait Islander Australians and non-Indigenous Australians (45). 
 
It’s promising to hear that as part of the 2014-2015 Federal Budget, $95 million over 
three years from July 2015 has been allocated to a program called ‘Better Start to Life’ 
which includes identifying and targeting funding to increase Aboriginal and Torres Strait 
Islander families’ access to advice and assistance with breastfeeding, nutrition and 
parenting, and monitoring development milestones (46). Hopefully this funding will help 
improve nutritional status of these children but the failure to effectively screen and 
manage anaemic children based on CARPA must also be addressed.  
 
The prevalence of anaemia was highest in ‘very remote’ areas and decreased with 
decreasing remoteness. These findings are consistent with results from the ‘2012-2013 
Australian Aboriginal and Torres Strait Islander Health Survey’ where (10.1% in remote 
compared to 6.9% in non-remote areas) (47). Poor supply of  nutritious food contributes 
to poor nutrition and diseases such as anaemia, particularly in remote Australia (48). 
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Although these results were for adults aged ≥ 18 years, the causes for this disparity are 
likely to be the same. These findings further highlight the need for improved access to 
and education on good nutrition.  
Screening for anaemia  
All children in this group should have been screened for anaemia but only two-thirds were 
screened. This is lower than that reported in the NT AHKPIs (overall 72% for 2013 and 
range between 22% to 100% for individual services, unpublished 2014 data) and in the 
HU5K data (70%). It is possible that this difference could be related to the differences in 
the study designs mentioned in previous section.  
Treatment of anaemia 
Less than 1% of anaemic children were treated with iron supplements, only 28% of 
children living in areas where hookworm is common were treated with albendazole, and 
only 23% had a follow-up Hb test within 4 weeks. According to a smaller study on 398 
Aboriginal children aged 6 to 12 months in northern NT in 2013, 20% of mothers of 
anaemic children were given dietary advice, 27% of anaemic children were administered 
a complete course of albendazole, 30% treated with a complete course of iron, and 28% 
did not receive any iron treatment. A follow-up Hb was checked in 60% of anaemic 
children and 26% of infants with Hb <90g/L received folate (40). 
 
In an audit of electronic medical record data of Aboriginal children aged < 6 years 
attending PHC services in NT, QLD, SA, WA and NSW in 2007, 22% (range 0-100) of 
children had a Hb test, 39% (range 0-100) of anaemic children were treated with 
albendazole, 48% (range 0-100) had an iron supplement prescription, and 47% (range 0-
100) had a follow up Hb assessment (29). 
 
Our findings are of extreme clinical and public health concern and must be confirmed. If 
our findings are correct, this is a major public health concern as defined by the WHO. 
Previously reported barriers to treatment include high staff turnover; fragmented models 
of care and staff poorly prepared for their roles (40), inappropriate guidelines (not just 
CARPA guidelines, refers to jurisdictional guidelines for ‘Far West’ NSW, QLD, NT, SA and 
WA) that compromise the systematic approach to screening and case finding, (49) and 
varied knowledge of health practitioners about the frequency and severity anaemia in 
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children and its potential consequences in children (50). These barriers must be 
addressed as a high priority. 
Limitations  
This study is based on an analysis of electronic medical record data entered into PCIS in 
the course of providing clinical care to children; and are therefore subject to multiple 
potential biases. The study therefore lacks internal validity (the extent to which the 
results are truly representative of the study population) and cannot be generalised to the 
source population (51). I have categorised these biases in terms of selection and 
measurement biases.   
Measurement bias 
Measurement bias is an error in the estimate of frequency or association arising from a 
systematic error in the measurement of the exposure or outcome factor (51). The data 
reflect only what was documented in the electronic patient record; it is therefore possible 
that misclassification of ‘outcome/anaemia’ and ‘exposure/treatment’ and variables may 
have biased the results i.e. under or overestimated the prevalence of anaemia and/or the 
frequency of effective management: 
Misclassification of the ‘outcome/anaemia’ variable 
- Children may have been recorded as anaemic based on an incorrect low result 
from the diagnostic device used to measure Hb levels. This would overestimate 
the proportion of children with anaemia. In a similar way, if the diagnostic device 
gave an incorrectly high Hb result, this would underestimate the prevalence of 
anaemia. The haemoglobinometers have been used to screen for anaemia as part 
of routine practice in the NT for the past 30 years. Currently the HemoCue 
haemoglobinometer is used (52). The HemoCue has a reasonable  sensitivity 
(85%) and specificity (94%) in detecting anaemia (10, 53), and the sensitivity is 
reported to reach 100% in controlled laboratory conditions (54). However, the 
reproducibility, accuracy and precision of the HemoCue results are highly 
dependent on the conditions under which the test has been conducted in the 
clinic, whether venous or capillary blood had been collected and whether the 
HemoCue products were stored in appropriate storage conditions, particularly in 
humid climates (55, 56). It is not possible to quantify the effect of this potential 
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bias on our findings because I have no knowledge of the quality control 
procedures used by the multiple clinics for the HemoCue. 
- My coding in Stata could have incorrectly classified children as being anaemic. 
However, I checked my coding with a senior researcher at the Menzies School of 
Health Research, so this bias is therefore unlikely.  
Misclassification of the ‘age variable’ affecting the outcome  
- It is possible a child’s date of birth may have been incorrectly entered, thus 
affecting the estimation of the age-specific prevalence of anaemia. It is not 
possible to know how likely this bias is without further investigations. 
Misclassification or the ‘treatment/exposure’ variable 
- Treatment may have been recorded and entered into the wrong section of the 
medical electronic record and therefore wasn’t extracted by NT DoH for this 
analysis. Personal communication from a senior staff member from Menzies 
School of Health Research advised that clinical data (including treatment data) are 
often written in the ‘notes’ section of the electronic medical record and not where 
the data should be entered. This bias is likely to have under-estimated the 
treatment frequency in our analysis. 
- Treatment may have been given correctly but was not recorded in the electronic 
medical record. Personal communication from a staff member at NT DoH advised 
that the treatment data were ‘messy’. This bias is also likely to have under-
estimated the treatment frequency. 
- The treatment may have not been given correctly, but was recorded as being 
given. This could overestimate the true frequency of treatment. It is not possible 
to know how likely this bias is without further investigations. 
- Treatment may have been prescribed but was not administered by the parents. 
This could overestimate the true frequency of treatment. Similarly, the parents 
may have administered the treatment but this was no recorded in the electronic 
medical record. This will have underestimated the true frequency. It is not 
possible to know how likely this bias is without further investigations. 
Selection bias 
Selection bias is an error in the estimate of frequency or association arising from the 
manner in which subjects are selected from the sampling frame into the study population 
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(51). Our source population was children attending NT DoH services, our sampling frame 
(database population) was the children entered into PCIS database, and our study 
population were all children recorded to have anaemia (Figure 3). Through these 
different stages of selection, it is possible that we may have included and/or excluded 
children incorrectly where the study population may not be truly representative of the 
sampling frame and therefore of the source population i.e. the denominators for 
assessing prevalence of anaemia or the frequency of treatment may be biased. The study 
may not be generalizable to the sampling frame and/or source population if: 
- Not all children attending NT DoH services had a record on PCIS - this affects the 
size of the denominator population.  
- Children were incorrectly included or excluded into the study based that would 
affect the size of the denominator population. This may either under- or over-
estimate the prevalence of anaemia. 
- All children are screened for anaemia, but clinicians may preferentially screen 
children considered more likely to be anaemic i.e. biased selection of children 
with anaemia which could overestimate the prevalence of anaemia. 
- It is possible that not all data on children entered into PCIS were extracted and 
included in the Excel files sent to me - this reduces the denominator population. 
This may either under- or over-estimate the prevalence of anaemia. 
- By merging datasets one-to-one using the variable ‘Result Date’ I excluded 
children who were treated the day after, or a few days after from the analysis - 
this will underestimate the proportion of children were treated. This could be one 
explanation for why the proportion of anaemic children being treated is so low. 
Changing eligibility over time 
The case definition for anaemia and the recommended treatment has remained the same 
from 2008 to 2013 (11). 
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Figure 3: Hierarchy of study population showing the levels of selection bias 
 
Other limitations 
I could not assess the extent to which all CARPA guidelines on the management of 
anaemia were addressed by the PHC services. I could not assess how many anaemic 
children had a medical review after the initial diagnosis, a full blood examination or 
received dietary advice because the relevant data were not included in the dataset 
forwarded to me. Due to long delays in receiving the data, I was unable to review 
individual records to assess the dose and duration of treatments in time for submitting 
my thesis. 
Use of non-parametric tests 
A limitation of this study is that I used non-parametric tests to identify statistically 
significant differences in the analysis. According to Kirkwood and Sterne (57), non-
parametric tests can lack power compared to parametric tests, particularly when working 
with small sample sizes. However, our sample size was relatively large for most estimates 
except for assessing children with ‘moderate’ and ‘severe’ anaemia categorised by ARIA. 
It was inappropriate to use parametric tests as the data were not normally distributed. 
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Conclusions 
The prevalence of anaemia among children aged 6 months to 3 years attending NT DoH 
services between 2008 and 2013 is a ‘severe’ public health problem, as defined by WHO. 
The prevalence was highest amongst children aged 6 -11 months as may have been 
expected, and in ‘very remote’ areas suggesting inadequate access to, and intake of, iron 
rich foods required to support rapid growth during this stage of life.  
Although, based on the data collected, a very low proportion of anaemic children were 
recorded as treated according to best practice guidelines, our findings are subject to 
multiple potential biases described under the  ‘limitations’ section. 
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Recommendations 
Our recommendations, detailed below, include: the need to validate the study results, 
assess barriers to implementing CARPA Guidelines, train health staff to improve data 
entry and patient management, and conduct culturally appropriate health promotion 
activities to improve nutrition in the community.  
 
1. Validate study results 
a. Check that the findings from this study are based on valid data, i.e. that 
they are not due to selection or measurement biases inherent in analysing 
administrative data. One example for doing this is by studying a random 
sample of records from NT DoH services to assess the validity of the data 
used in the analysis. 
2. Assess barriers to implementing CARPA guidelines 
a. If the findings are confirmed, conduct a systematic study with staff from 
PHC services (both ACCHOs and NT DoH) to assess reasons for low 
frequency of screening and of managing children consistent with CARPA 
guidelines. 
3. Train health staff to improve data entry and patient management 
a. Refresher training on PCIS for staff from PHC services to improve data 
entry and the quality and validity of electronic medical records. 
b. Refresher training on anaemia and CARPA Guidelines to improve 
management for each individual case. 
4. Conduct culturally appropriate health promotion activities to improve nutrition in 
the community 
a. Educate communities around anaemia and its serious long term 
consequences. 
b. Conduct a systematic study with both communities and practitioners from 
PHC services to find a culturally appropriate and sustainable way of 
improving the diets for these young Aboriginal and Torres Strait Islander 
children. 
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Appendix 1:  Human studies showing the health and behavioural impacts of anaemia and iron-deficiency anaemia by age and location (non-
exhaustive list) 
Outcomes Age 
0-15 months 6-12 months 12-24 months 2-5 years 5-8 years 8-11 years 11-15 years > 15 years 
Poor cognitive 
development 
Chile (58) 
(59) 
USA (60) 
Guatemala 
(61) 
Chile (59)  
Costa Rica 
(62-65), 
Chile; (66), 
Guatemala 
(61) 
 
Indonesia 
(67) 
India (68) Thailand (69) 
Indonesia 
(70),  India 
(68) 
Thailand (69), 
India (68) 
USA (71) 
Poor 
psychomotor 
development 
Chile (58) 
(72),   
USA (60) 
Chile (59) 
(72),  Japan 
(10-14 
months) (73) 
UK (74), 
Costa Rica 
(28), UK (75) 
 
     
Poorer speech 
development 
Japan (73) Japan (73) Japan (73)      
Poorer attention   Costa Rica 
(28) 
 
     
Behavioural 
disturbances 
 Japan (76) Costa Rica 
(64) 
     
Alterations in 
sleep wake cycle 
   USA (77) USA (77) USA (77)   
Impaired immune 
system 
 Chile (78) Chile (78)      
Impaired 
temperature 
       Venezuela 
(79) 
Impaired growth   UK (75)      
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Appendix 2: Primary health care services in the Northern Territory by patient information 
recall systems 
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Appendix 3: Variables sent from the Northern Territory Department of Health 
 
Datasets used in this analysis 
Demographic data (6,658 unique records) 
Variable Used in this analysis? 
Child Person ID Yes 
PCIS Birth Date Yes 
Indigenous Status Description Yes 
Midwives Birth Gestational Age No, because NT DoH warned data were 
of very poor quality and advised us to 
obtain this information from the 
Perinatal National Minimal Dataset but 
time did not allow for this 
Midwives Birth Weight No, because NT DoH warned data were 
of very poor quality and advised us to 
obtain this information from the 
Perinatal National Minimal Dataset but 
time did not allow for this 
 
Haemoglobin data (26,458 records – 4,590 unique records) 
Variable Used in this analysis? 
Child Person ID Yes 
Service Clinic Name Yes 
Result Date Yes 
Result Definition Yes 
Result Component Yes 
Result Measure Yes 
Result Unit Yes 
 
 
Medications (7,564 records – 3,154 unique records)  
Variable Used in this analysis? 
Child Person ID Yes 
Dose Start Date Yes 
Dose End Date Yes 
Medication Yes 
Minimum Dose No 
Dose Unit Yes 
Dose Duration No 
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Datasets not used in this analysis 
Full blood examination data (6,484 records - 345 unique records) 
Variable Used in this analysis? 
Child Person ID 
 
No 
Service Clinic Name 
 
No 
Result Definition 
 
No 
Result Component 
 
No 
Date 
 
No 
Result Measure 
 
No 
Result Unit 
 
No 
*Not included in this analysis owing to time constraints. Merging datasets as a one-to-one 
merge was not possible because ‘Result Date’ from Hb dataset does not match ‘Result Date’ 
from this dataset and there are multiple records per child. More time needed to sort out these 
data. 
 
Weight (110,517 records – 5,911 unique records) 
Variable Used in this analysis 
Child Person ID 
 
No 
Service Clinic Name 
 
No 
Result Component 
 
No 
Result Date 
 
No 
Result Measure 
 
No 
Result Unit 
 
No 
*These data were going to be used to assess different growth patterns between anaemic 
children receiving best practice care compared and those who didn’t, but owing to time 
constraints this analysis was not possible to do in time for submission of the bound volume. 
 
Height and length (26,673 records – 4,888 unique records) 
Variable Used in this analysis 
Child Person ID 
 
No 
Service Clinic Name 
 
No 
Result Component 
 
No 
Result Date 
 
No 
Result Measure 
 
No 
Result Unit 
 
No 
*These data were going to be used to assess different growth patterns between anaemic 
children receiving best practice care compared and those who didn’t, but owing to time 
constraints this analysis was not possible to do in time for submission of the bound volume. 
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Preface 
On 1 May 2014, the Therapeutic Goods Administration (TGA) was notified of three 
cases of Ralstonia bacteraemia from two different hospitals in South Australia (SA). 
Initial investigations carried out by the SA Department of Health (DoH) revealed that 
one or two batches of Provive propofol were the only common exposure between the 
three cases. On 2 May 2014, the TGA quarantined the two implicated batches of 
propofol, released a statement (Appendix 1) advising health professionals to avoid using 
Provive propofol and another product, Sandoz 1%, that was manufactured at the same 
site as the Provive. In response to the TGA’s announcement, between 5 and 8 of May 
2014, a further four cases of Ralstonia bacteraemia were reported by the Queensland 
(QLD) DoH and one from the Victorian (VIC) DoH. All cases had received Provive 
propofol 1% solution. On 9 May 2014, the TGA initiated a multijurisdictional 
epidemiological investigation to assess the possibility of a causal association between 
the administration of propofol and Ralstonia bacteraemia, and to identify possible 
sources of contamination. 
On 8 May 2014, Associate Professor Martyn Kirk sent an email to all Master of Applied 
Epidemiology (MAE) scholars placed in Canberra informing us of this suspected 
multijurisdictional outbreak, and asked if any of us were interested in assisting with this 
investigation under the supervision of Associate Professor Mahomed Patel. I, along with 
Fiona May, eagerly put our hands up to be involved. 
On 9 May 2014, the Australian Health Protection Principal Committee (AHPPC) decided 
that a Communicable Disease Network of Australia (CDNA) working group (WG) would 
be convened (list of members shown in Appendix 2) to conduct the multijurisdictional 
outbreak investigation (MJOI). The CDNA-WG included representatives from all State 
and Territory Health Departments, and the office of Health Protection and the TGA of 
the Australian Government Department of Health, with QLD DoH as the secretariat. An 
epidemiological investigation team comprising two MAE scholars (myself and Fiona 
May) and a lecturer from the Australian National University MAE Program (Mahomed 
Patel) was convened as part of the WG to coordinate the epidemiological investigation 
and to communicate the findings back to the CDNA-WG. 
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Investigatory role 
This outbreak investigation was a team effort. I worked on this outbreak with Fiona May 
under the supervision of Associate Professor Mahomed Patel. My role was varied and 
included the following: 
 my role, in collaboration with Fiona, was to: 
o enter data from case notes documented by TGA staff  into an Excel 
spreadsheet to create the line list and generate the epidemic curve; 
o analyse the case series data; 
o follow up missing data by contacting respective jurisdictions; 
o modify the QLD DoH Ralstonia case report form for this study;  
o analyse and interpret data collected for all stages of the study and  
generate hypotheses; 
o write up and edit multiple reports to the Communicable Disease 
Network Australia (CDNA) (Appendix 3), the Expert Panel, the TGA, the 
AHPPC and ProMED alert (Appendix 4); 
 I conducted a rapid literature review in the early stages of the investigation to 
identify reports on past outbreaks associated with propofol and Ralstonia spp. 
and to determine the growth characteristics of Ralstonia spp. in propofol 
solution (Appendix 5); 
 for the MJOI report, Fiona, Mahomed and I took the lead on separate 
components of the report. I was responsible for writing the introduction, 
summary of cases and results of applying the Bradford-Hill framework to our 
findings; 
 I co-facilitated the Delphi rounds; 
 I attended all CDNA-WG meetings with the working group. 
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Lessons learnt  
Lesson learnt What I would do next time 
Well defined governance of an 
outbreak investigation is very 
important. There are no specific 
guidelines or resources for 
responding to a multijurisdictional 
outbreak of a non-notifiable 
disease in Australia. 
Define CDNA-WG members’ responsibilities and 
availabilities at the beginning of the investigation. 
Recommendations posted on one 
website insufficient to reach all 
health professionals involved with 
administering intravenous 
medications. 
In addition to posting recommendations on the 
TGA website, post recommendations on health 
department’s websites, as well as ask members of 
the CDNA and the AHPPC to share the 
recommendations with their networks. 
High response rates are difficult to 
achieve even for questionnaires 
distributed to public health 
professionals. 
1. Request jurisdictions to nominate one person 
to be responsible for completing 
questionnaires, such as other MAE scholars 
placed in the relevant jurisdictions. 
2. Prioritise survey questions to try to make 
Ralstonia case report form shorter. 
3. Modify questions for the Delphi approach 
that allow for more yes/no answers to try to 
focus respondent’s answers. 
Obtaining WGS results can take a 
long time if a request for results to 
be expedited is not made. 
Request the tests to be expedited and use 
laboratories within the Public Health Laboratory 
Network such as the Public Health Microbiology, 
Communicable Disease, Forensic and Scientific 
Services, Queensland. 
Difficult to exclude other possible 
sources of contamination without 
environmental investigations. 
1. Arrange to inspect the manufacturing facility 
and take swabs of the areas where propofol 
is manufactured to first of all see if Ralstonia 
is present and secondly, to see the genetic 
similarity between the isolates obtained from 
the factory and the patient isolates here.  
2. Inspect hospitals/take swabs of areas where 
patients were administered propofol to 
identify other possible sources of Ralstonia 
spp. 
3. Inspect laboratories/take swabs where 
propofol was tested to see if laboratories are 
contaminated with the same strains of 
Ralstonia spp. 
4. Ensure the use of appropriate control vials in 
all testing undertaken as part of the 
investigation. 
Challenging to synthesise large 
volumes of qualitative information 
from the Delphi questions 
(Appendices 15 to 17c).  
Consider using software designed to analyse 
qualitative data to assist with Delphi analysis. 
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WGS provides a powerful tool for 
outbreak investigations such as 
this, but loses its usefulness if it 
takes too long to get the results. 
Samples were sent to UQCCR in 
May 2014 and results were not 
available until October 2014. 
Request the tests to be expedited (available 
within a fortnight) and use laboratories within the 
Public Health Laboratory Network. 
Have a face to face debrief after an 
investigation (particularly a difficult 
one) to capture and document 
lessons learnt. 
Debrief with TGA, CDNA, AHPPC and the WG. 
Public health impact 
The TGA posted on their website a reminder for all health professionals in Australia on 
the importance of using aseptic technique when preparing and administering 
intravenous medication, with a particular focus on the need to swab the rubber stopper 
of any vial with a suitable disinfectant prior to drawing up sterile solutions 
This investigation highlighted the importance of strict aseptic techniques and the need 
for clearer instructions in the product information of medications, and ongoing 
continuing education for health professionals. This investigation also highlighted the 
need for guidelines on how to respond to multijurisdictional outbreaks of non-notifiable 
diseases in Australia as there are for notifiable diseases. 
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Abstract 
Background 
On 1 May 2014, the Therapeutic Goods Administration (TGA) was notified of three 
cases of Ralstonia bacteraemia from two different hospitals in South Australia (SA). 
Initial investigations carried out by the SA Department of Health (DoH) revealed that 
one or two batches of Provive propofol were the only common exposure between the 
three cases. On 2 May 2014, the TGA quarantined the two implicated batches, released 
a statement (Appendix 1) advising health professionals to avoid the use of Provive 
propofol and as another product, Sandoz 1% that was manufactured at the same site as 
the Provive. In response to the TGA’s announcement, between the 5 and 8 of May 
2014, a further four cases of Ralstonia bacteraemia were reported by the Queensland 
(QLD) DoH and one from the Victorian (VIC) DoH. All cases had received Provive 
propofol 1% solution. On 9 May 2014, The TGA initiated a multijurisdictional 
epidemiological investigation. 
Objectives 
1. To assess the possibility of a causal association between the administration of 
propofol and Ralstonia bacteraemia that occurred since 1 January 2014, and to 
identify possible sources of contamination. 
2. To explore other possible sources of exposure of the cases to Ralstonia spp.  
Methods 
The TGA requested via OzBugs (Australasian Society for Infectious Diseases) and 
internationally via ProMED (Appendix 4) that any cases of Ralstonia bacteraemia 
occurring since 1 January 2014 be reported to the TGA. A case was defined as anyone 
reported with a blood culture positive for Ralstonia spp. since 1 January 2014 based on 
the recommendation of the Australian Health Protection Principal Committee (AHPPC) 
teleconference held on 9 May 2014. 
Initially, the TGA commenced its own investigations which involved identifying 
implicated batches of propofol and placing them in quarantine, collating and reviewing 
reports of possible cases reported by the States and Territories and undertaking 
microbiological investigations of the commercial propofol samples and containers.  We 
entered relevant data collected by the TGA into excel to create a line list (Appendix 6) 
and followed up any missing data with the jurisdictions. To obtain further information 
on other possible sources of Ralstonia spp. we adapted a case report form originally 
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developed by QLD DoH (Appendix 7) to collect demographic and clinical data, as well as 
details relating to the administration of the propofol and the clinical unit. A copy of the 
original case report form and our adapted version are shown in appendices 7 and 8, 
respectively.   
The TGA, SA Pathology, Applied Microbiology Services (ams) Laboratories, Claris 
Lifesciences (India) (manufacturer of the suspected propofol 1% emulsion products) and 
ESR (on behalf of Medsafe New Zealand) tested the propofol solution for sterility, 
microbial contamination and bacterial endotoxin. The TGA, SA Pathology and ams 
Laboratories also tested the flip-off lids and external surface of the rubber stoppers of 
the propofol vials for microbial contamination. All patient isolates were identified by 
culture, Vitek or matrix-assisted laser desorption/ionization (MALDI-TOF) and 16S 
sequencing at the respective hospital laboratories. To determine similarity between the 
species, all patient isolates were sent to the University of Queensland Centre for Clinical 
Research (UQCCR) for DiversiLab® analysis and whole genome sequencing (WGS). We 
applied the Bradford Hill framework and the Delphi method to assess the likelihood of a 
causal association between the administration of propofol and Ralstonia bacteraemia. 
Results 
Eight cases were reported from 1 April and 4 May 2014 and an additional three cases 
between 26 June and 11 of September 2014. Because our epidemiological investigation 
was completed before the notification of the last three cases; this investigation report is 
focused on the initial eight cases.  
Four cases were from QLD, three from SA, and one from VIC. Two QLD cases were from 
the Gold Coast University Hospital (GCUH), one from Royal Brisbane Women’s Hospital 
(RBWH) and one from The Prince Charles Hospital (TPCH). The VIC case was from a 
private hospital in Warrnambool. While two of the SA cases were from Royal Adelaide 
Hospital (RAH), the third was from a private hospital.  
The ages of the cases ranged from 28 – 64 years.  All of the initial eight cases received 
propofol between 1 and 27 April before the onset of their bacteraemia. The exact 
batches administered were confirmed only for the case from TPCH, while batch details 
used in the other cases were either not known or narrowed down to two or four 
possible batches. The time interval between propofol administration and the onset of 
symptoms of bacteraemia ranged from 1 hour to 23 days.  
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Six patient isolates were identified as Ralstonia mannitolilytica (three from QLD, two 
from SA, one from VIC), one as R. picketti (SA) and one as R. insidiosa (QLD). Of the R. 
mannitolilytica isolates, the isolates from SA patients (from SA private and RAH SA) were 
indistinguishable from each other as were three QLD isolates (two from GCUH and one 
from RBWH). However the R. mannitolilytica isolates from the three states (QLD, SA and 
VIC) were all different to each other.  
No evidence of bacterial contamination of the propofol solution was found, however, 
18% of the flip off caps and external surface of the rubber stoppers were positive for 
bacterial contamination. The species isolated included Bacillus spp., Gram positive 
cocci, coagulase negative staphylococci and R. mannitolilytica. The latter was isolated 
from one pooled sample of lids and rubber stoppers from five vials from one implicated 
batch by SA Pathology. This species of R. mannitolilytica was 97% identical to the R. 
mannitolilytica species isolated from the two SA cases.  
Because of the uncertainty of a causal association, we used the Bradford Hill framework 
to assess the likelihood of a causal association between the administration of propofol 
and Ralstonia bacteraemia. Using this framework, we concluded that the contaminated 
vial cap/rubber stopper could have been the common source for the two R. 
mannitolilytica cases from SA, however, it was difficult to assign the cap/rubber stopper 
of the propofol vial as the common source for the five genetically different species of 
Ralstonia occurring in three different states with none of the species being common 
across the three states.  
The expert panel that took part in the Delphi method reached consensus on three 
issues: 
1. There was no evidence to suggest that the propofol solution was contaminated 
with Ralstonia spp.; 
2. The external surface of the injection vials, including the outer surface of the 
rubber stopper and the inner surface of injection vial lid, should not be expected 
to be sterile; 
3. The source of the two cases with Ralstonia bacteraemia at the GCUH was 
contaminated bottled water. 
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The panel could not reach consensus on the source of Ralstonia for the RBWH, SA, 
TPCH and VIC cases. 
Conclusion 
Based on the evidence available at the time, there was no evidence to suggest an 
epidemiological link to implicate propofol as the common source of Ralstonia spp. for all 
eight cases. The propofol solution passed all sterility, bacterial endotoxin and microbial 
contamination tests but 18% of the flip-off caps and external surfaces of the rubber 
stoppers were contaminated with a variety of bacterial species including R. 
mannitolilytica. Investigations conducted by GCUH revealed that bottled water 
contaminated with R. mannitolilytica was the source of Ralstonia in the two GCUH cases 
but the source of Ralstonia in the other cases could not be determined. Even though a 
common source of infection could not be determined, this investigation highlighted the 
need for proper aseptic techniques when administering intravenous injections to 
patients. 
*On 21 October 2014 (after our investigations had been completed) the WGS results 
became available. They revealed that the R. mannitolilytica VIC isolate was 
indistinguishable from the two R. mannitolilytica isolates from SA and from the R. 
mannitolilytica isolated from the outer surface of the propofol vial. These R. 
mannitolilytica isolates from SA, VIC and the outer surface of the propofol vial were 
genetically different from the three R. mannitolilytica isolates from QLD.  
This new evidence provides stronger evidence to implicate the outer surface of the 
propofol vial as a possible common source for the two R. mannitolilytica SA cases and 
the VIC case, and therefore further highlights the need for strict aseptic technique when 
administering intravenous medications. However, the previously mentioned limitations 
which prevented us from being able to implicate the outer surface of the propofol vial 
with certainty still remain.  
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Introduction 
Ralstonia  
Ralstonia spp. are a large group of gram negative, aerobic bacteria that are emerging as 
opportunistic pathogens (1). They have had various name changes over the years as 
genetic identification of bacteria has improved. In the past they have been known as 
Pseudomonas (2, 3) and Burkholderia (3, 4). They are found in soil and many different 
types of water sources (1) including municipal drinking supplies (5), bottled mineral 
water (6), hospital water supplies (7), laboratory-based high purity water systems (8),  
industrial ultra-pure/high-purity water (9-11) and space shuttle water systems (12). 
They are hardy organisms capable of surviving a wide range of disinfectants and 
antimicrobials (13).  R. Pickettii, R. insidiosa and R. mannitolilytica have been isolated 
from a variety of clinical specimens including blood, urine and cerebrospinal fluid (14), 
and lung sputum of cystic fibrosis patients (15, 16).  
Nosocomial outbreaks and multijurisdictional outbreaks caused by Ralstonia have been 
reported previously and have been largely attributed to contaminated medical devices 
(17-22) and solutions (7, 23-27, 28 , 29 , 30), both contaminated at the hospital or at 
the time of manufacture or from an unknown source (31, 32). 
Propofol 
Propofol is a general anaesthetic widely used in Australia in adults and children aged 
three years and over (33). The TGA estimates that approximately 4,806 vials of Provive 
propofol 1% solution are used across Australia each day (33).  
Propofol is a lipid-based, emulsive anaesthetic (33). It is an excellent growth medium for 
a wide variety of microorganisms (gram positive and negative bacteria, and yeasts) (34-
50). The lipid based emulsion in propofol provides a rich environment for the 
microorganisms to thrive (51-56). No studies have specifically investigated growth of 
Ralstonia in propofol solution, however, biochemically similar species of bacteria such 
as B. cepacia and Pseudomonas do proliferate rapidly in propofol solution (43, 44, 51, 
53, 57). Microbial contamination of propofol results in rapid multiplication after an 
initial latent period ranging from around two to 24 hours (35, 39, 43, 44, 46, 47, 57, 58).  
A Ralstonia related outbreak has not previously been reported in the peer-reviewed 
literature from contaminated propofol solution. 
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Notification of outbreak 
On 1 May 2014, the SA DoH notified the TGA of three patients in two different hospitals 
in SA who developed Ralstonia bacteraemia. Initial investigations carried out by SA DoH 
revealed Provive propofol as the only common exposure between the three cases. 
Either one or two batches of Provive propofol were initially implicated (A030906 and/or 
A030907). On the following day (2 May) the TGA quarantined the two implicated 
batches and released a statement advising health professionals to avoid the use of 
Provive as well as the Sandoz 1% propofol products because both products are 
manufactured by the same company [Claris Life Sciences at the same manufacturing 
site in India] (Appendix 1). Following the TGA’s announcement, an additional four 
patients with Ralstonia bacteraemia were reported from QLD DoH and one from VIC 
DoH, all of whom had received propofol. The TGA initiated a multijurisdictional 
epidemiological investigation to gather data for assessing a possible causal association 
between propofol administration and Ralstonia bacteraemia, and to identify possible 
sources of contamination. 
Study objectives 
1. to assess the possibility of a causal association between the administration of
propofol and Ralstonia bacteraemia that occurred since 1 January 2014, and to
identify possible sources of contamination;
2. to explore other possible sources of exposure of the cases to Ralstonia spp.
Methods 
This section describes the methods we used to answer the study objectives. In brief, the 
TGA started the investigation with epidemiological and laboratory investigations, and a 
review of the manufacturer’s documentation of the environmental investigations 
conducted by the manufacturer. In addition to assisting with the epidemiological 
investigations, we entered and analysed the data originally collected by the TGA and 
assessed whether the propofol was causally associated with the Ralstonia bacteraemias 
by applying the Bradford hill framework followed by the Delphi approach. 
Epidemiological investigation 
The TGA requested via OzBugs (Australasian Society for Infectious Diseases) and 
internationally via ProMED (Appendix 4) that any cases of Ralstonia bacteraemia 
occurring since 1 January 2014 be reported to the TGA. A case was defined as anyone 
reported with a blood culture positive for Ralstonia spp. since 1 January 2014 based on 
the recommendation of the AHPPC teleconference held on 9 May 2014. This date was 
Chapter 5.1 
5.1-12 
 
selected based on information we received from the Australian distributor of Provive 
propofol, AFT Pharmaceuticals who advised that the implicated batches were not 
distributed in Australia until 2014. 
Initially, the TGA commenced their own investigations which involved identifying 
implicated batches of propofol and placing them in quarantine, collating and reviewing 
reports of possible cases reported by the States and Territories and undertaking 
microbiological investigations. We entered relevant data collected by the TGA into Excel 
to create a line list (Appendix 6) and followed up any missing data with the jurisdictions.  
To obtain further information on other possible sources of Ralstonia spp. we adapted 
the case report form developed originally by QLD DoH for our study; it included 
demographic and clinical data, as well as details relating to the administration of the 
propofol and the clinical unit. Copies of the original case report form and our adapted 
version are shown in appendices 7 and 8, respectively.  
To establish whether the number of Ralstonia cases was an increase from baseline in 
Australia, Dr Gary Lum requested data on previous isolations of Ralstonia bacteraemia 
from all laboratories affiliated with the Public Health Laboratory Network (PHLN). 
Laboratory investigations 
Testing patient isolates 
Blood culture isolates were initially identified as Ralstonia species by culture and further 
analysed by Vitek (automated microbial identification system) or MALDI-TOF and 16S 
sequencing at the respective hospital laboratories  
To determine how similar the strains were, all isolates were sent to the University of 
Queensland Centre for Clinical Research (UQCCR) for DiversiLab®  analysis (a 
commercial method that gives a percentage of clonality i.e. how similar the strains are) 
and WGS (a method that reveals an organism’s whole genome sequence) (59). WGS 
was conducted using an Illumina HiSeq2500 and phylogenomic software in the Beatson 
laboratory at UQCCR. 
Testing propofol vials 
The TGA, SA Pathology, Applied Microbiology Services (ams) Laboratories, Claris 
Lifesciences (India) and ESR (New Zealand) tested the propofol solution for sterility, 
microbial contamination and bacterial endotoxin. The TGA, SA Pathology and ams 
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Laboratories also tested the flip-off lids and external surfaces of the rubber stoppers of 
the propofol vials for microbial contamination (60). 
Environmental investigations 
Notifying clinicians were requested to provide results from any environmental swabs or 
other tests conducted at the facility/units where the cases were administered the 
propofol. 
The TGA reviewed Claris Lifesciences Ltd.’s documents to review processes for 
manufacturing propofol 1% emulsion for injection products. 
Assessing causation 
We initially applied the Bradford Hill framework to assess the causal association 
between the administration of propofol and Ralstonia bacteraemia followed by the 
Delphi method.  
The Delphi method 
The Delphi method was used to explore and collect independent judgments from an 
expert panel on the likelihood that the initial eight cases of Ralstonia bacteraemia were 
causally associated with propofol. The CDNA-WG nominated a panel of experts which 
consisted of three infectious disease physicians (two of whom were professors of 
infectious diseases), two clinical microbiologists, an epidemiologist and a public health 
physician. The list of members is shown in Appendix 9. The Delphi method is a 
communication technique used to achieve consensus within an expert panel through a 
series of questions and anonymous discussions (61). In total three rounds of the Delphi 
method were conducted over a period of two months. The purpose of the first round 
was to obtain comments and suggestions on the appropriateness of a set of 
issues/questions to be explored by the panel. The purpose of the second round was for 
panel members to respond to the questions agreed upon in the preceding round and 
the purpose of the third round was for members to comment on each other’s 
responses and the facilitator’s conclusions and to reconsider their initial responses 
(from the second round) and to assess the plausibility of six hypotheses posed by the 
facilitators. At the end of each round, we (the facilitators) synthesised and summarised 
each of the responses which we then re-distributed for discussion.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
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Results 
This section describes the results of our investigations. I first describe the 
epidemiological findings, followed by the laboratory and environmental findings, and I 
conclude this section by describing the results of the Delphi method.   
Epidemiological findings  
In total, eleven cases of Ralstonia bacteraemia were reported between 1 April and 11 
September 2014 (Figure 1). Eight cases were reported from 1 April and 4 May 2014 and 
an additional three cases were reported between 26 June and 11 of September. The 
initial investigation was conducted in mid - June and completed before the notification 
of the last three cases; therefore this investigation report is focused on the initial eight 
cases.  
The initial eight cases 
Eight cases were reported since 1 January 2014 (Figure 1). Four cases were from QLD, 
three from SA, and one from VIC (Figure 2). Two QLD cases were from the Gold Coast 
University Hospital (GCUH), one from Royal Brisbane Women’s Hospital (RBWH) and 
one from The Prince Charles Hospital (TPCH). The VIC case was from a private hospital 
in Warrnambool. Two of the SA cases were from Royal Adelaide Hospital (RAH) and the 
third from a private hospital. The ages of the cases ranged from 28 – 64 years.  
All eight cases received propofol between 1 and 27 April (< 1 day to 23 days prior to 
onset) before onset of bacteraemia (Figure 1). Six cases received Provive, one received 
the Sandoz product only and one received both Provive and Sandoz propofol (Appendix 
6). The exact batches administered were confirmed only for the case from TPCH 
(Sandoz Propofol Batch number A031110 and A030504), while batch details used in the 
other cases were either not known or narrowed down to two or four possible batches. 
Date of onset of bacteraemia ranged from 1 April to 4 May. The time interval between 
propofol administration and onset of symptoms of bacteraemia ranged from 1 hour to 
23 days. The shortest intervals of one hour and 5 hours were in two patients who had 
had endoscopies in SA and VIC respectively, while the longer intervals of 23 days and 
either 16 or 23 days were in patients at the GCUH, in known intravenous drug users, 
one of whom also had tricuspid endocarditis. The one patient with an interval of 17 
days had severe influenza pneumonia at the TPCH. The intervals for the remaining three 
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patients ranged from four to six days (the epidemiological line list is shown in Appendix 
6). 
Cases identified after the initial investigation 
Three additional Ralstonia bacteraemic cases were reported after the initial 
investigation. One case was reported from RBWH on 26 June 2014, and had had not 
received any propofol. He was a 59 years old and was admitted to TCPH hospital on 29 
May 2014 and later transferred to RBWH. He was receiving chemotherapy for acute 
myeloid leukaemia.  
Another case was reported on 3 September 2014 from VIC and another on 11 
September 2014 from SA. Both of these cases had received propofol however, no 
further demographic or clinical information is known about these additional two cases. 
 
Figure 1: Epidemic curve showing the eight cases with Ralstonia bacteraemia since 1 
January 2014 by date of detection of infection and date of propofol administration 
Colour coding shows genetic similarity of clinical isolates of the eight initial cases based 
on DiversiLab® results. P = date when propofol was administered. PI = dates of propofol 
infusion. For “VIC” and “SA private”, date of propofol administered was same as 
detection of bacteraemia. QLD = Queensland, SA = South Australia, VIC = private 
hospital in Warrnambool, RAH = Royal Adelaide Hospital, GCUH = Gold Coast University 
Hospital, RBWH = Royal Brisbane & Women’s Hospital, TPCH = The Prince Charles 
Hospital, ENDO = gastro-intestinal endoscopy unit, OT = operating theatre, ICU = 
intensive care unit. 
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Non-bacteraemic cases 
GCUH also reported eight patients with non-bacteraemic Ralstonia infections. Six of 
these patients had Ralstonia isolated from their sputum or trachea, one had Ralstonia 
isolated from their urine and one had Ralstonia isolated from an unknown source. The 
results of 16S rRNA, DiversiLab® analysis, specimen types, source of isolates and the 
history of previous administration of propofol are shown in Appendix 10. 
Was this a real increase in cases? 
Reports provided by laboratories affiliated with the PHLN revealed that the number of 
isolations of Ralstonia from blood samples since 2012 ranged between zero to three per 
State/Territory annually, and an estimated average of four cases nationally (Appendix 
11). 
Laboratory investigations 
Testing of patient isolates for the eight initial cases 
16S rRNA 
The 16S rRNA sequencing results showed that of the eight initial bacteraemic cases, six 
patient isolates were identified as R. mannitolilytica (three from QLD, two from SA, one 
from VIC), one as R. picketti (SA) and one as R. insidiosa (QLD) (Figures 2 and 3). 
DiversiLab® 
DiversiLab® analysis determined that we had five genetically different strains of 
Ralstonia amongst the three different species (Appendix 10). Of the R. mannitolilytica 
isolates, the two SA isolates (from SA private and RAH SA) were indistinguishable from 
each other as were the three QLD isolates (two from GCUH and one from RBWH). 
However the R. mannitolilytica isolates between the three states (QLD, SA and VIC) 
were all different to each other (Table 1). 
WGS 
The WGS results revealed that the R. mannitolilytica VIC isolate was indistinguishable 
from the two R. mannitolilytica isolates from SA and from the R. mannitolilytica isolated 
from the outer surface of the propofol vial. The three QLD isolates R. mannitolilytica 
were also indistinguishable from each other, but were easily distinguishable from the SA 
and VIC isolates (Figure 3 and Table 1). *This information became available to us after 
the initial investigation and report write up had been completed. 
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Figure 2: Map of Australia showing the eight cases of Ralstonia bacteraemia in South 
Australia, Queensland and Victoria since 1 January 2014 by location 
 
Table 1: Summary of laboratory results for the initial eight cases in South Australia, 
Queensland and Victoria, 1 April to 26 June 2014 
State Hospital Specimen Bottled 
water 
Propofol 16S rRNA DiversiLab WGS 
SA RAH Blood No Yes R. picketti Singleton 2 Clade 
2 
SA RAH Blood No Yes R. mannitolilytica Cluster 3 Clade 
3b 
SA Private Blood No Yes R. mannitolilytica Cluster 3 Clade 
3b 
QLD GCUH Blood Yes Yes R. mannitolilytica Cluster 1 Clade 
3a 
QLD GCUH Blood Yes Yes R. mannitolilytica Cluster 1 Clade 
3a 
QLD RBWH Blood Yes Yes R. mannitolilytica Cluster 2 Clade 
3a 
QLD TPCH Blood No Yes R. insidiosa Singleton 6 Clade 
1 
VIC Private Blood No Yes R. mannitolilytica Singleton 3 Clade 
3b 
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Figure 3: Cases of Ralstonia bacteraemia by state, hospital and possible source of 
exposure, 1 April to 26 June 2014 
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Testing of patient isolates for cases identified after the initial investigation 
The isolate from the ninth case reported from RBWH on 26 June who had not received 
propofol was indistinguishable (on DiversiLab®) to the isolates from the first case at the 
RBWH and the isolates from the two cases at the GCUH. At this stage there is no genetic 
(WGS or DiversiLab®) information on the isolates from the last two cases. 
Non-bacteraemic cases 
The Ralstonia isolates from the non-bacteraemic cases were R. mannitolilytica, 
indistinguishable from the R. mannitolilytica isolated from GCUH and RBWH Ralstonia 
bacteraemia cases (Appendix 10). 
Results from GCUH Investigation 
The GCUH conducted their own outbreak investigation into their two cases with 
Ralstonia bacteraemia and eight cases with Ralstonia isolates from other samples. Their 
investigation concluded that the source of Ralstonia at the GCUH was bottled water 
contaminated with R. mannitolilytica. 
Testing of propofol vials 
The detailed results of the propofol testing are shown in Appendix 12. But overall, from 
25 batches, the propofol solution from 1,683 vials were tested for sterility, 97 were 
tested for the presence of bacterial endotoxin and 91 vials were tested for microbial 
contamination by the TGA, SA Pathology, Applied Microbiology Services (ams) 
Laboratories, Claris Lifesciences (India) and ESR (New Zealand). All samples passed the 
criteria for the tests for sterility and bacterial endotoxins, and for microbial 
contamination testing of vial contents. 
A total of 524 flip-off caps and external surfaces of rubber stoppers from 15 product 
batches were also tested by SA Pathology, ams Laboratories and the TGA for microbial 
contamination. Eighteen percent (n = 88) were positive for bacteria. TGA isolated 
Bacillus spp., and Gram positive cocci. SA Pathology isolated R. mannitolilytica, Bacillus 
spp. and Coagulase negative staphylococci. R. mannitolilytica was isolated from one 
pooled sample of flip-off lids and swabs of the external surface of rubber stoppers from 
five vials from one of the implicated batches (A030907).  The R. mannitolilytica, isolated 
from the top surface of the vial was identified by DiversiLab® analysis as being closely 
related (97% similarity) to the R. mannitolilytica isolated from the two SA cases. SA 
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Pathology did not use controls during testing. This batch was sent to the TGA for testing 
but the TGA was not able to replicate this result. 
Environmental investigations 
The notifying clinicians did not provide any data on swab/specimens or samples of 
medical products from other possible sources for any of the cases. Details of the type of 
environmental samples collected and tested, if any, were not provided by any of the 
hospitals. The TGA’s investigations of the documentation of the manufacturer’s 
processes for manufacturing propofol 1% emulsion for injection products did not find 
any deviations from approved processes. 
Next step, analytical study? 
Alternative scenarios were simulated to assess whether a historical cohort study or case 
control study could yield meaningful results to assess the causal association between 
the administration of propofol and Ralstonia bacteraemia (appendices 13a and 13b). 
We generated scenarios where the eight cases were compared with controls (case 
control study) and with a cohort of patients (case cohort) who had been in the same 
facility as the cases during the period when the cases had received propofol, but who 
did not have Ralstonia bacteraemia. We made the assumption that when each case was 
in a facility, there were at least ten other patients in the same facility who had the 
chance of receiving propofol and that the proportion of control subjects who had 
received propofol ranged between 15% and 90%.  We calculated the Odds Ratios (OR) 
for each of these possible scenarios as shown in appendices 13a and 13b. 
The shaded rows in both tables (appendices 13a and 13b) show the percentage of 
controls who received propofol at the point at which the OR becomes statistically 
significant. Based on the results of these simulations we decided that neither a case 
control nor a case cohort study would yield a statistically significant OR and/or relative 
risk because all the control subjects in an endoscopy/colonoscopy unit and around 50% 
- 60% of subjects in an Intensive Care Unit or theatre are likely to have received 
propofol. These scenarios revealed that our sample size (n = 8) was too small to be able 
to conduct an analytical study that would produce results of statistical significance. 
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Assessing causation 
Bradford Hill Framework 
We applied the Bradford Hill framework to assess the causal association between the 
administration of propofol and Ralstonia bacteraemia (Appendix 14). From this analysis 
we concluded that the contaminated flip-off cap/rubber stopper could have been the 
common source for the two R. mannitolilytica cases from SA if we can accept that the 
Ralstonia isolated from the vial cap rubber stopper was a valid result and not a 
contaminant (not possible to know without using controls) and if the WGS further 
confirms that these three isolates are genetically identical. *These findings were further 
supported by the WGS results.  
However, it was difficult to assign the flip-off cap/rubber stopper of the propofol vial as 
the common source for the five genetically different species of Ralstonia occurring in 
three different states with no overlap in species between states (Figure 2). 
Using this framework, we were not able to confirm a causal association between the 
flip-off/rubber stopper and all eight cases. We therefore decided to use the Delphi 
method with a group of experts to help formulate and explore additional hypotheses, 
and in this way, to offer alternative explanations for this unusual increase in Ralstonia 
bacteraemias. 
Delphi results 
Delphi round 1 results 
In Round 1 the expert Panel Members offered comments and suggestions on the issues 
and the questions for consideration. The panel agreed on the following eight 
questions/issues to be discussed: 
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Question 1: What incubation period could be considered consistent with a causal association 
between propofol administration and bacteraemia? 
Question 2: If we assumed that propofol administration was causally associated with 
bacteraemia, can we conclude that pre-existing contamination of the propofol solution was 
unlikely and that the vial cap and/or rubber stoppers were more likely to have been the source 
of the Ralstonia? 
Question 3: How confidently can we exclude other possible sources of exposure (apart from 
propofol administration) to Ralstonia in some or all the cases?  
Question 4: How likely is it that a patient with Ralstonia bacteraemia but without signs of a 
pulmonary infection may have transmitted Ralstonia to another patient as an explanation of 
why the same strain of Ralstonia was isolated from the sputum or tracheal aspirate of a 
patient who never received propofol? 
Question 5a: How should we interpret the finding of the Ralstonia isolate from the vial cap, 
noting the caveat from SA Pathology?  
Question 5b: How should we interpret the TGA result of contamination of the internal surface 
of flip-off seal and rubber stopper with other bacteria?  
Question 5c: How do these interpretations influence your judgement of the hypothesis that 
propofol administration is causally associated with Ralstonia bacteraemia? 
Question 6: Can we confidently implicate or exclude propofol administration as the cause of 
Ralstonia bacteraemia in some or all the cases? Where and when could the propofol/vial have 
been contaminated? 
Question 7: Noting the genetic similarity between the R. mannitolilytica isolate from the 
propofol vial cap and the clinical isolates from the two cases in different SA hospitals (RAH and 
SA Private), and the distinctive R. picketti isolate from the second patient in the same 
neurosurgical unit of the RAH, can we conclude that Ralstonia bacteraemia in all three cases 
was causally associated with the administration of propofol, and that the propofol/vial did not 
become contaminated in the respective clinical unit? 
Question 8: How confident can we be that the cases reported in QLD and/or VIC with diverse 
genetic strains were also causally associated with the administration of propofol because all of 
them had received propofol? 
Question 9: Based on the DiversiLab® results and on the uncertainty of the batch number of 
propofol vials used in SA, VIC and QLD, what plausible hypotheses could we formulate on the 
likely site/s of contamination? More specifically, how likely is it that the propofol/vial may have 
been contaminated (a) at some stage before delivery to the clinical unit and (b) after arrival in 
the clinical unit? 
Question 10: What is the likelihood the propofol/vial was contaminated at the site of 
manufacture at Claris Life Sciences (India)? 
 
Chapter 5.1 
5.1-23 
 
Delphi round 2 results 
In Round 2, six of the seven Panel Members provided their independent responses to a 
total of twelve questions agreed upon in the first round. Individual responses are shown 
in Appendix 15. 
Delphi round 3 results 
Panel members were given a summary of responses from Round 2 together with the 
facilitators’ conclusions and selected literature references. They were invited to 
comment on these and offer their opinions on six hypotheses in the different clinical 
settings from which cases had been reported with Ralstonia bacteraemia. Five of the 
seven Panel Members commented on the Round 2 responses to the twelve questions 
and the facilitators’ conclusions (Appendices 16,17a, 17b, 17c). 
Summary of Delphi results 
The expert panel reached consensus on three issues: 
1. There is no evidence to suggest that the propofol was contaminated with 
Ralstonia spp. 
2. The external surface of the injection vials, including the outer surface of the 
rubber stopper and the inner surface of injection vial lid, should not be expected 
to be sterile 
3. The source of the two cases with Ralstonia bacteraemia at the GCUH was 
contaminated bottled water 
The panel could not reach consensus on the source of Ralstonia for the RBWH, SA, 
TPCH and VIC cases 
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Discussion  
This chapter describes an unusual increase of cases with Ralstonia bacteraemia that 
occurred from 1 April to 26 June 2014. A common source of infection could not be 
confirmed for all cases due to the availability of a small sample size of cases (n=8) and 
insufficient laboratory-based evidence. Bottled water contaminated with R. 
mannitolilytica was the source of Ralstonia for the two GCUH cases and possibly the 
RBWH cases; however an epidemiological link between the cases in these two hospitals 
could not be established. The source of Ralstonia in the SA, TPCH and VIC cases could 
not be established and no information is known about the most recent VIC or SA cases 
and therefore cannot be discussed. 
There was no evidence to suggest that the propofol solution was contaminated with 
Ralstonia spp. However, a small proportion of the outer surface of the rubber stoppers 
and the inner surface of the flip-off lids from the propofol vials were found to be 
contaminated with a range of bacterial species including a strain of R. mannitolilytica 
that was indistinguishable from the R. mannitolilytica cases in SA; however it was not 
possible to establish causation and exclude other confounding factors (such as 
exposures to other intravenous substances or acupuncture needles). 
Prior to notification of the ninth case, all cases had received propofol prior to the onset 
of bacteraemia which led us to the hypothesis that Ralstonia bacteraemia was probably 
associated with the administration of propofol. Usually the next step in an outbreak 
investigation after the hypothesis generating step is to test the formulated hypothesis 
using an analytical study. However, our small sample size (n = 8) prevented us from 
being able to conduct an analytical study that would yield statistically significant results. 
Therefore instead of an analytical study to test the hypothesis, we applied the Bradford 
Hill framework to determine the possibility of a causal association. Through this analysis 
we concluded that the contaminated vial cap and rubber stopper could have been the 
common source for the two cases in different hospitals in SA if the SA Pathology results 
were valid. However, we were still not able to explain how the vial cap and rubber 
stopper could be the common source for all the cases in the three states, given that the 
Ralstonia isolates belonged to four different genotypes of Ralstonia (excluding the 
GCUH and RBWH isolates), and that not one strain of Ralstonia occurred in more than 
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one state.  So to try to find an explanation for this unusual increase in cases of reported 
Ralstonia bacteraemias we used the Delphi method. 
In line with the laboratory evidence, the Delphi panel concluded that the propofol 
solution was not contaminated and was therefore not the source of the Ralstonia. 
However, the panel was not able to reach consensus on whether the contamination of 
the external surface of the rubber stopper of the propofol vial was the common cause 
of the five cases with bacteraemia (excluding RBWH and GCUH cases) due to insufficient 
evidence. 
It was not possible to completely exclude the propofol vial because the strain of R. 
mannitolilytica that was isolated from the pooled sample of rubber stopper external 
surfaces and flip off caps from one implicated batch in SA was identical to the R. 
mannitolilytica strain isolated from the two SA cases. However, this evidence (which is 
the strongest evidence to link the propofol with the Ralstonia bacteraemia) came with 
caveats reported by SA Pathology: ‘The technician attempted to use sterile technique 
but the removal of the vial lids was difficult. Contamination may have been introduced 
during sampling as evidenced by the mixture of cutaneous flora [coagulase negative 
staphylococci] in the sub-cultures. With that caveat, an isolate of R. mannitolilytica has 
been obtained from an implicated box of propofol (A030907). Ralstonia spp. are rarely 
isolated in our laboratory’.  Further to this, control vials were not used during testing in 
the laboratory, so we could not be certain whether this strain of Ralstonia (which is an 
environmental organism and a common contaminant of laboratories) was from the vial 
and not from the laboratory itself. Furthermore, these results could not be replicated by 
the TGA. There is also a lack of information on the genetic variability of Ralstonia 
isolates in SA hospitals and laboratories which prevents us from knowing the 
significance of finding three strains with an identical genetic pattern. 
It was also difficult to be able to implicate the propofol vial with certainty for the other 
reasons: 
1. It is estimated that approximately 4,806 vials of Provive propofol 1% emulsion 
are used across Australia each day. If the propofol vial had been contaminated 
at the point of manufacture, why were there only eight cases? And why were 
none of the strains found in more one state? While a polymicrobial 
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contamination of the propofol vial is plausible, it is highly unlikely that there 
would be no overlap in strains between the states. As one of the Expert Panel 
Members stated ‘We would expect closer clonal similarities between cases if pre-
existing contamination was the source’. 
2. It was also difficult to implicate the propofol without being able to exclude all 
other possible sources of Ralstonia. All cases were exposed to many other 
possible sources of Ralstonia that are common in health care settings, but 
without completed case report forms or environmental investigations, these 
other sources could not be excluded. 
Discussion of the WGS results provided post investigation 
The WGS results became available after our investigation had been completed. The 
WGS results confirmed the previous laboratory findings but also provided new evidence 
that linked the earlier VIC case to the two SA cases and the outer surface of the rubber 
stopper or flip-off lid of the propofol vial. In light of this evidence, it is possible that we 
had two different outbreaks occurring at the same time: the QLD outbreak caused by 
the contaminated bottled water and a SA and VIC outbreak caused by a pre-existing 
contamination of the outer surface of the rubber stopper or flip-off lid of the propofol 
vial, with two extra sporadic cases being notified as a result of heightened surveillance. 
However, even in light of this new evidence, questions still remain unanswered that 
prevent us from confirming this hypothesis. If there was a pre-existing contamination, it 
is still difficult to envisage how this resulted in so few cases across Australia, especially 
among immunocompromised patients in ICUs where propofol is used extensively (62). It 
could be that there was sporadic contamination of the vials at the manufacturing site 
(or somewhere else between the manufacturing site and the point of distribution to SA 
and VIC) with different strains of Ralstonia, and that these cases occurred as a result of 
a lack in aseptic technique in the SA and VIC hospitals. However, we cannot be certain 
of this without further evidence. Even so, the manufacturer doesn’t guarantee that the 
exterior surface of the vial is sterile, only a sterile solution (33). 
We do not have any information on the genetic variability of Ralstonia isolates in the 
environment, and particularly in the health care settings (hospitals and endoscopy 
units) which prevent us from interpreting the significance of finding four strains with an 
identical genetic pattern in two different states. 
Chapter 5.1 
5.1-27 
 
The role of potential confounders to explain the bacteraemia also cannot be excluded. 
All of the cases had multiple invasive procedures and were therefore exposed to many 
other possible sources of infection with Ralstonia that we were not able to control for. 
We therefore could not know with any certainty the true source of these Ralstonia 
bacteraemias.  
Limitations 
There were a number of limitations to this study - the most important one was having 
insufficient evidence to either implicate or exclude the propofol. Having a small sample 
size prevented us from conducting an analytical epidemiological study that could yield 
statistically significant results. We therefore had to resort to the Delphi method to 
reach consensus on the most plausible hypotheses. Even then, the group of experts 
could not reach consensus on all issues. A low response rate for the case report forms 
from notifying health professionals meant that important data on cases and the 
environments the cases were exposed to had not been collected. It was therefore not 
possible to assess or control for confounding factors.  
Conclusion 
We could not find evidence to confirm the administration of propofol was the common 
source of Ralstonia spp. for the five cases of Ralstonia bacteraemia in the three 
jurisdictions. Bottled water contaminated with R. mannitolilytica was the source of 
Ralstonia in the two GCUH cases (and possibly in the case who had not received 
propofol at RBWH) but the source of Ralstonia in the other cases could not be 
confirmed.  
This investigation was a complex, interesting investigation. While we could not find a 
common source of infection, it produced some very important findings. It revealed 
there is confusion among clinicians and anaesthetists on the need to swab the external 
surface of the rubber stopper before drawing up the propofol solution. Eighteen per 
cent of the flip off cap/and or external surfaces of the rubber stoppers were 
contaminated with a variety of bacterial species. The manufacturer does not guarantee 
these outer surfaces to be sterile, and this is also not expected by regulatory authorities 
such as the TGA. Australian guidelines should therefore be revised to include clearer 
instructions on the need to swab the external surface of the rubber stopper with a 
suitable disinfectant prior to drawing up any sterile solution. In addition, there should 
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be ongoing continuing education made available to all health professionals across 
Australia responsible for administering medical solutions to patients. 
*On 21 October 2014, the WGS results became available to us after the initial 
investigation had already been completed. The WGS analysis revealed that the R. 
mannitolilytica VIC isolate was indistinguishable from the two R. mannitolilytica isolates 
from SA and from the R. mannitolilytica isolated from the outer surface of the propofol 
vial. These R. mannitolilytica isolates from SA, VIC and the outer surface of the propofol 
vial were still genetically different from the three R. mannitolilytica isolates from QLD. 
This new evidence provides stronger evidence to implicate the outer surface of the 
propofol vial as a possible common source for the two R. mannitolilytica SA cases and 
the VIC case, and therefore further highlights the need for strict aseptic technique when 
administering intravenous medications. However, the previously mentioned limitations 
which prevented us from being able to implicate the outer surface of the propofol vial 
with certainty still remain.  
Recommendations 
At the last AHPPC meeting one member said that the outbreak is not over until the 
cases stop. I agree with that member’s statement. The additional three cases reported 
after our initial investigation suggests that this outbreak may not be over. I therefore 
think the next steps should be to: 
1. continue active surveillance to detect any future cases and to have these cases 
reported back to a central group such as the CDNA-WG. This should be done 
until the number of reported cases of Ralstonia bacteraemia returns to baseline; 
2. collect more information from the last two cases reported in VIC and SA similar 
to the information we tried to collect for the initial eight cases; and investigate 
any common supply routes between SA and VIC;   
3. communicate to all relevant health professionals and relevant associations to 
notify those involved with administering propofol (and other intravenous 
medications) in Australia to emphasize the importance of using aseptic 
technique when preparing and administering intravenous medication, with a 
particular focus on the need to swab the rubber stopper of any vial prior to 
drawing up sterile solutions; 
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4. consider revising the Australian label and package inserts of IV medication so 
that they clearly state the need to swab the rubber stopper prior to drawing up 
the sterile solutions; 
5. consider conducting a cross sectional study to investigate the proportion of 
external surfaces of rubber stoppers on propofol vials (or other IV vials)  that are 
contaminated with bacteria and communicate findings back to public health 
professionals; 
6. consider conducting a survey to investigate and further explore the 
misconceptions and practices  among relevant public health professionals about 
the external surfaces of a rubber stopper being sterile. 
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Appendix 1: Safety advisory – potential bacterial contamination, Therapeutic Goods 
Administration, 2 May 2014 
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Appendix 2: Members of the Communicable Disease Network of Australia Working 
Group, 2014 
1. Dr Alexandra Greig 
2. Associate Professor Ann Koehler 
3. Dr Barry Combs 
4. Dr Bronwen Harvey 
5. Dr Claire Heney 
6. Dr Gary Lum   
7. Dr Heidi Carroll (CDNA-WG Coordinator) 
8. John Marquess 
9. Dr Mark Veitch 
10. Dr Melissa McRae  
11. Dr Peter Markey 
12. Rosemary Steinhardt  
13. Dr Sean Tobin  
14. Dr Sonya Bennett  
15. Karen Longstaff  
16. Dr Alex Stevenson  
17. Associate Professor Mohamed Patel 
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Disease Network of Australia, 26 May 2014 
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Appendix 4: ProMED alert – Ralstonia Pickettii, sepsis – Australia: contaminated propofol, 
alert 22 May 2014 
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Appendix 5: Focused literature review assessing the level of contamination that could be 
expected in the propofol solution at the time of administration if the propofol solution had 
been contaminated at the point of manufacture many weeks or months earlier 
 
Abstract 
Study Objective 
To review the literature to assess the level of contamination that could be expected in the 
propofol solution at the time of administration if the propofol solution had been 
contaminated at the point of manufacture many weeks or months earlier. 
Methods 
We searched PubMed for publications on the growth characteristics of Ralstonia spp. in 
propofol using specific questions and search terms to guide the search. The Boolean logical 
operator ‘AND’ was used to link search terms and the Booelan wildcard character ‘*’ was 
used to find variations on the search terms grow(th)*,  charact*, inhibit* and bacteria*. The 
species’ previous names (Burkholderia and Psuedomonas) were also included in the search 
terms. 
Main Results 
We included nine studies in this review because they all provided information on the growth 
of bacteria that are biochemically similar to Ralstonia spp. in propofol. We could not access 
four studies. Of these studies, two showed that propofol supported the growth of bacteria 
including P. aeruginosa and one study did not provide information on the growth of P. 
aeruginosa in the propofol alone (1). The fourth publication was a case report but provided 
no information on the growth characteristics of P. aeruginosa propofol (2). 
Conclusions 
Seven of the nine publications showed that propofol not only supports microbial growth, but 
results in rapid multiplication. These findings show that if the propofol was contaminated 
with Ralstonia spp. at the point of manufacture, we could expect the vials to have been 
heavily contaminated with Ralstonia spp. by the time it was drawn up for clinical use many 
weeks later. 
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1. Introduction 
Between April and May of 2014, an unusual increase in the number of cases with Ralstonia 
bacteraemia was reported from six hospitals in three Australian states. Initial investigations 
suggested the source of the Ralstonia species was propofol because only people 
administered the drug developed the infection. A multijurisdictional investigation could not 
find evidence that the propofol solution was contaminated with Ralstonia spp., although the 
flip off caps and external surface of the rubber stoppers of some propofol vials were 
contaminated with multiple bacterial species including R. mannitolylitica; the latter isolate 
was 97% identical on DiversiLab® analysis and genetically indistinguishable using whole 
genome sequencing to clinical isolates of R. mannitolylitica from two of the cases.  
Ralstonia spp. previously known as Pseudomonas (3, 4) and Burkholderia (4, 5) are a large 
group of gram negative, aerobic bacteria that are emerging as opportunistic pathogens. They 
are found in soil and different water sources (6) including municipal drinking supplies (7), 
bottled mineral water (8), hospital water supplies (9), laboratory-based high purity water 
systems (10), industrial ultra-pure/high-purity water (11-13) and space shuttle water systems 
(14). They are hardy organisms capable of surviving a wide range of disinfectants and 
antimicrobials (15).  R. Pickettii, R. insidiosa and R. mannitolylitica have been isolated from a 
variety of clinical specimens including blood, urine and cerebrospinal fluid (16), and lung 
sputum of cystic fibrosis patients (17, 18).  
Propofol (2,6-diisopropylphenol) is a widely used general anaesthetic and approximately 
4,806 vials of Provive propofol 1% solution are used across Australia each day (19).  Propofol 
is a lipid-based, emulsion containing glycerol, purified egg phosphatide, sodium hydroxide, 
and soya bean oil (20) and provides an excellent growth medium for a variety of gram 
positive and negative bacteria, and yeasts (1, 21-43). Although Ethylenediaminetetraacetic 
acid (EDTA) is added to the solution as an antibacterial agent, its effectiveness has been 
questioned (44, 45).  
For this study, we reviewed the literature to assess the level of contamination that could be 
expected in the propofol solution at the time of administration if the propofol solution had 
been contaminated at the point of manufacture many weeks or months earlier. 
2. Methods 
We searched PubMed for publications on the growth characteristics of Ralstonia spp. in 
propofol using specific questions and search terms to guide the search, as detailed in Table 1. 
The Boolean logical operator ‘AND’ was used to link search terms and the Booelan wildcard 
character ‘*’ was used to find variations on the search terms grow(th)*,  charact*, inhibit* 
and bacteria*. The species’ previous names (Burkholderia and Psuedomonas) were also 
included in the search terms. 
 
The title and abstract for each of the references was reviewed. Articles that provided 
information on the growth of bacteria biochemically similar to Ralstonia spp. in propofol 
were included.  
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Table 1: Results of the literature search for specific questions and search terms using PubMed 
Specific question Search terms No. of 
publications 
identified 
No. of 
publications 
included 
No. of 
publications 
excluded 
No. 
could 
not 
access 
Does propofol 
solution support the 
growth of 
Ralstonia? 
1. Grow* AND 
Ralstonia AND 
Propofol 
0 0 0 0 
2. Ralstonia AND 
propofol 
0 0 0 0 
3. Grow* AND 
Propofol AND 
Pseudomonas 
14 9 0 4 
4. Grow* AND 
Propofol AND 
Burkholderia 
2 (already 
identified   in 
search 3) 
1 0 1 
Does propofol 
solution inhibit the 
growth of 
Ralstonia? 
5. Ralstonia AND 
inhib* AND growth 
AND Propofol 
0 0 0 0 
6. Ralstonia AND 
inhib* AND 
Propofol 
0 0 0 0 
7. Pseudomonas AND 
inhib* AND growth 
AND Propofol 
7 (already 
identified in 
search 3) 
4 0 3 
8. Pseudomonas AND 
inhib* AND 
Propofol 
This search produces the same results as 7. above. 
9. Burkholderia AND 
inhib* AND growth 
AND Propofol 
0 0 0 0 
10. Burkholderia AND 
inhib* AND 
Propofol 
0 0 0 0 
What are the 
growth 
characteristics of 
Ralstonia in 
propofol? 
11. Grow* AND 
charact* AND 
Ralstonia AND 
propofol 
0 0 0 0 
12. Grow* AND 
charact* AND 
Pseudomonas AND 
propofol 
0 0 0 0 
13. Grow*AND 
charact* AND 
Burkholderia AND 
propofol 
0 0 0 0 
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3. Results 
We included nine studies in this review (21, 23, 30, 45-49). We could not access four studies 
(1, 2, 50, 51). Of these, three (1, 50, 51) investigated the growth of a variety of organisms 
(including P. aeruginosa) in propofol, and investigated the antimicrobial effects of propofol 
mixed with other solutions. Overall, from the abstracts, two studies showed that propofol 
supported the growth of bacteria including (P. aeruginosa) (50, 51) and one abstract did not 
provide information on the growth characteristics of P. aeruginosa in propofol (1).  Brief 
summaries of the abstracts are provided below. The fourth publication was a report on a case 
that developed septic shock after receiving cosmetic surgery. Blood cultures of the case were 
positive for P. cepacia and contamination of propofol was suspected, but no further details 
were given (2).  
Harvey et al., 2003 evaluated the growth of 4 different microorganisms (one of which was P. 
aeruginosa) in propofol, methohexital (an intravenous anaesthetic that may be used for 
induction of anaesthesia), and 1:1 and 1:3 mixtures if propofol and methohexital. They found 
that combining Diprivan or generic propofol with methohexital in a 1:1 or 1:3 mixture ratio 
resulted in a solution that (like methohexital alone) inhibited growth of P. aeruginosa for 48 
hours. Further information on the growth of P. aeruginosa in the propofol only solution was 
not available in the abstract (1). 
Joubert et al., (2005) assessed bactericidal properties of serial mixtures of propofol and 
thiopentone and found that propofol supported the growth of all organisms tested (including 
P. aeruginosa). They also found that mixtures of propofol and thiopentone at a ratio less than 
1:1 did not retain bactericidal properties (50). Further information on the growth of P. 
aeruginosa was not available in the abstract. 
Keles et al., (2006) assessed the antimicrobial effects of dexmedetomidine and etomidate-
lipuro, and to compare these effects with those of midazolam and propofol on a range of 
bacteria including P. aeruginosa. They found Midazolam inhibited the growth of bacteria but 
that propofol had no antimicrobial effects on the organisms tested (including P. aeruginosa) 
(51).  
 
Growth of Pseudomonas aeruginosa in propofol 
Inoculates of 1-2 x 104 Pseudomonas aeruginosa (ATCC 27853) (Oxoid/UK) per ml into 1% 
propofol (Propofol® % 1 Fresenius) were incubated at 35°C for 24 hours. After an initial lag 
time of 2 hours, P. aeruginosa grew exponentially reaching ≥ 1 x 105 colony forming units per 
millilitre (cfu.ml-1) at 8 hours (Figure 1). The cfu.ml-1 count at 24 hours was not reported (46). 
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Figure 1: Growth rates of P.aeruginosa (and other organisms tested) in 1% propofol solution in 2-hour 
periods (46)1 
 
Guzelant et al., (2008) inoculated 4 x 105 cfu.ml-1 of P.aeruginosa (clinical isolate) into 
propofol (Pofol® 1%; Dongkook pharmaceutical Co., South Korea) at 35°C and found 59 x 10-2 
colonies at five hours and >1,000 x 10-2  at 24 hours post inoculation (47). 
Ravenelle et al., (2008) inoculated 104 cfu/ml of P.aeruginosa (ATCC 6538) into Diprivan® 
(Astra Zeneca) and incubated at 35°C. Twenty-four hours post inoculation the authors 
counted >35 x 103 cfu/mL. This study also reported that EDTA (a microbial growth retardant) 
present in Diprivan® controlled microbial growth for the first few hours, but was then 
superseded by a period of exponential growth (48). 
Apan et al., (2007) also found exponential growth of P. aeruginosa 24 hours post inoculation 
into propofol (21). The authors inoculated 5 x 105 colonies of P.aeruginosa (ATCC 50143) into 
propofol (type not stated) for 24 hours at 37°C. Results are shown in Figure 2. 
 
 
                                                          
1 I will request permission from the publishers to include all figures in this publication. 
Fig  2: 
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 Another study showed, that 24 hours post inoculation, P. aeruginosa (ATCC 27853) increased 
from an initial inoculation of 5 x 105 cfu/mL to >5,000 CFUs (45) in propofol (Deprivan 1%; 
Zeneca Pharmaceuticals, Wilmington, DE). 
Berry et al. (1993) inoculated propofol (Diprivan ICI) with P. aeruginosa (NCTC 10662) with a 
concentration of 103 cfu.ml-1 and allowed the bacteria to grow at 20°C and 37°C. The growth 
of the bacteria was measured at 6, 12 and 24 hours. At 20°C a 10-fold increase was recorded 
at 6 hours, and 105 -fold increase was recorded at 24 hours. At 37°C, a 103 -fold increase 
occurred at 6 hours, and a 107 - fold increase occurred at 24 hours. Viable organisms of P. 
aeruginosa were still obtained from the propofol solution at 7 days post inoculation after 
being incubated at 4°C (23). 
Holroyd et al., (2014) investigated the efficacy of a new intravenous cleaning device 
compared with 70% isopropyl alcohol prep pads. They contaminated a variety of devices and 
used contaminated propofol as a control. After inoculation with 0.5 McFarland standard of P. 
aeruginosa (ATCC 27853), they also found exponential growth after 24 hours of incubation 
(49). 
These studies were further supported by a letter to the editor which reported that P. 
aeruginosa (ATC 27853) grew ‘vigorously’ in 1% propofol after incubation for 24 hours (52). 
No further details were given. 
 
Growth of Burkholderia cepacia in propofol 
Obayashi et al. (2003) found rapid proliferation of Burkholderia cepacia (clinical isolate) at 30 
°C in propofol (Diprivan 10mg/ml) over a seven day period (Figure 3) (30). 
 
 
Figure 3: Viability of S. marcescens at 30 °C in Soybean Oil (O) and propofol (   ) and of B. cepacia at 30 
°C in Soybean Oil (   ) and Propofol ( )(30) 
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In contrast to these studies however, two studies (24, 35) reported that propofol had weak 
bactericidal effects on the growth of P. aeruginosa. Crowther et al., (1996) inoculated P. 
aeruginosa (ATCC 27853) into propofol (Diprivan®; Zeneca Pharma, Mississauga, Ontario, 
Canada) vials and then the vials were sub plated out at 0, 3, 6, 12 and 42 intervals and stored 
at 20°C between samplings. The plates were then incubated at 35°C for 24 hours to find a 
modest decrease in growth of P. aeruginosa (Figure 4) (24).  
 
Figure 4: Number of colony forming units of Pseudomonas aeruginosa counted over a 24 hour period 
after inoculation in various agents (24) 
Wachwoski et al., (1999) used a similar methodology, similar strain of P. aeruginosa (ATCC 
27853) and a similar brand of propofol (Diprivan®; Zeneca Pharma, Mississauga, Ontario, 
Canada) to that reported by Crowther (24), and also reported a decline in growth of P. 
aeruginosa 24 hours post inoculation (Figure 5) (35). 
 
Figure 5:  Number of colony-forming units of Pseudomonas aeruginosa counted over 24 houtrs after 
inoculation in various mixtures. *P <0.05 significantly different from baseline (time 0). P = propofol 
(35). 
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4. Discussion 
Seven of the nine publications identified in this review showed that propofol not only 
supports microbial growth, but results in rapid multiplication (21, 23, 30, 45-48). 
Propofol is a lipid-based, emulsion containing glycerol, purified egg phosphatide, sodium 
hydroxide, and soya bean oil (20) and thus provides an excellent growth medium for a variety 
of gram positive and negative bacteria, and yeasts including P. aeruginosa (1, 21-25, 27-37). 
The manufacturer’s guidelines therefore recommend that strict aseptic technique should be 
used when handling and administering propofol (53-55). 
Two studies (24, 35) however reported that propofol had a weak bactericidal effect on the 
growth of P. aeruginosa. The main difference between this study and the six of the seven 
studies that reported exponential growth of P. aeruginosa or B. cepacia is that both Crowther 
et al., (1996) and Wachowski et al., (1999) stored the samples at 20°C between sampling 
times, whereas the other studies incubated their samples at higher temperatures: 30°C (30), 
35°C (46-49) and 37°C (21, 45). The optimal range for growth of P. aeruginosa is 37°C (range 
4°C to 42°C) (56). It is possible that the lower temperature that Crowther and Wachowski’s 
samples were stored at slowed down the growth of P. aeruginosa, however Berry at al., 
(1993) also stored their samples at 20°C and showed exponential growth of P. aeruginosa by 
24 hours (23). However, there were many differences between Berry, Wachowski and 
Crowther’s studies which could be related to the differences in results. The main obvious 
differences are that different strains of P. aeruginosa were used: Berry et al., (1993) used P. 
aeruginosa (NCTC 10662) and Crowther et al., (1996) and Wachowski et al., (1998) used P. 
aeruginosa (ATCC 27853), and different propofol solutions were used: Berry et al., (1993) 
used Diprivan (ICI) and Crowther et al., (1996) and Wachowski et al., (1998) used Diprivan® 
(Zeneca Pharma, Mississauga, Ontario, Canada).  
We are not certain why these two studies present conflicting findings, however, the majority 
of the evidence shows that propofol supports exponential growth of biochemically similar 
bacteria to Ralstonia spp. 
It is possible that we missed publications by not searching other search engines such as 
MEDLINE, however we would have expected that if there were additional publications they 
would have been identified through cross referencing or ‘suggested articles’ on the PubMed. 
 
5. Conclusion 
These studies suggest that if the propofol were contaminated with Ralstonia spp. at the point 
of manufacture, we could expect the vials to have been heavily contaminated with Ralstonia 
spp. by the time it was drawn up for clinical use many weeks later. 
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Appendix 6: Line list of cases of Ralstonia bacteraemia 
Hospital* Diagnosis Adm 
date 
Day/time 
propofol first 
administered 
Day/time 
of  onset 
of 
infection 
Incubation 
period 
Species Diversilab 
result (same 
colour for 
identical 
strains) 
Possible batches 
(date of manufacture) 
Vict, 
ENDO 
Colonoscopy - polypectomy,  
acupuncture needles in situ 27/3 to 3/4 
1/4 1/4 
13:10 
1/4 
18:00 
5 hours R.mann Diff to all 
other isolates 
Batch numbers 
unknown, could be up 
to 4 different batches 
SA 
Private 
hospital, 
ENDO 
Upper endoscopy and colonoscopy, 
metastatic cancer (diagnosed for the 
first time). CT scan with IV contrast on 
1/4/2014 
17/4 17/4 
14:35 
17/4 
16:10 
2 hours R.mann Identical to 1 
strain from 
RAH 
Provive batches:  
A030906 (09/2013) 
A030907 (09/2013)  
(3 other batches may 
also be implicated) 
RBWH, 
OT 
Myelodysplastic, rheumatic heart 
disease with mitral valve replacement 
atrial fibrillation. Multiple opportunities 
for infection in ICU since 30/3  
30/3 15/4 
22:35  
18/4 
before 
07:30 
3 days R.mann Identical to 3 
strains from 
GCUH 
Provive batches:  
A031195 (11/2013) 
A031202 (11/2013) 
A031203 (11/2013) 
A031210 (11/2013) 
RAH,  
ICU 
Motor vehicle accident, multiple 
opportunities for infection in ICU since 
13/4 
13/4 13/4 
Infusion 
started in the 
morning  
18/4 
9:00 
5 days R.mann Ident SA priv Provive batches:  
A030906 (09/2013)  
A030907 (09/2013) 
RAH,  
ICU  
Subarachnoid hg, multiple 
opportunities for infection in ICU since 
20/4 
20/4 20/4 
time 
unspecified 
23/4 
16:00 
3 hr <4 
days 
R.pick Diff to all 
other isolates 
Provive batches:  
A030906  (09/2013) 
A030907 (09/2013) 
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GCUH,  
OT 
Septic hip, 3 previous joint 
washouts(previously grown S.aureus 
and S. Lugdenensis). History of 
alcohol abuse and IV drug use. 
Multiple opportunities for infection in 
ICU since 2/4 
2/4 8/4 
11.30 
1/5 
time 
unspecified 
23 days R.mann Strain ident 
to RBWH & 
GCUH  
Provive batches:  
A031195 (11/2013) 
A031202 (11/2013) 
A031203 (11/2013) 
A031210 (11/2013) 
A030071 (unknown) 
A020648 (unknown) 
A020647 (unknown) 
A031196 (unknown) 
A030085 (unknown)  
GCUH, 
ICU  
Shoulder arthritis, cavitating 
pneumonia and tricuspid endocarditis. 
History of IV drug use, hepatitis C 
infection.  
31/3 8/4 
time 
unspecified                
1/5  
time 
unspecified 
23 days 
16 days 
1 day after 
R.mann Strain ident 
to RBWH & 
GCUH  
Provive batches:  
A031195 (11/2013) 
A031202 (11/2013) 
A031203 (11/2013) 
A031210 (11/2013) 
A030071 (unknown) 
A020648 (unknown) 
A020647 (unknown) 
A031196 (unknown) 
A030085 (unknown)  
TPCH,  
ICU 
Influenza pneumonia, respiratory 
failure, ICU since 15/4 
15/4 17/4 
 18:23 
4/5 time 
unspecified 
7 days R.ins Different to 
all other 
isolates 
Sandoz batches:  
A031110 and A030504 
RBWH Interhospital transfer from TPCH with 
AML 
29/5 N/A 15/6 time 
unspecified 
Unknown R.mann Strain ident 
to RBWH & 
GCUH 
N/A 
*ENDO = endoscopy ward, OT = operating theatre, ICU = intensive care unit 
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Appendix 7: Original Ralstonia case report form developed by Queensland Department of Health 
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Appendix 8: Adapted Ralstonia case report form for multijurisdictional investigation into cases of Ralstonia bacteraemia 1 April to 26 June 2014 
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Appendix 9: List of expert panel members who participated in the Delphi rounds  
1. Professor Bart Currie 
2. Professor David Paterson 
3. Associate professor Allen Cheng 
4. Associate professor Ann Koehler 
5. Dr Claire Heney 
6. Dr Melissa McRae 
7. Dr Barry Combs
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Appendix 10: DiversiLab® results, including association with propofol 
 
 
 
 
 
 
 
 
 
 
 
 
 
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
NA
NA
NA
TA= tracheal aspirate 
QLD=Queensland SA=South Australia
*= old isolates from storage
Multiple isolates from the same patient 
are in coloured boxes
Received 
propofol
NA
yesBlood
Clone 1
Identity
=94 -98%
Clone 2
Identity
=93 -
99%
Clone 4
Identity
=97-99%
Clone 5
Clone 3
Clone 6
Identity
=50-58%
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Appendix 11: Frequency of Ralstonia isolated from blood cultures, number of requests for 
blood culture and number that were positive, 2009 - 2014 
State Years 
Number of Ralstonia 
blood isolate 
Number of blood 
requests (years) 
Number of blood 
requests positive for 
bacteria (years) 
SA 
Jan 2013 – 
March 2014 
0 
34, 801 in Financial 
year (FY) 2012-2013 
3603 (FY 2012-
2013) 
NT 2013-2014 0   
ACT 
2012 
2013 
1 
0 
18654 
18026 
 
TAS 
2012 0 13604 
 
2013 0 15665 
WA 
2012 – 2014 (to 
date) 
1   
 QLD 
2011 1 139570 
 
2012 2 141154 
2013 3 141920 
2014 (to date) 4 57810 
NSW 
1998 1 
  
2001 1 
2003 1 
2009 3 
2010-2014 (to 
date) 
0 
VIC 
2004-2013 
2014 
5 
1 
 
6060 (average per 
year, 2004 - 2013) 
NSW data from SWAPS, HAPS, ICPMR, SEALS, SYDPATH and PALMS 
VIC data from VICNISS (healthcare associated infection surveillance system) and PHLN 
SA data from PHLN and SA pathology 
ACT data from TCH, CALVARY and NCPH 
TAS data from RHH 
WA data from PATHWEST 
NT data from RDH 
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Appendix 12: Results of microbiological testing of propofol solution, flip-off caps and external surfaces of the rubber stoppers  
Batch 
number 
Laboratory1 Test for 
Sterility2(vials 
tested) 
Test for 
Bacterial 
Endotoxins3 
(vials tested) 
Microbial 
Contamination Test4 - 
vial contents 
(vials tested) 
Microbial Contamination Test - flip-off lid 
and rubber stopper external surfaces5 
No. positive for 
bacterial 
growth/no. tested 
Bacteria isolated 
A030906 A Pass (20) Pass (1) Pass (3) 12/80 Bacillus species, 
Gram-positive cocci 
B Pass (80) Pass (4) - - - 
C - - Pass (12) 10/14 pools 6, 7 
(total 70 tested) 
Bacillus species x 10 
Coagulase-negative 
staphylococci x 3 
A030907 A Pass (20) Pass (1) Pass (3) 7/80 Bacillus species, 
Gram-positive cocci 
B Pass (80) Pass (4) - - - 
C - - Pass (10) 15/18 pools6, 7 
(total 90 tested) 
Bacillus species x 10 
Coagulase-negative 
staphylococci x 5 
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Batch 
number 
Laboratory1 Test for 
Sterility2(vials 
tested) 
Test for 
Bacterial 
Endotoxins3 
(vials tested) 
Microbial 
Contamination Test4 - 
vial contents 
(vials tested) 
Microbial Contamination Test - flip-off lid 
and rubber stopper external surfaces5 
No. positive for 
bacterial 
growth/no. tested 
Bacteria isolated 
Ralstonia 
mannitolilytica(1 
pool)7 
A031266 A - Pass (1) - - - 
B Pass (61) Pass (4) - - - 
D Pass (20) Pass (1) Pass (20) 0/20 - 
A031267 A - Pass (1) - - - 
B Pass (61) Pass (4) - - - 
D Pass (20) Pass (1) Pass (20) 0/20 - 
A040081 A - Pass (1) - - - 
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Batch 
number 
Laboratory1 Test for 
Sterility2(vials 
tested) 
Test for 
Bacterial 
Endotoxins3 
(vials tested) 
Microbial 
Contamination Test4 - 
vial contents 
(vials tested) 
Microbial Contamination Test - flip-off lid 
and rubber stopper external surfaces5 
No. positive for 
bacterial 
growth/no. tested 
Bacteria isolated 
B Pass (61) Pass (4) - - - 
D Pass (20) Pass (1) Pass (20) 0/20 - 
A031282 B Pass (60) Pass (3) - - - 
E Pass (20) Pass (2) - - - 
A031283 B Pass (60) Pass (3) - - - 
E Pass (20) Pass (2) - - - 
A030021 A - Pass (1) - - - 
B Pass (60) Pass (3) - - - 
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Batch 
number 
Laboratory1 Test for 
Sterility2(vials 
tested) 
Test for 
Bacterial 
Endotoxins3 
(vials tested) 
Microbial 
Contamination Test4 - 
vial contents 
(vials tested) 
Microbial Contamination Test - flip-off lid 
and rubber stopper external surfaces5 
No. positive for 
bacterial 
growth/no. tested 
Bacteria isolated 
A030146 A - Pass (1) - - - 
B Pass (60) Pass (3) - - - 
A030293 A - Pass (1) Pass (3) - - 
B Pass (60) Pass (3) - - - 
A0308728 B Pass (60) Pass (4) - - - 
A0308398 B Pass (40) Pass (4) - - - 
A0308408 B Pass (40) Pass (4) - - - 
A0309328 B Pass (60) Pass (4) - - - 
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Batch 
number 
Laboratory1 Test for 
Sterility2(vials 
tested) 
Test for 
Bacterial 
Endotoxins3 
(vials tested) 
Microbial 
Contamination Test4 - 
vial contents 
(vials tested) 
Microbial Contamination Test - flip-off lid 
and rubber stopper external surfaces5 
No. positive for 
bacterial 
growth/no. tested 
Bacteria isolated 
A0309368 B Pass (60) Pass (4) - - - 
A0309378 B Pass (60) Pass (4) - - - 
A031027 B Pass (60) Pass (4) - - - 
A031069 B Pass (60) Pass (4) - - - 
A030504 B Pass (60) Pass (3) - - - 
A031202 B Pass (60) Pass (3) - - - 
A030288 B Pass (60) Pass (3) - - - 
A031203 A - - - 0/5 - 
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Batch 
number 
Laboratory1 Test for 
Sterility2(vials 
tested) 
Test for 
Bacterial 
Endotoxins3 
(vials tested) 
Microbial 
Contamination Test4 - 
vial contents 
(vials tested) 
Microbial Contamination Test - flip-off lid 
and rubber stopper external surfaces5 
No. positive for 
bacterial 
growth/no. tested 
Bacteria isolated 
B Pass (60) Pass (3) - - - 
A031210 A - - - 1/5 Gram-positive cocci 
B Pass (60) Pass (3) - - - 
A030085 A - - - 2/20 Bacillus species, 
Gram-positive cocci 
B Pass (60) Pass (3) - - - 
A031195 A - - - 1/20 Bacillus species, 
Gram-positive cocci 
B Pass (60) Pass (3) - - - 
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Batch 
number 
Laboratory1 Test for 
Sterility2(vials 
tested) 
Test for 
Bacterial 
Endotoxins3 
(vials tested) 
Microbial 
Contamination Test4 - 
vial contents 
(vials tested) 
Microbial Contamination Test - flip-off lid 
and rubber stopper external surfaces5 
No. positive for 
bacterial 
growth/no. tested 
Bacteria isolated 
A031196 A - - - 2/20 Bacillus species, 
Gram-positive cocci 
B Pass (60) Pass (3) - - - 
A031256 A - - - 5/18 Bacillus species, 
Gram-positive cocci 
B Pass (60) Pass (3) - - - 
A031110 A - - - 4/20 Bacillus species, 
Gram-positive cocci 
B Pass (60) Pass (3) - - - 
A020647 A - - - 0/2 - 
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Batch 
number 
Laboratory1 Test for 
Sterility2(vials 
tested) 
Test for 
Bacterial 
Endotoxins3 
(vials tested) 
Microbial 
Contamination Test4 - 
vial contents 
(vials tested) 
Microbial Contamination Test - flip-off lid 
and rubber stopper external surfaces5 
No. positive for 
bacterial 
growth/no. tested 
Bacteria isolated 
B Pass (60) Pass (3) - - - 
A020648 A - - - 1/19 Bacillus species 
B Pass (60) Pass (3) - - - 
A030071 A - - - 1/15 Gram-positive cocci 
B Pass (60) Pass (3) - - - 
Notes 
1. Laboratories 
A. TGA 
B. Manufacturer 
C. External laboratory7 
D. External laboratory 
E. External laboratory 
2. The Test for Sterility is a standard pharmacopoeial batch release test for an injectable medicine. A 'Pass' result means that no microbial contamination 
was detected in the portion of the samples that were tested. Each test uses 20 vials. 
3. The Test for Bacterial Endotoxins is a standard pharmacopoeial batch release test for an injectable medicine. A 'Pass' result means that bacterial 
endotoxins were not detected in the portion of the samples that were tested. 
Chapter 5.1 
5.1-74 
 
4. The Microbial Contamination Test is not applicable to a sterile medicine. It was performed only as an adjunct test to estimate the level of microbial 
contamination should vial contents be contaminated. A 'Pass' result means that no microbial contamination was detected in the portion of the samples 
that were tested. 
5. Flip-off lid and rubber stopper external surface swab tests were performed to assess bacterial contamination on these surfaces. 
6. Testing was performed on pooled samples. Each pool contained the flip-off lids and swabs from the external surface of rubber stoppers from 5 vials. 
7. Laboratory C has placed the following caveats on their test results: 
o The laboratory holds accreditation for testing of human diagnostic samples and for testing of clinical, non-human specimens for investigation of 
nosocomial infections in outbreaks and/or individuals, e.g. gastrointestinal endoscopes, vascular catheter tips and transfusion bags. The laboratory 
has limited accreditation for environmental testing 
o Testing of the flip-off lids and external surface of the rubber stoppers included testing of the entire flip-off lid after disinfection of the outer surface of 
the lid with 70% alcohol. Aseptic techniques were used; however, removal of vial lids was difficult and adventitious contamination might have been 
introduced during the sampling and testing processes, e.g. the detection of coagulase-negative staphylococci in some pools. Isolation of Bacillus 
species from some pools might reflect lack of sporicidal activity of 70% alcohol used for disinfection of external surfaces of vial lids. 
o Test methods were adapted in-house. Test methods have not been fully validated and results should be interpreted accordingly. 
o Ralstonia mannitolilytica was isolated from 1 of 32 pools. Ralstonia species are rarely recognised as contaminants in this laboratory. 
8. These batches were not supplied to Australia or New Zealand 
9. Where a laboratory did not perform a test as part of the investigation the cell has a hyphen and is shaded
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Appendix 13a: Simulated case-control study 
Number of cases with 
Ralstonia bacteraemia 
Number in study base without Ralstonia bacteraemia Odds Ratio 
Received 
propofol 
Did not 
receive 
propofol 
Number 
eligible as 
controls 
Number 
selected as 
controls 
(3/case) 
% who 
received 
propofol 
Number in 
study base  
who received 
propofol 
Number of 
controls who 
received 
propofol 
Point 
estimate 
95% CI p-value 
8 
0 80 24 
90 72 22 Undefined 0.2, ∞* 0.6 
64 51.2 15 Undefined 1.1, ∞* 0.05 
50 40 12 Undefined 1.8, ∞* 0.01 
25 20 6 Undefined 5.2, ∞* <0.001 
1 90 27 
90 81 24 1.0 0.1, 59.0 0.70 
50 45 14 7.4 0.8, 354.4 0.05 
40 36 11 11.6 1.2, 547.7 0.01 
25 23 7 22.9 2.2, 1062.9 0.002 
2 100 30 
90 90 27 0.4 0.04, 6.3 0.37 
50 50 15 4.0 0.6, 43.4 0.09 
35 35 11 6.9 1.1, 74.4 0.02 
25 25 8 11.0 1.6, 119.1 0.005 
3 110 33 
90 99 30 0.3 0.03, 2.5 0.15 
50 55 17 2.5 0.5, 16.9 0.19 
30 33 10 6.1 1.1, 41.6 0.02 
25 28 8 8.3 1.5, 57.4 0.01 
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Appendix 13b: Simulated cohort study 
Number of cases with Ralstonia 
bacteraemia 
Number in cohort  without Ralstonia bacteraemia OR=RR 
Received propofol 
Did not 
receive 
propofol 
Total number in 
cohort 
% who received 
propofol 
Number who 
received propofol 
Point estimate 95% CI p-value 
8 
0 80 
90 72 Undefined 0.2, ∞* 0.45 
65 52 Undefined 1.1, ∞* 0.04 
50 40 Undefined 2.0, ∞* 0.006 
25 20 Undefined 5.9, ∞* <0.001 
1 90 
90 81 0.89 0.1, 43.8 0.63 
50 45 8.0 0.99, 3602.6 0.03 
45 41 9.6 1.2, 432.6 0.01 
25 23 23.3 2.8, 1048.7 <0.001 
2 100 
90 90 0.44 0.07, 4.9 0.30 
50 50 4.0 0.74, 40.0 0.07 
40 40 6.0 1.1, 59.9 0.02 
25 25 12.0 2.1, 120.0 <0.001 
3 110 
90 99 0.3 0.06, 2.01 0.12 
50 55 2.7 0.6, 16.3 0.13 
35 39 4.9 1.1, 29.6 0.02 
25 28 7.8 1.7, 47.9 0.003 
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Appendix 14: Assessing the standard of evidence based on the Bradford Hill framework  
Standard of evidence 
suggested by 
Bradford Hill 
Evidence for and against each standard  
(we have stated ‘Uncertain’ where data are lacking or we lack appropriate technical knowledge) 
Strength of 
association between 
exposure and 
outcome 
For 
All cases with Ralstonia bacteraemia received propofol (this could be restated as ‘risk of disease is zero if propofol was not 
administered’) 
Six of the eight cases received a single brand of propofol, Provive, one received both Provive and the Sandoz product, and one 
received only the Sandoz product. 
Uncertain 
The strength of association refers typically to the value of the OR and/or RR. Based on the results of our simulations of a case control 
or case cohort study, we are unlikely to obtain a statistically significant result if we conducted a case control or case cohort study. This 
is because the study would have low power with only eight cases (or even with nine cases if we included the case from WA), the 
presence of multiple confounders (i.e. other opportunities to acquire the infection) and the potential multiple selection and 
measurement biases inherent in a retrospective study. 
The strength of association with vials from specific propofol batch numbers is unknown. The exact batches administered are 
confirmed only for the patient at TPCH (Sandoz Propofol A031110 and A030504), while batch details for the other cases are either 
not known or could be narrowed down to two or four possible batches. In total, up to seven different batches may be implicated (as 
shown in the line list): 
 three SA cases received either batch number A030906 or A030907 
 three QLD cases received either batch number A031195, A031202, A031203, or A031210 
 batch number for the VIC case is unknown 
Propofol is frequently used in hospitals. Preliminary data suggest that more than 80,000 vials from the implicated batches were 
distributed across Australia before the quarantine date on 2 May 2014, and it has been difficult to determine the number already 
used. If we assume 50% have been used, then the risk of getting bacteraemia is eight episodes from 40,000 vials used.  
 
Consistency of our 
findings across 
For 
Multistate nosocomial outbreaks of Ralstonia outbreaks have been reported from contamination of medical products (24, 26, 63-65). 
Chapter 5.1 
5.1-78 
 
different populations Multistate nosocomial outbreak as a result of intrinsic contamination of propofol have been reported in the literature (20, 25, 66). 
Multistate nosocomial outbreak caused by polyclonal (≥2 isolates) contamination of a medical product have been reported in the 
literature (20, 27, 28).  
Specificity in the 
relationship between 
exposure and 
outcome 
For 
An isolate of Ralstonia from the lid of a vial of propofol (A030907) is genetically identical to clinical isolates from two patients 
managed at the two hospitals in SA (based on DiversiLab results).  
This result could not be replicated when vials from the same batch were retested at a later date. SA Pathology laboratory reported it 
“has NATA accreditation for human diagnostic work and sterility testing of bronchoscopes but does not hold extensive NATA 
environmental-testing accreditation. The methodology was specifically adapted in-house to test these propofol vials. The method has 
not been fully validated and results should be interpreted accordingly….. The technician attempted to use sterile technique but the 
removal of the vial lids was difficult. Contamination may have been introduced during sampling as evidenced by the mixture of 
cutaneous flora in the sub-cultures”.  
Against 
Strains of Ralstonia belong to five genetically different groups (three different groups of R. mannitolilytica, one of R. Pickettii, one of 
R. insidiosa) as shown in the updated DiversiLab results. None of the strains are found in more than one state. 
 One cluster and one singleton in SA (R. mannitolilytica and R. Pickettii respectively)  
 One cluster and one singleton in QLD (R. mannitolilytica and R. insidiosa respectively) 
 A singleton in VIC (R. mannitolilytica)  
The specificity of association by propofol batch number is uncertain. There are up to seven different batches implicated and it is not 
known which batch numbers were used in six cases. 
The cluster of cases with R. mannitolilytica in QLD isolated from blood cultures in cases who received propofol includes an isolate 
from a tracheal aspirate in a patient who did not receive propofol. 
Temporality, i.e. the 
outcome occurred 
after (and not 
before) exposure  
For 
All cases received propofol between 1 hour and 23 days before developing clinical infection. 
Uncertain 
Some clinicians have expressed uncertainty about the interval acceptable to be defined as the incubation period. In two cases the 
incubation period was one and five hours respectively (both of whom were given propofol immediately before an endoscopy) and in 
two other cases, the incubation periods is 23 days.  
We need to clarify and define the incubation period to be used in our analysis. 
Biological gradient, 
i.e. dose-effect 
relationship between 
For 
The very short incubation periods of one and five hours have been interpreted as a dose-response relationship because patients 
being prepared for an endoscopy are given large bolus dose/s of propofol.  
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exposure and 
outcome 
Uncertain 
Is a dose response relationship plausible if only the vial or the cap of the vial was contaminated but not the propofol solution? We do 
not have (would not be able to collect) validated data on the practice of drawing up the propofol and changing syringe needles before 
injecting patients. This information is also relevant to explain the mechanism of transmitting the infection when considering ‘biological 
plausibility’ (in the next row). 
Biological Plausibility 
of the association 
between 
For 
The propofol solution and/or vial could have been contaminated if sterilisation procedures at the manufacturing facility were 
inadequate. 
The propofol packages and vials could have been contaminated during transport, distribution of supplies and in the process of 
drawing up and injecting the propofol solution. 
The propofol packages and vials could have been contaminated with multiple strains of Ralstonia. 
Uncertain 
Contamination with five genetically different strains of Ralstonia, but cases in each state having unique genotypes requires 
explanation.  
Coherence (“cause-
effect relationship 
does not conflict 
with what is known 
of the natural history 
and biology of the 
disease” 
For 
Polyclonal Ralstonia contamination of medical solutions as well as of medical devices has been reported (20, 27, 28) 
Uncertain 
We have not yet found literature reports of contamination of a medical product with five different strains of the same bacteria, and 
where each state has a unique genotype 
Experimental 
evidence “removing 
exposure” or lab-
based experiments 
For 
No new cases were reported after the propofol was quarantined on 2 May. No new cases were reported among those who received 
propofol between the 27th of April and the date of quarantine on the 2nd of May (5 days). 
Uncertain 
This observation needs to be interpreted with caution; the last date propofol can be implicated was on 27 April: the patient from 
TPCH received only the Sandoz product and the isolate has a unique genotype compared with isolates from the other cases in QLD 
(TPCH has a specialist respiratory unit and a heart (?-lung) transplant unit). Could this case be classified as a possible ‘sporadic’ case 
infected from another case. If this is accepted as a possibility, then we could say that no further cases related to propofol were 
reported between 23 April and the day propofol was quarantined on 2 May, i.e. nine days. 
Analogy For 
Multiple strains of other bacteria contaminating medical solutions and devices have been reported. 
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Appendix 15: Key points transcribed from each Panel Member’s response and facilitators’ conclusions on each question 
Question Key points transcribed from each Panel Member’s responses Facilitators’ conclusion 
Q 1: excluded   
Q 2: If we assumed that 
propofol administration 
was causally associated 
with bacteraemia, can we 
conclude that pre-existing 
contamination of the 
propofol solution was 
unlikely and that the vial 
cap and/or rubber stoppers 
were more likely to have 
been the source of the 
Ralstonia? 
“Yes” 
“This may be a reasonable conclusion”. For cases where onset was rapid, “explanations could 
include contamination of propofol solution in the syringe at the time of drawing up of propofol 
….[and] internal contamination of these vials with Ralstonia prior to opening of the vials”. 
Response to question 5c included “[the laboratory results “do not generally support internal 
contamination of the product” 
 “… it was more likely that the outside cap or on the top of the bung was contaminated.”  
“I think this is the most plausible explanation, but other sources are also possible. It is difficult to 
prove a negative, and it is possible but unlikely that contamination of a small proportion of the 
propofol may have occurred but has not been detected”. Response to question 5c included “The 
finding that the internal contents of propofol tested negative for bacterial growth and endotoxin is 
reassuring” 
“…it is possible that the Ralstonia was inside the bottle….it can survive under the cap….”We can 
come to any conclusions as to whether it was more likely to be in the bottle or under the cap as 
both are possible.” 
“…our understanding of Ralstonia species is limited. I would expect closer clonal similarities 
between cases if pre-existing contamination was the source.” 
 
The vial cap and/or 
rubber stoppers rather 
than the propofol solution 
was the more likely 
source of the Ralstonia, 
but other sources of the 
bacteria cannot be 
excluded 
Q 3: How confidently can 
we exclude other possible 
sources of exposure (apart 
from propofol 
administration) to 
Ralstonia in some or all the 
cases?  
“Confident in the 2 SA mannitolilytica cases. Not confident in any of the others. But await WGS to 
make this even stronger link in SA” 
“In the case who had acupuncture, it is possible that this was the source of his bacteraemia, but 
without signs of local infection at the acupuncture sites, not highly likely. Generally infections 
secondary to acupuncture involve skin flora, though environmental organisms such as 
mycobacteria can also occur.” 
“It is difficult to confidently exclude other possible sources of exposure as the data on the excel 
Vial cap/rubber stopper 
was a likely source in the 
SA cases (if supported by 
WGS), but other sources 
of Ralstonia spp cannot 
be excluded for the other 
cases. 
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spreadsheet….. [SA case after endoscopy] has less other exposures which could be excluded.” 
“I do not think that we have a smoking gun. I note that other, more common exposures have been 
associated with Ralstonia outbreaks…… Pseudo-outbreaks have also been associated with 
contaminated laboratory fluids” 
“In view of the latest case at the RBWH with no propofol association, we can confidently say that 
there must be other sources for the bacteraemias. It has always been the case for the Gold Coast 
respiratory carriage patients that there must be other sources” 
“Of patients receiving propfol, 99.9% will also receive a saline flush if not a N/Saline infusion and 
obviously an IV catheter.” 
 
Q 4: How likely is it that a 
patient with Ralstonia 
bacteraemia but without 
signs of a pulmonary 
infection may have 
transmitted Ralstonia to 
another patient as an 
explanation of why the 
same strain of Ralstonia 
was isolated from the 
sputum or tracheal 
aspirate of a patient who 
never received propofol? 
“Very Unlikely” 
“This is quite possible – it’s usually due to cross infection in the wards when staff don’t ….follow r 
standard precautions” 
“It is more likely that both these patients were infected from as yet unknown common 
environmental source (not propofol)” 
“This usually suggests environmental contamination as a common source” 
“Highly unlikely” 
“Seems highly unlikely” 
 
Environmental 
contamination is the 
more likely source 
Q 5a: How should we 
interpret the finding of the 
Ralstonia isolate from the 
vial cap, noting the caveat 
from SA Pathology?  
 
“Await WGS but it is a very strong link given the Diversilab results and that we don’t culture 
Ralstonia commonly” 
“… very likely that the isolation of Ralstonia from under a vial cap, and an isolate which was 
identical to one of the clinical isolates in SA, is significant, and not the result of laboratory 
contamination” 
 “..strongly suggests that vials of propofol were contaminated by Ralstonia on the outside by a 
unknown mechanism” 
Three members consider 
the isolation of Ralstonia 
from the vial cap to be 
significant, and one of 
them awaits confirmation 
with the results of the 
WGS. 
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“We cannot say if the Ralstonia contaminated the vial cap and infected the patient from a 
common environmental source, or (less likely given the rarity of the organism) was a result of 
laboratory contamination. The significance of contamination of the external surface of the vial (as 
distinct to the vial contents) is uncertain”. Response to question 5b: “We have no control group of 
other vials” 
“We do not have Diversilab patterns for commonly found Ralstonia isolates in SA so if there is lot 
of variation, then it is likely that these strains are causally related. If there is no variation (i.e. every 
single isolate of Ralstonia in SA is identical) then it is less likely / unlikely”. Response to Question 5c 
“One needs to read the SA caveat very carefully and note their methodology. Specimens were 
pooled and they state that it was difficult to get the lids off. If Ralstonia lives in the tap water and 
is an environmental contaminant, is it possible that this isolate was not actually from the vial?” 
 “Although the caveat does not fault the lab the reason we have NATA accreditation is to have 
confidence in the laboratory process when interpreting lab results in situations such as this” 
 
Three members do not 
appear to be as convinced 
of the clinical significance 
of the finding in making a 
causal association. 
Q 5b: How should we 
interpret the TGA result of 
contamination of the 
internal surface of flip-off 
seal and rubber stopper 
with other bacteria?  
 
“It shows how commonly such contamination may well be present” 
“…this is likely to represent microbial contamination of the exterior of the vials…… I would suggest 
that these batches have much heavier bacterial contamination than would be expected on such a 
product, and I think that the detection of so many cases of this unusual bacteraemia in patients 
who have received this product supports this” 
“….the external surface of the propofol vials can be contaminated with environmental bacteria” 
“We have no control group of other vials, but I would not expect the external surfaces of vials to 
be sterile, and the organisms isolated (moulds and bacillus particularly) are typical environmental 
organisms” 
“This is an expected result. As the area under the vial lid is not expected to be sterile which is why 
it is cleaned. If cleaning protocols are not followed, then there may be many bacteraemias with 
bacillus spp. etc that are causally related to contaminants under the lid. These are difficult to 
detect but no doubt occur all the time. Ralstonia is so uncommon that we have picked this 
outbreak up” 
Vial cap/rubber stopper 
were contaminated with 
environmental bacteria. 
Refer to literature review 
in Appendix 2: the plastic 
flip-off lid does not 
maintain sterility of the 
rubber stopper (Hilliard et 
al 2013; Buckley et al, 
1994) 
Q 5c: How do these 
interpretations influence 
“Support it, but it is the molecular typing that provides the “smoking gun” Similar to our summary in 
5a: two members support 
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your judgement of the 
hypothesis that propofol 
administration is causally 
associated with Ralstonia 
bacteraemia? 
 
“They support it strongly. However they do not generally support internal contamination of the 
product” 
“The evidence suggests that there was Ralstonia contamination of the external surface of propofol 
vials that were in SA hospitals ….. It is possible but not conclusive that Ralstonia [Pickettii] 
infections of SA case and [R. mannitolilytica] in Vic case. Even with the finding of contamination of 
the vial cap there is still insufficient evidence to implicate propofol administration as the cause of 
the QLD cases”  
“… most likely explanation is that the external surfaces of the vial have become contaminated with 
Ralstonia and that injections of bacteria has been caused by poor aseptic technique. I do not think 
that other potentially common exposures other than propofol have been excluded” 
“…the propofol was causally related in the SA cases …….. Propofol cannot be implicated in all cases 
and it is very odd to have 2 or maybe 3 Ralstonia outbreaks simultaneously.   One needs to read 
the SA caveat very carefully and note their methodology. Specimens were pooled and they state 
that it was difficult to get the lids off. If Ralstonia lives in the tap water and is an environmental 
contaminant, is it possible that this isolate was not actually from the vial?” 
the hypothesis, and one 
of them awaits 
confirmation with the 
results of the WGS. Three 
members appear not to 
be as convinced, and the 
sixth member did not 
respond to this question. 
Q 6: Can we confidently 
implicate or exclude 
propofol administration as 
the cause of Ralstonia 
bacteraemia in some or all 
the cases? 
 
“Yes for SA if the WGS confirms the close relatedness of the 2 clinical and 1 vials isolates. All other 
cases much less clear link to propofol” 
“No, as I have said before, with contamination of the top of the vials during the late manufacturing 
process by environmental organisms it would be unlikely that all isolates were identical. Some 
might be. The DiversiLab results support this” 
“…it would be presumptuous to confidently implicate or exclude propofol administration but the 
evidence shows that some cases are more likely to be associated with propofol administration 
than others” 
“Neither. The finding that the internal contents of propofol tested negative for bacterial growth 
and endotoxin is reassuring.”  
“SA cases with same pattern as vial isolate (if we believe the isolate was from the vial): highly 
suspicious. Others: possible association as the vials could have been contaminated with a variety 
of Ralstonia spp. Latest RBWH case: exclude” 
“…the number of confounders and the different in bacterial genetics is so varied that it seems 
difficult to confidently assign causation” 
Two members suggest 
propofol administration is 
a likely cause for the cases 
in SA, and one of them 
awaits confirmation with 
the result of WGS. 
One member suggests 
that contamination of the 
vial at the manufacturing 
site could explain the 
diverse genotypes - two 
genotypes in SA cases, 
and one genotype each in 
the case from TPCH and 
VIC. 
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Q 7: Noting the genetic 
similarity between the R. 
mannitolilytica isolate from 
the propofol vial cap and 
the clinical isolates from 
the two cases in different 
SA hospitals (RAH and SA 
Private), and the distinctive 
R. Pickettii isolate from the 
second patient in the same 
neurosurgical unit of the 
RAH, can we conclude that 
Ralstonia bacteraemia in all 
three cases was causally 
associated with the 
administration of propofol, 
and that the propofol/vial 
did not become 
contaminated in the 
respective clinical unit? 
 
“If WGS confirms all 3 clonal then not in clinical unit for those 2 R. mannitolilytica cases. Pickettii 
case less robust link and will remain only speculative but propofol a possible source for same 
reason as the other 2” 
“Yes. It would be highly unlikely that there was any other explanation”. 
“…unlikely that contamination of the external surface of the vials occurred at the respective 
clinical unit as the RAH and SA private patients have the same molecular type” 
“No. The Ralstonia Pickettii is clearly different. The Ralstonia mannitolilytica isolates are related, 
but there is insufficient evidence that contamination of the propofol is implicated. However, it is 
possible that a very small proportion of propofol may be contaminated” 
“One cannot be conclusive about the R. Pickettii patient but it is possible that the vials were 
contaminated with a range of Ralstonias”. “One assumes all 3 associated either with propofol or 
perhaps a skin cleaning preparation for example”. 
 
One member accepts 
propofol administration 
was source, three accept 
this explanation for the 
two cases with R.m (one 
of them accepts if this 
was confirmed with 
WGS).  
Three members are 
uncertain about the 
source for the case with 
R.p. One member says 
there is insufficient 
evidence to implicate 
propofol, although this is 
possible.  
Three members agree 
that it is unlikely that 
contamination occurred 
in the clinical unit. 
Q 8: How confident can we 
be that the cases reported 
in QLD and/or VIC with 
diverse genetic strains 
were also causally 
associated with the 
administration of propofol 
because all of them had 
received propofol? 
 
“Less robust link and will remain only speculative but propofol a possible source for same reason 
as the 2 in SA. I.e. multiple contaminations of separate vials/batches etc.” 
“No propofol, no bacteraemia. However I note the recent detection of contamination in water 
(drinking?) in Qld – these patients were not bacteraemic (as far as I know at this stage)” [Note 
updates described on page 1: two patients at the GCUH had bacteraemia and the source of 
infections at this hospital has been attributed to bottled water. One case at the RBWH who 
developed Ralstonia bacteraemia on 15 June had not receive propofol] 
“No. They would have received multiple other potential exposures that have been previously 
associated with Ralstonia outbreaks, such as saline or heparin flushes” 
“They may be associated but the source may not be the propofol, but water for injection, skin 
The source of infection in 
the two bacteraemic 
cases at the GCUH, and 
possibly of the first case 
reported from the RBWH 
in May was unlikely to be 
propofol. 
Source of the infection in 
the case from VIC is 
uncertain. 
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cleaning solution” 
“It is possible case in VIC was due to propofol contaminated from external surface of the vial but 
insufficient evidence to implicate propofol administration as the cause of the QLD. (Abstracted 
from response provided to question 5)” 
 
 
Q 7  (should have been Q 
9): Based on the DiversiLab 
results and on the 
uncertainty of the batch 
number of propofol vials 
used in SA, VIC and QLD, 
what plausible hypotheses 
could we formulate on the 
likely site/s of 
contamination? More 
specifically, how likely is it 
that the propofol/vial may 
have been contaminated 
(a) at some stage before 
delivery to the clinical unit 
and (b) after arrival in the 
clinical unit? 
 
“Yes for the 2 SA cases if WGS confirms clonality and also a likely yes for any clusters confirmed by 
WGS where cases occurred at more than 1 clinical unit. (b) after arrival in the clinical unit – still 
possible where cases not linked by WGS to cases at another clinical unit” 
“Contamination at the factory is the only plausible explanation. This factory has a poor safety 
record and has been documented to violate production standards in the past. It is incredible that 
the TGA would accept the company’s word that they are following their documented procedures, 
and not do its own inspection, given the company’s history, once the suspicion of contamination 
was again raised” 
“..most likely explanation is that the external surfaces of the vials have become contaminated with 
Ralstonia and that injections of bacteria has been caused by poor aseptic technique” 
“Impossible to say where the contamination occurred. Perhaps if we knew the pattern of 
Ralstonia isolates in India at the factory, we could come to a conclusion. We also need to know the 
pattern of common Ralstonia isolates in the environment in Australia” 
“Difficult to say when contamination may have occurred but likely to have happen prior to 
distribution of the propofol to the SA hospitals” 
One member did not respond to this question. 
One member considers 
contamination at the 
factory as “the only 
plausible explanation” 
and another member 
considers this acceptable 
if clonality can be 
confirmed with WGS. One 
member considers 
contamination occurred 
at some point before 
propofol was distributed 
to SA hospitals. Two other 
members are open-
minded about the locality 
where the vial may have 
been contaminated. 
Q 8 (should have been 
Q10): What is the 
likelihood the propofol/vial 
was contaminated at the 
site of manufacture at 
Claris Life Sciences (India)? 
“Given the processes I’ve been told about re final cleaning of sealed vials with water sprays, it 
does seem most likely that this may well be responsible for contamination of the outside of 
already sealed vials before final packaging. Ralstonia is very much a water bug” 
“Highly likely” [See list below for supplementary comments from this member**] 
“There is insufficient information to answer this question” 
“There is insufficient evidence to support this, as there are multiple steps from manufacture to 
One member considers 
this “highly likely” and 
another “most likely”. 
Three members say there 
is insufficient information 
to answer the question. 
One member considers 
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 distribution that are common to all vials. It is also possible that another exposure is implicated. I 
note there are no reports elsewhere in the world reported on ProMed, which might be expected 
following the Australian alert on a product presumably used in multiple countries” 
“One cannot come to any conclusion about when / where the vials were contaminated…… Difficult 
to say unless the Ralstonia is isolated from inside the vial” 
“If we assume the cases in different states are linked then that is the only plausible option. 
Alternatively, the one Victorian case is consistent with our estimated background rate but this 
appears different for other states”  
this possible “if we 
assume the cases in 
different states are 
linked”. 
** The number of cases is indeed low considering the numbers of vials which have been used, however: 
 many clinicians may have followed appropriate procedures for disinfection of the rubber stopper 
 many clinicians may have only drawn up propofol for procedures immediately prior to the procedure 
 this organism is not highly pathogenic and bacteraemia would be more likely to be symptomatic in people who were immunosuppressed, as was the 
case for almost all of those cases detected 
 many people with transient bacteraemia might not have presented for assessment or been investigated fully (i.e. blood cultures taken) 
 not all vials may have been contaminated – this is quite likely – however it may be that those vials which were contaminated were quite heavily 
contaminated 
We have not seen outbreaks of Ralstonia bacteraemia associated concurrently with the use of any other brand of propofol, or any other injectable 
medication, or commonly used devices, during this time period
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Appendix 16: List of the twelve questions and facilitators’ conclusions based on members responses in Round 2, members’ Round 3 comments on 
these conclusions and facilitators revised conclusions 
Question 
Facilitators’ 
conclusions (included 
in Round 3) 
Comments from each Panel Member to Facilitators’ conclusions 
Facilitators’ revised 
conclusions 
Q 1: What incubation 
period could be 
considered consistent 
with a causal 
association between 
propofol 
administration and 
bacteraemia?” 
Exclude responses to 
this question from 
further analysis 
because there are 
multiple potential 
confounders for the 
estimated incubation 
period in many cases; 
retain all eight cases 
as being potentially 
associated with 
propofol 
administration 
No comments or objections to this conclusion from any member 
 
Unchanged from original 
conclusion. 
Q 2: If we assumed 
that propofol 
administration was 
causally associated 
with bacteraemia, can 
we conclude that pre-
existing 
contamination of the 
propofol solution was 
unlikely and that the 
vial cap and/or rubber 
stoppers were more 
likely to have been 
The vial cap and/or 
rubber stoppers 
rather than the 
propofol solution was 
the more likely 
source of the 
Ralstonia, but other 
sources of the 
bacteria cannot be 
excluded 
 
 “But possibly only for the 2 SA cases” 
 “Agree” 
 “There is no requirement that the external surfaces of vials to be sterile” 
 “Agree that the vial cap/rubber stoppers are the more likely source of the 
contamination for the majority of bacteraemia cases. Other sources of the 
bacteria cannot be excluded IN EVERY CASE, and notably in Qld there is a 
higher background rate which is no doubt climate-related.” In response to a 
comment by a fellow Panel Member about clonal similarities in pre-existing 
contamination, “If this was internal to the vial, agree. If external contamination 
would not necessarily expect clonal similarities.” 
Unchanged from original 
conclusion, and confirmed 
with the responses in 
Table 2. 
Chapter 5.1 
5.1-88 
 
the source of the 
Ralstonia? 
Q 3: How confidently 
can we exclude other 
possible sources of 
exposure (apart from 
propofol 
administration) to 
Ralstonia in some or 
all the cases?  
Vial cap/rubber 
stopper was a likely 
source in the SA cases 
(if supported by 
WGS), but other 
sources of Ralstonia 
spp. cannot be 
excluded for the 
other cases. 
Added a qualifier to this statement by inserting “2 R. mannitolilytica” before 
“SA cases” 
Added a qualifier to this statement by inserting “as evidenced by the Diversilab 
results (if one assumes the lid isolate was real). I would however check the 
local bottled water supply to see if Ralstonia is isolated and then put the 
isolates through DiversiLab just in case!” 
“agree” 
In response to the comment by the facilitators desiring support by WGS “Need 
to get over this fixation with WGS. It isn’t going to prove a thing. Environmental 
contamination = diversity. We started out with three species; how can anyone 
not understand that WGS will never prove that they are the same, because 
they aren’t.” In response to a statement by a fellow member that “we can 
confidently say that there must be other sources for the bacteraemias [in 
QLD]”, “Qld has always had a background rate of Ralstonia infection – this one 
case (RBWH with no propofol association) doesn’t disprove that there has been 
a problem with the propofol.” In response to a comment by a fellow Panel 
Member about respiratory carriage patients, “Most labs wouldn’t even work 
up these isolates – this could be occurring all over the country.”In response to 
a comment by a fellow Panel Member “Of patients receiving propofol, 99.9% 
will also receive a saline flush if not a N/Saline infusion and obviously an IV 
catheter”, this member said “The SA private hospital patient who developed 
bacteraemia within hours did not have a saline flush. His anaesthetist 
specifically stated this.”  
Unchanged from original 
conclusion, except that 
one member has 
questioned the value of 
the WGS in either proving 
or disproving the 
association. 
 
Q 4: How likely is it 
that a patient with 
Ralstonia 
bacteraemia but 
without signs of a 
pulmonary infection 
Environmental 
contamination is the 
more likely source  
No comment 
 “ Agreed” 
 “Would add contamination of another source eg saline/water as a possible 
common source” 
“and many laboratories would not bother to identify Ralstonia in respiratory 
Environmental 
contamination or another 
common source such as 
saline/water is the more 
likely explanation. 
 
Chapter 5.1 
5.1-89 
 
may have transmitted 
Ralstonia to another 
patient as an 
explanation of why 
the same strain of 
Ralstonia was isolated 
from the sputum or 
tracheal aspirate of a 
patient who never 
received propofol? 
specimens as it is not considered a significant pathogen (exceptions such as 
cystic fibrosis patients).” 
Q 5a: How should we 
interpret the finding 
of the Ralstonia 
isolate from the vial 
cap, noting the caveat 
from SA Pathology?  
 
Three members 
consider the isolation 
of Ralstonia from the 
vial cap to be 
significant, and one of 
them awaits 
confirmation with the 
results of the WGS. 
Three members do 
not appear to be as 
convinced of the 
clinical significance of 
the finding in making 
a causal association. 
“R. spp. are very diverse and if WGS shows few differences in snps between 
the vial cap strain and the 2 clinical ones then they almost certainly are causally 
linked, even though the specific transmission mechanism remains speculative” 
“I think the diversilab results are sufficient to link the lid and patient isolates (if 
the lid isolate is not a contam).” 
“I agree – probably significant finding but causal link cannot be established, 
particularly causal link to propofol cannot be established without establishing 
that Ralstonia isn’t found on other common sources eg saline” 
“Next question: If the result had been obtained by TGA, what would everyone 
be saying?” 
 
Members agree that 
isolation of Ralstonia from 
the propofol vial cap 
shows a likely link. 
However, one member 
stated this finding does 
not establish a causal link 
nor does it rule out other 
sources of the infection. 
Q 5b: How should we 
interpret the TGA 
result of 
contamination of the 
internal surface of 
flip-off seal and 
rubber stopper with 
Vial cap/rubber 
stopper were 
contaminated with 
environmental 
bacteria. 
Refer to literature 
review in Appendix 2 
No comment 
“Agreed” 
“agree” 
“Agree” 
Members agree that the 
vial cap/rubber stopper 
was contaminated with 
environmental bacteria, 
and that this is not 
unexpected. 
Chapter 5.1 
5.1-90 
 
other bacteria?  
Q 5c: How do these 
interpretations 
influence your 
judgement of the 
hypothesis that 
propofol 
administration is 
causally associated 
with Ralstonia 
bacteraemia? 
 
Similar to our 
summary in 5a: two 
members support the 
hypothesis, and one 
of them awaits 
confirmation with the 
results of the WGS. 
Three members 
appear not to be as 
convinced, and the 
sixth member did not 
respond to this 
question. 
No comment 
“As 5a” 
“There is no “control” to implicate propofol specifically” 
In response to the comment “Support it, but it is the molecular typing that 
provides the ’smoking gun’” made by a Panel Member says “strongly disagree – 
this would probably be true if it was internal contamination of the vials” 
Two members consider 
this an acceptable 
hypothesis (i.e. source of 
Ralstonia in the SA cases 
was the vial cap/rubber 
stopper; one member 
pointed out that as 
control vials were not 
used by the SA Pathology 
laboratory, a definitive 
conclusion is not possible. 
Q 6: Can we 
confidently implicate 
or exclude propofol 
administration as the 
cause of Ralstonia 
bacteraemia in some 
or all the cases? 
 
(a) Two members 
suggest propofol 
administration is a 
likely cause for the 
cases in SA, and one 
of them awaits 
confirmation with the 
result of WGS. (b) 
One member 
suggests that 
contamination of the 
vial at the 
manufacturing site 
could explain the 
diverse genotypes - 
two genotypes in SA 
cases, and one 
genotype each in the 
In response to (b): “yes is possible but will remain speculative in comparison to 
the matched SA cases/vial cap” 
“As in 5a, propofol is implicated if lid isolate is not a contaminant.” 
“Cannot be confident either way” 
No comment 
Unchanged from original 
conclusion. 
Chapter 5.1 
5.1-91 
 
case from TPCH and 
VIC  
Q 7: Noting the 
genetic similarity 
between the R. 
mannitolilytica isolate 
from the propofol vial 
cap and the clinical 
isolates from the two 
cases in different SA 
hospitals (RAH and SA 
Private), and the 
distinctive R. Pickettii 
isolate from the 
second patient in the 
same neurosurgical 
unit of the RAH, can 
we conclude that 
Ralstonia 
bacteraemia in all 
three cases was 
causally associated 
with the 
administration of 
propofol, and that the 
propofol/vial did not 
become 
contaminated in the 
respective clinical 
unit? 
One member accepts 
propofol 
administration was 
source, three accept 
this explanation for 
the two cases with 
R.m (one of them 
accepts if this was 
confirmed with WGS).  
Three members are 
uncertain about the 
source for the case 
with R.p. One 
member says there is 
insufficient evidence 
to implicate propofol, 
although this is 
possible.  
Three members agree 
that it is unlikely that 
contamination 
occurred in the 
clinical unit. 
No comment 
“All answers seem to concur, the evidence for 2 cases is strong, but the likely 
cause of the R. Pickettii as well, and for all 3 more likely that contamination 
occurred related to the bottle not in the clinical units.” 
“Probable (not definite) cause for Rm cases, but certainly not for Rp case. 
Agree [with comment that contamination of the vial was unlikely to have 
occurred in the clinical unit]” 
No comment 
Unchanged from original 
conclusion. 
Q 8: How confident 
can we be that the 
The source of 
infection in the two 
No comment The cases at the GCUH are 
related to the bottled 
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cases reported in QLD 
and/or VIC with 
diverse genetic strains 
were also causally 
associated with the 
administration of 
propofol because all 
of them had received 
propofol? 
 
bacteraemic cases at 
the GCUH, and 
possibly of the first 
case reported from 
the RBWH in May was 
unlikely to be 
propofol. 
Source of the 
infection in the case 
from VIC is uncertain. 
“We now know that the QLD outbreak is in all likelihood related to the bottled 
water.” 
“agree” 
“The most recent cases associated with water are a different ‘outbreak’. Qld 
had cases at the RBH that were associated with propofol. The finding of 
sporadic cases that weren’t doesn’t mean that none of them were” 
water, and the likely link 
between the bottled 
water and the first case at 
the RBWH (isolate is also 
of the Cluster 2 genotype) 
is not yet known. The 
source of the other cases 
in QLD and VIC remain 
speculative. 
Q 9: Based on the 
DiversiLab results and 
on the uncertainty of 
the batch number of 
propofol vials used in 
SA, VIC and QLD, what 
plausible hypotheses 
could we formulate 
on the likely site/s of 
contamination? More 
specifically, how likely 
is it that the 
propofol/vial may 
have been 
contaminated (a) at 
some stage before 
delivery to the clinical 
unit and (b) after 
arrival in the clinical 
unit? 
One member 
considers 
contamination at the 
factory as “the only 
plausible 
explanation” and 
another member 
considers this 
acceptable if clonality 
can be confirmed 
with WGS. One 
member considers 
contamination 
occurred at some 
point before propofol 
was distributed to SA 
hospitals. Two other 
members are open-
minded about the 
locality where the vial 
may have been 
contaminated. 
No comment 
“QLD cases are considered separately. Most likely that the contamination 
happened at time a) [before delivery to the clinical unit].” 
“agree” 
No comment 
Unchanged from original 
conclusion, except for the 
exclusion of the cases 
from GCUH that was 
attributed to the bottled 
water. 
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Q 10: What is the 
likelihood the 
propofol/vial was 
contaminated at the 
site of manufacture at 
Claris Life Sciences 
(India)? 
 
One member 
considers this “highly 
likely” and another 
“most likely”. Three 
members say there is 
insufficient 
information to 
answer the question. 
One member 
considers this 
possible “if we 
assume the cases in 
different states are 
linked”. 
No comment 
Insufficient info, unlikely. 
“there is insufficient information”  
In response to a comment by a Panel Member who commented on the lack of 
cases reported in other parts of the world “Perhaps this person needed to have 
heard TGA report on the amount of packaging that surrounds these vials, 
which might make them understand better that a multihospital, let alone 
multistate, outbreak of bacteraemias from this very rare pathogen is unlikely to 
have been due to contamination along the distribution trail” 
One member accepted 
this as an explanation 
while two members said 
there was insufficient 
information, one of whom 
considered this to be 
“unlikely”. Two members 
did not comment in Round 
3; however, in Round 2, 
one stated “insufficient 
information” while 
another responded “most 
likely”. 
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Appendix 17a: Panel Members’ assessment of the plausibility of the six hypotheses in the various clinical settings 
Hypothesis on 
source of 
Ralstonia 
Plausibility of hypotheses. 
Please select one of the following categories *:  
“Almost Certain, Highly Likely, Likely/Probable, Unlikely, Almost Certainly Not” 
Facilitators’ conclusions 
Two cases from 
SA with R. 
mannitolilytica 
Case from SA 
with   R. Pickettii 
Case from VIC 
with R. 
mannitolilytica 
Case from 
TPCH with R. 
insidiosa 
Case from 
RBWH with R. 
mannitolilytica 
Two cases 
from GCUH 
with R. 
mannitolilytica 
1. Propofol 
solution 
contaminated at 
the 
manufacturing 
site 
Unlikely x2 
Almost certainly 
not x3 
Unlikely x2 
Almost certainly 
not x3 
Unlikely x1 
Almost 
certainly not 
x4 
Unlikely x1 
Almost 
certainly not 
x4 
Unlikely x1 
Almost 
certainly not 
x4 
Unlikely x1 
Almost 
certainly not 
X4 
Consensus: “Almost certainly 
not” or “unlikely” 
2. Propofol 
solution and vial 
cap/rubber 
stopper 
contaminated at 
the 
manufacturing 
site 
One [vial cap] 
possible, other 
[solution] 
unlikely  
Unlikely x2 
Almost certainly 
not x2 
Unlikely x2 
Almost certainly 
not x3 
Unlikely x1 
Almost 
certainly not 
x4 
Unlikely x1 
Almost 
certainly not 
x4 
Unlikely x1 
Almost 
certainly not 
x4 
Unlikely x1 
Almost 
certainly not 
x4 
Consensus: “Almost 
certainly” not or “unlikely” 
3. Only vial 
cap/rubber 
stopper 
contaminated at 
the 
manufacturing 
site 
Almost certain 
x1 
Likely/Probable 
x1 
Unlikely x2 
Insufficient 
information x1 
Almost certain 
x1 
Possible still!! x1 
Unlikely x1 
Almost certainly 
not x1 
Insufficient 
Almost certain 
x1 
Possible still!! 
x1 
Almost 
certainly not 
x2 
Insufficient 
Possible x1 
Almost 
certainly not 
x2 
Insufficient 
information x1 
No response 
x1 
Almost certain 
x1 
Unlikely x 1 
Almost 
certainly not 
x2 
No response 
x1 
Almost certain 
x1 
Unlikely x1 
Almost 
certainly not 
x2 
No response 
x1 
One member states this is 
“Almost certain” in all the 
settings except “Possible” for 
the case at the TPCH.  
For the two SA cases with 
R.m, one other member 
considers this “likely” but two 
other members consider this 
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information x1 information x1 “unlikely” or “almost certainly 
not”. The fifth member states 
there is “insufficient 
information”.  
For the Vic and QLD cases, 
three members state “Almost 
certainly not” or “unlikely”, 
while the fourth states 
“Insufficient information”. 
4. Vial 
cap/rubber 
stopper 
contaminated 
after leaving 
manufacturing 
site but before 
stocked in the 
clinical unit 
Likely/Probable 
x2 
Possible still!! 
Almost certainly 
not x1 
Insufficient 
information x1 
Likely/Probable 
x1 
Possible still!! x1 
Almost certainly 
not x2 
Insufficient 
information x1 
Possible still!! 
x1 
Almost 
certainly not 
x3 
Insufficient 
information x1 
Almost 
certainly not 
x3 
Insufficient 
information x1 
No response 
x1 
Likely/Probabl
e x1 
Almost 
certainly not 
x3 
No response 
x1 
Likely/Probabl
e x1 
Almost 
certainly not 
x3 
No response 
x1 
Three members agreed: 
“Almost certainly not” for the 
cases in QLD and VIC. Three 
members agree this is 
likely/possible for the SA 
cases with R. m. For the SA 
case with R. p, two consider 
this likely/possible, and two 
“Almost certainly not”. 
5. Vial 
cap/rubber 
stopper 
contaminated in 
clinical unit due 
to poor aseptic 
techniques 
Likely/Probable 
x2 
Unlikely x2 
Insufficient 
information x1 
Likely/Probable 
x1 
Possible still!! x1 
Unlikely x1 
Almost certainly 
not x1 
Insufficient 
information x1 
Possible still!!  
x1 
Unlikely x1 
Almost 
certainly not 
x2 
Insufficient 
information x1 
Unlikely x1 
Almost 
certainly not 
x2 
Insufficient 
information x1  
No response 
x1 
Likely/Probabl
e x1 
Unlikely x1 
Almost 
certainly not 
x2 
No response 
x1 
Likely/Probabl
e x1 
Unlikely x1 
Almost 
certainly not 
x2 
No response 
x1 
Two members state this is 
“likely” or “possible” for the 
three cases in SA. Three 
members agree this is 
“unlikely” or “almost certainly 
not” for the cases from QLD 
and VIC, and two members 
state the same for the SA 
case with R p. 
6. Contaminati
on was not on 
the propofol vial 
cap/rubber 
Unlikely x3 
Almost certainly 
not x1 
Insufficient 
Likely/Probable 
x1 
Possible still!! x1 
Unlikely x1 
Likely/Probabl
e x1 
Possible still!! 
x1 
Likely/Probabl
e x1 
Almost 
certainly not 
Unlikely x1 
Almost 
certainly not 
x3 
Unlikely x1 
Almost 
certainly not 
x3 
Four members agreed that 
this is “Almost certainly not” 
or “Unlikely” for the cases 
with R. m in SA, the GCUH 
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stopper, but in 
the clinical 
environment or 
injecting 
equipment in 
the clinical unit 
information x1 Almost certainly 
not x1 
Insufficient 
information x1 
Almost 
certainly not 
x2 
Insufficient 
information x1 
x2 
Insufficient 
information x1 
No response 
x1 
No response 
x1 
No response 
x1 
and RBWH, and two 
members state the same for 
the case from TPCH and VIC. 
Two members consider this 
to be “likely” or “possible” for 
the SA case with R.p and the 
case from VIC. 
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Appendix 17b: Comments from Panel Members related to their responses in Table 1A.  
Hypothesis on source of Ralstonia Member’s comments related to their response to each hypothesis (only three respondents) 
1. Propofol solution 
contaminated at the 
manufacturing site 
Expect more cases if a batch contamination of the fluid itself. 
Unlikely/almost certainly not. Without further evidence from VIC, it is impossible to comment and likewise tricky to draw 
a conclusion regarding the SA R. Pickettii case. 
 Almost certainly not. 
2. Propofol solution and vial 
cap/rubber stopper contaminated 
at the manufacturing site 
Expect more cases if a batch contamination of the fluid itself. 
Unlikely/almost certainly not. 
Almost certainly not. 
3. Only vial cap/rubber stopper 
contaminated at the 
manufacturing site 
Possible still for Qld cases if not linked to the contaminated water and the typing of the water strain doesn’t match the 
case. 
Unlikely/almost certainly not. 
Almost certain. 
4. Vial cap/rubber stopper 
contaminated after leaving 
manufacturing site but before 
stocked in the clinical unit 
Possible still for Qld cases if not linked to the contaminated water and the typing of the water strain doesn’t match the 
case. 
Plausible/worth considering. 
Almost certainly not. 
5. Vial cap/rubber stopper 
contaminated in clinical unit due 
to poor aseptic techniques 
SA Rm cases unlikely - 2 separate clinical units – assuming clonality on WGS.  Possible still for Qld cases if not linked to the 
contaminated water and the typing of the water strain doesn’t match the case. 
Plausible/Likely in SA. 
Unlikely. 
6. Contamination was not on the 
propofol vial cap/rubber stopper, 
but in the clinical environment or 
injecting equipment in the clinical 
unit 
SA Rm cases unlikely - 2 separate clinical units – assuming clonality on WGS.  Possible still for Qld cases if not linked to the 
contaminated water and the typing of the water strain doesn’t match the case. 
Plausible/worth considering. 
Almost certainly not. 
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Appendix 17c: Comments from Table 2A. 
Hypothesis on 
source of Ralstonia 
Member’s comments related to their categorisation of plausibility of each hypothesis 
Facilitator’s comments – I think we could skip this 
as we have already commented in the last column 
of Table 2 
1. Propofol 
solution 
contaminated 
at the 
manufacturing 
site 
Bart: Expect more cases if a batch contamination of the fluid itself 
Claire: Unlikely/almost certainly not. Without further evidence from VIC, it is 
impossible to comment and likewise tricky to draw a conclusion regarding the SA R. 
Pickettii case 
Ann: Almost certainly not 
The three members who left comments all agree 
this is unlikely 
2. Propofol 
solution and 
vial 
cap/rubber 
stopper 
contaminated 
at the 
manufacturing 
site 
Bart: Expect more cases if a batch contamination of the fluid itself 
Claire: Unlikely/almost certainly not. 
Ann: Almost certainly not 
The three members who left comments all agree 
this is unlikely 
3. Only vial 
cap/rubber 
stopper 
contaminated 
at the 
manufacturing 
site 
Bart: Possible still for Qld cases if not linked to the contaminated water and the 
typing of the water strain doesn’t match the case 
Claire: Unlikely/almost certainly not. 
Ann: Almost certain 
Assuming QLD cases are not related to propofol, 
two members agree this is unlikely, one member 
says this is almost certain 
4. Vial 
cap/rubber 
stopper 
contaminated 
after leaving 
Bart: Possible still for Qld cases if not linked to the contaminated water and the 
typing of the water strain doesn’t match the case 
Claire: Plausible/worth considering 
Ann: Almost certainly not 
Assuming QLD cases are not related to propofol, 
two members agree this is unlikely, one member 
says this is plausible 
Chapter 5.1 
5.1-99 
 
manufacturing 
site but before 
stocked in the 
clinical unit 
5. Vial 
cap/rubber 
stopper 
contaminated 
in clinical unit 
due to poor 
aseptic 
techniques 
Bart: 1. SA Rm cases unlikely - 2 separate clinical units – assuming clonality on WGS 
2. Possible still for Qld cases if not linked to the contaminated water and the typing 
of the water strain doesn’t match the case 
Claire: Plausible/Likely in SA 
Ann: unlikely 
Assuming QLD cases are not related to propofol, 
two members agree that this is unlikely, while 
one member says this is plausible in SA 
6. Contamination 
was not on 
the propofol 
vial 
cap/rubber 
stopper, but in 
the clinical 
environment 
or injecting 
equipment in 
the clinical 
unit 
Bart: 1. SA Rm cases unlikely - 2 separate clinical units – assuming clonality on WGS 
2. Possible still for Qld cases if not linked to the contaminated water and the typing 
of the water strain doesn’t match the case 
Claire: Plausible/worth considering 
Ann: Almost certainly not 
Assuming QLD cases are not related to propofol, 
two members agree that this is unlikely, while 
one member says this is plausible in SA 
Summary   
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Experiences from the field in Sierra Leone,  
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‘The Ebola epidemic ravaging parts of West Africa is the most severe acute 
public health emergency seen in modern times. Never before in recorded 
history has a biosafety level four pathogen infected so many people so 
quickly, over such a broad geographical area, for so long’ (1). 
 
 
MAE course requirement: Outbreak Investigation 
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Preface 
This chapter describes my experiences working with the World Health Organization 
(WHO) supporting their response to the Ebola Virus Disease (EVD) outbreak in Sierra 
Leone in West Africa, 2014 - 2015. On 8 December 2014, the coordinator of the Master 
of Philosophy in Applied Epidemiology (MAE) program, Martyn Kirk, sent an email to the 
MAE2014 cohort informing us that there was an ongoing need for field epidemiologists 
to assist with the response to the EVD outbreak in West Africa. Martyn advised that if 
we were interested in assisting with the response, and if we had the support of our field 
placement supervisors, that they would support our deployments through the WHO 
Global Outbreak Alert and Response Network (GOARN). As soon as I read this email I 
put my hand up. I spoke with my field and academic supervisors and all were in support. 
Although, I initially didn’t get short listed through GOARN, I was among one of the 
nominees later put forward by Martyn Kirk to undergo pre-deployment training with 
the WHO Western Pacific Region Office (WPRO) as part of their response. A few months 
later, on 14 April 2014, I received an email from WPRO advising me that they were 
initiating the process for my deployment to support their response to the EVD outbreak 
in West Africa. After a detailed medical check, nine vaccinations, three online training 
courses and many signed forms later, on 21 May 2015 I was off to Sierra Leone, 
assigned to the Port Loko district.  
 
I have felt very privileged to be able to contribute to and support WPRO on the ground 
in their response to the EVD outbreak in Sierra Leone. My time in Sierra Leone working 
as a trainee field epidemiologist was life changing and further cemented in me that this 
is exactly the kind of work I want to do. 
 
This chapter describes my role and general responsibilities in the outbreak, the 
structure of the investigation teams and also provides a detailed description of a cluster 
investigation that I was involved with. Within this cluster, I led the investigations in 
three out of the six villages it affected. In Appendix 1 I provide the PowerPoint slides 
from a presentation that I made to the Indigenous Health Divisional forum (my field 
placement) describing my experiences working on this outbreak.   
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Investigatory role 
I spent ten weeks (21 May to 28 July 2015) in Port Loko district. Port Loko district is one 
of ten districts in Sierra Leone and is the fourth most populous district for all of Sierra 
Leone. It is a mostly rural area and its major activities are mining and farming (2). 
Specific tasks of my mission outlined in the Terms of Reference were (under the 
guidance of the field coordinator): 
1. to provide technical support to the function of surveillance and epidemiology;
2. to support surveillance activities in affected and neighbouring districts, especially
in terms of active case finding and contact tracing;
3. to assist in outbreak response, especially in field investigation;
4. to contribute to the training of health personnel and community sensitisation;
5. to prepare regular information products including daily situation reports on the
evolution of the outbreak, ongoing and planned activities; and
6. to undertake other duties that the field coordinator may assign.
The majority of my time was spent in the field conducting field investigations, 
supporting surveillance activities in Port Loko district by conducting active case finding 
and contact tracing, while responding to the needs of people under quarantine. With 
the support and guidance from the field coordinator and the overall lead epidemiologist 
for Port Loko district, I was the epidemiological lead for three outbreak investigations in 
three villages and one investigation into a secret burial. These cluster outbreaks and 
secret burials affected eight villages spanning four chiefdoms of Port Loko district. As 
the epidemiological lead, my role included: 
o Overall management of the outbreak response teams (break down of field
epidemiological teams is shown in Figure 1).
o Conducting interviews to identify contacts to be line listed and quarantined
(with the team).
o Conducting risk assessment of contacts based on exposure to the cases, to
separate high risk contacts from low risk contacts in quarantine homes (with the
team). Anyone considered a contact (high and low risk) went into quarantine.
High risk contacts were quarantined in separate homes to those who were low
risk.
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o Taking a census of affected villages so the people who were not put into
quarantine could also be monitored (with the team). This also required entering
the census data into Excel and creating monitoring sheets for contact tracers.
o Working with surveillance teams to identify the location of missing contacts and
arrange for them to be placed into quarantine if found.
o Liaising with partners (The Department for International Development, OXFAM,
Plan, World Food Programme, The United Nations Children’s Fund) to ensure
quarantine homes had adequate access to toilets, food, water, washing and
sanitary materials, and mosquito nets, as well as people to look after the farms
for the farmers under quarantine.
o Ongoing monitoring and supervision of quarantine homes, particularly homes
with high risk contacts to ensure these homes were being visited twice daily by:
contact tracers, social mobilisation teams, psychosocial teams and to identify
any other concerns from the quarantine homes and pass on any concerns to
relevant organisations.
o Preparing investigation reports and regular updates for the WHO
epidemiological lead and field coordinator.
Figure 1: Break down of outbreak investigation teams and organisations in Port Loko, 
Sierra Leone in 2015  
*DHMT - District Health Management Team, WHO - World Health Organization, CDC -The Centers for
Disease Control and Prevention, UNFPA – United Nations Population Fund
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In addition to these investigations, I also worked with international partner 
organisations including GOAL, The US Centers for Disease Control and Prevention (CDC) 
and local Sierra Leonean department of health staff from the District Health 
Management Team (DHMT) on ‘silent section’ surveillance plans, and provided technical 
support in the field to surveillance officers when they were conducting the silent 
section assessments. The purpose of the silent section surveillance assessments was to 
identify communities that were not reporting illnesses to the District Emergency 
Response Committee ([DERC] a committee comprising all local and international 
organisations present on the ground in Port Loko district responding to the outbreak), 
so that surveillance systems in these communities could be strengthened. 
It was also a requirement for WHO field epidemiologists to attend the following daily 
meetings if there was nothing urgent to attend to in the field.  
1. 7.30am: DHMT surveillance officer meeting to plan the day’s activities, assess
needs and provide support.
2. 8.30am: epidemiology technical meeting with WHO, The CDC, DHMT, and GOAL
to set epidemiological/surveillance priorities for the day and discuss challenges.
3. 5.00pm: ‘After Action Review’ meetings with surveillance officers, to review the
day’s activities, agree on the next day’s activities and to address data quality
issues from field surveys.
4. 6.00pm: meeting with the DERC.
5. 7.00pm: WHO internal meeting.
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Lessons learnt  
I learnt many lessons through working on this outbreak. One of the biggest lessons I 
learnt is how important community engagement is to controlling a disease. You can 
have a good understanding of how to control a disease – you can understand 
everything about a disease from the biological, medical, and epidemiological 
perspectives, but if you don’t understand the people and have a way of communicating 
to the people in a way that speaks to them, and have interventions that are culturally 
appropriate - the biomedical knowledge of how to control a disease becomes less 
useful.  
 
I learnt how damaging mistrust and misperceptions can be in this setting. There were 
people we could not help because they didn’t trust or believe that we could help them, 
so instead of seeking help they ran away, unintentionally spreading the disease further. 
In this setting it can be very difficult to get truthful answers from people regarding their 
level contact with a case, or another person’s level of contact with a case for fear of 
going into quarantine, or for fear of being punished for looking after sick people and not 
reporting them. 
 
While there was still an element of chaos, so much seemed to work well e.g. good 
vehicle transport, internet (was still a bit intermittent, especially  when it rained, but it 
was still much better than I was expecting) and daily reports from the laboratory so we 
had access to sample results within 24 hours (sometimes sooner if requested). I could 
see and benefited from the hard work of the many people who had been on the ground 
before me, who worked hard to put reporting and logistical mechanisms and systems in 
place. 
 
I also learnt that an outbreak of this scale has devastating effects on other diseases too. 
The whole country and health response was focused on controlling one deadly disease 
but other diseases didn’t stop; in fact the under-five child mortality rate had increased 
as a result of this outbreak. Mothers were too scared to take their children to be 
vaccinated for fear of being sent to an ETU, so vaccine-preventable diseases increased. 
There was a measles outbreak happening at the same time while I was there and little 
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attention (that I could see) could be paid to that. The health system was completely 
over-stretched. 
Public health impact 
No secondary transmission occurred in two of the three village cluster investigations or 
from the secret burial cluster that we worked on. Even though much of the 
international community was slow to respond to this outbreak overall, the multinational 
response efforts have helped control the outbreak. This response has also led to 
building up the skills for many of the local outbreak responders and to rebuilding Sierra 
Leone’s health system. Sierra Leone currently (December 2015) remains EVD 
transmission free, but many organisations like WHO remain while the country maintains 
heightened surveillance and continues to strengthen the surveillance system, and to 
ensure the country is prepared to respond should there be a re-emergence (3).  In 
addition to this, they are now starting to focus on addressing other public health issues, 
such as the very high rates of maternal and child deaths.  
 
I shared my experience working in Sierra Leone with the Indigenous Health Division (my 
field placement) through a presentation. In this presentation I provided a brief summary 
of EVD, how it is transmitted, a summary of the EVD outbreak in West Africa, how I got 
involved and I briefly described the cluster investigation I supported. Through this 
presentation I shared with colleagues the challenges this outbreak response faced, 
highlighting the importance of community engagement. This is something that is not 
only important in this outbreak setting but also core to Aboriginal and Torres Strait 
Islander public health. We discussed that we face similar challenges here in Aboriginal 
and Torres Strait Islander health – the importance of cultural traditions, fear, 
misperceptions and lack of trust. Community engagement is integral to the success of 
any Aboriginal and Torres Strait Islander project or health program.
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Abstract 
Background 
On 21 May 2015, I was deployed to provide epidemiological support to the response to 
the Ebola Virus Disease (EVD) outbreak in Sierra Leone. This chapter describes a cluster 
investigation I was involved with. The aims of this investigation were to: 
1. Identify contacts of an index case.
2. Quarantine high and low risk contacts in separate high and low risk quarantine
homes.
3. Monitor contacts for 21 days from their last date of contact with the case and to
send them to Ebola Treatment Units (ETU) if they developed any EVD symptoms.
4. Send symptomatic contacts meeting the suspected case definition to an ETU.
5. Locate missing contacts.
6. Identify the source of infection for cases.
Methods 
To identify contacts and source of the cases, we interviewed family and community 
members. High and low risk contacts were quarantined separately. Contract tracers 
visited the contacts at least twice a day. If contacts showed any signs of EVD, they were 
sent to an ETU for treatment and testing. Cases in the cluster were summarised by age, 
gender, onset, outcome and risk factor. A disease transmission tree was developed to 
describe links between cases and the timeline of events. 
Results 
This transmission chain was triggered by a missing contact from another cluster. This 
transmission chain lasted three months, spanned six villages and two districts. There 
were 13 confirmed cases of EVD and two suspected cases. Of these 87% (n = 13) died. 
Seventy-three percent of cases (n = 11) were female. The median age of cases was 28 
years (range: 11 days to 65 years). The date of onset ranged from 26 April 2015 to 10 
July 2015. Of those who died, seven died in the community and six died in the ETU. A 
total of 294 contacts were identified. Of these, 73 were classified as high risk. Sixteen 
high risk contacts ran away before they could be quarantined. Of these, five were found 
and quarantined, four were found and taken to an ETU, one was found dead in the 
community and another was found dead in the community after giving birth, and five 
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were never found. The risk factors identified for developing EVD in this cluster 
investigation were:  washing and burying the dead body of an EVD case (53%, n = 8), 
sleeping in the same room or having close living contact with an EVD case, (13%, n = 2), 
caring for a symptomatic EVD case (7%, n = 1),  assisting with the delivery of an infant 
born from an EVD  mother (13%, n = 2), and being born to an EVD case (7%, n = 1) or 
exposure to EVD positive breast milk (7%, n = 1).  
 
Conclusion 
This investigation shows the impact a missing contact can have in this outbreak setting 
and how essential it is to have a complete and accurate contact list to prevent disease 
transmission. This cluster was driven by challenges that have persisted throughout this 
outbreak: fear, mistrust of response efforts, limited understanding of EVD, community 
misperceptions and a stronghold on cultural traditions. A stronger emphasis on 
community engagement might have reduced the risk of disease for some of the cases in 
this cluster.  
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Background 
Ebola virus 
Ebola Virus Disease (EVD) is a zoonotic disease caused by a virus of the family 
Filoviridae, genus Ebolavirus (4). It was first discovered in 1976 near the Ebola River in 
the Democratic Republic of Congo (5). Since then, sporadic outbreaks have been 
described in several other African countries (6), and some Western countries (Figure 2). 
There are five known strains of Ebola, of which four (one to four listed below) are 
known to cause disease in humans: 
1. Ebola virus (Zaire ebolavirus - ZEBOV) (5).
2. Sudan virus (Sudan ebolavirus - SEBOV) (7).
3. Taï Forest virus (Taï Forest ebolavirus, formerly Côte d’Ivoire ebolavirus -
CIEBOV) (8).
4. Bundibugyo virus (Bundibugyo ebolavirus - BEBOV) (9).
5. Reston virus (Reston ebolavirus - REBOV) - causes disease in non-human
primates, but not reported in humans (10).
Figure 2: Locations of Ebolavirus disease (EVD) outbreaks in humans and infections in 
animals 
(A) Regions of Africa that have previously reported outbreaks of EVD caused by ZEBOV,
SEBOV, and BEBOV. The Tai Forest region in Côte d’Ivoire was the only region of West
Africa to report a case of EVD caused by CIEBOV prior to the 2013-2015 outbreak. (B)
REBOV has been introduced into the USA several times between 1989 to 1996 via
imported macaques and into Italy in 1992 (C). (D) REBOV was imported into the
Philippines also via imported primates and has also been detected in pigs on two farms
in the Philippines (11).
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The disease 
Infection with Ebola virus causes an acute viral syndrome in human and non-human 
primates (monkeys, gorillas, chimpanzees) and possibly other mammalian species (11). 
The disease, EVD, is characterised typically by three phases:  
 
Phase 1: non-specific fever, headache, and myalgia. 
Phase 2: gastrointestinal phase (which usually includes diarrhoea and vomiting). 
Phase 3: neurological manifestations and bleeding (12).  
 
The case fatality rate varies depending on the strain of the Ebola virus, the route of 
entry of the virus, the age of the patient and where the patient is being treated (11, 12). 
ZEBOV species are reported to be the most deadly species, with a case fatality rate 
ranging from 60% to 90%, followed by the SEBOV virus which has a case fatality ranging 
from 40% to 60%. For the one Bundibugyo virus outbreak that has occurred, the case 
fatality rate was 25% and the one person infected with Taï Forest virus survived (11). 
The reservoir 
Bats are believed to be the natural reservoir for Ebola virus (13). While a range of other 
hosts including rodents (14), arthropods and even plants have also been suggested as 
potential reservoirs (15). 
Transmission 
Humans become infected with Ebola virus via contact with infected body fluids such as 
blood, urine, saliva, sweat, faeces, vomit, breast milk and semen. The virus requires 
entry into the body through mucosal surfaces or breaks in the skin (11). Outbreaks of 
EVD among humans are believed to be triggered by the introduction of the disease into 
the human population from the animal reservoir (16) and the outbreak is sustained 
through person to person transmission (Figure 3). 
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Figure 3: Ebola virus transmission cycle (17) 
 
The West African Outbreak, 2014 - 2015 
On 23 March 2014, the WHO was notified by the Ministry of Health of Guinea of an 
outbreak of EVD in Guinea (18). The epidemic spread rapidly from Guinea (19) to the 
bordering countries of Sierra Leone and Liberia. The outbreak reached a further seven 
countries [Italy (20), Mali (21), Nigeria (22), Senegal (23), Spain (24), the United 
Kingdom (25), and the United States of America (26)] through infected healthcare 
workers. The last of these cases was an Italian health care worker who developed 
symptoms after returning home to Italy on 10 May 2015 [reported to WHO on 12 May 
2015 (20)]. On 8 August 2014, the WHO declared the outbreak as a public health 
emergency of international concern (PHEIC) (27). A PHEIC is an extraordinary event that 
poses risk to the international community and may require an international coordinated 
response by member states of the International Health Regulations (2005) (IHR). The 
decision to declare a PHEIC currently sits with the WHO Director-General and requires 
the convening of the IHR Emergency Committee. The IHR committee advises the WHO 
Director-General on health measures to be implemented to prevent or reduce 
international spread (28).  
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As of 29 November 2015, the WHO has reported a total of 28,637 clinically compatible 
cases of EVD acquired in West Africa, or related to the West African outbreak. Of these, 
11,306 people have died (29). Liberia, Guinea and Sierra Leone have had the majority of 
cases (Figure 4) (30). 
 
 
Figure 4: As of 29 November 2015, total number of EVD cases and deaths linked to West 
Africa outbreak (31) 
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WHO stated that ‘The Ebola epidemic ravaging parts of West Africa is the most severe 
acute public health emergency seen in modern times. Never before in recorded history 
has a biosafety level four pathogen infected so many people so quickly, over such a 
broad geographical area, for so long’ (1). After an initial delay, a  multinational group 
including Ministries of Health, The Centers for Disease Control and Prevention (CDC), 
the WHO, OXFAM (Oxford Committee for Famine and Relief), GOAL, The United Nations 
Children’s Fund (UNICEF), Red Cross1 and other partners have been working hard to 
reduce transmission and bring the outbreak to an end in West Africa (32). 
Case numbers have dropped dramatically since early 2015, and Liberia, Italy, Mali, 
Nigeria, Senegal and Spain, the United Kingdom and Sierra Leone have all since been 
declared EVD transmission free (33-39). As of 29 November 2015 the last case in Guinea 
tested negative for the second time on 16 November 2015, and if there are no further 
cases, Guinea could be declared EVD transmission free on 28 December 2015. On 20 
November 2015, three EVD cases were reported in Liberia (40) after the country was 
declared EVD transmission free for the second time on 3 September 2015 (37).    
 
 
 
 
 
                                                 
1 Role of partner organisations in Sierra Leone:  
WHO took the lead with coordinating the response in Port Loko district while focusing on surveillance and 
epidemiology, infection prevention control, information and communications and logistics. 
CDC provided assistance with surveillance, contact tracing, data management, and laboratory testing and 
health education. They also provided logistics, staffing, communication, analytics, management and other 
support functions for the response.   
OXFAM focused on community health and water, sanitation and hygiene programs.  
GOAL supported social mobilisation and surveillance activities as well as assisted with the running of an 
Ebola treatment unit, and training security personnel in infection control.  
UNICEF focused on care for children, social mobilisation, building community care centres, and 
community support for survivors, and was a provider of supplies (protective gloves, safety goggles, 
intravenous fluids medicines, soap and chlorine). 
Red Cross focused on raising awareness in the communities about EVD and on prevention messages, as 
well as contact tracing and providing psychosocial support.  
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Introduction to Sierra Leone 
Sierra Leone is a country located in West Africa. It borders Guinea to the north-east, 
Liberia to the south-east and the Atlantic Ocean to the south-west (Figure 5) (41). 
Despite being a mineral and agriculturally rich country, 60% of the population live on 
less than US$1.25 a day (42). It ranks 180 out of 187 on the Human Development Index 
in 2011. Approximately, 42% of the population are under the age of 15 years and the 
estimated life expectancy at birth is 57.7 years. Forty-one percent are literate and 70% 
are unemployed or underemployed (42). The major economic activities for the country 
is farming and mining (41). Prior to the EVD outbreak, Sierra Leone had a ratio of 
approximately one to two doctors per 100,000 people. The same ratio was also 
reported for Guinea and Liberia (43). 
 
 
Figure 5: Sierra Leone borders Guinea to the north-east, Liberia to the south-east and 
the Atlantic Ocean to the south-west in West Africa (44) 
 
As of 2014, Sierra Leone has a population of approximately 6,315,627 (45) and is made 
up of 16 ethnic groups. The two largest ethnic groups are the Temne and the Mende 
People (41). Sierra Leone’s official language is English but Krio is the most widely spoken 
language throughout the country, and is a shared language that unites the 16 ethnic 
groups (42). 
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Geographically, Sierra Leone is broken down into four regions: Northern Province, 
Eastern Province, Southern Province and the Western area. These four regions are 
further broken down into 14 districts (Figure 6), 149 chiefdoms and then villages (46). 
The capital of Sierra Leone is Freetown and is located in the Western area region (41). 
Figure 6: The 14 districts of Sierra Leone (47) 
Port Loko district  
Port Loko is a district located in Northern Province. It is made up of 11 chiefdoms (46) 
and has an estimated population of 500,992 (48). It is the most populous district in the 
Northern Province and is the fourth most populous district for all of Sierra Leone. The 
district's major economic activities are mining and farming (mainly rice, cassava, and 
sweet potato) (2). The largest ethnic group in Port Loko is the Temne people (48). After 
Freetown, Port Loko has had the largest cumulative number of EVD cases to date (49). 
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Cluster X investigation in Port Loko district, Sierra Leone 2015 
Scenario 
A 45 year old female (index case) attended the secret burials of relatives in Kambia 
district (borders to the north of Port Loko district) around 17 April 2015. She is 
estimated to have developed symptoms of EVD on 26 April 2015. On 27 April 2015 
(while symptomatic), she travelled from Kambia district to Village 1 in Port Loko district 
where she died from EVD on 2 May 2015. From this case, 113 contacts were 
quarantined in Village 1.  A grandson (ten year old male) of the index case (missed on 
the contact list), developed EVD symptoms on 3 May 2015 and was sent to a traditional 
healer in Kambia district for treatment. After his condition did not improve, he was 
collected by his other grandmother to be cared for at home by family. He was taken 
back to a house where eleven of his relatives lived in Village 2.  
 
This missing contact triggered a transmission chain that we did not become alerted to 
until this child’s grandfather sought treatment from the local Primary Health Unit (PHU) 
on 6 June 2015. This is when our investigations began. 
 
This section describes the investigations and control measures undertaken by the 
investigation teams comprising staff from WHO, CDC and District Health Management 
Team (DHMT), originating from a missed contact (ten year old male described above) 
who became a case. I was the epidemiological lead for the investigations conducted in 
three of the six villages involved in this cluster. 
Objectives  
1. To identify contacts of the index case. 
2. To quarantine high and low risk contacts in separate high and low risk 
quarantine homes. 
3. To monitor contacts for 21 days from their last date of contact with a case and 
to send them to Ebola Treatment Units (ETU) if they developed EVD symptoms. 
4. To send symptomatic contacts meeting the suspected case definition to an ETU. 
5. To locate missing contacts. 
6. To identify the source of infection for cases. 
Methods 
To identify contacts and source of the cases, we interviewed family members, 
neighbours, community members, section chiefs - anybody we thought could be 
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possible contacts, or who would provide us with information regarding contacts. These 
were unstructured interviews and we conducted the interviews with the chiefdom 
surveillance officers. These surveillance officers knew the communities and translated 
for us. This also led to building up the epidemiological investigation skills of the 
chiefdom surveillance officers.  
 
Once contacts were identified we classified them as high or low risk depending on their 
level of contact with the case. Level of contact was categorised as follows: 
1. Touched the bodily fluids of the case (high risk). 
2. Direct physical contact with the body of the case (live/dead) (high risk). 
3. Touched or shared linens, clothes or dishes, eating utensils of the case (lower 
risk). 
4. Slept, ate, or spent time in the same household or room as the case (lower risk). 
Anyone considered a contact (high and low risk) went into quarantine. High risk 
contacts were quarantined in separate homes to those who were low risk. Both high 
and low risk contacts in quarantine were monitored by contact tracers. Contact tracers 
visited the contacts at least twice a day. They would take the temperature of the 
contact and record any symptoms. Both high and low risk contacts in quarantine were 
immediately removed and taken to an ETU for testing if they showed any sign of EVD 
illness. 
 
People in quarantine were also visited regularly by social mobilisers. The role of social 
mobilisers was to educate people in quarantine about EVD, how to prevent 
transmission and infection with EVD while in quarantine (and after), and to report 
suspected symptomatic cases. 
 
A person was considered a suspected case if they met one or more of the following:  
1. a person with fever and ≥ 3 of the following symptoms 
a. vomiting; 
b. headache;  
c. nausea; 
d. diarrhoea;  
e. difficulty breathing;  
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f. fatigue; 
g. abdominal pain; 
h.  loss of appetite; 
i.  muscle or joint pain;  
j. unexplained bleeding;  
k. difficulty swallowing; 
l. and hiccups; 
2. a symptomatic person (see list above) who attended a funeral or cared for 
someone who was sick; and 
3. an unexplained death (50). 
 
A person was a confirmed case if they tested positive with a reverse-transcription 
polymerase chain reaction (RT-PCR) test specific for Ebola virus (50). 
 
Cases in the cluster were summarised by age, gender, onset, outcome and risk factor. A 
disease transmission tree was developed to describe links between cases and the 
timeline of events. 
Results  
The ten year old boy who was a missing contact (case 2, Figure 7) triggered a 
transmission chain that lasted three months, spanned six villages (located in six 
separate chiefdoms) and two districts. In total (including the index case), there were 13 
confirmed cases and two suspected cases (Figure 7). Of these 87% (n = 13) died. 
Twenty-seven percent (n = 4) were male and 73% (n = 11) were female. The median age 
of cases was 28 years (range: 11 days to 65 years). The date of onset ranged from 26 
April 2015 to 10 July 2015. Of those who died, seven died in the community and six died 
in the ETU. Of those who died in the ETU, five were already in the later stages of the 
disease (phases two and three) by the time they were admitted to the ETU.  
 
In the transmission chain stemming from the ten year old boy (case 2), a total of 294 
contacts were identified. Of these, 73 were classified as high risk. Twelve high risk 
contacts developed laboratory confirmed EVD. Two high risk contacts were suspected 
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to have developed EVD, but this could not be confirmed because they had already been 
buried secretly before samples could be collected. No low risk contacts developed EVD.  
 
Sixteen high risk contacts ran away before they could be quarantined. Of these, five 
were found and quarantined, four were found and taken straight to an ETU, one was 
found dead in the community, another was also found dead in the community after 
having died shortly after giving birth to a baby girl and five were never found. Of these 
five who were never found, four were reported to have fled to Guinea and are reported 
to still be alive, and the other fled to another district in Port Loko, but his final health 
status is not known. 
 
Interventions consisted of quarantining high and low risk cases into separate quarantine 
homes, monitoring and educating contacts while in quarantine and immediate removal 
and transport of suspected symptomatic cases to an ETU for testing and treatment.  
 
 
Within this cluster, risk factors for developing EVD were:   
 washing and burying the dead body of an EVD case (53%, n = 8); 
  sleeping in the same room or having close living contact with an EVD case; 
(13%, n = 2); 
 caring for a symptomatic EVD case (7%, n = 1); 
 assisting with the labour of an EVD  case without wearing appropriate personal 
protective equipment (13%, n = 2); and 
  being born to an EVD case (7%, n = 1) or exposure to EVD positive breast milk 
(7%, n = 1). 
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Figure 7: Transmission tree showing confirmed and suspected cases of EVD, and their 
outcome, in Port Loko district for cluster X from 26 April 2015 to 11 July 2015 
Chapter 5.2 
5.2-23 
 
Discussion 
This chapter describes the findings of the epidemiological investigations and 
interventions conducted in response to a cluster of EVD cases that occurred from from 
26 April 2015 to 10 July 2015 in two districts in Sierra Leone. 
 
A higher proportion of women in this cluster developed EVD in comparison to men. This 
is inconsistent with the WHO reports which report that the total number of cumulative 
EVD cases has been similar in males and female (51). The higher proportion of females 
affected by EVD in this cluster might be explained by the females in this family taking on 
more of a role in caring for their sick family members, and by the fact that one of the 
key transmission events was the delivery of a baby, of which only women attended. 
These risk factors may vary in proportions within small clusters, but even out when the 
data are analysed overall for the whole West Africa outbreak. 
 
The median age of EVD cases affected in this cluster is consistent with previous studies 
that have reported the median age of their cases to be 26 and 28 years (50, 52). It is 
also a likely to be a reflection of the young age of the population – people aged 15-35 
years comprise one third of the Sierra Leonean population (42) 
 
The case fatality rate for this cluster was high. The WHO reports the case fatality rate 
for the West African outbreak overall to be 50% (30). However, this is among 
hospitalised patients (53). Being admitted to an ETU is associated with a 50% reduction 
in death (54) and the chance of survival is also increased the earlier a case is admitted 
(55). Within this cluster, seven cases never made it to an ETU and of the six who did get 
admitted to an ETU, five were already in the later stages of EVD.  
 
Fifteen high risk contacts ran away before they could be quarantined. Contacts fleeing 
to avoid quarantine or fleeing during quarantine has been one of the challenges for the 
overall outbreak response (56). Some of the reasons contacts are reported to flee 
include: mistrust of response efforts, limited understanding of EVD, community 
misperceptions, fear of ETUs, stigma associated with being a contact and being in 
quarantine, and financial and social pressures while in quarantine (56, 57). 
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Taking part in unsafe burial practices was the most common risk factor for developing 
EVD in this cluster. This is consistent with previous findings from this outbreak (50) and 
past outbreaks (58, 59).  In November 2014, WHO in Sierra Leone estimated that 80% of 
cases were linked to unsafe burial practices (43). In Sierra Leone, some traditional burial 
practices include bathing or anointing others with the water that has been used to wash 
a corpse, and/or to sleep near the corpse for several nights (43). Because unsafe burials 
were identified as high risk practices, the Government of Sierra Leone mandated safe 
burial practices. However, strong cultural burial traditions made this a difficult 
intervention to enforce (43, 57). 
 
The second highest risk factor for developing EVD in this cluster was sleeping in the 
same room or having close living contact with a case. This is consistent with risk factors 
reported previously in this West African outbreak (30, 50, 60), as well as in other EVD 
outbreaks (58, 59). 
 
Assisting with the birth of an infant when the mother is EVD positive is a high risk event 
(61). A pregnant woman with EVD is contagious through the normal means of contact 
with blood, saliva, sweat, vomit, urine and faeces, but also to the infant and delivery 
assistants through the amniotic fluid (61). Assisting with the labour of an EVD case must 
be done wearing appropriate personal protective equipment to reduce the risk of 
disease transmission (61, 62).  Two cases in this cluster did not wear appropriate 
personal protective equipment when assisting with a high risk birth from an EVD 
positive mother.  
 
Very little is known about infants born to EVD positive mothers. Recent data have 
shown that in utero transmission of EVD from the mother to the foetus occurs (63).  
Previous studies have also reported suspected EVD in infants born to EVD mothers, all 
of which died within 19 days of being born to EVD positive mothers (60, 64), however 
the EVD status of the infants could not be confirmed with laboratory testing (60, 64). 
What is not clear in these studies and in this cluster, is whether the infants become 
infected in utero, during delivery, or through contact with other body fluids after 
delivery. Up until very recently, no infant born to an EVD positive mother had been 
known to survive beyond the neonatal period (61). However, the last reported case in 
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Guinea was an infant born to an EVD positive mother. She was born in an ETU, treated 
with experimental anti-viral medications and tested negative for EVD for the second 
time on 16 November 2015 (65). 
 
The last case for this transmission chain was a 13 month old breastfeeding child. The 
source for this case is likely to be the EVD positive breast milk. Ebola virus has been 
detected in breast milk previously, however little is known about the infectivity of the 
breast milk (66), how long the breast milk remains infectious or when the virus appears 
(67). Further studies are needed to understand this risk factor for EVD. 
 
This cluster investigation illustrated several of the many challenges that have persisted 
throughout the whole EVD outbreak response in West Africa: mistrust of response 
efforts, limited understanding of EVD, community misperceptions, and highly mobile 
populations (56, 57) (as evidenced in this cluster by contacts fleeing), and burials being 
conducted in secret. The WHO reports that the successful control of an EVD outbreak 
requires the following key interventions: safe burials, contact tracing, early 
identification of cases, rapid isolation, accessible and timely laboratory testing, and care 
for those infected (68). In this outbreak many of the aforementioned challenges 
hindered the implementation and success of these interventions. What is missing in this 
list that would address some of these challenges is a strong emphasis on community 
engagement. Community engagement should be embedded and intertwined 
throughout this list of the interventions. Community engagement that includes 
information and advice that is culturally appropriate so that people can make informed 
decisions to reduce the risk to themselves and others. This includes the engagement of 
trusted local leaders and even traditional healers. Seeking care from a traditional healer 
was banned in Sierra Leone (69) which led to sick people seeking care from these 
trusted healers in secret which drove silent or undetected transmission chains. 
Traditional healers should have been brought into the response, not excluded from it.  
 
Engaging with communities and building up trust takes time – an element that is often a 
luxury in an outbreak setting - but at the same time could be one of the keys to its 
success. As stated by The United Nations ‘The outbreak in West Africa will end when we 
get to zero cases. To achieve this goal, communities must be at the heart of the 
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response. If people with Ebola are to come forward and transmission is to be 
interrupted, communities must be fully involved in, and owning, the outbreak’ (70). 
In spite of these challenges, this cluster came to an end on 11 July 2015, along with the 
many other Sierra Leonean clusters. The country reached 42 days without a case on 7 
November 2015, meaning it was able to be declared EVD free, and to date (29 
November 2015) remains EVD transmission free (39). 
Conclusion 
This was a complex cluster driven by challenges that have persisted throughout this 
outbreak: fear, mistrust of response efforts, limited understanding of EVD, community 
misperceptions and a stronghold on cultural traditions. Despite being over a year into 
the outbreak, these challenges were still present. A stronger emphasis on community 
engagement might have reduced the risk of disease for some of the cases in this cluster. 
This investigation also shows the impact a missing contact can have in this outbreak 
setting and how essential it is to have a complete and accurate contact list to control an 
outbreak. 
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Appendix 1: Presentation to Indigenous Health Divisional Forum describing experiences 
from the field working as part of the response to the Ebola Virus Disease Outbreak in 
Sierra Leone, 28 October 2015 
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Presentation notes for cluster investigation slides (by slide number): 
26: This circle represents a ten year old boy who had close contact with an Ebola case 
(his grandmother). He starts to feel unwell. His family start to fear for his life so they 
send him to a local herbalist. 
27: The herbalist is not able to fix him so his other grandmother comes to collect him. 
28: She takes him back to her family home to care for him where another 11 people 
live.  
29: Sadly this 10 year old boy dies. 
30: Shortly after, the grandmother also dies. Both bodies are washed and buried 
secretly.  Traditional burial practices in Sierra Leone include washing and dressing the 
bodies of their dead loved ones. A practice that is both culturally very important for 
Sierra Leoneans but a practice that is also currently illegal in Sierra Leone because a 
body infected with EVD is at its most infectious when the person dies or just after. 
31: The protocol at the moment is to call a number to arrange for the dead body to be 
buried in a safe way. This means that people that look like this come to the place where 
the person has died, decontaminate the body with chlorine, place the body in a doubled 
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up body bag and bury the body without allowing for the body to be washed or touched 
by loved ones. A practice that really clashes with local traditions, but needed from an 
outbreak control perspective. Unfortunately, this family did not do this, and this 
resulted in the disease spreading. 
32: The next person to fall ill from the house was a 9 year old girl. 
33: Followed by the head of the household. 
34: For some reason the head of the household is the first one to reach out to the 
health system. He goes to the local public health unit. It’s at this first contact with the 
health system that we become alerted to this cluster. As soon as we become alerted, 
we are quick to go to the village where this case has come from to carry out our 
interviews to try to identify who is at risk and to find out who should be placed under 
quarantine to try to stop this cluster from spreading further. But we are not fast 
enough. On the same day that this man goes to the PHU, the worst possible thing from 
an outbreak perspective happens…. 
35: All of these people run away in different directions. 
36: We manage to get 5 of them back but for 3 it’s too late. They are already showing 
late stage symptoms when they are found. They are taken to an ETU but sadly die 
shortly after.  
 
Unfortunately, we don’t find this woman who is a pregnant woman close to term. She 
runs to her auntie’s house who is a traditional birth attendant, goes into labour and 
gives birth to a baby girl but dies shortly after, followed by her baby girl who dies 11 
days later. Through the delivery and her travel to her auntie’s, she starts transmission 
chains 3 different villages. 
 
These 3 men were never to be found during my time there. They were reported to have 
fled to Guinea. If they are alive, they have still not returned back to their home. It may 
be awhile before they do, because if they return home now, they run the risk of going 
to jail for being involved in secret burials. 
 
I just wanted to highlight this complex cluster to you all because I think this cluster 
highlights the impact fear, misperceptions and a lack of trust and community 
engagement can have in this setting. 
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What really stood out for me from working on this outbreak was - I learnt that you can 
understand everything about the disease from a biological, medical, physiological 
perspective but if you don’t understand the people and have a way of communicating 
to the people in a way that speaks to them, and have interventions that are culturally 
appropriate, knowledge of the disease can becomes less useful. 
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Chapter 5.3 Appendix - Hepatitis A Case Control Study 
I assisted with a multijurisdictional outbreak investigation into 19 cases of Hepatitis A 
that were suspected to be linked to the consumption of Brand A frozen mixed berries. 
A population-based case-control study was conducted to determine a statistical 
association between consumption of the product and recent infection with Hepatitis 
A. Controls were recruited with frequency matching (based on age group and Local
Government Area) of two controls per case. Controls were sourced from state and 
territory notifiable disease databases, and were people with a previous history of 
infection with Salmonella species. 
Selection criteria for controls were as follows: 
1. notified to health departments in the two weeks prior to the onset date of the
Hepatitis A case;
2. same age group as the case (0-4 years, 5-17 years, 18-49 years and 50 +
years);
3. resides in the same Local Government Area or Health Region/District/Service
as the Hepatitis A case; and
4. control (Salmonella case) is not part of an outbreak investigation.
Exclusion criteria for controls were as follows: 
1. past infection with Hepatitis A or reports having had symptoms consistent
with a diagnosis of Hepatitis A (i.e. Jaundice);
2. previous vaccination for Hepatitis A or have received Normal Human
Immunoglobulin (NHIG) in the exposure period of interest;
3. those not contactable by telephone (mobile or landline);
4. those who are not English-speaking or unable to give coherent answers to
questions;
5. those who travelled overseas during the two months prior to their notification
date;
6. those who lived in a country/region with high or very high Hepatitis A
endemicity for at least one year of the first five years of life; and
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7. those who had close contact with a person known or suspected to have
Hepatitis A during the study period of interest (2-7 week exposure period of
corresponding case);
Eligible controls were randomly sorted into a list, and starting from the top, controls 
were selected into the study until two controls who met the selection criteria were 
interviewed for each case. 
My role was to recruit and interview controls from Queensland to match Queensland 
cases, via telephone, and to enter their questionnaire data into NetEpi. NetEpi is an 
online password protected software used to enter and analyse data from 
epidemiological investigations (1). The questionnaire contained questions on 
eligibility, consent, demographics and structured questions on a limited range of fresh 
and frozen foods to assess potential exposures during the 5 week period prior to their 
illness.  
As the controls were Salmonella cases, I also administered an extra questionnaire (to 
those who were interested) to collect information on their potential exposures in the 
five days leading up to the onset of their Salmonella illness in case they could be later 
linked to an outbreak. 
I recruited and interviewed nine controls over a period of 3 ½ weeks. Of the 30 
controls that I tried to recruit, one refused, five were ineligible, and 15 could not be 
reached. Prior to contacting the controls I contacted their general practitioner (GP) as 
a courtesy to advise them that I would be calling their patient to ask them to take part 
in the study, and to ensure that the patient had been advised of their Salmonella test 
results. I was not involved with the data analysis or interpretation of the results for 
this outbreak investigation, so it is therefore not discussed in this section. 
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Lessons learnt: 
1. It is difficult to recruit controls and it takes time. Not including calls made to
the GPs, I made a total of 68 calls over a period of 3 ½ weeks to recruit nine
controls. The longer it takes to recruit the controls, the higher the chance the
study will be affected by recall bias in participants. I think the time that it took
to recruit the controls would have created a recall bias in this study.
2. Finding the best time to reach controls was difficult and variable. While calling
out of hours resulted in a better response rate, it was not unusual to
encounter a disgruntled person on the other end of the phone for having
called them out of work hours.
3. I learnt the importance and challenge of reading out questions in a neutral
manner and exactly as they are written. This is important to avoid or reduce
interviewer (information) bias but this can also make it difficult to sound
natural.
4. It is difficult to interview parents of young children who have undergone a
serious illness. One parent in particular had gone through a very traumatic
time with her son having been so ill as a result of his Salmonella infection, she
thought she was going to lose her child. This was a very delicate conversation
to have which has made me think that perhaps there should be a class taught
to MAEs on how to speak appropriately to people who are emotionally
charged and on how to build rapport. She requested additional information
from the Queensland Department of Health regarding the species of
Salmonella that had infected her son, and of any known outbreaks that had
occurred at the same time her son became infected. I contacted the
Queensland Department of Health regarding this control’s situation and her
request for further information. The Queensland Department of Health
responded quickly and I was able to go back to her with advice and the
information she requested.
5. I learnt that there is a good structure and system in place with OzFoodNet on
how to respond at a multijurisdictional level to foodborne outbreaks. This was
interesting to observe particularly considering that the same systems were not
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in place to manage the multijurisdictional investigation into the increase in 
Ralstonia cases that I investigated in the previous year. This system allows for 
a timely, well-coordinated multijurisdictional response. 
6. It can be difficult to read your own handwriting! If data aren’t entered within a
short timeframe after the telephone interview has taken place, this can lead
to errors with data entry and potential non-differential misclassifications.
7. It can be difficult in some cases to apply the exclusion/inclusion criteria – for
example, some of the controls could not remember if they had previously had
the Hepatitis A vaccination prior to travel. This information had to be teased
out by trying to find out if they had any vaccinations at all prior to travel. As a
result of this, it is possible that people who had the Hepatitis A vaccination but
could not remember and who said no, could have been erroneously included
into the study and potentially have biased the results towards the null. In
situations where participants were not sure, I excluded them from the study.
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